












Modulation of Brain Chemistry with Small Molecule Probes: From Opioid to 






















Submitted in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy  



















































Madalee M. Gassaway 
All rights reserved 
Abstract 
 
Modulation of Brain Chemistry with Small Molecule Probes: From Opioid to 
Growth Factor Signaling Systems 
 
Madalee M. Gassaway 
 
 
 This report describes the use of small molecule probes in the modulation of brain 
chemistry with the ultimate goal of developing novel therapeutics for the treatment of mood 
disorders. With an increasing number of people suffering from depression, there is a need to 
explore more diverse mechanisms of these diseases to better understand their cause and therefore 
provide insight into their treatment. Chapter 1 serves as an introduction and describes the current 
understanding of depression mechanisms, as well as a history of antidepressant therapeutics. The 
chapter then goes on to discuss, in depth, the mechanisms of G Protein-Coupled Receptor 
(GPCR) function and the implications of biased signaling. There is also an introductory overview 
of basic pharmacological terms. The chapter finishes with a summary of current technology 
available to measure GPCR function, including those utilized in the rest of this report. 
 The remainder of the report is broken up into two parts. In the first part, I will describe 
my work to understand the opioid receptor system in the context of mood disorders. In Chapter 
2, the atypical antidepressant tianeptine is discovered to act through the mu-opioid receptor 
(MOR), and a biochemical exploration is reported including an exploration of its unique 
properties in the context of G protein-dependent and -independent signaling, as well as 
preliminary in vivo and structure activity relationship studies into the mechanism of action. In 
Chapter 3, I will describe the biological characterization of the Mitragyna speciosa alkaloids at 
the opioid receptors. In particular, the major alkaloids mitragynine and 7-OH mitragynine are 
found to be partial agonists at the MOR and antagonists at the kappa-opioid receptor (KOR) with 
apparent G protein bias. In Chapter 4, alkaloids inspired by those found in Tabernanthe iboga, 
such as ibogaine, are synthesized and characterized at the opioid receptors. Through a novel 12-
hydroxy-oxaibogamine scaffold, opioid activity is uncovered that is greatly increased in 
comparison to the ibogaine metabolite noribogaine. Analogs tested have varying degrees of 
potency and efficacy at all three opioid receptors, and one analog in particular is found to be a 
selective G protein biased partial KOR agonist. In Chapter 5, I will conclude the opioid section 
by taking a critical examination of commonly used assays for measuring arrestin recruitment by 
dissecting assay components and analyzing what is necessary to determine accurate calculations 
of bias within a cellular system. The alleged G protein bias of KOR agonist dynorphin is studied 
at great length, and a discussion on the future of understanding ligand bias is presented. 
 In the second part of this report, I move away from opioids and instead focus on the 
growth factor signaling system as a second approach to uncovering novel therapeutics for 
depression. In Chapter 6, I describe a second potential mechanism of action of the natural 
product ibogaine in the context of glial cell line-derived neurotrophic factor (GDNF) signaling. 
The deconstructed iboga analog XL-008 is studied that is a superior releaser of GDNF and 
potentiates the signaling of a second growth factor, fibroblast growth factor 2 (FGF2). In the 
final Chapter 7, I look to the FGF family, both receptor and growth factor, as a novel target for 
depression. In order to identify small molecule modulators of the FGF receptor 1 (FGFR1), cell-
based assays are developed and validated in a pilot screen. The strength of these assays are 
assessed, and the initial results from a full high throughput screen are presented. 
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Chapter 1 – An Introduction into Depression, Opioids, and Pharmacology 
Depression: Symptoms and Mechanisms 
 Symptoms of Depression. Depression is a debilitating psychiatric disorder associated with 
feelings of melancholy, anxiety, helplessness, and general aversion to activity. It can also 
negatively affect sleep, energy levels, as well as psychomotor and cognitive functions. 
Depression (and major depressive disorder, MDD) also carries a high risk of morbidity and 
recurrence, making it an immense public health cost.1,2 One additional danger associated with 
depression is suicide, which is the third leading cause of death among 15-24 year olds. Slow 
onset of antidepressant efficacy of currently available therapeutics, therefore, becomes 
particularly dangerous as it is well documented to be associated with high levels of suicidal 
behavior.3 The World Health Organization estimates that at least 120 million people worldwide 
suffer from depression, and for these reasons it is estimated to be the leading cause of global 
burden of disease by 2030. 
Monoamine Hypothesis of Depression. Since the 
1960s, the monoamine hypothesis has been the leading 
theory of depression, namely that depressed patients 
have low concentrations of serotonin, norepinephrine, 
and dopamine.4–6 This hypothesis was initially developed based on two lines of evidence: 1) the 
alkaloid reserpine (Figure 1), a vesicular monoamine transporter inhibitor, caused depression in 
some patients and depression-like symptoms in animals7,8, and 2) the primary target of many 
antidepressants is to increase the synaptic concentration of monoamine neurotransmitters for 
activation at postsynaptic receptors. This mechanistic hypothesis has been the basis for the 
development of numerous modern day antidepressants (see below). However, more recent 
 
Figure 1. Chemical Structure of Indole 
Alkaloid Reserpine. 
 2 
clinical evidence suggests that depression is probably not simply caused by a depletion of 
monoamine neurotransmitters but that monoamine depletion plays a modulatory role on other 
neurobiological systems. For instance, depletion of monoamines in healthy subjects does not 
necessarily lead to depression.9 Further, in patients with untreated MDD, further depletion of 
monoamines does not increase depressive symptoms.10 Thus, the original monoamine hypothesis 
had to be revised.  
Glutamate Signaling in Depression. As the major excitatory neurotransmitter in the 
central nervous system (CNS), glutamate signaling contributes to more than half of the synapses 
in the brain. The ionotropic glutamate receptors, N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors, are ion channels 
that are permeable to sodium (Na+) and calcium (Ca2+) cations and depolarize neurons in 
response mostly to extracellular neurotransmitters (e.g. glutamate and Zn2+).11 There are also 
eight metabotropic glutamate receptors (mGluR1-8), located pre- and post-synaptically, that can 
mediate intracellular signaling through their activation of G protein signaling (see below). 
NMDA receptors, in particular, require co-agonist binding to both glycine and glutamate binding 
sites for ion channel opening, as well as dislodging of the magnesium ion (Mg2+) from the 
channel by depolarization (consequent to AMPA receptor activation); these channels are 
nonselective for Na+ and Ca2+.11 AMPA receptors mediate fast synaptic transmission, with the 
GluR2 subunit mediating ion permeability and phosphorylation of serine 818 by CaMKII leading 
to long-term potentiation (a persistent strengthening of synapses that is a fundamental 
mechanism for learning and memory formation).11  
Given the important role that glutamate signaling plays in synaptic function, there is little 
surprise of its role in MDD. For instance, clinical studies analyzing plasma, cerebrospinal fluid, 
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and serum, have found increased concentrations of both glutamate and glutamine in patients with 
MDD compared to healthy controls, as well as decreased serum and plasma glutamate levels 
following antidepressant treatment.12 In more direct measurements, proton magnetic resonance 
spectroscopy has found reduced glutamate/glutamine exchange in both subcortical and cortical 
regions of the brain in patients suffering from MDD.12 Additionally, postmortem studies of 
MDD patients have shown changes in NMDA receptor subunit expression, suggesting that 
depression might be associated with NMDA receptor hyperfunction in subcortical regions of the 
brain (hippocampus, locus coeruleus, and amygdala) and hypofunction in 
cortical regions of the brain (prefrontal, perirhinal, temporal cortices).12 
These hypotheses are further supported by the clinical results with 
noncompetitive NMDA receptor antagonist ketamine, a dissociative 
anesthetic and phencyclidine derivative (Figure 2). In a proof of concept randomized, double-
blind study, a single subanesthetic dose (0.5 mg/kg) of ketamine produced rapid antidepressant 
effects (within four hours) that lasted up to 72 hours compared to the placebo control13 (with the 
caveat that it is hard to control these trials as the placebo lacks the dissociative effects) – in 
contrast to the 4-12 week delay of other antidepressants currently available (see below).14 
Patients still experienced hallucinogenic effects at this dose, but these subsided within two hours 
prior to the onset of antidepressant effects. Follow-up studies have shown the effectiveness of 
ketamine in treatment resistant patients15–17 and alternate routes of administration, including 
oral.18–21 The positive results of ketamine highlight the importance of the glutamatergic system in 
understanding and treating depression, and offers a refreshing divergence from the heavily 
studied monoamine hypothesis. 
 
Figure 2. Structure 
of Ketamine. 
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Mesolimbic Rewards Pathway. The mesolimbic dopamine rewards pathway is 
traditionally linked to the rewarding effects of food, drugs of abuse, and sex – often through 
activation of dopaminergic transmission or by direct activation of mu-opioid receptors (MOR) in 
relevant brain regions (see below).22 However, many symptoms of depression, including 
anhedonia (the inability to feel pleasure), reduced motivation, and decreased energy levels, are in 
fact mediated by the nucleus accumbens (NAc) and the ventral tegmental area (VTA), two key 
players in the mesolimbic pathway.22 It therefore seems plausible that the dopaminergic reward 
circuit could be another key player in the mechanisms behind depression. Unfortunately, the 
exact involvement of the VTA-NAc pathway in mood disorders is not well understood. Through 
sporadic studies over the past several decades, researchers have found that in animal models of 
depression, stress potently activates dopaminergic neurons in the VTA and stimulates 
dopaminergic transmission to limbic targets in the NAc.23–25 Additionally, reports show that 
antidepressant treatments can actually alter dopaminergic activity in the VTA or its targets, while 
experimental manipulation of dopaminergic signaling in the VTA-NAc can modulate depression-
like behaviors in animal models.22–25 In humans, magnetic resonance imaging, MRI, and positron 
emission tomography, PET, have shown that depressed patients have decreased activity in the 
NAc and prefrontal cortex (PFC), as well as increased activity in the amygdala (important in fear 
responses).26–29 More recent optogenetic studies in mice on the VTA-NAc circuits reveal that 
selective inhibition of VTA dopamine neurons induces a depression-like phenotype that can be 
rescued with photoactivation30, while in contrast, phasic stimulation of these neurons during 
social-interaction tests induces a depression-susceptible phenotype31, indicating contradictory 
roles of these circuits. Additionally, a separate study showed that the mesoaccumbens 
glutamatergic input into the NAc actually mediated aversion rather than award, indicating 
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instead an excitatory input on 
the GABAergic interneurons 
studied.32 Due to the strong 
mechanistic focus on the 
other monoamine systems, 
like serotonin and norepinephrine, and brain regions (i.e. hippocampus) in depression, studies in 
the VTA-NAc regions have largely concentrated on addiction or schizophrenia. Additionally it is 
not well understood why aversive stimuli (i.e. stress) would produce a drug-like (or drug of 
abuse-like) response in the VTA dopaminergic system. One possibility is that stress activation of 
the VTA is a positive, coping mechanism that helps increase an individual’s motivation to cope 
actively to the current threat. Another possibility is that longer-term exposure to stress may cause 
pathological adaptations in the VTA-NAc pathway, which can sensitize individuals to drugs of 
abuse or contribute to depressive behaviors.22,33  
In any case, it is possible that in depressed individuals, there may be a dysfunctional or 
underactive rewards pathway, which would consequently exhibit a decreased ability to respond 
to natural rewards. Therefore, increasing the activity of the rewards pathway (e.g., through 
exogenous opioid administration) could offer a potential antidepressant therapy. For example, 
the effects of many antidepressants (Figure 3), such as imipramine, desipramine, clomipramine, 
and venlafaxine (see below), can be partially inhibited by 
naloxone, an opioid antagonist.34,35 Additionally, some 
antidepressants cause increased enkephalin (endogenous 
opioid) levels (both protein and mRNA) in the rewards 
circuits and other brain areas36,37, and imipramine increases 
 
Figure 4. Main Opioid Constituents 
from Papaver somniferum. 
 
Figure 3. Structures of Antidepressants Inhibited by Naloxone. 
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MOR expression in several brain regions.38 Although not well understood, there is a clear 
connection between antidepressants and the opioid system. In fact, until the 1950s, the “opium 
cure,” a low dose of opium, was quite effective at treating symptoms of depression.39 Opium, 
isolated from Papaver somniferum, and its constituent opioids, morphine and codeine, have been 
recognized for centuries as the leading therapeutics for pain and the inspiration for many semi-
synthetic opioids 
(Figure 4). While 
compounds like 
morphine are effective 
analgesics, they suffer 
from serious drawbacks including addiction potential, tolerance build-up, constipation, and 
respiratory depression – the latter being the key effect leading to overdose and death.40 
Therefore, opioids as antidepressants have largely fallen out of favor due to the negative 
perceptions from their abuse potential. However, there have also been a few infrequent reports 
(case studies and small controlled clinical trials) that indicate MOR agonists as being 
antidepressants, including the endogenous peptide β-endorphin, oxycodone, oxymorphone, 
methadone, tramadol, and buprenorphine (Figure 5).41–48 Additionally, many studies in animals 
have identified delta-opioid receptor (DOR) agonists with antidepressant-like effects.49,50 A 
better understanding of this mechanism in depression might allow the discovery of new, safe 
opioid antidepressants. 
Neurotrophin Hypothesis. Moving further away from monoamines, glutamate, and 
opioids, the growth factor systems offer yet another interesting possibility for understanding 
depression. Increasing evidence now suggests that a decrease of neurotrophic factors (NFs), 
Figure 5. Opioids with Clinical Evidence of Antidepressant Activity. 
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particularly brain-derived neurotrophic factor (BDNF), and therefore impaired synaptic plasticity 
may be responsible for some cases of depression. As small proteins with neurotrophic functions, 
NFs include nerve growth factor (NGF), BDNF, glial cell line-derived neurotrophic factor 
(GDNF, see Chapter 6), insulin-like growth factor (IGF), and fibroblast growth factor (FGF, see 
Chapter 7).51 Given their biological roles in maintaining neuronal survival, promoting 
differentiation, facilitating axonal growth, maintaining survival of mature neurons, and 
neurogenesis, it is no surprise that NFs may also mediate some symptoms of depression and 
other neuropsychiatric disorders.51 In the clinic, reduced BDNF mRNA levels have been 
identified in the hippocampus of animal models for depression52, as well as decreased serum 
BDNF levels in untreated depressed patients.53 Further, administration of BDNF directly to the 
animal brain produces antidepressant-like effects.54 Similar evidence is also being found for the 
FGF system, as well (see Chapter 7). Interestingly, BDNF levels are used as a biomarker for 
depression55, and the BDNF Met allele is associated with an increased risk of suicide in patients 
with MDD.56,57  
Through this growing body of evidence, Duman has suggested a neurotrophin hypothesis 
to explain the onset of depression, whereby NFs help to promote synaptic growth and maintain 
neuronal survival, and in contrast, decreased levels of NFs contribute to the hippocampal and 
prefrontal cortical atrophy observed in depressed patients.58 In this way, the actions of NFs may 
reverse the damage caused by depression, indicating an antidepressant therapeutic role for these 
proteins and interpretation of depression as a neurodegenerative disorder.59 Relying solely on 
increased NF expression to combat depression may be challenging, however. For instance, 
cAMP response element-binding protein (CREB)-mediated BDNF expression usually takes 2-3 
weeks to show antidepressant effects, which is not conducive with a rapid-acting response.60 
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Another alternative would be to target instead the receptors that NFs act upon, termed receptor 
tyrosine kinases (RTKs), as a more direct way to increase the signaling (see Chapter 7). 
Although the mechanisms of NF’s role in depression are still not fully understood, there is 
precedent to study this hypothesis further.     
 
Current Treatment Options for Depression are Limited  
Monoamine Oxidase 
Inhibitors (MAOIs). The first 
pharmacological treatment 
for depression was 
discovered somewhat serendipitously. Isoniazid (Figure 6) was first developed for the treatment 
of tuberculosis, significantly decreasing the mortality rate of this disease after only one year on 
the market.61 In 1953, a monoalkyl derivative of isoniazid, iproniazid (Figure 6), was developed 
that showed interesting euphoric and psychostimulating side effects in the clinic.61 These effects 
were analyzed in a separate clinical trial for patients with depression and remarkable 
improvements were visible in 70% of patients tested. Iproniazid was continually used, off-label, 
in patients suffering from MDD. This class of antidepressants is known as monoamine oxidase 
inhibitors (MAOI). MAO is an enzyme that oxidatively deaminates biogenic amines, and 
therefore an MAOI helps to increase the levels of these biogenic amines in presynaptic terminals. 
Unfortunately for long-term use, MAOIs have their own side effects. For example, iproniazid 
was ultimately removed from the market due to it causing hypertensive crises; in the presence of 
certain foods, like cheese or dairy products, which contain high levels of tyramine, irreversible 
MAOIs like iproniazid can further increase the levels of tyramine and norepinephrine in the 
 
Figure 6. Structures of Notable MAOIs. 
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sympathetic nervous system, leading to increased heart rate, hypertension, and sweating.61 While 
some reversible and selective MAOIs have been developed (see moclobemide and brofaromine, 
Figure 6), which are effective and do not carry the risk of hypertensive crisis, they do still have 
some side effects and are not available for use in the United States.  
 Tricyclic Antidepressants (TCAs). TCAs are characterized by their fused three-ring 
structure (see examples in Figure 3 above). Inspired by the success of the drug chloropromazine 
in the treatment of schizophrenia, there was a push in the early 1950s by Roland Kuhn and Geigy 
Ltd in Basel, Switzerland to find more antipsychotic drugs.62 The tricyclic drug imipramine was 
developed in 1958, and while not effective as an antipsychotic, it showed improvements in 
patients suffering from depression.63 In comparison to MAOIs, imipramine showed improved 
side effects, and in 1959 became the first antidepressant approved for use by the Food and Drug 
Administration (FDA). TCAs are the only antidepressants classified by their structure rather than 
by their mechanism of action, as the mechanism of action of imipramine was not known. It is 
now widely recognized that TCAs bind quite promiscuously in the central nervous system 
(CNS), and are not limited to inhibition of norepinephrine and serotonin transporters (which 
likely contribute to the antidepressant effects); other effects include blocking adrenergic α1 and 
α2 receptors, muscarinic receptors, and histamine H1 receptors.64 Based on the often non-
selective actions of TCAs, the side effects are numerous and debilitating, including dizziness, 
memory impairments, and 
drowsiness. 
 Selective Serotonin 
Reuptake Inhibitors (SSRIs). 
Following the identification 
 
Figure 7. Structures of Notable SSRIs. 
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of the monoamine hypothesis for depression, serotonin was identified as a clear player in MDD. 
For instance, a postmortem study on patients who suffered depressive suicides revealed 
decreased concentrations of serotonin.65 Based on these findings, Eli Lilly began developing 
drugs that would selectively inhibit the reuptake of serotonin at serotonin transporters, thus 
increasing presynaptic concentrations of serotonin to act upon postsynaptic serotonin receptors. 
In 1974, fluoxetine became the first SSRI to be published. (Figure 7).66 Given its increased 
selectivity in comparison to other antidepressants, fluoxetine was approved by the FDA in 1987 
and is currently marketed under the trade name Prozac®. Other well-known SSRIs include 
sertraline (Zoloft®), citalopram (Celexa®), paroxetine (Paxil®), and escitalopram (Lexapro®) 
(Figure 7). While more selective than other drugs, SSRIs still suffer from side effects, including 
nausea, insomnia, and sexual dysfunction.67 Additionally there are an increasing number of 
patients with MDD termed “SSRI-resistant,” indicating that these drugs are not effective in all 
populations of patients.68 
 Atypical Classes of Antidepressants. 
There are a few additional classes of more 
atypical antidepressants available. 
Bupropion (Wellbutrin®, Figure 8) is 
primarily a dopamine-norepinephrine 
reuptake inhibitor with low risk of sexual 
dysfunction and limited dry mouth, nausea, 
and insomnia.69–71 Serotonin-norepinephrine 
reuptake inhibitors (SNRIs) have also been 
developed, including venlafaxine (Effexor®), which act mechanistically similar to TCAs without 
 
Figure 8. Structures of Some Atypical Antidepressants. 
 11 
off-target activity at adrenergic, histamine, muscarinic, dopamine, and serotonin receptors.69 The 
side effects, though, are similar to other antidepressants.71 Selective norepinephrine reuptake 
inhibitors, like reboxetine and atomoxetine (Figure 8), have been developed.72 One of the more 
recent antidepressants to be approved by the FDA is vortioxetine (Brintellix®, Figure 8), a more 
multi-action drug functioning as an agonist at 5-HT1A, a partial agonist at 5-HT1B, an antagonist 
at 5-HT3A and 5-HT7, and a serotonin reuptake inhibitor with considerable affinity for dopamine 
and norepinephrine transporters.73 Vortioxetine is supposed to have a lower risk for sexual 
dysfunction and weight gain, and offers potential improvements to cognitive function. Ketamine 
has been shown clinically to have fast-acting antidepressant effects (see above).12,74,75 Although 
promising, ketamine is not currently FDA-approved for general use as an antidepressant (only 
off-label). Another atypical antidepressant is tianeptine (Figure 8). Marketed in non-English 
speaking countries as a serotonin reuptake enhancer, tianeptine is known to modulate the 
glutamatergic system and have numerous neurorestorative properties.76,77 Until recently, its 
mechanism of action has remained elusive (see Chapter 2) and its approval in the United States 
has not been pursued.78 
 
Filling the Void in Antidepressant Therapeutics 
Although the use of antidepressants continues to rise, and our general understanding of 
the mechanisms behind depression continues to improve, the development of new antidepressant 
drugs has faltered. There remain populations of patients who are resistant to these medications, 
and with less than a third of patients gaining remission, the low rate of response, slow onset of 
improvements, and staggering number of side effects make current depression therapeutics 
unacceptable.75 As we move forward, more effort should be devoted to developing these 
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promising antidepressants, like ketamine and tianeptine, which offer a refreshing view on 
treating depression and may fill the void in available therapeutics. The main obstacle to 
overcome, however, is understanding better the direct molecular mechanisms of depression; 
current treatments work upstream of the target that actually mediates the depressive responses, 
which slows down effects significantly. If we can better understand the direct causes for 
depression among different populations of patients, then we will be better equipped to develop 
more effective drugs that will provide rapid relief.  
In gaining inspiration for new antidepressant therapeutics, one can look to several 
interesting scaffolds from nature and beyond. In addition to the atypical antidepressant tianeptine 
described above, alkaloids from both Mitragyna speciosa and Tabernanthe iboga have been 
utilized for centuries for their intriguing psychological and physiological properties. Ibogaine, in 
particular, from Tabernanthe iboga, has shown numerous clinical and preclinical results 
indicating its effects on drug abuse and addiction.79 In trying to understand the mechanism of 
action of both tianeptine and these alkaloids, the complex signaling of G Protein-Coupled 
Receptors emerges – in particular that of the opioid neurochemical system. By studying the 
signaling of these compounds further in the context of their obvious effects on neurochemistry 
and depression, a viable target emerges for advanced mechanistic understanding of mood 
disorders. 
 
G Protein-Coupled Receptor (GPCR) Signaling – the Opioid Receptors 
Signaling Cascades of GPCRs. The signaling cascades initiated by GPCRs are complex, 
and the study of these processes can be quite complicated. Activation of the GPCR first leads to 
the G protein (guanine nucleotide-binding protein) dependent signaling pathways (Figure 9), 
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beginning with dissociation of the alpha G protein subunit from the beta-gamma G protein 
subunits, which then go on to activate their respective downstream targets. There are many 
downstream targets for the alpha G proteins depending on the subtype. For instance, downstream 
targets can include adenylyl cyclase  (activation to produce more cyclic AMP (cAMP) in Gαs-
coupled GPCRs (stimulation = Gαs); or inhibition to produce less cAMP in Gαi/o-coupled GPCRs 
(inhibition = Gαi/o)), phospholipase C (activation by Gαq/11-coupled GPCRs to cause increased 
calcium levels within the cell), or RhoGEF (rho guanine nucleotide exchange factor; activation 
by Gα12/13-coupled GPCRs leads to Rho kinase activation, ROCK 1/2).80–82 For the beta-gamma 
G protein subunits, depending on the GPCR subtype, downstream targets include ion channels, 
adenylyl cyclase (indirectly), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) regulation, 
and extracellular signal–regulated kinases (ERK) regulation. They also are inhibitors of the alpha 
G protein subunits, 
where association of the 
beta-gamma complex to 
a GDP-bound alpha G 
protein leads to 
inactivation of the G 
proteins. Additionally, 
the beta-gamma G 
protein subunits are 





Figure 9. Summary of G Protein- and Arrestin-Dependent Signaling Pathways 
Following GPCR Activation. 
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(GRKs) to the receptor for phosphorylation of the serine and threonine residues.83,84 Upon GPCR 
phosphorylation, arrestins can be recruited to the receptor, thus activating the G protein 
independent signaling cascades (Figure 9).  
Arrestins are important proteins for signaling within the cell, as well. Arrestins have 
classically been divided into two distinct subtypes, visual arrestins and non-visual arrestins 
simply due to the fact that the first arrestins were identified in photoreceptors. Arrestin-1 (or S-
antigen) and arrestin-4 (or X-arrestin, cone arrestin) are mainly expressed in rod and cone 
photoreceptors of the eye retina and bind to rhodopsin, cone opsins, and various downstream 
signaling targets, including c-Jun N-terminal kinase 3 (JNK3), microtubules, Mdm2, parkin, and 
calmodulin.85 The non-visual arrestins, arrestin-2 (or β-arrestin, β-arrestin1) and arrestin-3 (or β-
arrestin2, hTHY-ARRX) are expressed in virtually all cell types and bind many non-visual 
GPCRs (i.e. non-rhodopsin receptors). Additionally, these non-visual arrestins activate other 
downstream signaling pathways, including mitogen-activated protein kinases (MAPK) 
(apoptosis signal regulated kinase 1, ASK1; mitogen-activated protein kinase 4 and 7, MMK4/7; 
JNK1/2/3; proto-oncogene, c-Raf1; mitogen-activated protein kinase kinase, MEK1; 
extracellular signal-regulated kinases 1/2, ERK1/2; p38), ubiquitin ligases (mouse double minute 
2 homolog, Mdm2; atrophin-1-interacting protein 4, AIP4; parkin) for receptor recycling, 
calmodulin, and others.85 Arrestins play key roles in mediating receptor desensitization 
(tolerance build-up to receptor activation by blocking GPCR coupling to G proteins) and 
downregulation (decrease of surface levels of receptor, via arrestin-catalyzed receptor 
internalization or clathrin-dependent endocytosis of receptors from the cell surface).  
In the context of a specific GPCR, opioid receptors like MOR, KOR, or DOR, are Gi/o 
coupled GPCRs. Activation of this GPCR leads to dissociation of the Gα from the Gβγ, which 
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goes on to suppress adenylyl cyclase activity, resulting in decreased cAMP levels.86 The Gβγ 
proteins go on to open G protein-coupled inwardly-rectifying potassium channels (GIRKs), 
causing hyperpolarization of the cells (and possibly resulting in acute analgesic effects).87 The 
Gβγ proteins also help sequester GRKs to phosphorylate the serine and threonine residues on the 
receptor, providing a binding site for arrestin 3. The arrestin 3 signaling cascade ultimately leads 
to receptor internalization.86  
 Unconventional Signaling of GPCRs. Signaling is additionally complex by more 
unconventional signaling networks of GPCRs. For example, GPCRs can directly interact with 
downstream effectors through specific protein-protein interaction domains such as the PDZ 
domain.88 Additionally, there is emerging evidence that downstream effectors might also be 
mediated through transactivation of other receptors by GPCRs. For instance, some ERK 
signaling by GPCRs may in fact be mediated through transactivation of receptor tyrosine kinases 
(RTKs).89 This transactivation usually occurs via two distinct mechanisms. One mechanism is 
ligand-independent and involves the physical association of the RTK and GPCR in a complex 
with downstream second messengers like Ca2+ and kinase Src.89 The second mechanism requires 
a GPCR-mediated untethering of a membrane-bound RTK ligand that, once released, will 
activate the RTK and lead to downstream signaling (“inside-out” model; named because an 
untethered membrane-bound RTK factor inside the cell is released and act on the outside face of 
the RTK).89 Recent examples for the first mechanism show that the epidermal growth factor 
receptor (EGFR) might be able to form a complex with either the angiotensin AT1 receptor90  or 
the β2 adrenoceptors, leading to Src-dependent activation of ERK pathways and other cascades.91 
However RTK activation more likely occurs through an inside-out mechanism by which the 
GPCR activates a metalloprotease that causes proteolytic release of the membrane-bound EGFR 
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pro-ligand (heparin-binding EGF, Hb-EGF), which then activates EGFR and causes ERK 
signaling.89 Additionally, there are reports of the mu-opioid receptor (MOR) leading to 
transactivation of the fibroblast growth factor receptor in C6 glioma cells92, as well as adenosine 
A2A mediated transactivation of Trk receptors.93  
 In addition to transactivation mechanisms, some receptors are reported to form 
heteromers, or two different receptors physically associating to make a dimer. There are many 
examples of MOR-DOR heteromers, which may hold potential for improving analgesic 
therapeutics. For example, morphine-induced analgesia can be potentiated by DOR ligands, and 
an alleged MOR-DOR specific agonist is being developed that avoids the unwanted side effects 
associated with chronic morphine use.94–96 Heteromer theories should, however, be approached 
with caution as there are some questions as to whether these complexes exist in native tissues or 
are physiologically relevant.97,98 Additionally some splice variants of GPCRs can elicit 
interesting signaling cascades. For instance, the truncated six-transmembrane splice variant of 
MOR (lacking exon 1) has been reported to induce potent analgesia in mice without unwanted 
side effects like respiratory depression, constipation, dependence, and reinforcing behavior. 99–101 
Additionally, small molecule IBNtxA has been reported to activate this MOR splice variant100, 
suggesting potential for pharmacological targeting. 
 
Understanding Ligand Bias: Pharmacology, Definitions, and Evidence 
A Lesson in Pharmacology Terms. Ligand interactions with a receptor are traditionally 
viewed as a function of two parameters: affinity (defines how tightly a ligand and receptor 
interact) and intrinsic efficacy (ability of a ligand to elicit a biological response once bound to a 
receptor).102 Ligand potency is thus defined as a measure of both affinity and efficacy and should 
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be compared to a reference ligand acting on the same receptor. Each receptor can have 
orthosteric ligands, which bind to the same site as the endogenous agonist, or allosteric ligands, 
which bind to a site separate from the endogenous agonist. Within each of these categories, 
ligands are typically designated into four categories: a. full agonists, which activate the receptor 
to elicit the highest biological responses possible; b. partial agonists, which activate the receptor 
to a fraction of the full response; c. antagonists, which inhibit the activation of the receptor by an 
agonist; and d. inverse agonists, which inhibit the constitutive activity of the receptor.102 It was 
classically thought that the efficacy of an agonist was linear (with receptor binding) and could be 
predicted by receptor occupancy theory, which states that receptors have either an active or 
inactive conformation with full/partial agonists and inverse agonists stabilizing the active and 
inactive conformations, respectively. According to this view, the response elicited by a ligand 
through the different signaling pathways should always be the same and be a function of the 
intrinsic efficacy of the agonist. Experimental evidence, however, suggests that this view of 
receptor/ligand interaction may be misleading. An increasing number of ligands are showing so-
called “imbalanced efficacies” for the different receptor-activated signaling pathways and 
suggests that efficacy might actually be pluridimensional rather than linear. For instance, some 
proteins that interact with GPCRs can affect receptor activation, producing differences in 
efficacy for the same ligand103,104, a phenomenon known as conditional efficacy.  Additionally, 
one ligand can act by different mechanisms within the same cellular context, acting as an agonist 
for one pathway and an antagonist for another105–107. Due to the high complexity with which 
signaling can occur in spite of traditional views of receptor occupancy, a more comprehensive 
view of receptor activation needs to be defined. 
Defining Functional Selectivity/Ligand Bias. The idea of ligand bias or functional 
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selectivity emerges from the interplay of multiple signaling cascades. An unbiased or balanced 
ligand is one that signals comparably through all the major signaling pathways of receptor 
activation, as suggested by receptor occupancy theory, or the concept of a single active and 
inactive receptor state. Often times, unbiased ligands are denoted full agonists and used as a 
reference for comparing the bias of new ligands. In the case of GPCRs, this feature would 
include signaling through both the G protein and arrestin pathways. Therefore a compound that 
shows preferences for one signaling cascade over another would be considered biased. In the 
context of GPCRs, the most common biased ligands are G protein biased or arrestin biased 
ligands, however one can envision a bias possible between any number of the downstream 
signaling pathways. One of the first examples of signal bias in a biological system was observed 
at MOR: Laura Bohn and co-workers found that mice lacking the β-arrestin2 (arrestin-3) gene 
showed a potentiated and prolonged analgesic effect from morphine. This suggested that 
inhibiting the β-arrestin2 signaling (as in the case of a G protein biased ligand) could greatly 
increase the effectiveness of morphine as an analgesic, a highly desirable characteristic for 
treating many opioid related side effects108 (see below).  
 Given that the classical two-state model for receptor activation is likely too simple to 
explain such diverse signaling effects, multiple receptor conformations responsible for the 
activation and signaling must be taken into account. According to this model, there are many 
different active conformations for a receptor, whereby a particular ligand might be able to 
activate (or inhibit) the different downstream effectors to varying degrees through initial 
interactions with the receptor. Arguably the most-studied GPCR in terms of structural 
connections to ligand bias is the β2 adrenergic receptor (β2AR). Kashai and co-workers showed 
that the weakly arrestin biased ligand carvedilol (Figure 10) caused Cys265 to become more 
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buried within the core of the receptor than the reference ligand isoproterenol using a chemical-
labeling approach coupled with mass spectrometry.109 Additionally, they showed that Lys263 near 
the edge of the third intracellular loop became more exposed. In a separate study, a covalently 
attached 19F-labeled NMR probe was used to observe differences in the motions of 
cytoplasmically facing cysteines (including Cys265) in the presence of different ligands, with 
carvedilol showing a shift in conformational equilibrium of transmembrane domain 6 (TM6) and 
transmembrane domain 7 (TM7).110 These studies are quite impressive considering that there is 
no strongly biased ligand known for the receptor and a crystal structure with these ligands is not 
yet available. 
 
Figure 10. Chemical Structures of Biased Ligands Discussed in this Introductory Chapter. 
 Some receptors with solved crystal structures have been studied to determine effects from 
biased ligands. The crystal structure of thermo-stabilized turkey β1 adrenergic receptor (β1AR) 
bound to weakly arrestin-biased carvedilol showed that, compared to an inverse agonist-bound 
structure (cyanopindolol, Figure 10), global conformations remained the same, except for some 
additional van der Waals contacts made with Leu101 in TM2, Asp200 and Tyr207 in the 
extracellular loop 2 (ECL2), Trp330 in TM7, and a hydrogen bond with Phe201 in ECL2 – all of 
which are similar to the structure obtained by crystallization with bucindolol (Figure 10), a 
different arrestin-biased ligand.111,112 There is overlap of these interactions with the known 




































in a crystal structure of active β2AR. Structural differences have also been noted between the 5-
HT1B and 5-HT2B receptors bound to an ergotamine ligand, which has shown a strong arrestin 
bias for the 5-HT2B receptor and a weak arrestin bias for the 5-HT1B receptor. Some of the 
additional contacts made in the presence of the ergotamine ligand with the 5-HT2B receptor are 
strikingly similar to those seen with carvedilol-bound β1AR.114,115 Although understanding the 
structural conformations within a receptor of ligand bias is in the early stages and will likely be a 
receptor-specific process, these studies provide evidence for a physical component to biased 
signaling. 
 There is also an important structural role for GRKs in arrestin recruitment to the GPCRs. 
So called “barcodes” for GRK-induced receptor phosphorylation on the C terminal end of 
GPCRs have been recognized that can regulate or even enhance arrestin recruitment to 
receptors.116 These results are generally supported by experiments showing that lack of GRKs or 
even deletion of serine or threonine phosphorylation sites on the C terminus can affect the 
affinity of arrestin for the receptor, thus modulating the downstream signaling of arrestin 
recruitment.117,118 Further, studies have shown that GRK-specific phosphorylation sites can 
account for different downstream signaling cascades. For instance, in the β2AR, GRK2 
phosphorylation sites lead to receptor internalization while GRK6 sites lead to ERK 
activation.116 Further, arrestin biased ligand carvedilol was shown to only induce 
phosphorylation of the GRK6 sites on β2AR, thus highlighting that even within the same 
signaling pathway (i.e. arrestin signaling) there may be some bias between downstream effectors 
– furthering the complexity with which receptors function. These results also suggest that 
perhaps ligands are capable of preferentially recruiting distinct GRKs to the receptors, leading to 
distinct phosphorylation barcodes that will ultimately impart unique arrestin function.   
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There is also a concept of “endogenous bias” whereby endogenous ligands for a receptor 
can have inherent bias for one signaling pathway over another. For example, CCL19 and CCL21, 
two endogenous ligands for the CC chemokine receptor 7, activate receptor desensitization, 
arrestin recruitment, and ERK1/2 signaling to a different degree even though they have similar G 
protein coupling efficiency.119,120 Additionally, there is known differential activation of the 
serotonin receptor, 5HT2A, in the presence of “trace amines.” Serotonin-induced receptor 
activation can trigger Akt signaling through an arrestin-3/Src-dependent pathway in mouse 
cortex and cortical neurons but not when N-methyltryptamines activate the receptor.121 Finally, 
even in the context of opioids, there is a possibility that endogenous peptide endomorphin-1 
might be G protein biased (when compared to control agonist DAMGO) – though the authors 
suggest that true bias cannot be determined until in vivo studies are performed.122  
In the context of opioid receptors, there have been serious efforts to develop G protein 
biased ligands as better therapeutics for pain that avoid the unwanted side effects of morphine 
use (respiratory depression, constipation, tolerance, physical dependence)40,86. G protein biased 
MOR agonists are reported with reduced respiratory depression and constipation, suggesting that 
these deleterious side effects are mediated through arrestin signaling.123 Additionally, KOR 
agonists can provide similar analgesic relief when compared to morphine and have the added 
benefit of not activating the dopamine reward pathway.124 However, KOR activation leads to 
dysphoria, or a feeling of helplessness, as well as hallucination.124–126 These effects, evident in 
potent compounds such as the KOR agonist salvinorin A127, lead to a particularly frightening 
experience for someone needing simple relief from pain. There are reports, however, that suggest 
these dysphoric effects are mediated through arrestin-dependent activation of the p38 MAPK 
pathway.125,126 Therefore, an agonist that is biased to the G protein-dependent signaling pathway 
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(and therefore has little to no signaling in the arrestin pathway) may offer a unique solution to 
some of these aversive effects from opioid signaling and represent a novel therapeutic avenue 
worth pursuing further.  
Distinguishing the Level of Bias for a Ligand. When studying a potentially unbalanced or 
biased ligand, it is important to determine the level to which the bias occurs. Often times for 
different experimental systems, whether due to receptor reserve (extra or unused receptors 
present in the cell) or signal amplification (one molecule activating many of the same 
downstream effectors), the biological response from a particular ligand may be completely 
different, with partial agonists appearing full and full agonists appearing partial, which ultimately 
makes it difficult to accurately determine the level of bias for one pathway over another. 
Therefore, the proper tools are needed to accurately quantify the bias from a particular 
compound. Always a ligand should be compared with an unbiased reference agonist, often the 
standard full agonist of the receptor. Without this comparison, there is little hope in gleaning 
meaningful information on the test ligand. Additionally, while it can be useful to see how a 
ligand compares to the control on one signaling pathway, in terms of potency and efficacy, at 
least two signaling pathways need to be analyzed in order to denote a ligand bias. Researchers 
have proposed many ways to quantify ligand bias into a so-called “bias factor” with mixed 
results. Some of the early attempts at quantification required either a rigorous comparison of 
efficacies from different ligands at equimolar concentrations or ligand concentrations that result 
in equiactive responses.128 These methods suffer in that they do not inherently take into account 
the affinity of a ligand for a receptor, which could greatly alter the downstream signaling 
outcomes.  
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A better approach can 
be found by utilizing the 
operational model developed 
by Black and Leff.129,130 The 
operational model examines the 
agonism of a compound by 
carefully analyzing the dose 
response curve, taking into 
account the ligand affinity (KA) 
for the receptor and the 
efficacy (τ) to activate a signaling pathway. The τ factor takes into account both receptor density, 
[Rt], and KE, which denotes the intensity of a response and the system’s ability to convert the 
receptor stimulus into a response (Figure 11). It then must be assumed that a ligand bias can be 
characterized by different active states of the receptor, each with their own ligand affinity or 
efficacy. Therefore the most common representation of the Black-Leff operational model for 
dose response curves can be seen in equation 1 below.131,132 
                                                   !"#$%&#! =  !![!]
!!!
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                      (1) 
where [A] denotes the agonist concentration, Em denotes the maximal response of the system, 
and n is the transducer slope, which links agonist concentration to the observed response (distinct 
from the Hill slope133, which describes instead the midpoint gradient derived from fitting a 
concentration-response curve). Figure 11 summarizes the ability of the Black-Leff operational 
model to quantify agonist bias. When data is fit using the operational model, agonism can be 
characterized as a function of both τ and KA, and a so-called transduction coefficient, log(τ/KA), 
 
Figure 11. Schematic Diagram of the Black-Leff Operational Model in 
the Quantification of Ligand Bias. In this model, a receptor 
conformation will be stabilized by the agonist, leading to a particular 
interaction with downstream signaling proteins (effectors). The affinity 
and efficacy (a measure of the “quality” of the receptor conformation) is 
dependent upon the signaling protein, which is unique to each pathway. 
The transduction coefficient of an agonist takes into account both the 
affinity and the efficacy for a particular pathway. Rt = receptor density; 
KE = ability of system to convert receptor stimulus into a response. 
Adapted from Kenakin.131  
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can characterize the agonism of any pathway within a cellular system where an agonist interacts 
with a receptor. When the transduction coefficient is normalized to a control, unbiased ligand  
(see below), a normalized factor, or ∆log(τ/KA), can be used to account for any natural bias 
within the system. Thus the bias for an agonist between distinct signaling pathways, p1 and p2, 
can be defined as follows in equations 2 and 3 as 
                                                                             !"#$ =  10∆∆!"# (! !!)!!!!!                                                                   (2) 
where 
∆∆log (! !!)!!!!!   
= log bias 
                                                                     = ∆log (! !!)!! − ∆log (! !!)!!                                                          (3) 
and where 
∆!"#(! !!) 
                                                                = !"#(! !!)!"#$%& −  !"#(! !!)!"#$%"&                                                  (4) 
 
A simplified version of the Black-Leff model uses a calculation of both efficacy and 
potency called the activity ratio or RA, which is denoted as the maximal response of an agonist 
divided by the EC50 (ligand concentration of half maximal response, a measure of potency). 
When properly compared to a control and analyzed through multiple pathways, a reasonable 
calculation for a ligand bias (Log[RA]) can be obtained (Equation 5).129,134,135 
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  There are many ways to represent bias factors such that comparisons between ligands are 
easy to follow and interpret. Most commonly used are graphical representations showing the 
mean values and error for ∆log(τ/KA)131, heat maps showing bias for any number of signaling 
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pathways represented by changing color136, and so-called webs of bias.137 No matter what 
method is chosen to calculate a bias factor for a particular ligand, there will always be a question 
of what level of bias is significant and will lead to differential effects in signaling. 
Examples of Ligand Bias. 6’-GNTI (Figure 12) has been reported by various scientists to 
be G protein biased at the KOR. Utilizing the same BRET assays described here, 6’-GNTI was 
initially found to be not only biased for the G protein signaling pathway but also an antagonist of 
the arrestin pathway.138 In a follow-up study from a different lab, the authors found that G 
protein signaling could not be recapitulated in mouse striatal membranes, an endogenous source 
of receptors rather than an overexpressed system, while downstream signaling (Akt pathway) in 
overexpressed CHO cells and native systems (striatal membranes) was consistent with previous 
reports.139 These results highlight that the in vitro pharmacology observed for 6’-GNTI might not 
be relevant in vivo or might be tissue or cell-specific. A more recent study tested 6’-GNTI in vivo 
for convulsant/seizure effects (likely in regard to reports that it activates KOR-DOR 
heteromers140), as well as aversive effects from KOR signaling. Mice given an intra-hippocampal 
injection of the drug were found to have an increased threshold for seizure and no conditioned 
place avoidance, a measure of aversion, indicating promise that some in vitro bias effects may be 
translatable into behavioral effects (although the latter may be related to completely different 
pharmacological/signaling phenomena).141 
Another example of ligand bias at KOR shows that at least for this receptor, bias is not 
limited to G protein versus arrestin signaling. The natural product collybolide (Figure 12), 
isolated from the mushroom Collybia maculata, is an agonist acting at KOR that shows greatly 
increased potency through the mitogen-activated protein kinase (ERK) pathway than does 
salvinorin A in human KOR expressing HEK cells using the [35S]GTPγS binding assay and 
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western blotting (see below discussion of assays).142 The in vitro signaling bias was supported in 
vivo by a 10-fold higher potency for blocking non-histamine mediated itch (or pruritus) in 
comparison to salvinorin A. This example highlights that ligand bias can exist between any two 
or more signaling pathways and ideally are supported by both in vitro and in vivo results. 
RB-64 (Figure 12), a diterpene salvinorin A analog and KOR agonist, has also been 
studied in vivo for potential behavioral effects of receptor signaling bias. Identified to have a bias 
 
Figure 12. Structures of Reported Biased Agonists Discussed. 
factor of 35 for G protein (measured in overexpressed cells using a cAMP sensor assay for G 





























































































some attempt to understand both the structural effects on the receptor from this compound144, as 
well as in vivo behavioral effects.145 It has been hypothesized that a G protein biased ligand 
would avoid aversive effects from KOR signaling125, but evidence is still limited to fully support 
such claims in vivo. RB-64 is one such compound that provides some insight into the behavioral 
effects of possible G protein bias. When administered to mice, RB-64 did induce potent 
analgesia without inducing any sedation or anhedonia-like symptoms, consistent with reports that 
arrestin-3 activity is essential for the sedative and anhedonia-like effects from KOR agonists. 
Unfortunately aversive effects were still present in a conditioned place aversion assay. This may 
not be surprising, however, as initial signaling bias was determined in artificial systems, and the 
compound likely has different signaling properties in brain tissue or cells. Therefore, RB-64 as a 
tool does help to resolve some of the mystery surrounding the behavioral effects of an in vitro G 
protein biased compound, however it does also suggest that, not surprisingly, even among G 
protein biased compounds there may be some distinction in their ultimate behavioral effects. 
 Biased ligands are also reported at other opioid receptors, like MOR. NAP (Figure 12), a 
naltrexamine derivative, was recently reported to be a partial MOR agonist for G protein 
activation ([35S]GTPγS binding assay, see below) and an arrestin-3 (β-arrestin2, determined in 
PathHunter®, see below) and intracellular calcium flux antagonist (calcium indicator used) in 
human MOR-CHO cells.146 As it is hypothesized that G protein-biased MOR agonists might 
have effects on blocking constipation symptoms, researchers tested NAP on ex vivo mouse 
colons and found that the compound reversed morphine-induced reduction in colon motility, 
though no comparison was made to other partial MOR agonists. NAP therefore represents an 
interesting lead as a treatment for opioid-induced constipation, although no evidence is provided 
about whether the compound has analgesic properties.  
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 Trevena’s compound TRV130 (Figure 12) is currently in clinical trials as a G protein 
biased MOR agonist for pain, as preliminary in vivo results were promising and showed less risk 
of respiratory depression and constipation.123 This profile has largely shown to translate into 
humans with lower incidence of nausea and vomiting, an indication that functional selectivity 
may improve some opioid side effects.147 Additionally, noribogaine, the active metabolite of the 
natural product ibogaine, has been reported to be a G protein biased KOR agonist.148 Given the 
weak agonism we observed from noribogaine at KOR (see Chapter 4), it seems unlikely that 
noribogaine represents a true biased ligand (for further discussion on these compounds, see 
Chapter 4). 
 However, biased ligands are not limited to the opioid receptors or even to the G protein 
signaling pathway. ML314 (Figure 12) is an arrestin-biased neurotensin receptor (NTR1) 
agonist (arrestin-3 translocation measurements in arrestin-3-GFP expressing cells and aequorin-
based calcium reporter assay for G protein) that shows promise in the treatment of 
methamphetamine addiction while inhibiting the G protein signaling pathway.149 In a rigorous 
study utilizing multiple animal models, researchers showed that ML314 attenuated 
methamphetamine-induced hyperlocomotion (excessive movement usually in response to 
increased stimulation of the nervous system and a positive phenotype of schizophrenia in some 
mice models) in both wildtype and dopamine transporter knock out mice, and reduced 
conditioned place preference from methamphetamine. Additionally, in rats ML314 blocked 
methamphetamine self-administration and acted as an allosteric enhancer of endogenous 
neurotensin binding. Not only then is ML314 an arrestin biased ligand, but it also seems to be an 
allosteric compound, which may help to account for its unique signaling and behavioral effects.   
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 Arrestin bias is also found at other GPCRs, including the dopamine D2 receptor (D2R), 
where it has been found to be particularly interesting as an anti-psychotic therapeutic. Three 
aripiprazole ligands (Figure 12), UNC9975, UNC0006, and UNC9994, were found to be arrestin 
biased D2R ligands that inhibited G protein signaling.150 Interestingly, UNC9975 showed potent 
anti-psychotic-like activity but did not have motoric side effects in mice, consistent with 
blockade of the G protein pathway. The anti-psychotic effects from these compounds were 
completely abolished in mice lacking arrestin-3 (β-arrestin2) with the addition of catalepsy 
effects. These effects were recapitulated favorably in mice with schizophrenia-like behaviors.151 
 Understanding the structural components of the receptor that lead to functional selectivity 
would show significant progress in the field. Rather than searching tirelessly for the next biased 
ligand, looking instead to the receptor might provide a more directed approach to developing 
improved therapeutics. Some attempts at elucidating the portions of receptors involved in 
dictating bias have been made. For example, at the D2R, important residues in the third 
intracellular loop were identified that could be mutated in such a way as to create a receptor with 
decreased arrestin recruitment which was unable to internalize.152 This example highlights the 
possibility of identifying receptor features key for functional selectivity. One can envision that if 
a biased receptor could be crystalized, computational predictions could be made to design 
ligands that would selectivity activate it or mimic the mutation, thus inducing the same bias.  
 
Tools to Study Pharmacology 
 Assays Available for the Measure of GPCR Functional Activity. Since the discovery of 
GPCRs in the late 1980s153, scientists have been striving for new and improved ways to measure 
the functional activity of GPCRs, both through G protein dependent and G protein independent 
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 pathways. The first example of measuring G protein activation utilized radioactive GTP. Known 
as the [35S]GTPγS 
binding assay, this 
method took advantage of 
the cell’s inability to 
metabolize the thioester 
linkage of this radioactive 
substrate in the activation 
cycle of the G protein 
subunits (Figure 13).154 
Rather than converting 
the active GTP-bound Gα subunit to the inactive GDP-bound Gα subunit via the actions of 
GTPase, the [35S]GTPγS-bound Gα subunit accumulates in the cell membranes, leading to an 
increased signal that can be detected with a scintillation counter. Although this method is still 
used by researchers today, it suffers from lack of sensitivity, even in over-expressed systems. 
Western blots have also been utilized since the early days of GPCR study to measure the 
activation of downstream signaling pathways such as ERK1/2 and Akt, however again this 
method is not particularly sensitive and is ultimately not appropriate for measuring subtle dose 
responses. These methods do have an advantage however that they can be performed in either 
endogenous or over-expressed systems, albeit with varying degrees of success. 
 While radioligand binding assays still remain the gold standard for measuring ligand 
affinity for a receptor, the tools available to measure receptor signaling continue to become 
increasingly sophisticated. Assay options in genetically modified systems are plentiful, offering 
 
Figure 13. Mechanism of the [35S]GTPγS Binding Assay for Measuring 
Functional Activity of GPCRs. 
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robust and reproducible measurement in clever and easy to use methods. The explosion of 
bioluminescent resonance energy transfer (BRET) assays is apparent in the numerous examples 
of their usage in measuring the pharmacology of ligands at GPCRs.155,156 Resonance energy 
transfer (RET) is an energy transfer mechanism possible between two light-sensitive molecules. 
An excited donor chromophore 
may transfer energy to an 
acceptor chromophore through 
nonradiative dipole-dipole 
coupling, provided that the donor 
and acceptor have adequate 
match of their spectra and 
orientation. Because the energy 
transfer is inversely proportional 
to the sixth power of the distance 
between the two chromophores, 
these RET techniques are sensitive to small changes in distance.157 As such, the BRET-based 
assays rely upon close proximity between the donor and acceptor molecules. Featured heavily in 
Chapters 2-5 is a G protein activation assay where the Gα subunit is tagged with RLuc8158, a 
BRET donor, and the Gγ subunit is tagged with mVenus159, a BRET acceptor. Luciferase 
converts the substrate coelenterazine h into an excited state intermediate that emits light when 
relaxing to its ground state, making a BRET interaction possible. In the presence of agonist, and 
 
Figure 14. Mechanism of the BRET-based G Protein Activation 
Assay. A. Schematic depiction of G protein activation assay. B. 
Production of light from luciferase and coelenterazine h. 
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subsequent dissociation of the α from the βγ subunits, the BRET donor signal increases and the 
BRET acceptor signal decreases, and an overall 
loss of the BRET signal (donor/acceptor) can be 
detected (Figure 14). BRET methods also exist 
to detect cAMP levels in cells, which are 
particularly useful for GαS- and Gαi/o-coupled 
GPCRs, such as the CAMYEL (cAMP sensor 
using YFP-Epac-RLuc) cAMP sensor (Figure 15). There are also virally delivered cAMP 
sensors that can be administered to more natural systems, like primary neurons, where receptors 
are expressed at endogenous levels and may better recapitulate signaling in vivo.160 These 
sensors, however, can be particularly difficult to utilize for measuring Gαi/o-coupled GPCRs, 
since basal levels of cAMP may be too low to observe cAMP inhibition in response to receptor 
activation. Additionally there are numerous reporter gene assays available that couple receptor 
activation to expression of a gene that codes for an enzyme that can act upon an exogenous 
reporter substrate added to the cells (Figure 16).  
 
Figure 16. Mechanism of Action for Reporter Gene Based G Protein Activation Assays. Activation of the GPCR 
leads to increased expression of beta-lactamase, which then reacts with an added substrate, creating a change in 
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Figure 15. Mechanism of BRET-based cAMP 
sensor, CAMYEL. 
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Invitrogen has a commercially available kit in which beta-lactamase is expressed in response to 
GPCR activation, which then can react with a FRET substrate, thus correlating agonist activity 
with changes in FRET dynamics.161 The FRET signal is buffered by the time required for protein 
synthesis and thus is a temporarily imprecise reporter of GPCR activation. While these methods 
are useful for initial in vitro pharmacology analysis of drugs and can often times have a large 
dynamic range, they are highly modified and thus may not be good models of the relevant 
endogenous systems. These assays are certainly a helpful starting point for understanding 
receptor signaling but of course should be used simultaneously with other assays, too.162 
An equally numerous amount of assays 
exist for measuring arrestin recruitment. Some 
early examples of arrestin measurement relied 
upon western blotting to look at downstream 
targets (such as p38 MAPK) or even arrestin 
itself.108,163 Others utilized imaging based 
approaches or receptor internalization as a way to infer the arrestin activity.138,164 However while 
useful, these techniques are not necessarily direct measures of arrestin recruitment. Much like for 
G protein activation, there are several BRET-based assays for monitoring arrestin recruitment in 
vitro. The first (BRET 
recruitment assay) utilizes 
receptors tagged with a 
BRET donor, like RLuc8, 
and arrestin tagged with the 
BRET acceptor, mVenus. 
 
Figure 17. Mechanism of the BRET-based Arrestin 
Recruitment Assay. 
 
Figure 18. Mechanism of the BRET-based Arrestin GAP43 Translocation 
Assay. 
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Upon receptor activation and arrestin recruitment, a BRET signal can be detected (Figure 17).138 
This method is limited by the ability to clone receptors tagged with the BRET donor, which can 
be challenging. As a complementary approach (BRET GAP43 translocation assay), the BRET 
acceptor, fluorescent protein citrine, is tethered to the membrane by the doubly palmitoylated 
fragment of GAP43, found in virtually all cells, and fused to an SH3 domain. The arrestin 
protein is then sandwiched between both the BRET donor RLuc8 and a low affinity SH3-binding 
peptide, Sp1. Upon arrestin recruitment to the receptor, Sp1 and SH3 bind, causing a proximity-
based BRET signal (Figure 18).152 The advantage of this method is that native receptors can be 
utilized, making the assay easily translatable over many GPCRs. Unfortunately, the assay is not 
necessarily compatible with every receptor construct, as varying levels of receptor expression in 
the cells seems to affect the success of the assay (see Chapter 5). 
 Reporter gene assays, such as the Tango assay, exist for measuring arrestin recruitment, 
as well (see Chapter 5). Depending on the reporter gene chosen and the substrate used for 
detection, it is possible to obtain 
quite a sensitive read-out for 
arrestin recruitment. DiscoverX 
also has a PathHunter® enzyme 
fragment complementation (EFC) 
assay for arrestin recruitment. In 
this assay, an N-terminal portion of 
beta-galactosidase is fused to the C terminus of stably expressed β-arrestin 2 (arrestin 3). Then a 
mutated amino-terminal fragment of beta-galactosidase (ProLink/enzyme donor, PK) is fused to 
the C-terminus of the GPCR. When arrestin is recruited to the receptor upon activation, the beta-
 
Figure 19. Mechanism of DiscoverX PathHunter® Assay for 
Arrestin Recruitment. 
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galactosidase enzyme is reconstituted and able to act upon a substrate added to the cells (Figure 
19).165 Much like with measuring G protein activation, these systems are highly modified 
compared to in vivo systems and thus should be used with caution. If the assay is not sensitive 
enough (or too sensitive), bias calculations could be skewed. 
 
Current Work 
 Given the complexity by which antidepressants elicit their behavioral effects and the 
clear need for better therapeutics, it is time to explore more exotic targets for treating depression. 
In particular, opioid and neurotrophin signaling offer two unique ways to tackle the poor 
therapeutics currently available for depression and anxiety. The literature precedent for such 
targets is clear, yet few researchers have given much attention to these understudied 
mechanisms. By studying these signaling cascades further, we can better understand how the 
different mechanisms overlap and therefore reveal the inner-workings of depression. In Part I, I 
will describe our efforts to understand the mechanisms of opioid receptor modulation in the 
context of depression and mood disorders, specifically through biochemical efforts that include 
in vitro pharmacology signaling studies, chemical synthesis, and some in vivo experiments. In 
particular, a significant effort is dedicated to exploring G protein bias within the various 
scaffolds as one solution to address the shortcomings of opioid receptor signaling, both for 
potential antidepressant and analgesic therapeutics. In Part II, I will describe the assay 
development and seminal work performed in our campaign to identify small molecule 
modulators of RTKs. Through these studies we have learned important indications that 
regulating brain chemistry through opioid receptor and RTK modulators reveals viable targets 
for antidepressant therapeutics, offering hope to those currently suffering from MDD.  
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Chapter 2 – Uncovering the Mechanism of Action of the Atypical 
Antidepressant Tianeptine 
Introduction 
Tianeptine (Figure 1) is a tricyclic antidepressant that is 
atypical both in structure and function. With a substituted 
dibenzothiazepine core that contains two heteroatoms along with the 
aminoheptanoic side chain, the unusual structure of tianeptine 
separates it from other traditional tricyclic drugs. It was first 
discovered by the French Society of Medical Research in the 1960s 
and is currently manufactured by Servier.1 In both controlled and open clinical trials, tianeptine 
has proven its efficacy as an antidepressant, including as a treatment in specific subsets of the 
population like elderly or alcoholic individuals.2,3 For these reasons, it is available for use in 
Europe and Asia (Coaxil), as well as in Latin America (Stablon).1,4 In terms of establishing better 
therapeutics for depression (see Introductory Chapter 1), researchers have identified three main 
goals which novel therapeutics should attain, including faster onset of antidepressant effects, 
efficacy in treatment-resistant subjects, and minimization of side effects, many of which 
tianeptine fulfills.5,6 First, tianeptine shows rapid efficacy against some depressive symptoms, 
both cognitive and anxiety. In patients with major depressive disorder (MDD) (aged 18 to 60 
years), a 25 to 50 mg/day dose of tianeptine showed initial improvements after only 7 days, in 
contrast to other antidepressants that require weeks to months for real results.3,7 Additionally, 
anxiety was found to be lessened after seven days of treatment with tianeptine.2 Second, 
tianeptine has shown promise in patients resistant to selective serotonin reuptake inhibitor (SSRI) 
therapy.8 In an open-label clinical trial, 150 patients with major depression who had partial to no 
response from SSRI therapy were given tianeptine in combination with an SSRI for six weeks, 
	




and significant improvements were measured even from the first week.8 Double-blind clinical 
trials should be completed to fully demonstrate these results. Finally, in comparison to other 
SSRIs and tricyclic antidepressants, tianeptine shows a superior side effect profile.6 Tricyclics 
typically cause sedative, autonomic, cardiovascular, and attention/memory side effects, while 
SSRIs can cause nausea and sexual dysfunction. Tianeptine, however, is markedly better in 
comparison with few notable side effects.3,9–12 Additionally, these clinical effects are also 
prevalent in many preclinical studies, warranting the comprehensive examination of tianeptine in 
many animal models.6,13 
Tianeptine’s effects extend beyond treatment of depression and anxiety. When studying 
the neuronal mechanisms behind depression, researchers are now uncovering a connection with 
loss of hippocampal volume, neuron dendrite shrinkage, glial cell loss, and impairments to 
neuroplasticity and cellular resilience.14–16 In several models, tianeptine has shown modulation of 
these effects. For example, tianeptine reversed the stress-induced decrease in hippocampal 
volume, as well as increased the concentration of cerebral metabolites and proliferation of 
granule precursor cells in the dentate gyrus in tree shrews that were subjected to psychological 
stress, highlighting its protective effect against stress-induced neuronal remodeling.17 Tianeptine 
has further been shown to modulate growth factor signaling in the hippocampus and amygdala of 
rodent models, specifically brain-derived neurotrophic factor (BDNF) and nerve growth factor 
(NGF), suggesting that tianeptine may promote neuroplasticity by increasing expression of these 
neuroplastic factors.18,19 Additionally, tianeptine reverses stress-induced inhibition of long-term 
potentiation (LTP) at excitatory synapses in the hippocampus and prefrontal cortex even after 
only hours of stress exposure.6 In terms of cognitive effects, tianeptine shows promising effects 
on spatial memory, focused attention behavior, learning, working memory, and memory 
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retention in rodents.6 Given the wide-ranging neurobiological effects of this neurorestorative 
agent, there is little surprise that much effort has been put into uncovering its mechanism of 
action.  
In early studies with tianeptine, it was found to increase 5-hydroxytryptamine (5-HT, 
serotonin) uptake in rat brains from either acute or chronic dosing with the drug. This 
enhancement of 5-HT uptake was noted in the hippocampus and cortex but not the 
mesencephalon.20,21 It is important to note, however, that several studies have contested this 
hypothesis, finding no marked changes in extracellular 5-HT levels (either increase or decrease) 
in the corticolimbic structures of conscious rats.22,23 This pharmacology is in stark contrast to 
other antidepressants, which usually elicit their function through inhibition of biogenic amine 
transporters (specifically dopamine transporter, DAT; serotonin transporter, SERT; 
noradrenergic transporter, NET).6 In fact, several studies have shown that tianeptine has no 
affinity for many obvious targets in the central nervous system. In particular, tianeptine has no 
affinity for adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin receptors (5-HT1, 5-
HT2, 5-HT3, 5-HT4, 5-HT5A, 5-HT6, 5-HT7), benzodiazepine receptors, gamma-aminobutyric 
acid receptors (GABA-B), and dopamine receptors (D1, D2, D3, D4, D5).24 Further, tianeptine 
does not inhibit monoamine oxidases (MAOa and MAOb), another common mechanism for 
antidepressants.25 
In addition to modulating serotonin levels in vivo, tianeptine is also known to modulate 
the glutamatergic system. For instance, tianeptine has been shown to inhibit pathological changes 
in glutamatergic neurotransmission in the hippocampus and amygdala of various animal models 
in response to stress.26,27 Further, chronic and acute treatment with tianeptine increased 
phosphorylation of the CaMKII-PKC (protein kinase C) site (serine 831) on the GluR1 subunit 
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of AMPA receptors in the hippocampus and frontal cortex of both mice and rats.24,28 Given the 
plentiful examples of tianeptine’s modulation of the glutamatergic system, many researchers 
have come to accept that tianeptine, like other fast-acting antidepressants (see ketamine, 
Introductory Chapter 1), exerts its antidepressant and neurorestorative effects through this 
system. Interestingly, however, tianeptine has no measurable affinity for these receptors or 
kainate receptors.6,24  
There are an increasing number of examples that indirectly connect the actions of 
tianeptine with the opioid system. Although tianeptine has no known affinity or modulatory 
properties at the dopamine receptors, systemic administration of tianeptine is reported to increase 
mesolimbic release of dopamine.29 This observation is of particular interest since mu-opioid 
receptor (MOR) agonists are reported to activate the mesolimbic rewards pathway, leading to the 
addictive properties of opioids.30,31 Further, in a case study involving a woman suffering from 
tianeptine and amitriptyline poisoning, administration of naloxone, an MOR antagonist, resulted 
in a rapid, full recovery of the patient, suggesting that either one of both of the antidepressants 
involved is functioning through the opioid system.32 Consequently, there is reason to study 
tianeptine further in the context of the opioid receptor system. 
Motivated by the impressive and wide-reaching biological effects of tianeptine, we 
became interested in elucidating its primary molecular target. This chapter will discuss the 
identification of tianeptine as an efficacious MOR and delta-opioid receptor (DOR) agonist in 
vitro. A full account of this work can be found in our published report.33 Further, we explore the 
functional activity of known metabolites of tianeptine. Finally, preliminary in vivo studies 
suggest that MOR agonism underlies the clinical, preclinical, and in vitro effects of tianeptine. 
Through this collection of new data on the functions of tianeptine, we suggest a new mode of 
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Identifying the Molecular Target of Tianeptine 
 
Figure 2. Tianeptine Binds to the Opioid Receptors. A. Radioligand ([3H]DAMGO) displacement assay on human 
MOR using morphine as a control. Tianeptine has a binding affinity of 382.7 ± 183.3 nM for MOR. B. Radioligand 
([3H]DADLE) displacement assay on human DOR using naltrindole as a control. Tianeptine has a binding affinity of 
> 10 µM for DOR. C. Radioligand ([3H]U-69,593) displacement assay on human KOR using salvinorin A as a 
control. Tianeptine shows no binding affinity for KOR. Data represent mean ± SEM of a representative experiment 
of n = 3 (MOR), n = 4 (DOR), n = 4 (KOR) independent experiments performed by PDSP. 
 
 Tianeptine Binds to the Opioid Receptors. In collaboration with the Psychoactive Drug 
Screening Program (PDSP), a much more extensive evaluation of tianeptine binding to human 
CNS targets was conducted. In addition to the receptors tested by Svenningsson and coworkers24, 
tianeptine was measured for its ability to bind to nicotinic acetylcholine receptors (α2β2, α3β2, 
α3β4, α4β2, α4β4, α7), cannabinoid receptors (CB1, 2), histamine receptors (H1, 3, 4), muscarinic 
acetylcholine receptors (M1-5), peripheral benzodiazepine receptors (PBR), sigma receptors (1, 
2), metabotropic glutamate receptors (mGluR1a, 2, 4, 5, 6, 8), and opioid receptors (MOR, DOR, 
and kappa-opioid receptor, KOR) using traditional radioligand binding assays in overexpressed 
cellular systems. As was observed before, tianeptine had no measurable affinity for most of these 
targets. The only exception was the opioid receptor family. Tianeptine bound to the MOR with a 
	 	 	








Ki = 383 ± 183 nM (Figure 2A). Tianeptine also showed some affinity for the DOR, however it 
was much weaker in comparison to that observed for the 
MOR (Ki > 10 µM, Figure 2B). There was no binding 
affinity of tianeptine at the KOR (Figure 2C). This separate 
measure of tianeptine’s binding affinity highlights again how 
clean the pharmacological profile is in comparison to other 
tricyclic antidepressants. In fact, the apparent selectivity of 
binding to only the opioid receptors may explain the 
improved side effect profile of tianeptine. Although the 
binding results of tianeptine to the opioid receptors may be surprising at first, its similarly bent 
structure in comparison to the classical opioid morphine does reveal indirectly that the two 
compounds could in theory have the same molecular target (Figure 3). A summary of binding 
affinities at the MOR and DOR can be found in Table 1. 
Tianeptine is an Agonist at the MOR. To complement the binding studies of tianeptine, 
the functional activity at the opioid receptors 
was measured utilizing bioluminescent 
resonance energy transfer (BRET) assays (see 
Chapter 1). Tianeptine was first characterized 
for its functional activity at the rodent isoforms of the receptors. In a BRET G protein activation 
assay, tianeptine was able to activate the mouse MOR (mMOR) with an EC50 of 641 ± 120 nM 
(Figure 4A). Additionally, tianeptine showed full agonism at the mouse DOR (mDOR) with an 
EC50 of 14.5 ± 6.6 µM (Figure 4B) and showed no agonism at the rat KOR (rKOR, Figure 4C). 
Table 1. Tianeptine Affinity at Opioid Receptors 
 Ki (µM)  
hMOR hDOR hKOR 
0.38 ± 0.18 > 10 X 
Data represent mean ± SEM (µM) of n ≥ 3 independent  
trials. “X” indicates not active. Data obtained by PDSP. 
 
	
Figure 3. Three-Dimensional 
representation of tianeptine (A) and 
morphine (B) reveal similar bent 
conformation. Minimized structures 
generated through PubChem3D.76 
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These data represent the first example of opioid receptor activity from tianeptine and could 
explain some of the preclinical effects observed. To confirm these results, tianeptine was 
 
Figure 4. Tianeptine is a Full Agonist at the Rodent Opioid Receptors. mMOR (A), mDOR (B), or rKOR (C) were 
co-expressed with with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the 
average of n ≥ 3, with error bars representing ± SEM. 
 
measured in a separate assay for cAMP inhibition. As a Gi/o-coupled G Protein Coupled 
Receptor (GPCR), the functional activity of MOR can be correlated to cAMP levels (see 
Introductory Chapter 1). Similarly to the G protein activation assay, tianeptine showed full 
agonism at the mMOR with an EC50 of 1.03 ± 0.10 µM (Figure 5A), as well as at the mDOR 
with an EC50 of 9.46 ± 1.34 µM (Figure 5B). Again, there was no agonist activity at the rKOR 
(Figure 5C). As a further measure of opioid activity, naltrexone (an MOR antagonist) dose- 
 
Figure 5. Tianeptine is a Full Agonist at the Rodent Opioid Receptors. mMOR (A), mDOR (B), or rKOR (C) were 
co-expressed with with GαoB, β1, γ2, and CAMYEL (cAMP sensor using YFP-Epac-RLuc) to assay cAMP 
inhibition. Curves represent the average of n ≥ 3, with error bars representing ± SEM. 
 
dependently inhibited the agonist signal from tianeptine, showing the specificity of the signal 
measured in the cells as belonging to mMOR (Figure 6A). A similar experiment was performed 
for mDOR, and TIPP-psi (a DOR antagonist) dose-dependently inhibited the agonist signal from 
tianeptine (Figure 6B). There are numerous reports from preclinical models that KOR 



























































































































antagonists show antidepressant actions.34,35 In order to rule out that the antidepressant effects of 
tianeptine are not in fact mediated through KOR antagonism, tianeptine was measured for its 
ability to dose-dependently inhibit the signal from KOR agonist U-50,488 (Figure 6C). 
Tianeptine was unable to inhibit the agonist signal from U-50,488, showing that tianeptine 
neither binds nor has any functional activity at this receptor through traditional mechanisms.  
 
Figure 6. Antagonist Profiles of Tianeptine at the Rodent Opioid Receptors. mMOR (A), mDOR (B), or rKOR (C) 
were co-expressed with with GαoB, β1, γ2, and CAMYEL to assay inhibition of cAMP inhibition. Naltrexone (A) or 
TIPP-psi (B) dose-dependently inhibit the cAMP inhibition of both tianeptine and the respective control. C. 
Tianeptine is unable to dose-dependently inhibit the signal from control U-50,488. Curves represent the average of n 
≥ 3, with error bars representing ± SEM. 
 
Although the in vitro results from the rodent receptors was promising, it was also 
important to study the effects of tianeptine at human receptors, not only for comparison with the 
human binding data obtained but also because of its use in humans currently. At the human 
MOR (hMOR), tianeptine again showed full agonism with an EC50 = 194 ± 70 nM for G protein 
activation (Figure 7A). This value very closely matches the binding affinity measured at the 
hMOR, suggesting high internal correlation between the different data sets. While tianeptine was 
also a full agonist at the human DOR (hDOR) for G protein activation, it showed much weaker 
potency (EC50 = 37.4 ± 11.2 µM, Figure 7B) in comparison to the mouse isoform. Therefore, 
although the selectivity for MOR in mouse is only 20-fold over DOR, it is close to 200-fold in 
humans. Given the low potency of tianeptine at hDOR, it seems unlikely to play a large role in 
its antidepressant and neurorestorative actions, though this might not be the case in mouse. Not 
surprisingly, tianeptine showed no agonist activity at the human KOR (hKOR, Figure 7C). As 
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before, tianeptine was measured for its agonist activity in the cAMP inhibition assay. At the 
hMOR, tianeptine showed full agonism with similar potency to that observed in the G protein 
activation assay (EC50 = 151 ± 45 nM, Figure 8A). Tianeptine also showed full agonism at the 
hDOR (EC50 = 12.2 ± 5.3 µM, Figure 8B). There was also no agonist activity at the hKOR in 
this assay (Figure 8C). A summary of the functional potencies of tianeptine at the opioid 
receptors can be found in Table 2. 
 
Figure 7. Tianeptine is a Full Agonist at the Human Opioid Receptors. hMOR (A), hDOR (B), or hKOR (C) were 
co-expressed with with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the 
average of n ≥ 3, with error bars representing ± SEM. 
 
 
Figure 8. Tianeptine is a Full Agonist at the Human Opioid Receptors. hMOR (A), hDOR (B), or hKOR (C) were 
co-expressed with with GαoB, β1, γ2, and CAMYEL to assay cAMP inhibition. Curves represent the average of n ≥ 
3, with error bars representing ± SEM. 
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Table 2. Tianeptine Functional Activity at Opioid Receptors 
 EC50 (µM) 
Assay mMOR hMOR mDOR hDOR rKOR hKOR 
G Protein 0.64 ± 0.12 0.19 ± 0.07 14.5 ± 6.6 37.4 ± 11.2 X X 
cAMP 1.0 ± 0.1 0.15 ± 0.05 9.5 ± 1.3 12.2 ± 5.3 X X 
Data represent mean ± SEM (nM) of n ≥ 3 independent trials. “X” indicates not active. 
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 In a study on pentylenetetrazole-induced seizure in mice, tianeptine was found to delay 
the onset time of seizures, purportedly 
through the adenosine A1 receptor 
(A1R).36 To rule out this functional 
activity, we had tianeptine measured for 
functional activity using the FLIPR® 
calcium assay. We found no direct agonist or antagonist activity of tianeptine on this receptor 
(Table 3).  
Functional Activity of Tianeptine Metabolites. Tianeptine readily undergoes β-oxidation 
to provide metabolites MC5 (aminopentanoic acid side 
chain) and MC3 (aminopropanoic acid side chain). This 
metabolism results in tianeptine having a reported half-
life of about only 15 minutes, and dosing is required three 
times a day for effect.37,38 Interestingly, MC5 does retain 
most agonist activity at hMOR (EC50 = 454 ± 174 nM, 
Figure 9A) when measured for G protein activation, 
however there is no measurable activity at hDOR. MC3, 
on the other hand, shows only minimal agonist activity at 
hMOR (EC50 = 24.9 ± 12.6 µM, Figure 9A) and no 
activity at hDOR. These results suggest that when 
tianeptine is metabolized to MC5, there may still be some 
effects exerted on hMOR and that these effects are likely 
Table 3. Tianeptine Activity at the Adenosine A1 Receptor 
Tianeptine A1 Receptor 
% Activation (10 µM) -0.9 ± 0.7 
% Activation (1 µM) -0.7 ± 2.2 
% Inhibition (10 µM) 1.0 ± 1.4 
% Inhibition (1 µM) -13.6 ± 2.4 
Data represent mean ± SEM (%) of n = 2 independent  
experiments. Data obtained by GenScript USA Inc. 
	
Figure 9. Agonist Activity of Tianeptine 
Metabolites at the Human Opioid 
Receptors. hMOR (A) or hDOR (B) 
were co-expressed with with GαoB-
RLuc8, β1, and mVenus-γ2 to assay G 
protein activation. Curves represent the 
average of n ≥ 3, with error bars 
representing ± SEM. 
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not modulated by the actions of the next metabolite, MC3. As expected, neither compound 
showed any activity at hKOR (data not shown). 
 
Figure 10. Agonist Activity of Tianeptine Metabolite MC5 at the Mouse Opioid Receptors. mMOR (A) or mDOR 
(B) were co-expressed with with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent 
the average of n = 3, with error bars representing ± SEM. 
 
MC5 was measured also for functional activity in the G protein activation assay at mouse 
MOR (mMOR). These measures will undoubtedly correlate more accurately with the future in 
vivo data than will the human in vitro data measured above. MC5 was active at the mMOR with 
an EC50 = 1.7 ± 0.9 µM (Figure 10A) and at the mDOR though with much weaker potency 
(EC50 > 20 µM, Figure 10B) in comparison to tianeptine. 
Measuring Other Signaling Pathways. Given the in vitro pharmacology results at the 
MOR, we were interested in studying other signaling 
pathways further. In particular, GPCRs signal through G 
protein-dependent pathways (i.e. G protein activation and 
cAMP inhibition), as well as G protein-independent 
pathways (i.e. arrestin). There are an increasing number of 
reports suggesting that G protein biased agonists may avoid 
some unwanted side effects from opioid signaling. In 
particular at the MOR, a G protein biased agonist may have 
analgesic properties without respiratory depression or constipation (see Chapter 1 for further 
A. B. 















































Figure 11. Tianeptine Fully 
Recruits Arrestin. hMOR was co-
expressed with Rluc8-arrestin3-Sp1, 
mem-linker-citrine-SH3, and GRK2. 
Data represent mean ± SEM of n = 




discussion),39 while compounds with balanced signaling may have lower tolerance build-up and 
abuse potential.40,41 As an atypical antidepressant, it is possible that the unique actions of 
tianeptine are due to the fact that it is a G protein biased MOR agonist. In fact, in combination 
with morphine, tianeptine has been shown to reduce tolerance and physical dependence42 while 
also preventing respiratory depression43, suggesting the possibility of functional selectivity. To 
measure the arrestin recruitment from tianeptine, the BRET GAP43 translocation assay was used 
(see Chapter 1 for further discussion).44 Interestingly, in this assay, tianeptine was able to recruit 
arrestin fully, suggesting that it is an unbiased ligand (Figure 11).  
To confirm these 
arrestin results, tianeptine 
was measured for its ability 
to cause receptor 
internalization. Recruitment 
of arrestin typically leads to 
receptor internalization45, 
so in this way receptor 
internalization can act as a 
“downstream” measure of arrestin activity. Using immunofluorescence as a qualitative measure 
of receptor internalization, tianeptine was found to internalize the MOR to the same extent as 
unbiased control ligand DAMGO (10 µM treatments, Figure 12A). Quantification of the 
population of cells internalizing receptors for a given field of view confirms that tianeptine 
shows high receptor internalization (Figure 12D), similarly to DAMGO (Figure 12B). The 
combined arrestin activity and receptor internalization measured for tianeptine does suggest that 
	
Figure 12. Tianeptine Causes Receptor Internalization. A. Tianeptine shows 
similar levels of receptor internalization when compared to control DAMGO 
in mMOR-CHO cells. Representative immunofluorescence images shown. 
B. Quantification of A. Compounds were used at 10 µM. On average, 30-60 
cells were analyzed for each treatment per experiment. Data represent mean 
± SEM of n = 3 independent experiments.	
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a more complex mechanism may be working to provide the unique behavioral effects known for 
this drug. 
In Vitro Pharmacokinetic Data on Tianeptine and MC5. Pharmacokinetic studies were 
performed with MC5 in the plasma (Figure 13C) and the brain (Figure 13D) in C57BL/6 mice 
alongside tianeptine at 30 mg/kg (intraperitoneal administration, i.p.). Tianeptine quickly peaked 
within five minutes and was nearly eliminated after 1 hour. In contrast, MC5 gradually reached a 
higher peak concentration than tianeptine and had a significantly longer half-life in comparison 
to tianeptine; it was detectable in the brain tissue for at least 8 hours, leading to a higher overall 
exposure (quantified by area under the curve). Therefore, given the short half-life of tianeptine, it 
seems likely that the metabolite MC5 might play a role in the behavioral effects observed for 
tianeptine. 
 
Figure 13. Pharmacokinetic Effects of Tianeptine and MC5 Metabolite. Plasma (A) and brain (B) concentrations ± 
SD of tianeptine and MC5 in C57BL/6 mice following a single administration of tianeptine (30 mg/kg ip). 
 
Discussion 
Mechanism of Action. These results describe the first identification of the primary 
molecular target of the antidepressant tianeptine as the MOR (and possibly the DOR). Given the 
heavy focus on the glutamatergic modulation of tianeptine in understanding its mechanism of 
action, the observed MOR agonism was surprising. Through our studies, we confirmed that 






















































tianeptine has no affinity for NMDA, AMPA, or kainate receptors, as well as the metabotropic 
glutamate receptors (mGluR1a, 2, 4, 5, 6, 8). It seems more likely, therefore, that tianeptine’s 
modulation of the glutamatergic system is indirect, at least in the concentration range measured 
(< 10 µM). Current dosing of tianeptine in humans (12.5 mg) or in rodents (10 mg/kg/day) leads 
to a 1 µM or 10 µM plasma concentration, respectively37,38, which does suggest that the 
concentration range of tianeptine is sufficient enough to activate the receptor system since 
potencies at the MOR were ~0.2-1 µM and at the DOR were ~12-34 µM. Based on this 
evidence, it is possible that MOR activation is the primary molecular event leading to 
tianeptine’s modulation of the glutamatergic system and subsequent antidepressant/anxiolytic 
effects. 
In order to understand better how tianeptine modulates the glutamatergic system via 
MOR, it is helpful to look to its actions in specific populations of neurons and synapses. MOR is 
widely expressed in the hippocampus, particularly on interneurons46, and is already recognized to 
modulate glutamatergic neurons.31 For example, MOR activation is known to decrease protein 
kinase A activity in dentate granule cells (rat), which leads to decreased NMDA receptor 
phosphorylation and activity, which could account for the corrective effects of tianeptine on 
stress-induced increases in NMDA receptor signaling.47 Additionally, one study suggests that 
acute morphine treatment activates CaMKII in the rat hippocampus48, which agrees with several 
other reports connecting the importance of the AMPA receptor subunit GluR1 phosphorylation 
(Ser831) in mediating the antidepressant effects of tianeptine. Therefore, activation of MORs (or 
DORs) in a hippocampal inhibitory interneuron would likely decrease their activity (GABA 
release) through hyperpolarization, leading to disinhibition of the CA1 glutamatergic neurons 
and enhanced excitability and synaptic plasticity (Figure 14), consistent with reports on  
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Figure 14. Potential Modulation of the Glutamateric System by Tianeptine in the Hippocampus. A. GABAergic 
interneurons exert an inhibitory signal on neighboring glutamatergic neurons through activation of GABA receptors 
in a drug naïve state. B. In the presence of tianeptine, activation of MOR hyperpolarizes the interneuron, causing a 
reduction of GABA release, and disinhibiting the glutamate signaling. This disinhibition increases Ca2+ influx 





































tianeptine’s effects in the CA1.6 These effects make sense, as the disinhibited glutamate 
signaling increases Ca2+ influx through NDMA receptors, activating CaMKII and increasing 
phosphorylation of AMPA receptor GluR1 subunits (Figure 14). Interestingly, chronic exposure 
to morphine leads to decreased CaMKII activity in the hippocampus46, as well as induced 
dephosphorylation-dependent internalization of AMPA receptors.49 These effects are in contrast 
to tianeptine, which retains enhanced AMPA receptor-mediated excitatory post-synaptic currents 
(ESPCs) and phosphorylation of GluR1 subunits even after chronic treatments.24,27 Therefore, 
the long-term effects in the hippocampus of tianeptine in comparison to classical opioids like 
morphine appear to be distinct, suggesting that there may be some divisions between the 
different classes of opioids. Although it is still unclear how these distinctions emerge, 
tianeptine’s unique long-term effects may explain its reduced tolerance development in 
depressed human patients.50 
As an opioid agonist, it is also important to understand how tianeptine might modulate 
the dopamine rewards pathway. It is well-known that activation of opioid receptors in the ventral 
tegmental area (VTA) and nucleus accumbens (NAc) can lead to increased dopamine signaling, 
which mediates reward responses to positive stimuli such as food or drugs of abuse. It makes 
sense then that dysregulation of these systems might play a role in mediating depressive states. 
This hypothesis is supported by reports of decreased NAc activity in depressed individuals.51,52 
Further, acute and chronic treatment of tianeptine elevates extracellular dopamine levels in both 
the NAc and prefrontal cortex.29,53 Tianeptine’s MOR (or DOR) activity combined with its lack 
of affinity for dopamine transporters or receptors suggests a more remote disinhibition of VTA-
NAc dopaminergic projections via MOR-mediated inhibition of GABAergic inhibitory 
interneurons in the VTA, just like classical opioids (Figure 15A). The increased inhibitory 
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activity of D2 receptors on the GABAergic neuron in the NAc decreases intracellular Ca2+ 
levels, leading to lessened CaMKII and PKC activity and ultimately decreased phosphorylation 
of AMPA receptor subunits GluR1 and GluR2. These subunits, however, appear to be 
differentially regulated by phosphorylation, where decreased phosphorylation increases 
trafficking of synaptic GluR2 and decreases GluR1 on the cell surface.24,54,55 This modulation of 
calcium levels in the NAc helps to normalize AMPA receptor signaling, which initiates long-
lasting antidepressant effects and the reward response. Interestingly, NMDA antagonists like 
ketamine act similarly in the NAc.56 This disinhibition of dopaminergic neurons in the VTA may  
 
Figure 15. Potential Modulation of the Mesolimbic Rewards Pathway by Tianeptine. A. Activation of MOR on 
GABAergic interneurons in the VTA by tianeptine causes increased release of dopamine in the ventral tegmental 
area. B. Dopamine release is also possible more remotely in the nucleus accumbens. Activation of inhibitory D2 
receptors (or activation of MORs directly) leads to decreased Ca2+ signaling (via glutamate signaling or NMDA 
receptor activity) via hyperpolarization, leading to a reward response. Reduced Ca2+ signaling also decreases 
CaMKII activity on phosphorylation of AMPA receptor subunits, resulting in enriched synaptic GluR2 and depleted 
synaptic GluR1, inducing LTP of the reward response. It is unclear whether these effects modulate other 
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also activate neighboring GABAergic neurons in the NAc, thus further modulating AMPA 
receptor activity in an area of the brain distinct from the hippocampus (Figure 15B). These 
effects are also competing with excitatory glutamateric inputs from other regions of the brain, 
like the hippocampus, and implicate the NAc as an important hub for mediating the mood-related 
signaling from various pathways. Therefore, the opioid-mediated glutamate receptor signaling in 
this region is likely connected with reward and antidepressant responses.31,57,58 The rewarding 
effects of tianeptine and other opioids are further confounded by the endogenous opioid release 
taking place simultaneously (Figure 15C). Exogenously administered opioids are known to have 
antidepressant effects, such as β-endorphin, which rapidly improved the depressive symptoms of 
MDD in the clinic.59 Additionally, untreated patients with MDD were shown to have decreased 
endogenous opioid release in response to social rejection and after the rewarding stimulus of 
social acceptance60, implicating an important role of opioids in modulating mood disorders. The 
therapeutic effects of tianeptine and other antidepressants may be compensating for reduced 
signaling of the endogenous opioid system and diminished natural reward response. 
Preliminary In Vivo Results Implicate MOR in Behavioral Effects of Tianeptine and 
MC5. In vivo characterization of both tianeptine and its metabolite MC5 are currently being 
pursued in the laboratory of Professor Rene Hen at Columbia University using both wildtype and 
MOR deficient mice. Our studies are utilizing the forced swim test for depression, where a 
decrease in immobility is correlated to antidepressant function,61 and the elevated plus maze 
(EPM) is being used to assess the anxiolytic effects of tianeptine. In this assay, anxious mice will 
be less likely to explore the open arms of an elevated plus; therefore, a reduction in anxiety can 
be correlated with more exploration of the open arms.62 In preliminary experiments, tianeptine is 
ineffective at decreasing immobility in MOR-deficient littermates in comparison to wildtype 
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mice, indicating that the antidepressant effects of tianeptine are dependent upon MOR. 
Analogous results are being found in the EPM, suggesting an MOR dependence in the anxiolytic 
effects of tianeptine, as well. Tianeptine is also showing positive effects in assays indicative of 
MOR agonist activity63–67, including hypophagia (reduced intake of food), analgesia, and 
hyperactivity, which are all reduced in MOR-deficient mice. These preliminary results indicate 
that both the antidepressant and opioid-like behaviors of tianeptine are likely mediated by MOR. 
As a first measure of target-specific behaviors from tianeptine, there is further evidence that 
MOR should be explored as a serious lead for new antidepressants.  
We are also studying the behavioral effects of MC5 in both wildtype and MOR deficient 
mice. Similar to tianeptine, MC5 is showing antidepressant effects in the forced swim test that 
seem to be absent in the MOR deficient littermates, suggesting that the effects of the forced 
swim test are likely mediated by MOR for both tianeptine and MC5. Although initially puzzled 
by how a drug with such a short half-life can cause remarkable effects in preclinical and clinical 
models, the observation of antidepressant effects from MC5, which has a much longer half-life 
and duration in the plasma and brain, indicates an important role in the mechanism of action of 
tianeptine. In the forced swim test for instance, which is performed 60 minutes after drug 
administration, antidepressant effects are evident from both tianeptine and MC5. Given the PK 
results from tianeptine, however, it seems unlikely that any tianeptine is present at this time, 
indicating that MC5 is likely mediating the behavioral effects at these later time points. 
Tianeptine dosing can thus provide acute effects while MC5 continues signaling through the 
same receptor target, thus allowing antidepressant effects to continue.  
Goals for Structure Activity Relationship (SAR) Studies. Through modifications of the 
tianeptine scaffold, two main goals can be addressed regarding the functional activity. First, with 
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a potency of approximately 200 nM at MOR, tianeptine is not a particularly potent compound, 
and therefore new analogs should be identified with superior potency at MOR. Second, as a 
therapeutic, tianeptine does not have ideal pharmacokinetic properties (see PK results above). 
Therefore, in theory, an analog that is similarly potent to tianeptine but is less susceptible to 
metabolism may be a superior therapeutic that would only require a once-daily dose. Using a 
streamlined synthetic strategy, with the help of Andrew Kruegel and Dr. Adam Henke, over 100 
tianeptine analogs have been synthesized to date that explore the regions in the scaffold that are 
important for MOR and DOR activity. A full study of the analogs synthesized and their 
relationship to our synthetic goals has been reported.68 
Abuse Potential of Tianeptine. Although the evidence is clear that tianeptine acts as an 
MOR agonist, there are some obvious concerns with developing a drug with opioid properties for 
treating depression. Opioids, such as morphine and oxycodone, are prescribed everyday to treat 
pain, but the medications also have extremely high abuse potential. It is estimated that in 2012, 
upwards of 12.5 million Americans abused prescription opioids69, and recent tragedies like the 
death of pop star Prince make consumers and drug developers alike hesitant to support the 
expansion of the opioid market. Tianeptine, however, has been widely used in Europe, Asia, and 
Latin America for decades now, so there is strong evidence to suggest that the abuse potential is 
low. In fact, after decades of usage, there are only a few isolated case studies on addiction or 
withdrawal symptoms associated with tianeptine.32,70–74 Further, in comparison to opioids of high 
abuse potential, like morphine, oxycodone, and fentanyl, tianeptine is orders of magnitude less 
potent. Therefore, the likelihood of tianeptine being abused is low, as evidence indicates that 
therapeutic effects on depression do not require high potency activity at MOR. There is also 
reason to believe that not all opioids are signaling in the same way (i.e. tianeptine versus 
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morphine), so it is possible that something special about tianeptine’s signaling provides 
antidepressant effects with lower risk of addiction. 
 
Conclusions 
 Herein we describe for the first time a distinct molecular target accounting for the 
numerous and unique properties of the atypical antidepressant tianeptine. Given the known 
modulation of MOR activation in several areas of the brain in a manner consistent with 
beneficial effects on mood, it is completely plausible that MOR represents the initial molecular 
signaling event for tianeptine. Through careful in vitro experimentation, tianeptine was found to 
be a full agonist at the MOR (and DOR), which are being further supported through in vivo 
studies. These studies provide the first true indication of MOR as a real target for treating 
depression, and the new tools developed here will allow further study into this new mechanism. 
Given the high complexity with which tianeptine modulates signaling in the brain (broad 
expression of opioid receptors in distinct brain regions, some opposing effects in different 
regions/cell types, interconnection of brain signaling through direct and indirect pathways that 
are not fully understood), future studies will aim to identify the particular circuits in the brain 
responsible for tianeptine’s effects, which will hopefully further distinguish this opioid from 
others and allow the development of safe and effective therapeutics. 
 
Experimental 
Preparation of MC3 and MC5 Metabolites (performed by Andrew Kruegel) 
General Considerations. Reagents and solvents were obtained from commercial sources 
and were used without further purification unless otherwise stated (including anhydrous 
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solvents). All reactions were performed in flame-dried glassware under an argon atmosphere 
unless otherwise stated and monitored by TLC using solvent mixtures appropriate to each 
reaction. All column chromatography was performed on silica gel (40-63µm). Nuclear magnetic 
resonance spectra were recorded on Bruker 400 or 500 MHz instruments as indicated. Chemical 
shifts are reported as δ values in ppm referenced to CDCl3 (1H NMR = 7.26 and 13C NMR = 
77.16) or CD3OD (1H NMR = 3.31 and 13C NMR = 49.00). Multiplicity is indicated as follows: 
s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); ddd (doublet of doublet of 




yl)amino)propanoate (1a). To a mixture of 3,11-dichloro-6-methyl-6,11-
dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (328 mg, 1.00 mmol) and β-alanine ethyl ester 
hydrochloride (184 mg, 1.20 mmol) was added nitromethane (2.0 mL) followed by triethylamine 
(335 µL, 243 mg, 2.40 mmol). The resulting mixture was warmed to 60 °C, stirred for 1 h, and 
then concentrated to give a sticky, colorless solid. This material was purified directly by column 
chromatography (20:1 CH2Cl2:Et2O, 3 column volumes → 7:3 CH2Cl2:Et2O, 3 column volumes) 
to provide the pure ester 1a as an extremely viscous, colorless oil (393 mg, 96%). 1H NMR (400 
MHz, CDCl3) δ 7.96 – 7.94 (m, 1H), 7.49 – 7.43 (m, 2H), 7.41 – 7.33 (m, 3H), 7.32 – 7.26 (m, 
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1H), 5.05 (s, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.39 (s, 3H), 2.82 – 2.69 (m, 2H), 2.60 – 2.40 (m, 
3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.7, 140.6, 138.8, 138.6, 136.9, 
134.5, 132.4, 131.1, 129.9, 129.5, 128.5, 128.3, 128.1, 65.9, 60.7, 43.6, 38.6, 34.9, 14.3. 
ethyl 5-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)pentanoate (1b). To a mixture of 3,11-dichloro-6-methyl-6,11-
dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (328 mg, 1.00 mmol) and ethyl 5-aminovalerate 
hydrochloride (218 mg, 1.20 mmol) was added nitromethane (2.0 mL) followed by triethylamine 
(335 µL, 243 mg, 2.40 mmol). The resulting mixture was warmed to 60 °C, stirred for 1 h, and 
then concentrated to give a sticky, colorless solid. To this material was added water (20 mL) and 
the mixture was extracted with Et2O (2 x 20 mL). The combined organics were washed with 
water (10 mL) and 10% NH4OH (10 mL), dried over Na2SO4, and concentrated to give a 
viscous, pale-yellow oil. This material was purified by column chromatography (40:1 
CH2Cl2:Et2O, 4 column volumes → 20:1 CH2Cl2:Et2O, 2 column volumes → 7:3 CH2Cl2:Et2O, 2 
column volumes) to provide the pure ester 1b as an extremely viscous, nearly colorless oil (256 
mg, 59%). 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 2.1 Hz, 1H), 7.48 – 7.33 (m, 5H), 7.32 – 
7.27 (m, 1H), 5.00 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.36 (s, 3H), 2.48 (t, J = 7.0 Hz, 2H), 2.27 (t, 
J = 7.3 Hz, 2H), 2.08 (br s, 1H), 1.70 – 1.58 (m, 2H), 1.58 – 1.44 (m, 2H), 1.24 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 173.6, 140.5, 138.7, 137.0, 134.4, 132.3, 131.3, 130.3, 
129.5, 128.6, 128.2, 128.1, 66.3, 60.4, 47.8, 38.8, 34.2, 29.6, 22.8, 14.4. 
3-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)propanoic acid hydrochloride (2a = MC3). To ester 1a (364 mg, 0.890 mmol) was 
added 0.5 M aqueous HCl (20 mL), and the mixture was stirred vigorously for 4.5 h at 80 °C. 
The solution was then concentrated in vacuo with heating to provide a foamy, colorless glass. In 
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order to remove residual HCl (causes esterification during NMR in CD3OD), this residue was re-
dissolved in a small quantity of water and concentrated again in vacuo with heating. This 
procedure was repeated once more to provide the pure hydrochloride salt 2a, free from residual 
HCl, as a foamy, colorless glass (364 mg, 98%, white solid when crushed). 1H NMR (400 MHz, 
CD3OD) δ 8.09 (d, J = 2.2 Hz, 1H), 7.94 (d, J = 8.3 Hz, 1H), 7.87 (dd, J = 8.2, 2.2 Hz, 1H), 7.77 
(dd, J = 7.8, 1.4 Hz, 1H), 7.68 – 7.63 (m, 1H), 7.60 (dd, J = 8.1, 1.3 Hz, 1H), 7.49 (td, J = 7.6, 
1.4 Hz, 1H), 6.02 (s, 1H), 3.33 – 3.26 (m, 1H), 3.28 (s, 3H), 3.17 – 3.06 (m, 1H), 2.83 – 2.68 (m, 
2H); 13C NMR (101 MHz, CD3OD) δ 174.2, 142.3, 142.1, 139.0, 137.1, 135.1, 134.7, 133.6, 
129.5, 129.3, 128.3, 127.8, 127.4, 68.1, 44.3, 39.4, 30.7. 
5-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)pentanoic acid hydrochloride (2b = MC5). To ester 1b (243 mg, 0.556 mmol) was 
added 0.5 M aqueous HCl (13 mL), and the mixture was stirred vigorously for 3 h at 80 °C. The 
solution was then concentrated in vacuo with heating to provide a foamy, nearly colorless glass. 
In order to remove residual HCl (causes esterification during NMR in CD3OD), this residue was 
re-dissolved in a small quantity of water and concentrated again in vacuo with heating. This 
procedure was repeated once more to provide the pure hydrochloride salt 2b, free from residual 
HCl, as a foamy, nearly colorless glass (243 mg, 98%, off-white solid when crushed). 1H NMR 
(400 MHz, CD3OD) δ 8.09 (d, J = 2.1 Hz, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.87 (dd, J = 8.2, 2.2 
Hz, 1H), 7.74 (dd, J = 7.8, 1.4 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.58 (dd, J = 8.1, 1.3 Hz, 1H), 7.49 
(td, J = 7.6, 1.4 Hz, 1H), 5.98 (s, 1H), 3.24 (s, 3H), 3.00 (ddd, J = 12.3, 9.6, 5.9 Hz, 1H), 2.86 
(ddd, J = 12.3, 9.6, 6.3 Hz, 1H), 2.31 (t, J = 7.0 Hz, 2H), 1.82 – 1.64 (m, 2H), 1.64 – 1.54 (m, 
2H); 13C NMR (101 MHz, CD3OD) δ 176.7, 142.5, 141.9, 138.8, 137.1, 135.2, 134.8, 133.5, 
129.4, 129.2, 128.5, 127.9, 127.1, 67.6, 48.1, 39.7, 33.8, 26.4, 22.7. 
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Biology 
Materials: BRET. HEK-293T cells were obtained from the American Type Culture 
Collection (Rockville, MD) and were cultured in a 5% CO2 atmosphere at 37 oC in Dulbecco’s 
Modified Eagle Medium (high glucose #11965; Life Technologies Corp.; Grand Island, NY) 
supplemented with 10% FBS (Premium Select, Atlanta Biologicals; Atlanta, GA) and 100 U/mL 
penicillin and 100 µg/mL streptomycin (#15140, Life Technologies). 
 DNA Constructs. The mouse MOR (mMOR), the mouse DOR (mDOR), and the rat 
KOR (rKOR) were provided by Dr. Lakshmi Devi at Mount Sinai Hospital. The hMOR, hDOR, 
hKOR, hα2AR, hα2BR, hα2CR and GRK2 were obtained from the Missouri S&T Resource Center. 
The human G protein constructs used here have been previously described and were provided by 
C. Galés or were obtained from the Missouri S&T Resource Center unless otherwise noted.12,13 
The G proteins used included untagged GαoB (GαoB); GαoB with Renilla luciferase 8 (RLuc8) 
inserted at position 91 (GαoB-RLuc8); Gβ1 (β1); untagged Gγ2 (γ2); Gγ2 which we fused to the 
full-length mVenus at its N-terminus via the amino acid linker GSAGT (mVenus-γ2). The 
plasmids employed in the arrestin recruitment assay, RLuc8-arrestin3-Sp1 and mem-linker-
citrine-SH3, were synthesized in-house as previously described.44 YFP-Epac-RLuc (CAMYEL) 
was obtained from ATCC (no. MBA-277).75 All constructs were sequence-confirmed prior to use 
in experiments. 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
106 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg MOR/DOR/KOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; cAMP Inhibition: 1.25 µg MOR/DOR/KOR, 1.25 µg 
GαoB, 1.25 µg β1, 1.25 µg γ2, 10 µg CAMYEL; BRET GAP43 Translocation: 2 µg hMOR, 0.25 
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µg Rluc8-arrestin3-Sp1, 5 µg mem-linker-citrine-SH3, 5 µg GRK2. Cells were maintained in the 
HEK-293T media described above. After 24 hours the media was changed, and the experiment 
was performed 24 hours later (48 hours after transfection). 
 BRET. Transfected cells were dissociated and re-suspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were re-
suspended in PBS. For agonist experiments, after 5 minutes, 5 µM of the luciferase substrate 
coelenterazine H was added to each well. After 5 minutes, ligands were added and the BRET 
signal was measured 5 minutes later on a PHERAstar FS plate reader. For cAMP, cells were first 
incubated with forskolin (1 µM) for 5 minutes prior to coelenteratzine h addition. For antagonist 
competition experiments, cells were pre-incubated with the antagonist at varying concentrations 
for 30 minutes. Coelenterazine H (5 µM) was then added to each well for 5 minutes. Following 
coelenterazine H incubation, a fixed concentration of the reference agonist (5x EC50) was added, 
and the BRET signal was measured at 30 minutes on a PHERAstar FS plate reader. The BRET 
signal was quantified by calculating the ratio of the light emitted by the energy acceptor, mVenus 
(510-540 nm) or citrine (510-540 nm), over the light emitted by the energy donor, RLuc8 (485 
nm). This drug-induced BRET signal was normalized using the Emax of [D-Ala2, N-Me-Phe4, 
Gly-ol5]-enkephalin (DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-50,488 as the maximal 
response at MOR, DOR, and KOR respectively. Dose response curves were fit using a three-
parameter logistic equation in GraphPad Prism 6. 
Human Ki Determination. Binding constants (Ki) at the human opioid receptors were 
generously determined using radioligand displacement experiments by the National Institute of 
Mental Health's Psychoactive Drug Screening Program, Contract #HHSN-271-2008-00025-C 
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(NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of 
North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda, MD, USA. 
For experimental details please refer to the PDSP website (https://pdspdb.unc.edu/pdspWeb/). In 
all cases, the reported Ki values are the average of 3 or more independent experiments, each run 
with triplicate wells for each ligand concentration. 
 Immunofluorescence. mMOR-CHO cells were grown in Ham’s F-12 supplemented with 
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin, and 200 µg/mL hygromycin B 
prior to the experiment. The cells were starved with serum free media for 3-5 hours before 
treatment with drugs (10 µM) for 5 min or 1 hr. Cells were then fixed with 4% formaldehyde in 
PBS, washed with PBS, permeabilized (0.25% Triton X-100 in PBS), washed, blocked (2% 
glycine, 2% bovine serum albumin in 50 mM NH4Cl) for 30 min at 37 oC and incubated 
overnight with anti-MOR antibodies (1:200 in blocking solution; Abcam #ab134054) at 4 oC. 
Cells were then washed 5X with PBS, blocked again for 30 min at 37 oC, and incubated with a 
mixture of anti-rabbit Alexa Fluor® 594 secondary antibody (1:1000 in blocking solution; Cell 
Signaling #8889) and Hoechst stain (1:10,000). The cells were then washed 5X in PBS and 
imaged on a Leica DMI4000B microscope.  
Pharmacokinetics. The pharmacokinetic study of tianeptine was conducted by Sai Life 
Sciences Limited (Hinjewadi, India). A group of 24 male C57BL/6 mice was administered 
tianeptine as a solution formulation in normal saline intraperitoneally at a dose of 30 mg/kg. 
Blood samples (approximately 60 µL) were collected under light isoflurane anesthesia from the 
retro-orbital plexus at 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h. Plasma samples were separated by 
centrifugation of whole blood and stored below -70 ºC until analysis. Immediately after 
collection of blood, brain samples were collected from each mouse at 0.08, 0.25, 0.5, 1, 2, 4, 8 
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and 24 h (3 mice per time point). Brain samples were homogenized using ice-cold phosphate-
buffered saline (pH 7.4), and homogenates were stored below -70 ºC until analysis. Total brain 
homogenate volume was three times the tissue weight. All samples were processed for analysis 
by protein precipitation using acetonitrile and analyzed to determine the concentrations of both 
tianeptine and MC5 by a fit-for-purpose LC/MS/MS method (lower limit of quantification = 2.02 
ng/mL in plasma and 1.01 ng/mL in brain). Pharmacokinetic parameters were calculated using 
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Chapter 3 – Exploring the Biological Activity of the Mitragyna speciosa 
Alkaloids at the Opioid Receptors 
 
Introduction 
Mitragyna speciosa (Figure 1) is a psychoactive plant known as “kratom” in Thailand or 
"biak biak" in Malaysia. It has been widely used by humans in Southeast Asia for many centuries 
to treat a variety of ailments, particularly among farm populations where it is used traditionally 
to combat fatigue and increase productivity.1 Kratom has additionally been used for centuries in 
socioreligious ceremonies, lending its name potentially from “Mithraic cults,” an ancient source 
of spiritual transcendence.2 The plant 
material is typically consumed as a tea, 
chewed directly, or smoked. The effects of 
kratom can vary depending on the amount 
consumed. The stimulating effects of 
kratom can be achieved at low doses, 
while more opioid-like effects 
predominate at higher doses. The plant, 
therefore, has been used as a general 
analgesic as well as a substitute for opium 
due to its euphoric and sedative effects. It 
is even used as a method to treat opioid 
withdrawal. Further, kratom has been used 
in the treatment of other conditions, such as fever, cough, diarrhea, and depression. Additionally, 
there is a precedent for recreational use and abuse of the plant, which has likely contributed to 
legal control of Mitragyna speciosa in both Thailand and Malaysia today. Interestingly, however, 
 
Figure 1. Leaves and fruiting bodies of Mitragyna 
speciosa and chemical structures of notable alkaloids.17 
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the origins of this kratom ban might not be as straightforward. “The Kratom Act” banned kratom 
use in Thailand in 1943 not due to its psychoactive properties (that would come later in the “Thai 
Narcotics Act” of 1979) but because the general population preferred cheaper kratom over 
heavily taxed opium, which was negatively impacting the government’s income.3 The plant does, 
however, remain uncontrolled outside its native regions.1,4–7 
 Given the extensive medicinal use of Mitragyna speciosa, there has been much study on 
the molecular constituents responsible for its psychoactive effects, and to date more than 40 
unique indole alkaloids having been identified in the plant.1,4,5,8 Mitragynine (Figure 1) has been 
generally acknowledged as the primary indole alkaloid constituent of Mitragyna speciosa, which 
accounts for up to 66% by mass of crude alkaloid extracts.4 Paynantheine, speciogynine, and 
speciociliatine have been identified as the other major alkaloids in the plant (Figure 1).4 Among 
the many different regional varieties of Mitragyna speciosa, the quantities of these major 
alkaloids, along with a wide variety of minor alkaloids, are considerably varied and can also vary 
depending on plant age. In interpreting the psychoactive effects of the plant, these considerations 
greatly complicate our understanding of which alkaloids are most important.1,4,5,8 Amongst the 
minor alkaloids, the oxidized mitragynine derivative 7-hydroxymitragynine (7-OH)9 (Figure 1) 
is most interesting due to its reported analgesic effects mediated through agonist activity at the 
mu-opioid receptor (MOR), which are known to exceed in potency those of the prototypical 
opioid agonist morphine.7,10 
 The mechanism of action of Mitragyna alkaloids has been studied both in vitro and in 
vivo. Takayama and coworkers, in particular, have published several studies indicating that the 
opioid receptor system is the primary mechanism for the psychoactive effects of these alkaloids. 
For instance, mitragynine and 7-OH both show nanomolar binding affinities for the MOR and 
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demonstrate functional activity in both ex vivo and in vivo studies.7,10 Guinea pig ilium, which is 
rich with MORs, was used to assess ex vivo functional activity of Mitragyna alkaloids, whereby 
MOR agonists can inhibit electrically induced twitching in the tissue. The alkaloids showed 
agonist properties in this assay.7,10 The antinociceptive effects (measured via the tail flick assay) 
of mitragynine and 7-OH have additionally been shown to be inhibited by the opioid antagonist 
naloxone in several rodent models, an indication of their agonist activity at the MOR.7,10,11 
Although there is evidence implicating the opioid receptor system in the analgesic effects of the 
Mitragyna alkaloids, specifically MOR, reports in the literature are conflicting. In a prominent 
study from the 1970s, mitragynine was found to induce behavioral effects in cats, and analgesic 
effects in rats, that were not reversed by treatment with nalorphine, an opioid antagonist.12 
Additionally, this study also found mitragynine to produce markedly less respiratory depression 
than the opium poppy-derived alkaloid codeine. Further, the biological activity of mitragynine is 
not exclusive to the opioid receptors. One report has shown mitragynine to bind to several non-
opioid CNS receptors, including the alpha-2 adrenergic receptor (α2R), adenosine A2a, dopamine 
D2, and the serotonin receptors 5-HT2C and 5-HT7, but no binding affinities were reported.13 The 
analgesic effects of mitragynine have also been shown to be inhibited not only by the α2R 
antagonist idazoxan, but also by the non-specific serotonin antagonist cyproheptadine, indicating 
that the notable biological activity of this alkaloid may be complex.14 
 Although the physiological in vivo and ex vivo tissue experiments (such as the ex vivo 
assay described above) are the only currently accessible methods to probe system level effects 
from compounds such as the Mitragyna alkaloids, these methods cannot provide molecular 
analysis of receptor activation and signaling. Given what the considerable number of conflicting 
reports suggests on the activity of Mitragyna alkaloids, it seems that such in vivo and ex vivo 
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assays still cannot solely substitute for studying receptor-level functionality in vitro. There have 
been recent studies on receptor-level functional activity for several synthetic oxidized 
mitragynine analogs in [35S]GTPγS binding assays using overexpressed cellular systems15, but 
no similar functional studies have been reported for mitragynine or for the other alkaloids in 
Mitragyna speciosa.16 This chapter will explore a systematic study of the Mitragyna alkaloids at 
the opioid receptors, assessing not only binding affinities but also receptor activation and other 
fundamental intracellular signaling pathways. Through thoughtful examination of the functional 
activity of these compounds, we bring a new perspective to the psychoactive properties of these 
compounds and highlight their further potential as novel therapeutics for pain and depression. 
Some of this work has been described in a recent publication.17 
 
Results 
 Biological Activity of Mitragyna Alkaloids at Rodent Opioid Receptors 
 Isolation of the Alkaloids From the Plant Material. The four major alkaloids of 
Mitragyna speciosa were isolated directly from the Thai strain of the plant, and 7-OH was 
prepared via photochemical 
oxidation of the major 
alkaloid mitragynine 
(performed by Andrew 
Kruegel).17 Only trace 
amounts of 7-OH could be 
detected in the extractions of the plant material (as observed by mass spectroscopy), and we were 
unable to isolate any of this alkaloid directly. Given these findings, it is unlikely that 7-OH is 
Table 1. Binding Affinity of Mitragyna Alkaloids at Mouse Receptors. 
 Ki (µM) 
Compound mMOR mKOR mDOR 
mitragynine 0.230 ± 0.047 0.231 ± 0.021 1.01 ± 0.05 
paynantheine 0.666 ± 0.083 0.888 ± 0.294 4.25 ± 0.73 
speciociliatine 0.0786 ± 0.0109 0.649 ± 0.169 1.16 ± 0.23 
speciogynine 0.578 ± 0.064 2.90 ± 0.49 7.95 ± 0.95 
7-OH 0.0366 ± 0.0041 0.132 ± 0.007 0.0906 ± 0.0085 




found as a major alkaloid from extractions of Mitragyna speciosa (although certainly amounts 
may vary between strains and batches), and it may therefore be inferred that it is not responsible 
for the psychoactive properties of the plant. Interestingly, we were able to convert a small 
amount of mitragynine into 7-OH simply using oxidation from the air in the presence of rose 
bengal (singlet oxygen generator), so it is possible that leaf batches exposed to sunlight for long 
periods of time may be able to produce measurable quantities of 7-OH in situ from mitragynine.  
Binding Affinity. In an attempt to determine the functional activity of the Mitragyna 
alkaloids at the opioid receptors, we first looked to study these natural products at the rodent 
receptors, as all previous studies were reported in animal tissues or cells. Using radioligand 
binding assays in chinese hamster ovary (CHO) cells stably expressing the murine MOR, DOR, 
or KOR, our collaborator Dr. Susruta Majumdar determined the binding affinity of all five 
Mitragyna alkaloids. All compounds bound to each opioid receptor to some degree, however 7-
OH showed the highest binding affinity for the opioid receptors with approximately 2.5- to 4-
fold selectivity for MOR over KOR and 
DOR (Table 1). These results were 
comparable with those reported in 
literature for 7-OH, but our affinities 
were much weaker for mitragynine at 
MOR and DOR7,10. We were therefore 
interested in measuring the functional 
activity of these alkaloids in cell-based 
assays. 
 
Figure 2. Agonist Activity of Mitragyna alkaloids and 7-
hydroxymitragyine (7-OH) at the mouse mu-opioid receptor 
(mMOR). mMOR was co-expressed with GαoB-RLuc8, β1, 
and mVenus-γ2 to assay G protein activation. 7-OH shows 
an EC50 = 38.3 ± 24.7 nM and EMax = 23% at mMOR. Curves 
represent the average of n ≥ 3, with error bars representing ± 
SEM. Positive control = [D-Ala2, N-Me-Phe4, Gly-ol5]-
enkephalin (DAMGO). 
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Functional Activity. Using BRET assays for G protein activation (see Chapter 1), we 
measured the agonist activity of all five Mitragyna alkaloids at the three opioid receptors. 
Interestingly, we found no measurable agonist activity of any of the five alkaloids at the three 
opioid receptors, with the exception of 7-OH, which showed partial agonism at both MOR and 
DOR (Figure 2 and Table 2, EC50 mMOR = 0.038 ± 0.025 µM (EMax = 23%); EC50 mDOR = 0.66 ± 
0.44 µM (EMax = 16%)). Given the known analgesic effects of mitragynine in animal models 
(mouse tail flick assay), we were surprised to observe no agonist activity from mitragynine itself.  
We next sought to 
measure the 
antagonist activity 
of these compounds 
at the rodent opioid 
receptors since we 
were unable to 
match the binding 
affinity of most alkaloids with agonist activity. Again the alkaloids paynantheine, speciociliatine, 
and speciogynine showed no antagonist activity at any of the opioid receptors (Table 2). When 
we measured the antagonism of mitragynine and 7-OH, however, we found that mitragynine was 
an antagonist at mMOR, while both mitragynine and 7-OH were antagonists at rKOR (Table 2). 
To further quantify the antagonism of mitragynine at MOR, we used Schild analysis to determine 
an A2 = 0.807 ± 0.573 µM (where log(Kd) = -pA2, an approximation of binding affinity, Kd) and 
a competitive mode of action based on the slope of the plot (Figure 3, slope = 1.23). While 
mitragynine may be a true antagonist at the mouse MOR, it is also possible that mitragynine 
 
Figure 3. Mitragynine is an antagonist at mMOR. mMOR was co-expressed with 
GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the 
average of n ≥ 3, with error bars representing ± SEM. A. Control agonist DAMGO 
was incubated with increasing concentrations of mitragynine. B. Schild plot of (A) 
reveals a competitive antagonist mode of action. 
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shows partial agonism that is below the detection limit of our functional assays. In this case, the 
antagonism of this very 
weak partial agonist could 
be detected at mMOR, as 
shown. This hypothesis also 
better explains the analgesic 
effects reported for 
mitragynine. Similarly, it is 
possible that low efficacy functional activity from the other three alkaloids, paynantheine, 
speciociliatine, and speciogynine, may be undetected in our assays and could therefore explain 
why the compounds bind the receptors but do not exhibit functional activity. 
We were particularly excited by the antagonism seen at rKOR by mitragynine and 7-OH. 
KOR antagonists are reported 
in animal models to have 
antidepressant effects and 
clinical trials are in the early 
stages for some known 
compounds.18–20 Therefore, 
mitragynine and 7-OH might 
have not only analgesic properties but also antidepressant effects, as well. To date, Mitragyna  
alkaloids had only been reported as KOR agonists21, based on assumptions from the in vivo data. 
These results represent the first study demonstrating functional activity at the KOR. 
Biological Activity of Mitragyna Alkaloids at Human Opioid Receptors 
Table 2. Functional Activity of Mitragyna Alkaloids at Mouse Receptors. 
 EC50 (EMax) or [IC50] (µM) 
Compound mMOR mKOR mDOR 
mitragynine A2 = 0.81 [> 10] X 
paynantheine X X X 
speciociliatine X X X 
speciogynine X X X 
7-OH 0.0383 ± 0.0247 
(23%) 
[> 10] 0.664 ± 0.435 
(16%) 
Data represent mean ± SEM (µM) of n ≥ 3 from G protein activation assays.  
A2 value determined through Schild analysis. “X” indicates not active in 
agonist or antagonist mode. 
Table 3. Binding Affinity of Mitragyna Alkaloids at Human Receptors. 
 Ki (µM) 
Compound hMOR hKOR hDOR 
mitragynine 0.233 ± 0.048 0.772 ± 0.207 > 10 
paynantheine 0.410 ± 0.152 2.56 ± 0.37 > 10 
speciociliatine 0.560 ± 0.168 0.329 ± 0.112 > 10 
speciogynine 0.728 ± 0.061 3.20 ± 0.36 > 10 
7-OH 0.047 ± 0.018 0.188 ± 0.038 0.219 ± 0.041 
Data represent mean ± SEM (µM) of n ≥ 3. Data collected by the 
Psychoactive Drug Screening Program (PDSP). 
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 Binding Affinity. Given the interesting therapeutic potential for these compounds and the 
heavy use of the plant material worldwide, it was important for us to explore the signaling at 
human receptors further. Up until our laboratory’s recent report on the functional activity of 
Mitragyna alkaloids17, there were no reports presenting data at the human variant of the 
receptors. In collaboration with the Psychoactive Drug Screening Program (PDSP, University of 
North Carolina, Chapel 
Hill), we measured the 
binding affinity of the five 
Mitragyna alkaloids at the 
human opioid receptors 
(Table 3). Interestingly, the 
affinities of the five 
alkaloids for the opioid receptors were similar between the two species, with the exception of 
those for DOR, which were markedly weaker at hDOR. Often there can be large discrepancies in 
data between different variants of receptors, as reported previously for chymases and toll-like 
receptors22,23; in fact, computational modeling of the two receptor variants may reveal key 
residues that impart species specificity for ligand binding. Nonetheless, the similar binding 
observed at the human receptors in comparison to the rodent receptors was encouraging. 
 Functional Activity. When measured for G protein activation using BRET assays, 
mitragynine showed partial agonism at the human MOR (Figure 4B) with an EC50 hMOR = 0.34 ±  
0.18 µM and EMax = 34%. In contrast, mitragynine showed antagonism at both KOR (Figure 5A, 
IC50 hKOR = 8.5 ± 7.6 µM) and DOR (Figure 5C, IC50 hDOR > 10 µM). Further Schild analysis 
showed an A2 of 1.4 ± 0.4 µM for hKOR antagonism and a competitive mode of action (Figure 
Table 4. Functional Activity of Mitragyna Alkaloids at Human Receptors. 
 EC50 (EMax) or [IC50] (µM) 
Compound hMOR hKOR hDOR 
mitragynine 0.339 ± 0.178 
(34%) 
[8.5 ± 7.6] 
A2 = 1.4 
[> 10] 
paynantheine [2.2 ± 10] [> 10] [> 10] 
speciociliatine [4.2 ± 1.6] [> 10] [> 10] 
speciogynine [5.7 ± 2.8] [> 10] [> 10] 
7-OH 0.0345 ± 0.0045 
(47%) 
[7.9 ± 3.7] 
pA2 = 0.49 
[> 10] 
Data represent mean ± SEM (µM) of n ≥ 3 from G protein activation assays.  
A2 value determined through Schild analysis. 
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6B, slope = 1.3). The KOR antagonism is similar to what was observed at the rat KOR. 
Mitragynine was also able to inhibit the agonism from control DAMGO, even as a partial  
 
Figure 4. Agonist Activity of Mitragyna alkaloids and 7-OH at the human opioid receptors. hMOR (A), hKOR (B), 
or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Mitragynine 
shows an EC50 = 339 ± 178 nM and EMax = 34 % at hMOR. 7-OH shows an EC50 = 34.5 ± 4.5 nM and EMax = 47% at 
hMOR. Curves represent the average of n ≥ 3, with error bars representing ± SEM. B. Positive control = U-50,488. 
C. Positive control = positive control = [D-Pen(2,5)]enkephalin (DPDPE). 
 
 
Figure 5. Antagonist Activity of Mitragyna alkaloids and 7-OH at the human opioid receptors. hMOR (A), hKOR 
(B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves 
represent the average of n ≥ 3, with error bars representing ± SEM. A. Inhibition of DAMGO, positive control = 
naloxone. B. Inhibition of U-50,488, positive control = nor-binaltorphimine (nor-BNI). C. Inhibition of DPDPE, 
positive control = TIPP-psi. In antagonist experiments, the agonist was used at 5x its EC50 concentration. 
 
agonist, and support the idea that low efficacy partial agonism at the mouse MOR may be too 
weak to detect in the assays and instead appears as antagonism. However, the other natural 
alkaloids paynantheine, speciociliatine, and speciogynine showed no agonist activity at 
concentrations up to 100 µM and only weak antagonist effects (Figures 4 and 5). These results 
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were comparable to the lack of agonist or antagonist activity at the rodent receptors. 7-OH was 
found to be a potent, partial agonist at the human MOR with EC50 hMOR = 34.5 ± 4.5 nM and EMax 
= 47% (Figure 4B), which was similar in potency to the activity at mMOR, but more 
efficacious. Again, 7-OH was measured as a competitive antagonist at both hKOR (Figure 5A, 
IC50 hKOR = 7.9 ± 3.7 µM) and hDOR (Figure C, IC50 hDOR = 15.6 ± 9.1 µM). In Schild analysis 
for hKOR antagonism, 7-OH showed an A2 = 490 ± 131 nM and a slope of 1.1 (Figure 6B). 
Similar to mitragynine, 7-OH was able to partially inhibit the response from control agonist 
DAMGO at hMOR. The functional activity of the Mitragyna alkaloids at the human opioid 
receptors is summarized in Table 4. 
 To confirm the 
agonist activity observed 
at the human opioid 
receptors, mitragynine 
and 7-OH were measured 
for their ability to inhibit 
cAMP production in an 
independent BRET assay. 
This assay uses 
CAMYEL, a BRET 
sensor that undergoes a 
conformational change in 
the presence of cAMP, 
which in turn alters the induced BRET signal (see Figure 15 in Chapter 1). Similar to the G 
 
Figure 6. Mitragynine and 7-OH are antagonists at hKOR. hKOR was co-
expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. 
Curves represent the average of n ≥ 3, with error bars representing ± SEM. A. 
Control agonist U-50,488 was incubated with increasing concentrations of 
mitragynine. B. Schild plot of (A) reveals a competitive antagonist mode of 
action. C. Control agonist U-50,488 was incubated with increasing 
concentrations of 7-OH. D. Schild plot of (C) reveals a competitive antagonist 
mode of action. 
 91 
protein activation results, both mitragynine and 7-OH were found to be partial agonists at the 
human MOR (Figure 7). Interestingly, 7-OH showed partial agonism at hDOR in this assay. 
Given the effects of downstream amplification and therefore greater sensitivity of cAMP 
inhibition in comparison to G protein activation, it is possible that the low efficacy agonism at 
hDOR was undetected in the G protein readout and thus only registered in antagonist mode. 
These results were also in line with the mouse data, where 7-OH induced low efficacy partial 
activation of mDOR. 
 
Figure 7. Agonist Activity of Mitragynine and 7-OH at the Human Opioid Receptors in the cAMP Inhibition Assay. 
hMOR (A), hKOR (B), or hDOR (C) were co-expressed with GαoB, β1, γ2, and CAMYEL to assay inhibition of 
forskolin-induced cAMP production. Mitragynine shows an EC50 = 259 ± 119 nM and EMax = 25% at hMOR. 7-OH 
shows an EC50 = 95 ± 27 nM and EMax = 52% at hMOR and weak partial agonism at hDOR. Curves represent the 
average of n ≥ 3, with error bars representing ± SEM. 
 
 Overall the functional activity and binding affinity observed for the five Mitragyna 
alkaloids at the opioid receptors is internally consistent, both in rodent and human species. This 
is further supported when the functional data (EC50 or IC50) are corrected by the Cheng-Prusoff 
equation.24 The pA2 values and slope measured via Schild analysis provide an additional 
favorable comparison to the binding data and is perhaps more rigorous than the Cheng-Prusoff 
correction. Again though the affinities for mitragynine at MOR and DOR appear much weaker 
than reported7,10, the similarities between our in vitro data and the reported relative in vivo 
potencies of either mitragynine or 7-OH lead us to conclude that the new functional data may be 
more reliable.  
Exploring Other Isomers of Mitragynine 



















































Figure 8. Retrosynthesis of Mitragynine for Access to Unnatural Isomers. 
 Synthesis of Mitragynine Isomers. In order to access the functional activity of some 
unnatural isomers of mitragynine, a total synthesis was employed that would allow modification 
of the A-D rings, if desired (Figure 8). Starting from 4-methoxyindole, the C ring was installed 
via a Bischler-Napieralski reaction to give a 3,4-dihydro-β-carboline. This intermediate was then 
subjected to an enantioselective, proline-catalyzed Mannich-Michael-type cyclization to install 
ring D and set the stereocenter at position 3. This step provided either the S enantiomer, 
ultimately leading to (-)-mitragynine (the natural isomer), or the R enantiomer, leading to the 
unnatural (+)-enantiomer. The ketone intermediates were then subjected to a Horner-Wadsworth-
Emmons reaction, followed by reduction, formylation, and methylation to give (-)-mitragynine, 
(Z)-mitragynine, or (+)-mitragynine. A full discussion of the synthesis (performed by Andrew 
Kruegel) was reported by our group in the literature.17 
 
Figure 9. Agonist Activity of Unnatural Mitragynine Isomers at the Human Opioid Receptors. hMOR (A), hKOR 
(B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. (Z)-
mitragynine shows an EC50 = 219 ± 71 nM and EMax = 38% at hMOR. (+)-mitragynine shows weak partial agonism 



















































































































 Functional Activity of Mitragynine Isomers. When 
measured for functional activity in the BRET-based assays for 
G protein activation, (Z)-mitragynine showed nearly identical 
activity at hMOR to (-)-mitragynine. Again, we observed 
partial agonism with an EC50 hMOR = 220 ± 71 nM and an EMax 
= 38% (Figure 9). Also, similarly to (-)-mitragynine, (Z)-
mitragynine was a weak KOR antagonist with IC50 hKOR = 42 ± 
15 µM (Figure 10). (Z)-Mitragynine showed no agonist or 
antagonist activity at hDOR (Figure 9 and Table 5). These 
data highlight that MOR appears more tolerant to changes in stereochemistry at the acrylate 
position than does KOR, as demonstrated by the identical potency at hMOR and weaker potency 
at hKOR for the Z-isomer. In contrast, (+)-mitragynine exhibited drastically different functional 
activity in comparison to the natural isomer (-)-mitragynine. While it was also a partial agonist at 
hMOR, it was an order of magnitude weaker in potency 
(Figure 9, EC50 hMOR = 3.3 ± 1.1 µM, EMax = 18%). This 
result makes sense as the active isomer (-)-mitragynine 
should be significantly more potent than the less active (+)-
isomer. The agonist activity of (+)-mitragynine was 
confirmed in the cAMP inhibition assay (Figure 11). 
Interestingly, (+)-mitragynine showed weak partial agonism 
at KOR (Figure 9, EC50 hKOR = 9.1 ± 4.3 µM, EMax = 31%), 
which represents the first example of such activity amongst 
 
Figure 10. (Z)-Mitragynine is a 
Competitive Antagonist at hKOR. 
hKOR was co-expressed with 
GαoB-RLuc8, β1, and mVenus-γ2 
to assay G protein activation. 
Curves represent the average of n 
≥ 3, with error bars representing ± 
SEM. 
 
Figure 11. (+)-Mitragynine is a 
Partial Agonist at hKOR in the 
cAMP Inhibition Assay. hKOR was 
co-expressed with GαoB, β1, γ2, and 
CAMYEL to assay forskolin-
induced cAMP inhibition. Curves 
represent the average of n ≥ 3, with 
error bars representing ± SEM. 
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the Mitragyna alkaloids. (+)-Mitragynine showed no agonist or antagonist activity at hDOR. It is 
possible that isolating the (+)-isomer of 7-OH might have the same effect on functional activity 
and provide another KOR agonist while retaining better MOR potency than mitragynine itself. A 
Mitragyna alkaloid that is both a partial KOR and MOR agonist may have both antidepressant 
effects from MOR and non-addictive analgesic effects from KOR. A summary of functional 
activity of mitragynine isomers can be found in Table 5.  
Mitragynine Pseudoindoxyl is an Interesting Pharmacological Tool 
 
Figure 12. Agonist Activity of Mitragynine Pseudoindoxyl at the Human Opioid Receptors. hMOR (A), hKOR (B), 
or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. MP shows an 
EC50 = 8.4 ± 5.9 nM (EMax = 52%) at hMOR and an EC50 = 29 ± 14 nM (EMax = 15%) at hDOR. Curves represent the 
average of n ≥ 4, with error bars representing ± SEM. 


















































































Table 5. Functional Activity of Mitragynine Isomers and Mitragynine Pseudoindoxyl (MP).  
EC50 (EMax) or [IC50] (µM) 
Compound hMOR mMOR hDOR mDOR hKOR 
(+)-mitragynine 3.34 ± 1.1 
(18%) 
- [>10] - 9.1 ± 4.3 
(31%) 
(Z)-mitragynine 0.219 ± 0.071 
(38%) 
- [>10] - [>10] 
MP 0.0084 ± 0.0059 
(52%) 
0.0088 ± 0.0073 
(23%) 
0.029 ± 0.014 
(15%) 
0.01 ± 0.002 
(50%) 
[4.8 ± 2.3] 
A2 = 0.078 ± 0.031 
Data represent mean ± SEM (µM) of n ≥ 3 from G protein activation assays. A2 value determined through Schild 
analysis. “-“ represents not tested. 
 
 95 
 Synthesis of Mitragynine Pseudoindoxyl. The rearrangement of 7-OH can lead to the 
formation of mitragynine pseudoindoxyl (MP), an alkaloid metabolite with a spiroketone moiety 
between rings B and C. Much like the other Mitragyna alkaloids, MP has been studied in terms 
of binding affinity at the opioid receptors (guinea pig brain) and analgesic properties, but no 
functional activity has been recorded to date.7 In fact, MP has been reported as a microbial 
metabolite of mitragynine.25 MP can be prepared synthetically from 7-OH under refluxing basic 
conditions (performed by Andrew Kruegel, see Experimental). Although the yield is quite low, 
we were able to isolate enough material for use in the functional assays. 
 Functional Activity of Mitragynine Pseudoindoxyl. MP showed partial agonist activity at 
MOR in both human (Figure 12, EC50 hMOR = 8.4 ± 5.9 nM, EMax = 52%) and mouse (Figure 13, 
EC50 mMOR = 8.8 ± 7.3 nM, EMax = 23%) species with higher potency than 7-OH. In fact, this 
Mitragyna alkaloid derivative represents the most potent compound at the MOR tested in this 
series so far. Additionally, MP showed potent partial agonism at DOR in both human (Figure 
12, EC50 hDOR = 28.9 ± 14 nM, EMax = 15%) and mouse species (Figure 13, EC50 mDOR = 10.1 ± 
 
 
Figure 13. Agonist Activity of Mitragynine Pseudoindoxyl at the Mouse Opioid Receptors. mMOR (A) or mDOR 
(B) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. MP shows an EC50 = 
8.8 ± 7.3 nM (EMax = 23%) at mMOR and an EC50 = 10 ± 2 nM (EMax = 50%) at mDOR. Curves represent the 
average of n = 3 with error bars representing ± SEM. 
 
 

















































Figure 14. Agonist Activity of MP at the Human Opioid Receptors in the cAMP Inhibition Assay. hMOR (A) or 
hDOR (B) were co-expressed with GαoB, β1, γ2, and CAMYEL to assay inhibition of forskolin-induced cAMP 
production. Curves represent the average of n ≥ 3, with error bars representing ± SEM. EC50 hMOR cAMP = 8.7 ± 3.6 




Figure 15. MP is an antagonist at hKOR. hKOR was co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay 
G protein activation. Curves represent the average of n = 4, with error bars representing ± SEM. A. Control agonist 
U-50,488 was incubated with increasing concentrations of MP. B. Schild plot of (A) reveals a competitive 
antagonist mode of action. 
 
1.9 nM, EMax = 50%). The agonism was also confirmed in the cAMP inhibition assay (Figure 
14). MP also acts as a KOR antagonist (Table 5, IC50 hKOR = 4.8 ± 2.3 µM). This KOR 
antagonism was further quantified via Schild analysis, which revealed an A2 of 77.6 ± 30.9 nM 
and slope of 0.84 (Figure 15). Interestingly, the EMax of U-50,488 does seem to decrease with 
increasing concentrations of MP, which would indicate some complex inhibition (either non-
competitive or uncompetitive). Given the increased potency observed at all three receptors by 
MP, it may represent an even more promising therapeutic lead in comparison to mitragynine 
itself, since a smaller dose should provide similar clinical effects. A summary of functional 
activity of mitragynine pseudoindoxyl can be found in Table 5. 






































































Exploring G Protein Independent Signaling Pathways of Mitragyna Alkaloids 
 Mitragyna Alkaloids do not Signal Through 
Arrestin. There is some evidence that functionally selective 
(or biased) agonists at the opioid receptors may offer 
promising analgesic or antidepressant effects without 
unwanted side effects from opioid signaling. It is not 
surprising to find that the search for functionally selective 
ligands is currently an active area of research.26–29 
Specifically there are reports that MOR agonists that signal 
exclusively through the G protein pathway and not the 
arrestin pathway (or a G protein biased agonist) avoid side 
effects such as constipation and respiratory depression, 
both thought to be mediated through arrestin signaling.30 
The benefit of G protein biased agonists is, however, not 
fully understood, as reports of reduced tolerance and 
addiction potential from unbiased MOR signaling are also 
plentiful.31,32 (See Introductory Chapter 1 for further discussion). Given the need to understand 
the therapeutic potential of both G protein and arrestin signaling better, we were interested in 
testing the active Mitragyna alkaloids for their ability to recruit arrestin. We used our BRET 
GAP43 translocation assay to measure the levels of arrestin recruitment. In this assay (see 
Figure 18 in Chapter 1), unmodified receptor is transfected along with arrestin-3 fused with 
luciferase and the SH3 binding domain, Sp1, along with the membrane protein GAP43 fused 
with the fluorescent protein citrine and an SH3 domain. Presumably, following receptor 
 
Figure 16. Mitragyna Alkaloids Are 
G Protein Biased. hMOR was co-
expressed with Rluc8-arrestin3-Sp1, 
mem-linker-citrine-SH3, and GRK2. 
Mitragyna alkaloids were measured 
for their ability to recruit arrestin in 
the standard method (A) or the 
competitive method33 (B). Data 
represent mean ± SEM of n ≥ 3. BRET 
GAP43 translocation assay used. 
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activation and arrestin recruitment to the receptor, Sp1 and the SH3 domain will be in close 
enough proximity for binding, stabilizing a protein complex that allows BRET to occur between 
the luciferase and citrine molecules. When mitragynine, 7-OH, and MP were tested for arrestin 
recruitment, mitragynine and 7-OH showed little measurable arrestin activity, while MP showed 
1-point activity (Figure 16A). These results were intriguing as it suggested that perhaps these 
Mitragyna alkaloids could in fact be G protein biased and offer beneficial therapeutic potential 
by eliminating some unwanted side effects in comparison to traditional opioids like morphine.  
 Calculating the Bias Factors of Mitragyna Alkaloids. In order to quantify the level of 
bias towards G protein for the Mitragyna alkaloids, it was necessary to fit the data using the 
Black-Leff operational model to get log(τ/KA), a measure of ligand bias (see Chapter 1 for 
further discussion). In performing these calculations, 7-OH and MP show a significant bias for G 
protein over arrestin, while mitragynine is closer to a neutral, unbiased ligand (Table 6). Given 
the lower efficacy and 
potency of mitragynine in 
comparison to 7-OH for G 
protein activation, the 
calculated bias for 
mitragynine seems 
reasonable. One issue with these calculations, however, is the obvious problem that there are no 
real curves for the compounds in the arrestin assay given the very low efficacy. In this case, the 
quantifications provided by the operational model may not be the most accurate, which 
ultimately obscures our understanding of the signaling. Laura Bohn has suggested a competitive 
method for analyzing functional selectivity, such that low efficacy compounds may be able to 





mitragynine -0.066 1.3 
7-OH 84 3.6 
MP 321 - 
Data represent mean ± SEM (µM) of n ≥ 3 from arrestin translocation 
assays. Bias factors were calculated using the Black-Leff operational model. 
“-“ indicates not calculated. 
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inhibit the arrestin signal from a full, unbiased agonist, thus providing a full curve with which to 
use in the operational model calculations.33 When mitragynine and 7-OH were utilized in 
antagonist mode for arrestin recruitment, they were both able to inhibit the arrestin recruitment 
from the control agonist DAMGO (Figure 16B). If these data are then fit with the operational 
model, the bias factors are much smaller than before (Table 6). Although both compounds do 
show a G protein bias when fit with the competitive mode, these changes are not significantly 
greater than the neutral control ligand. Given the large discrepancy in bias factors calculated in 
the two different methods, there is a greater need to study these ligands in vivo to measure their 
signaling in relevant cells for each physiological/behavioral effect (e.g., constipation, respiratory 
depression, tolerance 
development, dependence 
liability). Only with further 
testing will we understand 
how the different levels of 
bias in these compounds 
correlates to in vivo effects. 
 As additional 
evidence to support the G 
protein bias of the 
compounds, 7-OH was assessed for its ability to cause receptor internalization in CHO cells 
stably expressing mMOR. Receptor internalization is mediated by arrestin signaling, therefore, a 
ligand that is G protein biased should, in theory, be unable to cause receptor internalization.34,35 
Therefore, observing receptor internalization can be an indirect measure of arrestin signaling 
 
 
Figure 17. 7-OH Shows Less Receptor Internalization than DAMGO. The 
MOR internalization was imaged (A) using immunofluorescence and 
quantified (B). Compounds were used at 10 µM. Data represent one 
representative image of multiple independent experiments. On average, 
30-60 cells were analyzed for each treatment per experiment (n = 2).  
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from a ligand. Using immunofluorescence, 7-OH (10 µM) showed significantly less receptor 
internalization in comparison to DAMGO (10 µM) at 60 minutes (Figure 17). These receptor 
internalization measurements are in accord with the arrestin recruitment functional data and 
further support 7-OH as a G protein biased agonist. 
Mitragynine Pseudoindoxyl is a Potential Imaging Agent 
 Mitragynine Pseudoindoxyl as an Imaging Agent. Interestingly, MP is a fluorescent 
compound, and we hoped to 
utilize it as a tool to image 
opioid receptors in vitro or in 
vivo. Using two-photon 
microscopy, we first 
characterized the spectral 
properties of MP and found it 
to have a maximum excitation 
peak at 800 nm (Figure 18). Unfortunately in solution, MP was not as brightly fluorescent as we 
had hoped, and high concentrations of the compound were necessary for experiments in cells.  
 In initial experiments in HEK cells transiently expressing the hMOR, there was 
significant background fluorescence coming from the cells. Looking to the media formulations 
used, it was determined that small amounts of riboflavin contained in all medias and produced 
endogenously by cells may have contributed to this observed autofluorescence as riboflavin’s 
excitation and emission peaks overlap with that of MP (Emission = 525 nm). Instead of using 
normal Dulbecco’s modified eagle media, Hank’s Balanced Salt Solution was incubated with 
cells for the duration of imaging experiments to ensure that riboflavin would be minimized in 
Figure 18. Two-photon Excitation Spectrum for MP. The maximum 
excitation peak for MP is 800 nm. Data obtained by Dr. Mark 
Sonders. 
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cells. Using this set-up, MP quickly labeled structures within all cells (Figure 19A). This 
staining, unfortunately, was not blocked by addition of the MOR antagonist naloxone. Further 
analysis of the cell culture being used revealed that only a small percentage of cells present 
actually expressed the receptor (Figure 19B-C). Therefore, it is unlikely that the compound is 
staining the cells in an MOR-dependent manner.  
However, we were quite intrigued by the rapid staining of cellular structures and looked 
to the fluorescence lifetime of the compound for explanation. The fluorescence lifetime of MP 
was different in phosphate buffered saline (3.5 ns) versus chloroform (4.7 ns). Given the greater 
fluorescence lifetime in an organic solvent (chloroform) versus an aqueous solvent (phosphate 
buffered saline), it is not surprising that MP might be able to quickly stain lipid rich, nonpolar 
membrane structures within the cells. In terms of the labeling, the staining pattern seemed most 
similar to that of a dye for the Golgi apparatus. To test his hypothesis, we co-localized MP with a 
spectrally separated sphingolipid dye known to stain the Golgi. After pretreating with the 
sphingolipid dye, MP rapidly stained what appeared to be the same, small intracellular structures 
but not the plasma membrane, showing some overlap with the sphingolipid dye (Figure 20). 
 
Figure 19. Two-Photon Imaging with MP. A. MP (10 µM) was bath applied to HEK cells transiently expressing 
hMOR and imaged (Ex 800 nm/Em 525 nm). Data obtained by Dr. Mark Sonders. The same cells were then 
fixed and immunostained for MOR. Brightfield (B) and MOR (red, C) images reveal low transfection efficiency. 
Data represent one representative image of multiple independent experiments. 
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While further experiments are required to better explain the biological mechanism of this 
staining, it is possible that MP does label the Golgi apparatus, as hypothesized. Interestingly, the 
sphingolipid dye required more than 30 minutes to selectively stain the golgi, while staining with 
MP required less than 1 minute, indicating a potential use for MP as a fast stain of cellular 
structures (the identity of which is currently being determined). It seems likely that these two 
dyes either stain the Golgi via distinct mechanisms or MP is staining a different cellular structure 
that overlaps well with the Golgi. Unfortunately the brightness of MP is relatively low, and high 
concentrations of the drug (~3 orders of magnitude higher than the EC50 at MOR) were 
necessary to obtain images. Therefore, the overall potential of MP as an MOR imaging agent is 
limited. 
 
Figure 20. MP Co-localizes with Sphingolipid Golgi Stain. HEK cells transiently expressing hMOR were incubated 
with MP (10 µM) (A) before staining with Ceramide-bodipyTR sphingolipid golgi stain (B). C. Merge of the two 
images. Data represent one representative image of multiple experiments. 
 
Molecular Docking of Mitragyna Alkaloids at the MOR 
 Mitragynine Scaffold has Unique Binding Pose at MOR. In order to better understand the 
unique biological activity and SAR of the Mitragyna alkaloids, preliminary docking studies can 
be reviewed that describe the alkaloids in the binding pocket of the agonist-bound X-ray crystal 
structure of mMOR (PDBID = 5C1M)36 (Figure 21).17 The top-scored binding pose of 







A. B. C. 
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crystallized morphinan derivative BU72, with some important exceptions (compare Figure 21 to 
Figure 22). Even though there is a common polar interaction between the protonated amines in 
(-)-mitragynine and BU72 and D1473.32, which is known to be required for binding of classical 
opioid agonists and antagonists36,37, there are significant differences between other important 
ligand-receptor contacts. For example, in BU72 (Figure 22), the phenol occupies a hydrophobic 
pocket formed by TM5 and TM6 and also forms a water-mediated hydrogen bonding network 
with H2976.52. This interaction is common to opioid ligands in the morphinan class.16,37,38 Our 
docking studies, however, suggest that the methoxyindole portion of (-)-mitragynine is 
 
Figure 21. Docking of (-)-mitragynine and other analogs to the active µ-opioid receptor crystal structure. Top-
scoring binding poses of (A) (-)-mitragynine, (B) (Z)-mitragynine, (C) 7-hydroxymitragynine, and (D) 
antagonists paynantheine (pink) and speciogynine (cyan). Only residue sidechains within 4 Å of the ligand are 
reported. Polar interactions are shown as dotted lines. TM helices are shown in cartoon representation (in gray). 
ECL2 and part of TM5 have been omitted for clarity. Residues are labeled using one-letter amino acid code and 
Ballesteros and Weinstein’s generic numbering scheme. Data obtained by Dr. Marta Filizola. 
 
 104 
preferentially directed toward a different hydrophobic pocket formed by the residues of TM2 and 
TM3 (Figure 21A), which apparently has no way of forming an analogous hydrogen bonding 
network. Instead, the enol ether part of the β-methoxyacrylate of mitragynine appears to be 
directed into the same region as the phenol of BU72 (toward TM5 and TM6). Therefore, it seems 
that this functional group has a similar hydrogen bonding network with H2976.52.  
 Docking of the other 
mitragynine isomers described 
above also produced results that 
were in agreement with the in 
vitro activity data. For instance, 
(-)-mitragynine and (Z)-
mitragynine adopted a nearly 
identical binding pose, which is 
in accordance with the similar 
activities seen in vitro (Figure 
21). Similarly, the predicted low-
energy binding pose of 7-OH 
was also comparable, with all key functionalities, including the acrylate, ethyl group, tertiary 
amine, and indole, occupying similar positions (Figure 21C). Remarkably, the hydroxy group in 
the 7-position does not appear to make close contacts with the surface of the receptor, and 
therefore, any potential hydrogen bonding interactions do not seem to be the cause of the 
significant increase in potency seen by 7-OH in comparison to mitragynine. Rather, there is a 
slight bend introduced to the core structure by this modification, which perhaps is more 
 
Figure 22. Top-scored docking pose of (-)-mitragynine (green) 
compared with agonist BU72 (brown) bound to active MOR crystal 
structure. Only residue sidechains within 4 Å of BU72 are reported. 
Polar interactions are depicted as dotted lines. Crystal waters are 
shown as red sphere. TM helices are shown in cartoon representation 
(in gray). ECL2 and part of TM5 have been omitted for clarity. 
Residues are labeled using one-letter amino acid code and Ballesteros 
and Weinstein’s generic numbering scheme.83 Data obtained by Dr. 
Marta Filizola. Inset: structure of BU72. 
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important. Notably, 7-OH interacts with W2936.48 through both the ethyl and acrylate groups, 
while (-)-mitragynine interacts with this residue through its acrylate group only. While many 
different stereochemical configurations in the Mitragyna alkaloids studied appear to be sufficient 
to retain binding at hMOR, the absolute stereochemistry found in mitragynine is necessary for 
activation of the receptor. A full discussion on the binding poses of the natural and unnatural 
Mitragyna alkaloids can be found in our publication.17 
Biological Activity of Mitragyna Alkaloids at Non-Opioid Receptors 
 Binding Affinity at Human α2R. Given the reported binding of mitragynine at α2Rs13 (see 
Introduction), we were interested in exploring the pharmacology of Mitragyna alkaloids at 
other receptors in the CNS.  Additionally the adrenergic receptors are known to mediate 
analgesic properties, particularly the receptors in the spinal cord39, and therefore it was important 
to assess whether the Mitragyna alkaloids may impart some of their analgesic effects through the 
α2R. Again in collaboration with PDSP, mitragynine and the other Mitragyna alkaloids were 
measured for their binding affinity at the human α2AR, α2BR, and α2CR receptors using a 
radioligand binding 
assay. Mitragynine 
showed similar affinity 
for all three α2Rs, while 
interestingly, 7-OH did 
not bind to any of the 
them (Table 7). When assessing the three other natural Mitragyna alkaloids, paynantheine, 
speciociliatine, and speciogynine, there were notable differences in the binding affinities when 
compared to mitragynine or 7-OH (Table 7). Paynantheine and speciogynine showed much 
Table 7. Binding Affinity of Mitragyna Alkaloids at Adrenergic Receptors. 
 Ki (µM) 
Compound hα2A hα2B hα2C 
mitragynine 0.839 ± 0.193 2.26 ± 0.49 1.47 ± 0.42 
paynantheine 0.131 ± 0.022 0.947 ± 0.09 0.191 ± 0.04 
speciociliatine 1.54 ± 0.15 2.74 ±0.66 1.68 ± 0.42 
speciogynine 0.119 ± 0.031 1.21 ± 0.11 0.288 ± 0.107 
7-OH > 10 > 10 > 10 
Data represent mean ± SEM (µM) of n ≥ 3. Data collected by the 
Psychoactive Drug Screening Program (PDSP). 
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tighter binding to the α2A and the α2C receptors in comparison to mitragynine (approximately 8-
fold higher affinity at both receptors), with weaker binding at the α2B receptor. In contrast, 
speciociliatine showed binding affinities similar to mitragynine at all three receptors (Table 7), 
suggesting perhaps that the stereoconfiguration at position 19 shared between the two 
compounds (see Figure 8 above) could reduce affinity for binding at these adrenergic receptors.  
 
Figure 23. Agonist Activity of Mitragyna Alkaloids and 7-OH at the Human Adrenergic α2 Receptors. hα2A (A), 
hα2B (B), or hα2C (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. 
Curves represent the average of n = 3, with error bars representing ± SEM. Control agonist = UK-14,304. 
 
 Functional Activity at Human α2R. The Mitragyna alkaloids were first assessed for their 
agonist activity at each of the three adrenergic receptors (Figure 23) using the BRET assay for G 
protein activation. Interestingly, none of the five compounds displayed any agonist activity at the 
three adrenergic α2 receptors at concentrations up to 100 µM. In contrast, when the Mitragyna 
alkaloids were tested for their ability to inhibit the signal of full agonist UK-14,304, interesting 
results emerged. At the α2A receptor, mitragynine and speciociliatine were able to only weakly 
inhibit the agonist activity of UK-14,304 at the highest concentration tested (100 µM), while 
paynantheine and speciogynine showed full inhibition (Figure 24). Paynantheine and 
speciogynine again showed antagonism at the adrenergic α2B and α2C receptors, though with 
weakest inhibition of the α2B receptor. Mitragynine and speciociliatine showed inhibition only at 

























































































the 100 µM concentration at the adrenergic α2B and α2C receptors, and 7-OH was generally 
inactive at all three.  
 
Figure 24. Antagonist Activity of Mitragyna Alkaloids and 7-OH at the Human Adrenergic α2 Receptors. hα2A (A), 
hα2B (B), or hα2C (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. 
Curves represent the average of n ≥ 3, with error bars representing ± SEM. Competitive inhibition of UK-14,304, 
positive control = Rauwolscine. 
 
These results are in line with the binding affinities measured for the three receptors. 
Mitragynine and speciociliatine generally showed minimal antagonism, supporting their weak 
binding affinities in 




tighter binding affinity), 
in contrast, showed 
measurable inhibition at the three adrenergic α2 receptors. The functional data at these receptors 
match quite well with the binding affinities measured and do suggest that some effects in the 

























































































Table 4. Functional Activity of Mitragyna Alkaloids at Adrenergic Receptors. 
 IC50 (µM) 
Compound h α2A h α2B h α2C 
mitragynine > 10 > 10 > 10 
paynantheine > 10 > 10 6.3 ± 1.4 
speciociliatine > 10 > 10 > 10 
speciogynine > 10 > 10 4.5 ± 1.9 
7-OH X X X 
Data represent mean ± SEM (µM) of n ≥ 3 from G protein activation assays. “X”  
indicates not active. 
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plant material itself may be mediated through the adrenergic effects of the less prevalent 
alkaloids (Table 8). 
Functional Activity at Vesicular Monoamine 
Transporter 2 (VMAT2). We also wanted to assess the 
functional activity of the Mitragyna alkaloids at the 
monoamine transporters, given their connection to 
mechanisms of depression (see Introductory Chapter 1 or 
Discussion below). All Mitragyna alkaloids except 
speciociliatine were unable to inhibit rat VMAT2 at 
concentrations less than 100 µM (Figure 25). 
Speciociliatine was able to inhibit VMAT2 with an IC50 = 
121 ± 28 nM, consistent with its structural similarity to 
reserpine (stereoconfiguration of the rings C and D are 
identical), a typical VMAT2 inhibitor. All of the Mitragyna 
alkaloids were inactive at the human dopamine transporter (DAT), human serotonin transporter 
(SERT), and human norepinephrine transporter (NET) (data not shown).  
 
Discussion 
Opioid Activity of Mitragyna Alkaloids. These studies represent the first thorough 
examination of the Mitragyna alkaloids at the opioid receptors. Previous reports relied heavily on 
binding affinities, as well as ex vivo effects in guinea pig ileum, an anatomical area rich with 
opioid receptors, and in vivo analgesic effects in the tail flick assay.7 By simply assuming the 
agonist activity of the alkaloids as fact, much of the subtle signaling nuances were missed. 
 
Figure 25. Speciociliatine is a Rat 
VMAT2 Inhibitor. The Mitragyna 
alkaloids were measured for their 
ability to inhibit specific uptake of 
FFN206 at rat VMAT2 in HEK-293 
cells. Data represent mean ± SEM of n 
> 4 independent experiments. Data 
obtained by Yekaterina Kovalyova. 
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Takayama and co-workers recently collaborated with researchers at Mount Sinai to develop 
functional assays for their mitragynine analogs.15 Using the [35S]GTPγS binding assay (see 
Chapter 1 for more detail), they were able to measure the functional activity of a few semi-
synthetic mitragynine analogs, however even with the technology available, the researchers 
chose not to confirm the functional activity of the parent Mitragyna alkaloids. Thus, the 
functional activity of the Mitragyna alkaloids has not been examined in detail to date. In this 
study, mitragynine and 7-OH were found to be partial agonists at the human MOR and 
antagonists at the human KOR. As partial agonists, the compounds are able to elicit analgesic 
effects perhaps without the need to fully activate the receptor. This functional activity could 
potentially offer a way to safely consume the plant material with a lesser risk of overdosing.3,40–42 
For example, the partial MOR agonist buprenorphine is an effective analgesic that has a ceiling 
(maximum effect) in respiratory depression and is therefore perhaps a safer pain therapeutic in 
comparison to classical opioids morphine or fentanyl (see Chapter 4 for further discussion of 
buprenorphine).43 Additionally the KOR antagonism was both surprising and intriguing as a 
therapeutic option for depression. The in vivo reports on KOR antagonists18,44 suggest they may 
provide some antidepressant activity, which is only beginning to be studied in clinical trials.20 As 
dual MOR agonists/KOR antagonists, both mitragynine and 7-OH may be able to combat pain 
and depression simultaneously (again see buprenorphine), offering a promising lead for the 
development of new therapeutics. Often times, those suffering from chronic pain succumb to 
feelings of depression, making pharmacological management difficult.45 Therefore these types of 
dual therapeutics could find use in a diverse subset of patients. There were also similar activities 
measured with (Z)-mitragynine, as well as MP, which may both be additional leads to explore 
further. The other natural alkaloids, paynantheine, speciociliatine, and speciogynine, on the other 
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hand, showed only competitive antagonism at the human opioid receptors. As the first study on 
the functional activity of these alkaloids at human receptors, this work provides a better insight 
into the physiological effects of kratom and how these compounds might be translated into 
meaningful therapeutics for human use. 
G Protein Bias of Three Alkaloids. Interestingly, both mitragynine, 7-OH, and MP 
showed no apparent ability to recruit arrestin. As more examples of G protein-biased agonists 
continue to emerge at the opioid receptors, there is a need to better understand their signaling in 
relevant cells. As Laura Bohn highlights in a recent paper, there is not yet a clear connection 
between how in vitro bias results translate in vivo (see Chapter 5 for further discussion).26 If the 
G protein biased MOR agonists hold the answer to offering analgesic relief without respiratory 
depression, constipation, or tolerance development46, then we may be emerging into a new age of 
opioid therapeutics where they can be used clinically with less concern for serious side effects. 
Trevena has developed one such drug, TRV130, developed as a G protein-biased MOR agonist, 
that is showing promising results in the clinic,30,47 (see Chapter 4 for further discussion on this 
compound). Rigorous analysis of the data using the operational model in two different 
experimental set-ups showed 7-OH mitragynine to exhibit bias for the G protein pathway over 
the arrestin pathway, suggesting that even partial agonists, which may not be detected in the less 
sensitive arrestin assay, can still be identified as biased. However, it remains to be demonstrated 
that the pharmacological functional selectivity observed for this compound may translate to 
measurable physiological effects in vivo. 
 Mitragyna Alkaloids Have a Unique Binding Pose at MOR. In furthering our study of the 
Mitragyna alkaloids, we looked to find a structural basis for the unique biological activity 
observed in vitro. Computational models, while not as definitive as an x-ray crystal structure 
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obtained with bound ligand, offer an important insight into drug-receptor interactions. If 
computational results are reliable, then binding poses might help to explain pharmacological 
activity from drugs and even allow the design of new analogs for synthesis (when methods come 
to a point where the connections between the receptor and the physiology can be made through 
the many levels of complexity). In comparing the top-scored pose of mitragynine with 
morphinoid BU72 (Figure 22), it was clear that the two compounds do not adopt the same 
binding position within the MOR, indicating that it is possible the two compounds may stabilize 
different features of the binding pocket, which ultimately lead to distinct signaling cascades. 
These differences in binding pose may lead to insights in terms of the links between the binding 
and the receptor activation and signaling (e.g., explain why mitragynine has only partial agonism 
at MOR and is G protein biased). Additionally, 7-OH had a slightly altered binding pose even 
compared to mitragynine. Again, this may explain the increased potency observed in vitro for 7-
OH and the G protein bias. Given the level to which the computational docking confirms much 
of the in vitro results observed, it is possible that better analogs might be virtually designed that 
can target the various signaling pathways of interest. Additionally, given the unexpected KOR 
antagonism, it may be worth exploring computational modeling at this receptor, as well, which 
may provide a means to tune functional activities in both receptors with future analogs.  
Variation Between Rodent and Human Data. It has been widely accepted that 
mitragynine acts as an MOR agonist. However, given the variable results obtained here in 
regards to mitragynine at the mouse and human MOR, there is some uncertainty in interpreting 
the literature on the analgesic properties of Mitragyna alkaloids using animal models. The partial 
hMOR agonist activity of mitragynine can likely explain its analgesic effects in humans, but the 
interpretation of literature reports on analgesic effects elicited by this compound in rodent 
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models is now unclear, given the observation here of purely antagonistic effects from 
mitragynine at rodent opioid receptors in vitro. Another possibility is that the functional assays 
utilized here are not sensitive enough to detect very low efficacy partial agonist activity (on the 
order of <10% EMax). With downstream signaling amplification, these compounds could have a 
larger effect in vivo. As a very low efficacy partial agonist, mitragynine would still largely 
inhibit the activation by DAMGO, making its functional activity appear to be that of an 
antagonist.  
7-OH as a Natural Alkaloid of Mitragyna speciosa. Although it has been published that 
7-OH is an isolatable alkaloid from the plant material, we found no evidence to support this 
claim, other than trace amounts measurable by mass spectrometry. Given the apparent lack of 7-
OH measurable in the different strains of kratom leaves tested, it seems unlikely that 7-OH is a 
major constituent in the effects of the plant material in humans. A few possibilities may help to 
explain the inconsistencies, however. As discussed in the Results, 7-OH might just be present 
only in particular strains of kratom or oxidized from mitragynine directly in the presence of 
sunlight and atmospheric oxygen. These hypotheses are more likely than one where mitragynine 
is metabolized directly to 7-OH. Mitragynine has some metabolic stability in vitro (liver 
microsomes, simulated intestinal fluid), and in fact there is evidence suggesting that 7-OH can 
actually metabolize back into mitragynine.48 Therefore it seems likely that mitragynine is the 
main alkaloid responsible for the effects of kratom. 
Pharmacological Consequences of Adrenergic Activity. To understand the non-opioid 
biological activity of the Mitragyna alkaloids, it is helpful to revisit some closely related indole 
alkaloids that are structurally similar. Yohimbine (Figure 26), for instance, isolated from the 
bark of Pausinystalia johimbe and Rauvolfia evergreen trees, was first extracted in 1896 and has 
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been the focus of many total syntheses and is used in a veterinary setting to reverse anesthetic 
sedation, among many other uses.49–52 Known as one of the yohimban alkaloids, yohimbine is 
reported to bind to the adrenergic receptors (both α1 and α2), as well as serotonin receptors and 
dopamine receptors.53,54 Other 
diastereomers of yohimbine 
include corynanthine and 
rauwolscine (Figure 26), both of 
which bind to similar biological 
targets. If the E ring of 
yohimbine is further elaborated, 
with cis stereoconfiguration 
between the D and E rings as 
well as the opposite 
stereoconfiguration at position 3, 
the structure of reserpine (Figure 
26) emerges, which was also 
isolated from the roots of 
Rauwolfia serpentine in 195255 
and then synthesized by R.B. 
Woodward in 1958.56 Reserpine 
has been used in India to treat 
insanity and snakebites for 
centuries and was an influential 
 
Figure 26. Structures of Indole Alkaloids Closely Related to 
Mitragynine. Classical yohimban alkaloids share some structural 
features with the Mitragyna alkaloids. Yohimban alkaloid ajmalicine 
is shared by both Rauwolfia and Mitragyna plants. 
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player in the biogenic amine hypothesis for treating depression due to its inhibition of the 
vesicular monoamine transporter (VMAT)57; in the early days of use, reserpine treatment in 
some patients and animals caused depressive-like symptoms, which was later correlated to 
decreased stores of presynaptic norepinephrine, serotonin, and dopamine leading to the biogenic 
amine hypothesis (see Introductory Chapter 1 for further discussion).58 Functionally speaking, 
this structure is also moving away from adrenergic receptor activity. With the cis 
stereoconfiguration between the D and E rings, mitragynine has the stereoconfiguration of 
isoreserpine (epimer of reserpine with inverted C-3 center) at the C-D rings. This difference 
could explain why mitragynine is not an inhibitor of VMAT (see Figure 26 above). When the E 
ring of yohimbine is instead opened, the structure of the Mitragyna alkaloids emerge, first with 
the structures of paynantheine and speciogynine, which share the same trans configuration 
between rings D and E as yohimbine (Figure 26), and then with the opposite stereochemistry at 
position 19 to provide the structure of mitragynine. The stereocenter of the tetrahydrocarboline 
(position 3) remains the same in comparison to yohimbine. Indeed, the connection between 
yohimban alkaloids and Mitragyna alkaloids is clear, as the two plants even share alkaloids in 
common, such as ajmalicine (Figure 26).1,59 Although their biological activity is varied and 
diverse, these indole alkaloids share structural features that can be traced back to their 
biosynthesis in the plants. The Mitragyna alkaloids are unique in their functional activity at the 
opioid receptors, but perhaps it is their structural similarity to the yohimban alkaloids that 
accounts for some of their non-opioid activity. In particular, the stereochemical similarity of 
yohimbine with paynantheine and speciogynine at position 3 could explain these alkaloids’ 
increased potency at the α2Rs. 
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It has been widely reported that α2R agonists have therapeutic potential in pain 
management.60 Since many of the Mitragyna alkaloids tested here were found to bind to these α2 
adrenergic receptors, their functional activity was explored further. Interestingly, no agonist 
activity was found for the compounds at any of the α2Rs, which indicates that the analgesic 
properties of the kratom plant are likely mediated through the MOR, as the functional data 
shows. Some of the alkaloids, however, exhibited antagonism at the α2Rs, specifically 
paynantheine and speciogynine. Clinically, there are studies of α2R antagonists having 
antidepressant effects61–64, suggesting that perhaps the reported antidepressant effects of the 
kratom plant65 may be mediated through the alkaloids’ modulation of both the opioid receptors 
and the α2Rs. However other conflicting reports conclude that in fact, α2R agonists have 
antidepressant effects66,67, which implicates an unclear therapeutic role for these receptors in 
depression. There are additional reports of α2R antagonist effects on precipitated withdrawal. For 
example, yohimbine has been shown both clinically and in animal models to reduce the effects of 
precipitated withdrawal from opioid dependence and the addictive potential of MOR agonists in 
mice.68–70 Unfortunately, there are some conflicting reports. For instance, in mice, while one 
study reports that yohimbine reduces the symptoms of opioid withdrawal and dependence 
without effects on analgesia70, a second report finds yohimbine co-treatment with morphine to 
eliminate antinociceptive effects.71 In a separate study, yohimbine treatment in opioid-dependent 
patients elicited withdrawal symptoms and an increase in cravings for opioids (methadone)72, 
while α2R agonists have separately been reported to precipitate and shorten withdrawal 
symptoms in comparison to methadone administration.73 Although the results vary, there still 
does seem to be more indication in literature of benefit from α2R antagonists in treating opioid 
addiction, which could have important implications in the context of the Mitragyna alkaloids. A 
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recent study in humans noted that daily doses of kratom (tea consumption) for 7 days resulted in 
a maximum plasma concentration of mitragynine around 250 nM.74 Therefore, the combined α2R 
antagonistic effects of mitragynine, paynantheine, and speciogynine in a sample of kratom may 
be enough to elicit some effects on withdrawal. In fact, kratom has been widely used for treating 
opioid withdrawal1, which may be due in part to the α2R antagonists effects of some of the 
alkaloids. It is important to note, however, that a plasma concentration of 250 nM is quite low 
and is likely at a lower concentration in the brain. Additionally, given the low potency of 
mitragynine at the α2Rs and the even lower concentration of the alkaloids paynantheine and 
speciogynine in samples of kratom, it is unclear how much the adrenergic receptors are actually 
being modulated by these alkaloids through kratom consumption. Nonetheless the 
polypharmacology of these compounds is rich and interesting: agonism at MOR can provide 
both analgesic relief and antidepressant effects, while the partial efficacy at MOR and α2R 
antagonism may simultaneously offer a safer withdrawal from opioid addiction. Certainly, more 
conclusive studies should be published, however some Mitragyna alkaloids in the kratom plant 
may perhaps be useful tools to study these receptor effects. For instance, behavioral studies in 
vivo in mice lacking either the MOR or individual α2 adrenergic receptors may shed light on the 
pharmacological profile of the Mitragyna alkaloids in depression and addiction. Given these 
findings, the effects of raw Mitragyna alkaloid extracts in humans may be quite complex. 
However, if individual alkaloids are instead isolated for therapeutics, they are likely to have 




In this chapter, we characterized for the first time the Mitragyna alkaloids at the human 
opioid receptors and found surprisingly that mitragynine and 7-OH mitragynine were partial 
MOR agonists and KOR antagonists with weak antagonist effects at DOR. Additionally some 
isomers of mitragynine as well as MP were characterized in functional assays and helped to 
reveal important areas of the scaffold that appear to be tolerant to changes in stereochemistry. 
These studies will aid in future structure activity relationship explorations. Given the biological 
activity of these alkaloids, they hold great promise therapeutically, either isolated or together in 
the kratom plant material. As a first report of human functional activity of the Mitragyna 
alkaloids, this work will better inform both users of the plant material and medical professionals 





 General Considerations. Reagents and solvents were obtained from commercial sources 
and were used without further purification unless otherwise stated (including anhydrous 
solvents). All reactions were performed in flame-dried glassware under an argon atmosphere 
unless otherwise stated, and monitored by TLC using solvent mixtures appropriate to each 
reaction. All column chromatography was performed on silica gel (40-63µm). For compounds 
containing a basic nitrogen, Et3N was often used in the mobile phase in order to provide better 
resolution. In these cases, TLC plates were pre-soaked in the Et3N-containing solvent and then 
allowed to dry briefly before use in analysis, such that an accurate representation of Rf was 
obtained. Nuclear magnetic resonance spectra were recorded on 400 or 500 MHz instruments as 
indicated. Chemical shifts are reported as δ values in ppm referenced to CDCl3 (1H NMR = 7.26 
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and 13C NMR = 77.16) or (CD3)2SO (1H NMR = 2.50 and 13C NMR = 39.52). Multiplicity is 
indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); dt 
(doublet of triplets); td (triplet of doublets); m (multiplet); br (broad). In some cases, spectra are 
complicated by the presence of multiple conformers, resulting in peak broadening or additional 
splitting. As a result of these effects, multiple peaks may correspond to the same proton group or 
carbon atom. When possible, this is indicated by an "and" joining two listed peaks or spectral 
regions. All carbon peaks are rounded to one decimal place unless such rounding would cause 
two close peaks to become identical. In these cases, two decimal places are retained. Low-
resolution mass spectra (LRMS) were recorded on a quadrupole mass spectrometer (ionization 
mode: APCI+ or ESI+). High-resolution mass spectra (HRMS) were recorded on a quadrupole 
time-of-flight mass spectrometer (ionization mode: ESI+). 




Mitragynine pseudoindoxyl (MP) = methyl (E)-2-((2S,6'S,7'S,8a'S)-6'-ethyl-4-
methoxy-3-oxo-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-2,1'-indolizin]-7'-yl)-3-
methoxyacrylate. A fresh solution of sodium methoxide was prepared by dissolving Na metal 
(7.6 mg, 0.330 mmol) in anhydrous MeOH (5.6 mL) at room temperature. To this solution was 
then added 7-hydroxymitragynine (62.2 mg, 0.150 mmol) and the yellow solution was refluxed 
for 4.5 h (incomplete conversion). After cooling to room temperature, the reaction was diluted 
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with water (20 mL) and extracted with Et2O (3 x 20 mL). The combined organics were washed 
with water (10 mL) and brine (10 mL), dried over Na2SO4, and concentrated to provide a brown 
foam (60 mg). This material was purified by repeated preparative TLC (1 mm silica layer, 20 x 
20 cm plates; Plate 1: Et2O + 2% Et3N; Plate 2: 7:3 CH2Cl2:Et2O; Plate 3: Et2O + 2% Et3N) to 
provide spirocyclic product 5 as a foamy yellow solid (9.9 mg, 16%). Spectral properties 
matched those previously reported.9,75 1H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 8.1 Hz, 1H), 
7.28 (s, 1H), 6.40 (d, J = 8.1 Hz, 1H), 6.13 (d, J = 8.1 Hz, 1H), 5.11 (br s, 1H), 3.89 (s, 3H), 3.66 
(s, 3H), 3.62 (s, 3H), 3.12 (br s, 2H), 2.77 (d, J = 12.1 Hz, 1H), 2.41 – 2.28 (m, 2H), 2.28 – 2.08 
(m, 3H), 1.90 (br s, 1H), 1.64 (br s, 1H), 1.51 (br s, 1H), 1.23 – 1.16 (m, 1H), 1.16 – 1.08 (m, 
1H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 199.6, 169.0, 162.2, 160.4, 158.7, 
138.8, 125.7, 111.8, 103.9, 99.2, 75.3, 73.4, 61.6, 55.8, 54.9, 53.3, 51.3, 40.2, 38.5, 35.2, 23.9, 
19.4, 13.0; LR-MS calcd. for C23H31N2O5+ [M+H]+ 415.22, found 416.36. 
Biological Procedures 
 Materials: BRET. HEK-293T cells were obtained from the American Type Culture 
Collection (Rockville, MD) and were cultured in a 5% CO2 atmosphere at 37 oC in Dulbecco’s 
Modified Eagle Medium (high glucose #11965; Life Technologies Corp.; Grand Island, NY) 
supplemented with 10% FBS (Premium Select, Atlanta Biologicals; Atlanta, GA) and 100 U/mL 
penicillin and 100 µg/mL streptomycin (#15140, Life Technologies). 
 DNA Constructs. The mouse MOR (mMOR), the mouse DOR (mDOR), and the rat 
KOR (rKOR) were provided by Dr. Lakshmi Devi at Mount Sinai Hospital. The hMOR, hDOR, 
hKOR, hα2AR, hα2BR, hα2CR  and GRK2 were obtained from the Missouri S&T Resource 
Center. The human G protein constructs used here have been previously described and were 
provided by C. Galés or were obtained from the Missouri S&T Resource Center unless otherwise 
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noted.12,13 The G proteins used included untagged GαoB (GαoB); GαoB with Renilla luciferase 8 
(RLuc8) inserted at position 91 (GαoB-RLuc8); Gβ1 (β1); untagged Gγ2 (γ2); Gγ2 which we fused 
to the full-length mVenus at its N-terminus via the amino acid linker GSAGT (mVenus-γ2). The 
plasmids employed in the arrestin recruitment assay, RLuc8-arrestin3-Sp1 and mem-linker-
citrine-SH3, were synthesized in-house as previously described.76 YFP-Epac-RLuc (CAMYEL) 
was obtained from ATCC (no. MBA-277).77 All constructs were sequence-confirmed prior to use 
in experiments. 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
106 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg MOR/DOR/KOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; cAMP Inhibition: 1.25 µg MOR/DOR/KOR, 1.25 µg 
GαoB, 1.25 µg β1, 1.25 µg γ2, 10 µg CAMYEL; BRET GAP43 translocation: 2 µg hMOR, 0.25 
µg Rluc8-arrestin3-Sp1, 5 µg mem-linker-citrine-SH3, 5 µg GRK2. Cells were maintained in the 
HEK-293T media described above. After 24 hours the media was changed, and the experiment 
was performed 24 hours later (48 hours after transfection). 
 BRET. Transfected cells were dissociated and re-suspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were re-
suspended in PBS. For agonist experiments, after 5 minutes, 5 µM of the luciferase substrate 
coelenterazine H was added to each well. After 5 minutes, ligands were added and the BRET 
signal was measured 5 minutes later on a PHERAstar FS plate reader. For cAMP, cells were first 
incubated with forskolin (1 µM) for 5 minutes prior to coelenteratzine h addition. For antagonist 
competition experiments, cells were pre-incubated with the antagonist at varying concentrations 
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for 30 minutes. Coelenterazine H (5 µM) was then added to each well for 5 minutes. Following 
coelenterazine H incubation, a fixed concentration of the reference agonist (5x EC50) was added, 
and the BRET signal was measured at 30 minutes on a PHERAstar FS plate reader. The BRET 
signal was quantified by calculating the ratio of the light emitted by the energy acceptor, mVenus 
(510-540 nm) or citrine (510-540 nm), over the light emitted by the energy donor, RLuc8 (485 
nm). This drug-induced BRET signal was normalized using the Emax of [D-Ala2, N-Me-Phe4, 
Gly-ol5]-enkephalin (DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-50,488 as the maximal 
response at MOR, DOR, and KOR respectively. Dose response curves were fit using a three-
parameter logistic equation in GraphPad Prism 6. 
 Materials: Mouse Ki Determination. IBNtxA and [125I]BNtxA were synthesized at 
MSKCC as previously described.78–80 Na125I was purchased from Perkin-Elmer (Waltham, MA). 
 Radioligand Competition Binding Assays with Mouse Receptors (performed at 
Memorial Sloan Kettering Cancer Center by Dr Susruta Majumdar). [125I]BNtxA binding 
was carried out in membranes prepared from Chinese Hamster Ovary (CHO) cells stably 
expressing murine clones of MOR, DOR, and KOR, as previously described.78,80,81 Assays were 
performed at 25 °C for 90 min in 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM 
magnesium sulfate. After the incubation, the reaction was filtered through glass-fiber filters 
(Whatman Schleicher & Schuell, Keene, NH) and washed three times with 3 mL of ice-cold 50 
mM Tris-HCl, pH 7.4, on a semiautomatic cell harvester. Nonspecific binding was defined by 
addition of levallorphan (8 µM) to matching samples and was subtracted from total binding to 
yield specific binding. Ki values were calculated by nonlinear regression analysis (GraphPad 
Prism, San Diego, CA). Protein concentrations were determined using the Lowry method with 
BSA as the standard.82 
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 Human Ki Determination. Binding constants (Ki) at the human opioid receptors were 
generously determined using radioligand displacement experiments by the National Institute of 
Mental Health's Psychoactive Drug Screening Program, Contract #HHSN-271-2008-00025-C 
(NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of 
North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda, MD, USA. 
For experimental details please refer to the PDSP website (https://pdspdb.unc.edu/pdspWeb/). In 
all cases, the reported Ki values are the average of 3 or more independent experiments, each run 
with triplicate wells for each ligand concentration. 
 Imaging. 2P or confocal imaging with MP was performed on a Prairie Ultima or Leica 
SP5 upright microscopes equipped with either the Coherent Chameleon or MaiTai laser, 
respectively. Images were obtained using a 20x objection at 800 nm excitation wavelength. A 
525/50 nm emission filter was used. Drugs were applied via bath application. The BODIPY Tr 
Ceramide dye was purchased from Thermo Fisher Scientific (#D7540). 
 Immunofluorescence. mMOR-CHO cells were grown in Ham’s F-12 supplemented with 
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin, and 200 µg/mL hygromycin B 
prior to the experiment. The cells were starved with serum free media for 3-5 hours before 
treatment with drugs (10 µM) for 5 min or 1 hr. Cells were then fixed with 4% formaldehyde in 
PBS, washed with PBS, permeabilized (0.25% Triton X-100 in PBS), washed, blocked (2% 
glycine, 2% bovine serum albumin in 50 mM NH4Cl) for 30 min at 37 oC and incubated 
overnight with anti-MOR antibodies (1:200 in blocking solution; Abcam #ab134054) at 4 oC. 
Cells were then washed 5X with PBS, blocked again for 30 min at 37 oC, and incubated with a 
mixture of anti-rabbit Alexa Fluor® 594 secondary antibody (1:1000 in blocking solution; Cell 
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Signaling #8889) and Hoechst stain (1:10,000). The cells were then washed 5X in PBS and 
imaged on a Leica DMI400B microscope. 
 Inhibition of VMAT2. A HEK cell line stably expressing rVMAT2 (VMAT2-HEK) was 
kindly provided by Professor Robert Edwards of the Department of Neurology at the University 
of California San Francisco (UCSF). Cells were cultured in a 5% CO2 atmosphere at 37 oC in 
DMEM + GlutaMAX (Invitrogen #10569) supplemented with 10% FBS (Atlanta Biologicals) 
and 100 U/mL penicillin and 100 µg/mL streptomycin. 
 rVMAT2-HEK cells were seeded at a density of 0.04-0.05 x 106 cells per well in black 
flat-bottom 96-well plates and incubated in growth medium at 37 ºC for approximately 3 days to 
reach confluence. On the day of the experiment, the complete growth medium was aspirated, 
wells were washed with 200 µL PBS, and treated with 100 µL/well experimental medium 
(DMEM without phenol red containing 25 mM HEPES and 1% FBS) with DMSO (vehicle), the 
control inhibitor reserpine of varying concentrations, or experimental compound of varying 
concentrations. The cells were incubated for 30 min at 37 °C. FFN206 (100 µL/well of 1.5 µM 
solution in experimental medium) was added to each well and incubated for 60 min at 37 ºC. The 
experimental medium was aspirated, 120 µL of PBS was added to each well, and the cells were 
incubated for another 20 min at 37 °C. The experiment was terminated by replacement with 120 
µL fresh PBS into each well. The fluorescence uptake in cells was immediately recorded using a 
BioTek H1MF plate reader (3x3 area scan, bottom read mode) with excitation and emission 
wavelengths set at 368 nm and 464 nm, respectively.  Extent of inhibition was determined as the 
difference between signal and basal measurements: mean fluorescence uptake of FFN206 (with 
DMSO vehicle) minus that in the presence of the experimental compound. These values were 
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normalized to reserpine (100% inhibition) to yield a normalized fraction of inhibition. Dose 
response curves were fit using a three-parameter logistic equation in GraphPad Prism 6. 
Calculations 
Operational Model Ligand Bias Calculations. Log(τ/KA) for individual data sets was 
estimated using a GraphPad Prism program developed by Robert Lane. For full agonists, the 
LogKA values were set to zero. EMax, n (Hill slope), and basal values were shared across all data 
sets. It was important to use the calculated LogKA (functional affinity) from the data sets, since 
experimental binding affinity may not account for multiple active receptor conformations. The 
calculated Log(τ/KA) were then converted into bias factors as shown in the Chapter 1 (Equations 
2 and 3). 
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 The natural product and hallucinogen ibogaine, isolated from the shrub Tabernanthe 
iboga, together with other members of the 
iboga alkaloid family, including ibogamine, 
continue to be used in ritualistic ceremonies 
by shamans of a West African (Gabon) 
spiritual practice known as Bwiti (Figure 1).1–
3 More interestingly, in the past few decades 
ibogaine has been shown to hold real promise 
for treating substance use disorders (SUDs) by 
affecting not only craving and self-
administration of many drugs of abuse, 
including alcohol, opioids, and cocaine, but 
also symptoms of acute opioid withdrawal, 
such as mydriasis, sweating, elevated pulse 
rate, shivering, piloerection, diarrhea, or 
prolonged vomiting.4 These remarkable effects from ibogaine can be sustained for longer periods 
of time, as well (weeks to even months).5 While the clinical data represent a collection of 
uncontrolled studies and anecdotal reports5, these effects have also been observed in animal 
models.6–8 For instance ibogaine elicits dose-dependent decreases of morphine self-
administration in rats, which lasts in some rats for several days or weeks after a single dose.6 
 
Figure 1. Leaves and fruiting bodies of Tabernanthe 




Additionally, a single administration of ibogaine has been shown to dose-dependently decrease 
intake of both alcohol and cocaine in rats.7,8 
Although studied for many years, the mechanism of action explaining ibogaine’s unique 
properties is still unclear. Numerous reports show that ibogaine binds to and/or shows functional 
activity at many targets in the central nervous system (CNS) with modest micromolar affinity 
and/or potency, including the N-methyl-D-aspartate receptor (NMDAR), the dopamine and 
serotonin transporters (DAT and SERT, respectively), mu-opioid receptor (MOR), sigma 2 
receptor, 5-HT2a receptor, acetylcholine receptors, and others9–12, which makes ibogaine a 
controversial and potentially dangerous therapeutic. Additionally, ibogaine has been reported to 
cause heart arrhythmias12, which may be due to the inhibition of human ERG channels (potency 
near 4 µM).12,13 Studies on the pharmacology of both ibogaine and its metabolite noribogaine are 
ongoing.14,15 For instance, although ibogaine has been shown to be an NDMAR antagonist in 
tissue from different brain regions (potency of <10 µM)16–18, the activity at the MOR has not yet 
been confirmed, which does suggest an alternative mechanism by which ibogaine may 
ameliorate opioid withdrawal.19 Interestingly, a recent report by Mash and coworkers discusses 
the opioid activity of noribogaine (EC50 = 9 µM at the human kappa-opioid receptor, KOR)20, so 
it is possible that ibogaine’s effects on opioid withdrawal might in fact be mediated through its 
metabolite.15  
Given ibogaine’s polypharmacological actions and potentially dangerous side effects21, 
there is a great need to isolate the therapeutic mechanisms by studying alternative iboga analogs 
that may be more selective for the beneficial effects.22 Several research groups have been 
pursuing this course of action. Deborah Mash, for instance, has spent several decades exploring 
the clinical use of ibogaine, opening the first medically-based ibogaine clinic (Clear Sky 
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Recovery in Cancún, Mexico). Stanley Glick first identified the active metabolite noribogaine23, 
which has since demonstrated many promising effects in vivo24 and is now entering clinical trials 
in New Zealand.25 Additionally the iboga analog 18-methoxycoronaridine (18-MC) is effective 
at reducing self-administration of morphine, cocaine, ethanol, and nicotine in rodent models for 
addiction.26 As an antagonist of the α3β4 nicotinic receptor with greater selectivity in the CNS 
compared to ibogaine, 18-MC may be a suitable alternative to ibogaine. More exotic hypotheses 
connect ibogaine’s effects on alcohol addiction and cravings to the modulation of growth factor 
glial cell line-derived neurotrophic disorder (GDNF, see Chapter 6).27–30 There has also been a 
push to develop completely novel modifications to the ibogaine structure in the hopes of having 
more selective pharmacology within the CNS. Such compounds have been reported, which bind 
to dopamine and serotonin transporters, the KOR, and the NMDAR, but no follow-up on these 
studies have yet been reported.31 Given our ongoing interest in studying opioid receptor 
modulators32,33, we decided to utilize the latter approach in order to identify novel iboga alkaloid 
analogs that would show increased selectivity for the opioid receptors, which ultimately could 
provide beneficial therapeutics for pain, mood disorders, and substance mood disorders. 
This chapter will describe the synthesis and biological activity of a novel class of iboga 
alkaloid analogs. Utilizing the structure of the active metabolite noribogaine, we found that 12-
hydroxy-oxaibogamine analogs showed promising activity at the opioid receptors, increasing the 
potency compared to noribogaine up to 280-, 6.5-, and greater than 300-fold at KOR, MOR, and 
delta-opioid receptor (DOR), respectively. We also found that one compound in particular, 36c, 
shows apparent biased activation of KOR and therefore represents an interesting lead in the 




Biological Activity of Noribogaine at the Opioid Receptors 
Ibogaine is reported to bind quite promiscuously to receptors and transporters in the CNS 
(see Introduction), including many studies that show binding by both ibogaine and its active 
metabolite noribogaine to the opioid receptors with modest affinity.15,23,34–36 Additionally, Mash 
and co-workers showed that 
noribogaine stimulated 
[35S]GTPγS binding to rat 
thalamic membranes with  
an EC50 of 324 nM (EMax = 
100%), activity which could 
be competitively inhibited 
by the MOR antagonist 
naloxone. Ibogaine showed 
weak stimulation of 
[35S]GTPγS binding with a 
theoretical EC50 > 100 
mM.37 Given the low 
affinity with which ibogaine 
binds to the opioid receptors, 
it is unlikely that opioid  
receptor activation accounts for the unique biological effects observed from ibogaine 
administration. However it is possible that noribogaine, which binds in the submicromolar range 
Table 1. Reported Binding Affinities of Ibogaine (A) and its Metabolite 




Tissue KOR MOR DOR 
Bovine Cortex34 2.08 ± 0.23 > 100 > 100 
Calf Brain23 3.77 ± 0.81 11.04 ± 0.66 > 100 
Calf Brain15 2.2 ± 0.10 2.0 ± 0.15 > 10 
Rat Thalamus37 - 3.76 ± 0.223 - 
Rat Forebrain36 29.8 ± 8.3 - - 
Mouse Forebrain36 13.8 ± 0.60 - - 
Not specified35 3.16 - - 
    
B.    
 
Noribogaine 
Tissue KOR MOR DOR 
Calf Brain23 0.96 ± 0.080 2.66 ± 0.62 24.72 ± 2.26 
Calf Cortex15 0.61 ± 0.015 0.68 ± 0.016 5.2 ± 0.64 
Rat Thalamus37 - 0.16 ± 0.012 - 
Rat Forebrain36 0.28 ± 0.11 - - 
Mouse Forebrain36 1.2 ± 0.10 - - 













(approximately 10 fold greater affinity than ibogaine at MOR), may elicit some signaling 
through the opioid receptors if high enough concentrations are reached in the brain – highly 
likely in the situation of an “ibogaine reset” where multigram doses are taken (Table 1). 
Therefore it is plausible that noribogaine may act as a substitute for an abused opioid at opioid 
receptors and help to alleviate withdrawal symptoms. This hypothesis is in line with reported 
pharmacokinetic studies on ibogaine, which reveal micromolar concentrations reached in the 
brain.2,38–42 Additionally noribogaine has been reported to show binding at some of the 
monoamine transporters, specifically the dopamine transporter (DAT, IC50 = 3 µM), the 
vesicular monoamine transporter (VMAT, unspecified isoform, IC50 = 29 µM), and the serotonin 
transporter (SERT, IC50 = 0.04 µM).40 We also found noribogaine to inhibit human DAT, human 
SERT, and human NET with IC50 = 10.1 ± 6.6, 0.52 ± 0.07, and 43 ± 9.3 µM, respectively 
(Figure 2). 
 
Figure 2. Noribogaine Inhibits Human Monoamine Transporters. In overexpressed cells (EM4 or HEK-293), 
noribogaine inhibits the specific uptake of acridone dye NG54 at human DAT (A), SERT (B), and NET (C) with an 
IC50 = 10.1 ± 6.6, 0.52 ± 0.07, and 43 ± 9.3 µM, respectively. Data represent mean ± SD of n > 2 independent 
experiments. Data obtained by Yekaterina Kovalyova. 
 
In order to further characterize the opioid modulating activity of noribogaine, it was 
important to assess its activity in our own functional assays for G protein activation. Using 
bioluminescence resonance energy transfer (BRET) assays (see Chapter 1) in HEK cells 

































































































transiently expressing either KOR, MOR, or DOR, the agonist and antagonist activity of 
noribogaine was determined. Noribogaine displayed partial agonist activity at all three opioid 
receptors, with an EC50 of 5.6 ± 2.6 µM (Emax = 36%) at MOR and weaker potency at KOR (24.6 
± 8.8 µM, Emax = 43%) and DOR (>50 µM) (Figure 3). In comparison to previous literature  
 
Figure 3. Agonist Activity of Noribogaine at the Human Opioid Receptors. hKOR (A), hMOR (B), or hDOR (C) 
were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the 
average of n ≥ 6, with error bars representing ± SEM. A. Positive control = U-50,488. Noribogaine showed an EC50 
= 24.6 ± 8.8 µM and EMax = 43%. B. Positive control = [D-Ala2, N-Me-Phe4, Gly-ol5]-enkephalin (DAMGO). 
Noribogaine showed an EC50 = 5.6 ± 2.6 µM and EMax = 36%. C. Positive control = [D-Pen(2,5)]enkephalin 
(DPDPE). Noribogaine showed an EC50 > 50 µM. 
 
reports of functional activity (EC50 = 324 nM, EMax = 100% at rat MOR and EC50 = 9 µM, EMax = 
72% at human KOR) these data are comparable though somewhat weaker. Given the different 
species of MOR (rat versus humans) and assay ([35S]GTPγS binding for both versus BRET) 
tested previously, the potencies reported here do seem reasonable. Despite the noted differences 
between data sets generated by independent researchers, the data in aggregate support the 
hypothesis that high enough concentrations of noribogaine (produced by metabolism of 
ibogaine) could elicit physiologically relevant signaling through the opioid receptors. This 
hypothesis is supported by pharmacokinetic profiles of ibogaine in human (20 mg/kg oral dose) 
and monkey (25 mg/kg oral dose), where noribogaine can be detected (from ibogaine dose) in 
plasma at concentrations of ~ 2 µM and ~ 1 µM, respectively.38,39 Several separate studies found 
that the ibogaine concentration in rat brain following a single dose was higher than those found 
in plasma,41,43 suggesting that noribogaine might also exist at higher levels than those found in 






































































the plasma. A large, multi-gram dose of ibogaine (as used in the “reset”), therefore, is likely to 
result in significant amounts of noribogaine in plasma and brain. 
 
Discovery and Biological Activity of Novel Oxaibogamine Analogs 
 Initial Structure Activity Relationships (SAR) Reveal Alternate Scaffold. Inspired by the 
preliminary findings, we set out to explore the SAR of novel analogs that would improve the 
opioid activity. In preliminary studies, the opioid activity of three iboga alkaloid analogs  
 
Figure 4. Initial Structure Activity Relationships in the Iboga Alkaloid Scaffold. hKOR (A), hMOR (B), or hDOR 
(C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the 
average of n ≥ 3, with error bars representing ± SEM. Modification of the heteroarene moiety in structures 1-2 
reveals enhanced efficacy at hKOR (A). 
 
varied at the heteroatom (denoted X 
in Figure 5), including one known 
compound, ibogamine, was assessed. 
It was found that compared to 
ibogamine, which had no measurable 
activity at any of the three receptors, the benzofuran analogs (1a and 1b) showed a notable 















































































Ibogamine: X = NH-, 4-exo
1a: X = O-, 4-exo
1b: X = O-, 4-endo
2: X = S-, 4-endo
4
 
Figure 5. Design of 12-hydroxy-16-oxaibogamines as new opioid 
receptor modulators based on preliminary SAR studies. 
 137 
increase in efficacy at KOR, although still exhibiting a weak activity  (Figure 4). Both 
compounds showed no measurable activity at MOR or DOR. The lack of activity from 
ibogamine suggested that the 12-hydroxy functionality be wholly necessary (for the scaffold 
numbering, see Figure 5). This hypothesis is further supported when comparing the structures of 
ibogaine and noribogaine where there is a clear necessity for a metabolism of the methyl ether 
into the phenol functionality on the indole system in order to increase functional activity at the 
opioid receptors. Similar trends can be found in the classical opium-derived opioids. For instance, 
codeine is a weak analgesic that binds to the MOR with 300 times lower affinity than morphine 
and can be readily metabolized to morphine through a demethylation reaction, much like in 
ibogaine.44,45 It was therefore hypothesized that iboga analogs, containing both the 12-hydroxy 
substitution and the benzofuran heteroarene, would impart a greater potency at the opioid 
receptors (Figure 5). 
Synthesis of 12-Hydroxy-Oxaibogamine Analogs. Employing methods previously 
developed in our group46,47, the isoquinuclidine portion of the molecule was synthesized through 
a Diels-Alder reaction and subsequent tosylhydrazone formation to separate exo- and endo-
isomers (Scheme 1A). After tosyl hydrazone reduction and carbamate deprotection the 
secondary amines were coupled with the 5-methoxy benzofuran intermediate 12 via amine 
alkylation (Scheme 1B). These advanced intermediates were cyclized using the Ni-catalyzed C-
H functionalization reaction developed in our group to provide 12-methoxy-oxaibogamine 
analogs.46 A final demethylation with ethanethiol and aluminum chloride yielded the 12-
hydroxy-oxaibogamine analogs (Scheme 1C). For the benzothiophene intermediate 13c, 
electrophilic palladation conditions were necessary to complete the cyclization reaction (Scheme 
1D). This chemistry was optimized and completed by Andrew Kruegel. A summary list of the 
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first generation 12-hydroxy-oxaibogamine analogs 
can be found in Figure 6. 
Functional Activity of Novel 12-Hydroxy-
Oxaibogamine Analogs. The combination of both the 
benzofuran functionality with the 12-hydroxy 
substituent analogous to noribogaine proved to 
greatly increase both potency and efficacy in 
comparison to noribogaine itself. The exo-ethyl 
analog (15a) showed full agonism at all three opioid receptor subtypes (Figure 7, EC50 KOR = 
0.66 ± 0.13 µM; EC50 MOR = 0.98 ± 0.14 µM; EC50 DOR = 4.5 ± 1.2 µM), representing a major 
improvement in functional activity. The endo-ethyl analog (15b) interestingly showed 
differences in both potency and efficacy at the three receptors compared to the exo-isomers 
(Figure 7, EC50 KOR = 0.16 ± 0.09 µM (EMax = 100%); EC50 MOR = 0.83 ± 0.28 µM (EMax = 78%); 
EC50 DOR = 2.8 ± 1.6 µM (EMax = 29%)). Consequently, the 12-hydroxy substitution in these 
analogs proved to be crucial, while the exo- and endo-stereochemistry conveyed some control 
 
Figure 7. Agonist Activity of the First Generation 12-Hydroxy-Oxaibogamine Analogs at the Human Opioid 
Receptors. hKOR (A), hMOR (B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay 
G protein activation. Curves represent the average of n=3, with error bars representing ± SEM. Analog 15a shows 
EC50 KOR = 0.66 ± 0.13 µM (EMax = 100%), EC50 MOR = 0.98 ± 0.14 µM EMax = 100%), and EC50 DOR = 4.5 ± 1.2 µM. 
Analog 15b shows EC50 KOR = 0.16 ± 0.09 µM (EMax = 100%), EC50 MOR = 0.83 ± 0.28 µM (EMax = 78%), and EC50 
DOR = 2.8 ± 1.6 µM (EMax = 29%). 
 









































































Figure 6. First Generation Oxa- and Thia-
ibogamine Analog. 
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over efficacy and subtype selectivity. Analogs with the 12-methoxy substitution instead 
(analogous to ibogaine) showed much weaker potency and efficacy by orders of magnitude (14a 
and 14b, Table 2). Such SAR highlights the importance of the phenolic substitution for 
activation of the opioid receptors. The implications of such biological activity are quite 
intriguing. The idea of polypharmacology as a way to treat different diseases has been reported 
in the literature 
previously. A 
compound that activates 
both KOR and MOR 
offers a potentially 
improved physiological 




could result from 
combined modulation of 
the three opioid 
receptors. For example, 
the mood enhancement 
from MOR signaling 
combating the aversive effects of KOR activation, and KOR activation providing non-addictive 
pain relief (see Introductory Chapter 1 for further discussion), it is possible that this opioid 
Table 2. Summary of Functional Activity of Iboga Alkaloid Analogs at the 
Human Opioid Receptors. 
Compound KOR MOR DOR 
Noribogaine 24.6 ± 8.8 (43%) 5.6 ± 2.6 (36%) >50 
Ibogamine X X X 
1b 27.5 ± 2.4 (43%) X X 
1a 56.5 ± 11.2 (60%) X X 
2 21.0 ± 3.8 (50%) X X 
14a 23.9 ± 2.8 (62%) 38.6 ± 2.0 (50%) X 
14b 25.0 ± 17.1 (43%) X X 
15a 0.66 ± 0.13 (100%) 0.98 ± 0.14 (100%) 4.5 ± 1.2 (100%) 
15b 0.16 ± 0.09 (100%) 0.83 ± 0.28 (78%) 2.8 ± 1.6 (29%) 
15c 4.5 ± 3.4 (70%) 7.2 ± 4.2 (46%) >50 
30a 0.46 ± 0.27 (85%) 0.52 ± 0.16 (100%) 1.9 ± 1.5 (100%) 
30b 0.24 ± 0.06 (41%) 0.49 ± 0.2 (85%) 1.9 ± 0.8 (64%) 
30c 10.5 ± 1.1 (16%) 2.8 ± 0.1 (86%) 7.6 ± 1.6 (58%) 
32a 1.3 ± 0.3 (87%) 12.2 ± 6.5 (62%) 25.2 ± 4.7 (28%) 
32b 27 ± 5.9 (20%) > 50 > 50 
36a 1.7 ± 1.1 (26%) 4.7 ± 3.6 (24%) X 
36b 0.44 ± 0.06 (88%) 0.40 ± 0.06 (98%) 4.2 ± 0.7 (98%) 
36c 0.12 ± 0.01 (47%) X X 
36d 0.14 ± 0.006 (72%) 0.37 ± 0.24 (50%) 5.1 ± 2.2 (24%) 
36e 0.09 ± 0.02 (81%) 0.86 ± 0.02 (30%) 0.31 ± 0.0003 (20%) 
36f IC50 = 8.2 ± 0.5 
0.43 ± 0.23 
X X 
(5S)-46 1.4 ± 1.2 (41%) 4.2 ± 2.0 (61%) 10 ± 10 (20%) 
EC50 values are shown in µM with EMax relative to control shown in parentheses.  
Value in italics represents the pA2 determined through Schild analysis. “X” means 
inactive. Data shown represent mean ± SD of various replicates (µM). 
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polypharmacology may help to balance out the negative effects of signaling through each opioid 
receptor individually. It is unclear at this point what levels of activation from each receptor are 
necessary to provide the ideal “chord,” however compounds such as these offer a promising 
possibility for an all-in-one drug for treating pain and or depression. Further studying the SAR of 
this scaffold may reveal what tuning is necessary to provide the ideal combination of 
pharmacology. Similar analogs were also synthesized utilizing the benzothiophene core, which 
in the initial SAR studies showed improvement over the indole substitution, but while active at 
the opioid receptors, this heteroarene substitution was inferior when compared to benzofuran 
 
Figure 8. Benzothiophene 15c Shows Weaker Activity at the Opioid Receptors Compared to the Benzofuran 
Analog. hKOR (A), hMOR (B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G 
protein activation. Analog 15c shows EC50 KOR = 4.5 ± 3.4 µM (EMax = 70%), EC50 MOR = 7.2 ± 4.2 µM (EMax = 46%), 
and EC50 DOR > 50 µM. Curves represent the average of n=3, with error bars representing ± SEM. 
 
(Compound 15c, Figure 8, EC50 KOR = 4.5 ± 3.4 µM (EMax = 70%); EC50 MOR = 7.2 ± 4.2 µM 
(EMax = 46%); EC50 DOR > 50 µM). 
 Analogs 15a and 15c were also measured for their ability to inhibit monoamine 
transporters. At human DAT, 15a and 15c showed an IC50 = 8.4 ± 3.9 and 0.69 ± 0.16 µM, 
respectively (Figure 9a). At human SERT, 15a and 15c showed an IC50 = 2.6 ± 1.2 and 0.06 ± 
0.01 µM, respectively (Figure 9b). At human NET, 15a and 15c showed an IC50 = 14.9 ± 8.1 
and 7.0 ± 7.0 µM, respectively (Figure 9c). Based on these data, it appears that the 
benzothiophene moiety of analog 15c imparts a much stronger potency for inhibition of these 







































































monoamine transporters than does the benzofuran functionality. It also appears that these analogs, 
in general, have increased selectivity for SERT over DAT and NET. 
 
Figure 9. Oxa- and Thia-ibogamine Analogs Inhibit Human Monoamine Transporters. In overexpressed cells (EM4 
or HEK-293), analogs 15a and 15c inhibit the specific uptake of acridone dye NG54 at DAT (A), SERT (B), and 
NET (C). 15a showed an IC50 = 8.4 ± 3.9, 2.6 ± 1.2, and 14.9 ± 8.1 µM at DAT, SERT, and NET, respectively. 15c 
showed an IC50 = 0.69 ± 0.16, 0.06 ± 0.01, and 7.0 ± 7.0 µM at DAT, SERT, and NET, respectively. Data represent 
mean ± SD of n > 2 independent experiments. Data obtained by Yekaterina Kovalyova. 
 
Exploring the SAR of Exo- and Endo-Substituents Within the Oxaibogamine Scaffold 
Synthesis of Analogs Beyond the Ethyl Substituent. In an effort to understand the SAR 
surrounding the exo- and endo-substituents at position 4 (see Figure 5 above), a few key analogs 
were designed and synthesized. Looking to our exploration within the tianeptine scaffold (see 
Chapter 2), we wanted to synthesize compounds that contained a methoxy methyl ether at 
position 4. We were also interested in understanding how much space was available in the 
putative receptor binding pocket for both exo- and endo-substituents. Consequently, we chose to 
synthesize analogs with a bulky benzyl substituent in the exo- and endo-position. In order to 
study these compounds, a different synthetic route was needed to gain access to these novel 
isoquinuclidines. In contrast to the racemic route to the isoquinuclidine that utilized 
vinylmethylketone as the dienophile, we instead employed acrolein and an oxazolidine 
organocatalyst in the Diels- Alder reaction, followed by epimerization and reduction, to 
synthesize isoquinuclidine alcohol 17. These intermediates were then either be O-methylated to 
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intermediates 18a and 18b, or brominated and subjected to Suzuki conditions to obtain the endo-
benzyl isoquinuclidine 20 (Scheme 2A). This chemistry was optimized and completed with 
Andrew Kruegel and Dr. Souvik Rakshit. 
Due to limited amounts of intermediates, a separate synthetic scheme was devised for the 
exo-benzyl isoquinuclidine, which utilized more readily available materials. Dihydropyridine 
was reacted in a Diels-Alder reaction to yield the ethyl ester substituted isoquinuclidine 21, 
which was then hydrolyzed and converted into the Weinreb amide 23. This isoquinuclidine was 
then converted to phenyl ketone 24, reduced, iodinated, and reduced again before carefully 
isolating the exo-intermediate 27. These isoquinuclidines could then be reacted as before with 
heteroarene 12 followed by cyclization and demethylation to provide analogs 30. For endo- 
Scheme 3. Synthesis of Exo- and Endo-Substituted Phenyl and Ether Analogs. 
 
intermediates 28b and 28d, the substrates were apparently unreactive to the Ni-catalyzed 
cyclization conditions (Scheme 3A-B). The exo-phenyl analog 30c was synthesized by Andrew 
Kruegel. Presumably in the endo-configuration, the nitrogen at position 6 is more exposed due to 
1) TMSI
    CH2Cl2
    0 °C to R.T.
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the farther positioning of the ethyl substituent, which makes it substantially more basic. It is 
likely that the increased basicity provides a means to interfere with the catalytic species in the 
reaction, thus greatly reducing the reactivity of the substrate. For this reason, intermediates 28b 
and 28d had to be cyclized using traditional electrophilic palladation conditions (Scheme 3C). In 
the demethylation of exo-intermediate 29a, we were 
able to isolate both the singly (30a) and doubly 
(30b) demethylated analogs. Interestingly, in the 
demethylation of the endo-intermediate 31a, we 
were only able to isolate the doubly demethylated 
analog. This intermediate was found to be more 
reactive to demethylation conditions than the exo-
analog, leading to rapid conversion to the doubly 
demethylated analog 32a. A summary of this second generation of 12-hydroxy-oxaibogamine 
analogs is listed in Figure 10. 
 Functional Activity of Second Generation 12-Hydroxy-Oxaibogamine Analogs at the 
Opioid Receptors. The second generation oxaibogamine analogs 30 and 32 revealed interesting 
SAR at the opioid receptors. Analog 30a, for example, was in a similar potency range to the 
ethyl analogs 15a-b, showing tolerance in the exo-position for an ether substituent (Figure 11, 
EC50 KOR = 0.46 ± 0.27 µM (EMax = 85%); EC50 MOR = 0.52 ± 0.16 µM (EMax = 100%); EC50 DOR = 
1.9 ± 1.5 µM (EMax = 100%)). In the doubly demethylated analog 30b, the first example of 
partial agonism at KOR was observed with similar potency compared to the corresponding ethyl 
analogs (Figure 11, EC50 KOR = 0.24 ± 0.06 µM (EMax = 41%); EC50 MOR = 0.49 ± 0.2 µM (EMax = 
85%); EC50 DOR = 1.9 ± 0.8 µM (EMax = 64%)). We were pleased to see the modulation of opioid 
 
Figure 10. Second Generation 12-Hydroxy-
Oxaibogamine Analogs 30 and 32. 
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agonism to different levels of efficacy in this series of analogs, which indicated that tuning 
opioid potency and efficacy might be possible by alteration of this specific position. The doubly 
demethylated endo-alcohol 32a, showed similar potency compared to analogs 30a-b (Figure 11, 
EC50 KOR = 1.3 ± 0.3 µM (EMax = 87%); EC50 MOR = 12.2 ± 6.5 µM (EMax = 62%); EC50 DOR = 25 
± 5 (EMax = 28%)). 
 Figure 11. Agonist Activity of the Second Generation 12-Hydroxy-Oxaibogamine Analogs at the Human Opioid 
Receptors Highlighting Ether and Alcohol Substituents. hKOR (A), hMOR (B), or hDOR (C) were co-expressed 
with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Analog 30a shows EC50 KOR = 0.46 ± 0.27 µM 
(EMax = 85%), EC50 MOR = 0.52 ± 0.16 µM (EMax = 100%), and EC50 DOR = 1.9 ± 1.5 µM (EMax = 100%). Analog 30b 
shows EC50 KOR = 0.24 ± 0.06 µM (EMax = 41%), EC50 MOR = 0.49 ± 0.2 µM (EMax = 85%), and EC50 DOR = 1.9 ± 0.8 
µM (EMax = 64%). Analog 32 shows EC50 KOR = 1.3 ± 0.3 µM (EMax = 87%), EC50 MOR = 12.2 ± 6.5 µM (EMax = 62%), 
and EC50 DOR = 25 ± 5 (EMax = 28%). Curves represent the average of n > 2, with error bars representing ± SEM. 
  
The benzyl-substituted analogs 30c and 32b (Figure 12) were helpful in furthering our 
understanding of SAR in terms of the configuration at this position. While exo-analog 30c 
showed minimal activity at the opioid receptors (Figure 12, EC50 KOR = 10 ± 1 µM (EMax = 16%);  
 
Figure 12. Agonist Activity of the Second Generation 12-Hydroxy-Oxaibogamine Analogs at the Human Opioid 
Receptors Highlighting Benzyl Substituents. hKOR (A), hMOR (B), or hDOR (C) were co-expressed with GαoB-
RLuc8, β1, and mVenus-γ2 to assay G protein activation. Analog 30c shows EC50 KOR = 10 ± 1 µM (EMax = 16%), 
EC50 MOR = 2.8 ± 0.1 µM (EMax = 86%), and EC50 DOR = 7.6 ± 1.6 (EMax = 58%). Analog 32b shows EC50 KOR = 27 ± 6 
µM (EMax = 20%), EC50 MOR > 50 µM, and EC50 DOR > 50 µM.Curves represent the average of n = 2, with error bars 
representing ± SEM.  
 





















































































































































EC50 MOR = 2.8 ± 0.1 µM (EMax = 86%); EC50 DOR = 7.6 ± 1.6 (EMax = 58%)), the endo-benzyl 
analog 32b had even weaker activity (Figure 12, EC50 KOR = 27 ± 6 µM (EMax = 20%); EC50 MOR 
> 50 µM; EC50 DOR > 50 µM). The differences seen in endo- versus exo-substitutions in the ether 
and alcohol analogs were mirrored in the benzyl analogs, with exo-substituents being somewhat 
more potent. Indeed, given the steric bulk of the phenyl analogs, it is possible that there is less 
space in the binding pocket of the opioid receptors to accommodate such a large functional group 
in the endo-position. 
Synthesis and SAR of Oxaibogamines Leads to Novel Analogs with Biased Receptor 
Signaling 
Scheme 4. Synthesis of 7-Substituted 12-Hydroxy-Oxaibogamine Analogs. 
 
 Synthesis of Bridgehead-Substituted Analogs. In exploring the SAR of this scaffold 
further, we found that introduction of a new chiral center at position 7 in the bridgehead imparted 
promising biological activity. The required ketone intermediates 33 (Scheme 4A, 33a-b) were 
synthesized from benzofuranone 9 via a Wittig reaction. The deprotected isoquinuclidine was 
then coupled via a reductive amination with ketones 33 to provide a mixture of methyl- or ethyl-
substituted diastereomers (at the position 7). These diastereomers could be separated after the Ni-
catalyzed C-H activation reaction and then demethylated as described above (Scheme 4B). 














33a: R = Me
33b: R = Et
N
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Bn/MeO2C 1) TMSI, DCM
0 oC --> RT, 1.5 h
2) 33, Et3N, NaBH(OAc)3
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remained unreactive, even when subjected to the 
electrophilic palladation conditions shown in Schemes 
1D and 3C. This is in contrast to analog 36e where the 
opposite bridehead stereochemistry was able to be 
isolated, suggesting some difference in reactivity 
imparted by the 4 position. Chemistry was optimized 
and completed by Andrew Kruegel with the help of 
Elizaveta Kulko. A summary of the third generation 12-
hydroxy-oxaibogamine analogs can be found in Figure 13. 
 Functional Activity of Bridgehead-Substituted Analogs. Substitution of a methyl group on 
carbon 7 (see Figure 5 for numbering) proved to offer new opportunities for modulating opioid 
receptor activity. The endo- and exo-7 substituted exo-ethyl analogs showed modest potency at 
all three opioid receptors (Table 2). With the single switch to the endo-ethyl analogs (at the 
position 4), the two compounds showed a minor increase in potency at KOR and compound 36d 
showed partial agonism at all three receptors (Figure 14, EC50 KOR = 0.14 ± 0.006 µM (EMax = 
72%); EC50 MOR = 0.37 ± 0.24 µM (EMax = 50%); EC50 DOR = 5.1 ± 2.2 µM (EMax = 24%)), and 
 
Figure 14. Agonist Activity of Third Generation 12-Hydroxy-Oxaibogamine Analogs 36c-d. hKOR (A), hMOR (B), 
or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Analog 36c 
shows EC50 KOR = 0.12 ± 0.01 µM (EMax = 47%). Analog 36d shows EC50 KOR = 0.14 ± 0.006 µM (EMax = 72%), EC50 
MOR = 0.37 ± 0.24 µM (EMax = 50%), and EC50 DOR = 5.1 ± 2.2 µM (EMax = 24%). Curves represent the average of n ≥ 
3, with error bars representing ± SEM. 
 







































































Figure 13. Third Generation 12-Hydroxy-
Oxaibogamine Analogs 36a-f. 
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compound 36c showed selective partial agonism at KOR (Figure 14, EC50 KOR = 0.12 ± 0.01 µM 
(EMax = 47%)). While there is currently limited evidence, it is possible that a potent, partial 
agonist may avoid some of the unwanted side effects from opioid signaling (such as 
hallucinations at KOR or constipation at MOR) by not activating the receptor to its fullest, thus 
curbing the signaling in comparison to a fully efficacious drug. For example, the partial MOR 
agonist buprenorphine (see Discussion below) was shown to cause less respiratory depression in 
comparison to other opioids like levorphanol and methadone in rhesus monkeys, thus 
highlighting this principle.48 Drawing similarity from this example at MOR, as a selective partial 
KOR agonist, 36c may be less dysphoric than classical KOR agonists like salvinorin A and is 
likely to have low abuse potential. Ethyl substitutions on the bridgehead carbon also showed 
interesting activity at the opioid receptors. The compound 36e (“iso-ethyl” with respect to 15b) 
represents the most potent compound in the series at KOR and shows selectivity for KOR over 
MOR and DOR (Figure 15, EC50 KOR = 0.09 ± 0.02 µM (EMax = 81%); EC50 MOR = 0.86 ± 0.02 
µM (EMax = 30%); EC50 DOR = 0.31 ± 0.0003 µM (EMax = 20%)). The endo-ethyl analog (36f) 
 
Figure 15. Third Generation 12-Hydroxy-Oxaibogamine Analog 36e is a Potent and Selective KOR Agonist. hKOR 
(A), hMOR (B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein 
activation. Analog 36e shows EC50 KOR = 0.09 ± 0.02 µM (EMax = 81%), EC50 MOR = 0.86 ± 0.02 µM (EMax = 30%), 
and EC50 DOR = 0.31 ± 0.0003 µM (EMax = 20%). Curves represent the average of n = 3, with error bars representing 
± SEM.  
 
was unique in this series in that it shows antagonism at KOR (Figure 16, IC50 KOR = 8.2 ± 0.5 
µM), the only compound in this scaffold showing such biological activity. Additionally, Schild 
analysis of 36f revealed an A2 of 0.43 ± 0.23 µM and slope of 0.9 ± 0.03, indicating a 







































































competitive mode of action (Figure 16). While KOR antagonists have little therapeutic potential 
for pain, they are widely reported to have 
antidepressant effects in several animal 
models.49–51 Therefore additional testing on 
this compound is necessary to assess its 
potential for antidepressant therapy. Clinical 
trials with KOR antagonists are only just 
beginning.52 A phase I trial with selective 
KOR antagonist JDTic has concluded, but the 
compound caused tachycardia in some 
subjects and thus will not be continuing in 
additional trials aimed at assessing behavioral 
effects.53  
 New Analog Shows G Protein Biased 
Signaling. In order to better understand the 
biological activity within this scaffold, 
compound 36c was chosen as the most 
promising lead to move forward in more 
complex signaling studies. As a selective 
KOR agonist, compound 36c represents an 
alternative to MOR agonists, like morphine, 
for pain relief since KOR agonists do not 
activate the dopamine reward pathway (in fact, 
 
Figure 16. Third Generation 12-Hydroxy-
Oxaibogamine Analog 36f is a KOR Antagonist. 
hKOR was co-expressed with GαoB-RLuc8, β1, and 
mVenus-γ2 to assay G protein activation. A. 36f was 
tested for KOR antagonism. Control antagonist  = nor-
BNI, and agonist U-50,488 was used at 5x its EC50 
concentration. B. Control agonist U-50,488 was 
incubated with increasing concentrations of 36f. C. 
Schild plot of (B) reveals a competitive antagonist 
mode of action. Curves represent the average of n = 3, 
with error bars representing ± SEM. 
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KOR agonists negatively control the release and extracellular concentration of dopamine).54,55 As 
such, KOR agonists are a non-addictive therapeutic for pain. They do, however, have their own 
unwanted side effects, like dysphoria (see Introductory Chapter 1). While compound 36c may 
avoid some of these effects due its partial activation of the receptor, a more suitable alternative 
would be to avoid the unwanted side effects altogether. It is hypothesized that such unwanted 
side effects are mediated through the arrestin signaling associated with GPCR activation. 
Therefore, if a compound could selectively activate the G protein signaling cascade over the 
arrestin signaling, then this biased signaling could provide the analgesic benefits of receptor 
activation while avoiding the aversive side effects (again see Chapter 1).56,57  
 In order to assess whether compound 36c showed any arrestin recruitment, a different 
BRET assay was utilized. Using KOR tagged with RLuc8 (BRET donor) and Arrestin-3 tagged 
with the yellow fluorescent protein variant mVenus (BRET acceptor), a positive BRET signal 
can be correlated with arrestin recruitment. When compound 36c was tested in this BRET 
recruitment assay (see 
Introductory Chapter 1 
for more detail), there 
was no measurable 
recruitment of arrestin 
when compared to either 
the control U-50,488 or 
other oxaibogamine 
analogs 15a and 15b 
(Figure 17), thus indicating an extreme efficacy bias for G protein activation. Therefore, further 
 
Figure 17. 12-Hydroxy-Oxaibogamine Analog 36c Shows No Measureable 
Arrestin Recruitment. hKOR-RLuc8 was transfected with Arr3-Venus and 
GRK3. A. 36c shows an apparent bias towards G protein signaling with no 
obvious arrestin recruitment detected. B. Other 12-hydroxy-oxaibogamine 
analogs show arrestin recruitment similar to the control compound U-50,488. 
Curves represent the average of n ≥ 3, with error bars representing ± SEM. 
BRET recruitment assay used. 
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testing of 36c is warranted to determine if the unique biological activity observed in vitro 
translates into distinct behavioral effects in vivo, including for example, a lack of aversive side 
effects. 
Enantioselective Synthesis of Oxaibogamine Analog (5S)-46. In an attempt to better 
understand the biology of these new compounds, we decided to undertake an enantioselective 
synthesis of select analogs. In the current synthetic route described above, all compounds are 
synthesized in racemic form. Since the natural product ibogaine itself (and consequently its 
metabolite, noribogaine) are optically pure, there was interest in comparing the activity of our 
racemically prepared compounds with their active enantiomers (defined at carbon 5, see Figure 
5 above). Utilizing a previously described method for preparing enantiomerically enriched 
isoquinuclidines58, the required chiral oxazolidine catalyst 38 was synthesized from the 
corresponding amino alcohol and benzaldehyde (Scheme 5A). This organocatalyst was then 
utilized in a Diels-Alder reaction similar to that seen in Scheme 2A with dihydropyridine and 
acrolein to provide the endo-isoquinuclidine (Scheme 5B, (1R)-16). This material was then 
epimerized and reduced to provide 
both the exo- and endo- alcohols 
((1R)-17a and (1R)-17b) as the 1R-
enantiomer in ~85 and > 95% ee, 
respectively, determined on chiral 
HPLC. Due to the large bulk from the 
phenyl groups on the oxazolidine 
catalyst, control over the equilibrium 
between iminium intermediates from the dienophile is obtained, which effectively blocks one 
 
Figure 18. Oxazolidine Organocatalyst Leads to High 
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imminium face from attack by the diene, leading to high enantioselectivity (Figure 18). The si-
face attack allows for greater frontier orbital overlap between diene and dienophile, which 
ultimately enhances the 
enantioselectivity. We 
chose the enantiomer to 
synthesize based on the 
absolute configuration of 
ibogaine. In order to 
confirm the absolute 
stereochemistry of 
isoquinuclidines (1R)-17, a 
crystal structure was 
needed. Because (1R)-17 is isolated as an oil, it was necessary to convert it to a compound that 
not only could be crystallized, but also contained a heavy atom near the stereocenter in question. 
Based on these criteria, compound 42 was prepared (Scheme 5C), crystallized and the X-ray 
structure analysis obtained (the structure was solved by Serge Ruccolo in the Parkin laboratory); 
the absolute geometry was thus independently confirmed (Figure 19). 
 Next, isoquinuclidines (1R)-17 were subjected to a copper-catalyzed cross-coupling 
reaction59 to transform the alcohol into a methyl group, thus providing the desired 
enantiomerically enriched isoquinuclidines (Scheme 5D). Given the diverse scope of triflates 
and reaction conditions reported for this reaction, much optimization was required to obtain 
satisfying yields on our substrate (not included in this report). After converting the alcohol (1R)-
17 to a triflate, this material was used directly in the copper-catalyzed cross-coupling reaction 
 
Figure 19. X-Ray Crystal Structure of Isoquinuclidine 42 Confirms Relative 
and Absolute Configuration. 
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utilizing dilithium tetrachlorocuprate (II) and methyl magnesium bromide. Exploring various 
temperatures, reaction times, and reagent order, optimal conditions were determined (Table 3), 
which provided yields consistently >60% (highest yield obtained at 96%).  
 
 Once intermediates 43 were synthesized, the same synthetic route described in Scheme 4 
could be utilized. Given the consistently higher yields seen for exo-isomers both in the reductive 
amination and the nickel-catalyzed C-H activation reaction, it was decided that exo-intermediate 
43a should be carried forward through the rest of the synthesis and tested in our biological assays. 
Isoquinuclidine 43a was thus reacted with ketone 33a, cyclized, and demethylated as before to 
provide enantiomerically enriched (5S)-46 (>85% ee from (1R)-17a, Scheme 5D). 
 
Figure 20. Enantiomerically Enriched 12-Hydroxy-Oxaibogamine Analog Shows Similar Biological Activity to Its 
Racemic Form. hKOR (A), hMOR (B), or hDOR (C) were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to 
assay G protein activation. Analog 36a shows EC50 KOR = 1.7 ± 1.1 µM (EMax = 26%) and EC50 MOR = 4.7 ± 3.6 µM 
(EMax = 24%). Analog (5S)-46 shows EC50 KOR = 1.4 ± 1.2 µM (EMax = 24%), EC50 MOR = 4.2 ± 2.0 µM (EMax = 61%), 
and EC50 DOR = 10 ± 10 µM (EMax = 20%). Curves represent the average of n = 3, with error bars representing ± SEM. 
 
 Oxaibogamine Enantiomer Has Similar Functional Activity to its Racemic Analog. Next, 
we aimed to assess the biological activity of enantiomer (5S)-46 alongside the parent racemic 














































































 (mol%) Order of 
Addition 
Temp (°C ) Time (h) Conversion 
(Yield) 
1 3% 1. Li2CuCl4, MeMgBr -15 2 h à O/N Incomplete (<10%) 
2 3% à 9% 1. MeMgBr, Li2CuCl4 -15 à RT 2 h Complete (10%) 
3 20% 1. MeMgBr, Li2CuCl4 -15 1 h Complete (30%) 
4 20% 1. Li2CuCl4, MeMgBr -80 à -15 2 h Complete (43%) 
5 50% 1. Li2CuCl4, MeMgBr -45 30 m Complete (96%) 
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analog 36a (Figure 20). Interestingly, we found that their biological activities were similar 
across all three opioid receptors; racemic 36a showed weak activity at the KOR and MOR opioid 
receptors (EC50 KOR = 1.7 ± 1.1 µM (EMax = 26%); EC50 MOR = 4.7 ± 3.6 µM (EMax = 24%) and no 
activity at DOR in this concentration range; enantiomer (5S)-46 shows essentially the same 
activity at KOR (EC50 KOR = 1.4 ± 1.2 µM, EMax = 24%), while improved efficacy at MOR  (EC50 
MOR = 4.2 ± 2.0 µM, EMax = 61%), and marginal but detectable activity at DOR (EC50 DOR = 10 ± 
10 µM, EMax = 20%). Given the nearly identical potency and efficacy between racemic 36a and 
its enantiomer 46, it seems that the (5S)- and (5R)-enantiomer (untested) impart similar 
biological activity at KOR. At MOR it is plausible that weak partial agonism from the less active 
5R enantiomer may inhibit the activity of the more active 5S enantiomer in the racemic mixture. 
In order to confirm these findings, the (5R)-enantiomer of the compound should be synthesized 
for comparison. Since the biological activity of 36a and (5S)-46 were so similar, we decided 
against synthesizing other enantiomerically pure compounds at this time and will continue with 
the racemic forms in future in vivo studies. 
 
Discussion 
Mechanism of Action of Ibogaine. The non-selective nature of ibogaine’s binding within 
the CNS has led to a much-contested debate about its ultimate mechanism of action. Although 
ibogaine is reported to bind to many targets with only relatively weak affinities, the large dose of 
the drug administered during an “ibogaine reset” implies that high enough concentrations of the 
drug may be reached in the brain to make these weak targets relevant (see Introduction).2,41,42 
Given the known acute effects of the ibogaine treatment (severe hallucinations, nausea, vomiting, 
headaches)5 and binding affinities of ibogaine to CNS targets, a likely starting point in the 
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biological activity of ibogaine is NMDAR antagonism. NMDAR antagonists are well known to 
have dissociative effects and several of these compounds have been reported to attenuate the 
acquisition and/or expression of drug dependence (e.g., drug self administration and other 
aspects of drug dependence states).60,61 Further, ibogaine is well known to be a noncompetitive 
inhibitor of SERT (both in our laboratory and others), regulating the dissociation of serotonin 
into the cytoplasm, as well as at DAT.62,63 The effects of dual SERT-DAT inhibition in several 
animal models are known to reduce cocaine self-administration, which could additionally 
contribute to the unique properties of ibogaine on drug dependence. It is interesting that as a 
natural product, ibogaine is modulating the function of many CNS targets that are key players in 
psychiatry – namely selective serotonin reuptake inhibitors for depression and mood disorders 
and NMDAR antagonists for depression (see Introductory Chapter 1 for further discussion). In 
this regard, NMDAR antagonism can lead to increased brain-derived neurotrophic factor 
(BDNF) release and remodeling of brain circuitry64, perhaps in response to damage caused from 
drug dependence. In a similar manner, the known release of GDNF following ibogaine 
administration in rats may also act to reset the dopaminergic reward system resulting in 
decreased alcohol self-administration.27 
Upon first-pass metabolism of ibogaine to noribogaine, opioid activity may then play a 
role in the known effects of ibogaine. KOR activation by noribogaine may also contribute to the 
hallucinations, however with the added MOR activation may lead mood enhancement (after the 
dissociative effects subside). NMDAR is also known to potentiate MOR signaling and thus there 
is a possibility for additive or synergistic effects. In terms of reported side effects, there are 
reported cases of cardiac arrhythmia following ibogaine consumption. It is likely that these 
effects are caused by hERG channel blockade.12 This brief analysis leads to a reasonable 
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pharmacological hypothesis for both the acute and long-term effects of ibogaine reset, where the 
users emerge feeling hopeful and apparently free from addiction. 
Important SAR of Iboga Scaffold. In order to enhance the opioid activity in this scaffold, 
SAR was explored to find more potent compounds. Using a systematic approach, simple changes 
to the core iboga structure were made in order to understand what key features of the scaffold 
were necessary for opioid activity. This method of SAR exploration revealed the importance of 
benzofuran substitution within the iboga scaffold over the parent indole structure. When 
combined with the 12-hydroxy substitution of noribogaine, novel analogs were identified with 
greatly increased potency and efficacy when compared to noribogaine. Deborah Mash and 
colleagues are actively pursuing noribogaine itself in controlled clinical trials for opioid 
substance abuse, suggesting that both ibogaine and noribogaine are bioavailable compounds with 
proven clinical efficacy. In this regard, compounds such as those described here, being distinct 
yet closely related to ibogaine itself, will likely retain many of the favorable properties of this 
natural product, including blood brain barrier penetration, favorable pharmacokinetics and 
metabolism, and safety in human usage (noribogaine specifically)25, which highlights the 
therapeutic potential for these analogs.  
Implications of Polypharmacology. Successful drug candidates are often praised for their 
selectivity for one biological target over another. In fact, off target activity is a common downfall 
of lead candidates before reaching the clinical stage of development. If a drug binds to many 
targets at therapeutic doses, this can lead to unwanted side effects and muddle the beneficial 
signaling imparted by the main mechanism of action. Polypharmacology, however, is currently 
being utilized in the context of many diseases, including Alzheimer’s disease65, cancer66, 
viruses67, and anti-inflammatory diseases68. The idea of polypharmacology is interesting in the 
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context of opioid signaling as well. Buprenorphine, for instance, has mixed KOR antagonism and 
MOR partial agonism.69 Used clinically for treating both pain and substance abuse disorders, 
buprenorphine is as efficacious as morphine for analgesia but has a lower risk of respiratory 
depression.70 It has additionally been found in multiple clinical trials to have antidepressant 
effects, not surprising given its dual opioid activity.71–73 While some report the antidepressant 
effects of buprenorphine to be mediated solely through its KOR antagonism74, there is a likely 
contribution from MOR agonism, as well (see tianeptine Chapter 2). There are various other 
examples of mixed opioids: MP1104, an IBNtxA analog, is a KOR and DOR agonist with potent 
analgesic effects that does not cause aversion, preference, or rewarding behavior75; MGM-16 is a 
mitragynine alkaloid analog (see Chapter 3) that is 240 times more potent than morphine in the 
mouse tail-flick test and shows promise for treating neuropathic pain76; and a DOR 
antagonist/MOR agonist is being pursued in the clinic for the treatment of irritable bowel 
syndrome.77 Interestingly there is a report exploring the synthesis and characterization of iboga 
analogs with proposed activity at the opioid receptors. The study looks promising in that 
compounds tested show comparable analgesia to morphine in mice, however with nothing but 
binding data provided at the opioid receptors, it is difficult to appreciate the extent to which each 
opioid receptor plays a role in these in vivo results.78 Finally, selective targeting of MOR/DOR 
heteromers (See Introductory Chapter 1) represents a novel (yet controversial) form of 
polypharmacology.79  
With the three opioid receptors containing a high level of homology80, it is not surprising 
that they share some pharmacology. When activated, all three opioid receptors are known to have 
analgesic properties, however each holds unique cellular and physiological effects, as well. We 
have reported MOR agonists to also have antidepressant and anxiolytic effects32, while KOR 
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antagonists and DOR agonists have been shown to have antidepressant-like effects in rodents. 
One can imagine that finding the right combination of receptor activity may allow the tuning of 
desired effects while mitigating those that are undesired. In many ways, this concept is still in its 
infancy for therapeutic purposes, but it does expand the possibilities for finding the most 
effective treatments for patients, especially as we begin to understand on the molecular level 
what causes disease in any one individual. 
Biased Signaling as a Path to Better Therapeutics? It is widely reported that opioid 
activation can lead to many unwanted side effects.81 For instance, KOR activation, while offering 
a non-addictive alternative to morphine, is known to cause dysphoria and hallucinations.82 MOR 
activation may lead to addiction and also causes respiratory depression, constipation, and 
tolerance to therapeutic effects.83 Finally, DOR activation can to lead to seizures in animals,84–88 
albeit with limited known adverse effects in humans to date (see also Clinical Trial 
NCT00759395, unpublished).89 Considering these potentially dangerous side effects, it is not 
surprising that serious reservations cloud the development of new opioid therapeutics. However 
a new age of opioid usage is coming as scientists explore the idea of biased agonism suggested 
first by Laura Bohn90 for MOR and by Charles Chavkin56 for KOR (see Introductory Chapter 1 
for further background). It is hypothesized that if compounds can be identified with functional 
bias for G protein signaling over arrestin recruitment, then there is possibility for opioid 
therapeutics that will avoid deleterious effects altogether. Several examples are already showing 
promise both in literature and in the clinic. The KOR partial agonist 6’- guanidinonaltrindole (6’-
GNTI) has been reported by several groups to be G protein biased, acting as an antagonist of 
arrestin signaling and blocking receptor internalization.91,92 Although this compound shows real 
promise in the in vitro setting, its alleged inability to cross the blood brain barrier (BBB) has 
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halted the progress of study in vivo and in the clinic, highlighting the need for novel biased KOR 
agonists with improved brain penetration. Laura Bohn and coworkers have developed several 
brain-penetrant, functionally selective KOR agonists, however further exploration of these 
interesting compounds in vivo is unclear at this point.57 Additionally, Trevena has developed an 
MOR agonist, TRV130, that shows clear G protein bias in vitro, as well as potent analgesia with 
decreased respiratory suppression and gastrointestinal dysfunction.93 Currently TRV130 is in 
multiple clinical trials for post-operation (acute) pain, and thus scientists should observe direct 
evidence soon about how in vitro bias translates into human therapeutics. There is still an evident 
disconnect between what G protein bias actually means when applied to real therapeutic 
potential94, and therefore a greater effort needs to begin to move such studies to relevant circuits 
and cell types, and connect these findings with in vivo results. Compound 36c, reported here, 
stands out when compared to another G protein biased KOR agonist, like 6’-GNTI, for its 
improved physicochemical properties and potential BBB penetration and warrants further study 
in vivo. 
Arrestin does, however, regulate many important cellular functions, including receptor 
internalization and recycling (see Introductory Chapter 1 for more detail), making the benefit of 
developing G protein biased compounds unclear. For instance, morphine suffers from respiratory 
depression and tolerance development, but does not cause receptor internalization in every cell 
type, suggesting some level of G protein bias without beneficial effects.95 Further, Whistler and 
colleagues have found that MOR endocytosis actually reduces tolerance and dependence, 
suggesting that the mechanisms controlling some undesired opioid effects may be more complex 
than just biased versus unbiased signaling.96–98 One hypothesis suggests that prolonged MOR 
signaling could instead lead to the development of adverse effects rather than receptor 
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desensitization and endocytosis. In light of this evidence, exploring G protein biased compounds 




 Here we report on a new class of iboga alkaloid analogs that show much improved 
activation of the opioid receptors when compared to the ibogaine metabolite noribogaine. 
Through a targeted SAR exploration, we identified the necessity of the 12-oxaibogamine 
structure for opioid activity. Utilizing both organic chemistry to synthesize new analogs in this 
scaffold as well as in vitro pharmacology to measure the functional activity of these compounds, 
several analogs were identified with varying degrees of potency and efficacy at the KOR, MOR, 
and DOR. In particular, compound 36c shows apparent bias for G protein signaling over arrestin 
signaling in these assays. This compound and its close derivatives represent new leads for study 
in vivo. This G protein biased KOR agonist offers new hope for improved analgesic therapeutics 




 General Considerations. Reagents and solvents (including anhydrous solvents) were 
obtained from commercial sources and were used without further purification unless otherwise 
stated. All compounds were prepared in racemic form. All reactions were performed in flame-
dried glassware under argon atmosphere unless otherwise stated and monitored by TLC using 
solvent mixtures appropriate to each reaction. All column chromatography was performed on 
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silica gel (40-63 µm) and preparative TLC on 20 x 20 cm plates coated in a 1 mm silica layer. 
Nuclear magnetic resonance spectra were recorded on Bruker 300, 400, or 500 MHz instruments 
as indicated. Chemical shifts are reported as δ values in ppm referenced to CDCl3 (1H NMR = 
7.26 and 13C NMR = 77.16) or Methanol-d4 (1H NMR = 3.31 and 13C NMR = 49.00). 
Multiplicity is indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); p (pentet); h 
(heptet); dd (doublet of doublets); ddd (doublet of doublet of doublets); dt (doublet of triplets); td 
(triplet of doublets); dtd (doublet of triplet of doublets); ddt (double of doublet of triplets); m 
(multiplet); br (broad). For those described compounds containing a carbamate group, complex 
spectra with split peaks are observed. This effect can be ascribed to the presence of conformers 
about the carbamate group. Furthermore, compounds containing fluorine are subject to F-C 
coupling, resulting in splitting of some carbon peaks. As a result of these effects, multiple peaks 
may correspond to the same proton group or carbon atom. In some cases, this is indicated by an 
"and" joining two peaks or spectral regions. Alternatively, certain carbon peaks overlap and thus 
represent two carbons (indicated by (2C) designation). In all cases the assignments of these 
complex peaks were determined by COSY, HSQC, and/or DEPT-135 experiments. All carbon 
peaks are rounded to one decimal place unless such rounding would cause two close peaks to 
become identical. In these cases, two decimal places are retained. Low-resolution mass spectra 
(LR-MS) were recorded on a JEOL LCmate (ionization mode: APCI+). High-resolution mass 
spectra (HRMS) were acquired on a high-resolution sector-type double-focusing mass 
spectrometer (ionization mode: FAB+). In calculated high-resolution masses, the mass difference 
for loss of one electron has been taken into account for positive ions. 
 Compounds 3-19. The synthesis of compounds 3-19 was carried out as previously 
reported in our group.46,47 
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 endo-benzyl 7-benzyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (20). Potassium 
phenyltrifluoroborate (139 mg, 0.75 mmol) and bathophenanthroline (24 mg, 0.072 mmol) were 
combined with LiHMDS (376 mg, 2.25 mmol), NiBr2glyme (23 mg, 0.075 mmol), and sec-
butanol (1.5 ml) in a glovebox. The reaction was stirred at room temperature for 30 min. outside 
the glovebox followed by addition of bromide 19 (250 mg, 0.74 mmol). The reaction was then 
warmed to 60 °C and stirred for 21 h after which time it was cooled to room temperature and run 
through a short silica column with EtOAc (40 mL). The organics were concentrated to give a 
yellow oil, which was purified by column chromatography (6:1 hexanes:EtOAc) to give the pure 
product as a yellow oil (160.1 mg, 65%). 1H NMR (400 MHz, CDCl3) (spectrum complicated 
by conformers). δ 7.51 – 7.27 (m, 7H), 7.26 – 7.13 (m, 3H), 6.59 – 6.43 (m, 1.5H), 6.43 – 6.29 
(m, 0.5H), 5.18 (dd, J = 13.6, 6.4 Hz, 2H), 4.71 (dq, J = 4.9, 2.5 Hz, 0.5H), 4.54 (d, J = 6.2 Hz, 
0.5H), 3.31 (ddd, J = 10.1, 4.7, 2.4 Hz, 1H), 3.12 – 2.98 (m, 1H), 2.83 – 2.71 (m, 1H), 2.62 – 
2.32 (m, 3H), 1.99 – 1.85 (m, 0.6H), 1.79 (dt, J = 13.6, 4.9 Hz, 0.4H), 1.10 – 0.95 (m, 1H).13C 
NMR (101 MHz, CDCl3) (spectrum complicated by conformers and some minor impurities). δ 
155.43, 154.89, 140.08, 139.90, 137.42, 137.28, 135.42, 134.81, 131.14, 130.28, 129.17, 129.01, 
128.74, 128.12, 128.03, 127.61, 126.39, 77.80, 77.48, 77.16, 66.94, 49.36, 49.13, 47.48, 47.16, 
41.92, 40.80, 40.46, 31.57, 31.40, 30.41, 30.11. LR-MS calcd. for C22H24NO2+ [M+H]+ 334.18, 
found 334.35. 
Compounds 21-27. The synthesis of compounds 21-27 was carried out as previously 
reported in our group.47 
General Procedure for Preparation of N-arylalkylisoquinuclidines (28a-d). To a 
solution of a carbamate protected isoquinuclidine 18a-b or 20 or 27 (1 equivalent) in anhydrous 
CH2Cl2 (0.125 M, based on isoquinuclidine) at 0 °C was added iodotrimethylsilane (4 
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equivalents), and the resulting mixture was stirred for 10 min. at 0 °C and then at room temp. 
until TLC indicated that no isoquinuclidine remained (typically ~1 h). The reaction mixture was 
then concentrated to yield the deprotected isoquinuclidine hydroiodide salt in quantitative yield 
(for benzyl carbamate protected isoquinuclidines, the resulting salt was washed several times 
with hexanes to remove the benzyl iodide byproduct). To this material was added to 12 (1 
equivalent) and NaHCO3 (4 equivalents) followed by anhydrous CH3CN (0.208 M, based on 
isoquinuclidine), and the resulting mixture was refluxed until TLC indicated the disappearance 
of the bromide (typically >24 h). The reaction was then diluted with H2O, made strongly basic 
with aqueous NaOH, and extracted with CHCl3 (3x). The combined organics were washed with 
H2O, dried over Na2SO4, and concentrated to provide the crude product, which was purified by 
column chromatography with an appropriate solvent mixture (as described below for each 
compound). 
exo-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-7-(methoxymethyl)-2-
azabicyclo[2.2.2]oct-5-ene (28a). The product 28a was prepared according to the general 
procedure and was purified by column chromatography (15:1 hexanes:EtOAc, 2 column volumes 
 15:1 hexanes:EtOAc + 2% Et3N) and obtained as a light-brown oil (76.1 mg, 58%). 1H NMR 
(400 MHz, CDCl3) δ 7.46 (d, J = 1.2 Hz, 1H), 7.33 (d, J = 8.9 Hz, 1H), 6.97 (d, J = 2.6 Hz, 1H), 
6.87 (dd, J = 8.9, 2.6 Hz, 1H), 6.38 (ddd, J = 8.0, 6.4, 1.5 Hz, 1H), 6.30 (ddd, J = 8.1, 5.4, 1.4 Hz, 
1H), 3.86 (s, 3H), 3.54 (t, J = 9.0 Hz, 1H), 3.43 (dt, J = 5.4, 1.8 Hz, 1H), 3.33 (dd, J = 8.8, 5.7 
Hz, 1H), 3.27 (s, 3H), 3.06 (dd, J = 9.1, 2.4 Hz, 1H), 2.87 - 2.79 (m, 1H), 2.78 - 2.63 (m, 2H), 
2.53 (ddd, J = 11.2, 6.4, 2.6 Hz, 1H), 2.47 (ddd, J = 6.3, 4.6, 3.0 Hz, 1H), 1.93 (dt, J = 9.1, 2.6 
Hz, 1H), 1.74 (ddd, J = 5.5, 3.4, 2.0 Hz, 1H), 1.46 - 1.37 (m, 1H), 0.84 (ddd, J = 12.4, 5.2, 2.2 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 155.8, 150.3, 142.7, 133.6, 132.2, 129.2, 119.2, 112.6, 
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111.8, 102.5, 75.4, 58.8, 57.5, 56.2, 56.1, 53.8, 39.5, 31.4, 26.3, 22.9; LR-MS calcd. for 
C20H26NO3+ [M+H]+ 328.19, found 328.42. 
endo-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-7-(methoxymethyl)-2-
azabicyclo[2.2.2]oct-5-ene (28b). The product 28b was prepared according to the general 
procedure and was purified by column chromatography (5:1 hexanes:EtOAc with 2% Et3N) and 
obtained as a light-brown oil (173.1 mg, 50%). 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.1 
Hz, 1H), 7.32 (d, J = 8.9 Hz, 1H), 6.99 (d, J = 2.6 Hz, 1H), 6.87 (dd, J = 8.9, 2.6 Hz, 1H), 6.41 
(ddd, J = 8.1, 6.5, 1.4 Hz, 1H), 6.21 - 6.14 (m, 1H), 3.85 (s, 3H), 3.57 (ddd, J = 5.4, 2.9, 1.5 Hz, 
1H), 3.30 (s, 3H), 3.07 (dd, J = 9.5, 2.1 Hz, 1H), 3.01 - 2.97 (m, 2H), 2.89 - 2.72 (m, 3H), 2.59 - 
2.49 (m, 3H), 2.07 (dt, J = 9.6, 2.7 Hz, 1H), 1.72 (ddd, J = 12.3, 9.5, 2.8 Hz, 1H), 0.66 (ddt, J = 
12.5, 4.7, 2.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 156.1, 150.6, 142.7, 134.2, 130.2, 129.3, 
119.1, 113.1, 112.2, 102.7, 76.5, 59.0, 58.0, 56.4, 54.9, 54.9, 39.0, 31.4, 26.9, 23.4; LR-MS 
calcd. for C20H26NO3+ [M+H]+ 328.19, found 327.79. 
exo-7-benzyl-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2] oct-5-ene 
(28c). The product 28c was prepared according to the general procedure and was purified by 
column chromatography (20:1 hexanes:Et2O, 4 column volumes  20:1 hexanes:Et2O + 2% 
Et3N, 4 column volumes) and obtained as a pale-yellow oil (41.9 mg, 60%) as previously 
described.47 
endo-7-benzyl-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo [2.2.2]oct-5-ene 
(28d). The product 28d was prepared according to the general procedure and was purified by 
column chromatography (15:1 hexanes:EtOAc + 2% Et3N) and obtained as a pale-yellow oil 
(95.8 mg, 54%). 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.1 Hz, 1H), 7.38 (d, J = 8.9 Hz, 
1H), 7.34 - 7.31 (m, 2H), 7.26 - 7.21 (m, 3H), 7.02 (d, J = 2.6 Hz, 1H), 6.93 (dd, J = 8.9, 2.6 Hz, 
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1H), 6.53 (ddd, J = 7.9, 6.4, 1.4 Hz, 1H), 6.28 (ddd, J = 8.2, 5.4, 1.4 Hz, 1H), 3.90 (s, 3H), 3.32 
(ddd, J = 5.3, 2.7, 1.4 Hz, 1H), 3.10 (dd, J = 9.6, 2.1 Hz, 1H), 2.89 - 2.81 (m, 1H), 2.80 - 2.73 (m, 
2H), 2.62 - 2.54 (m, 3H), 2.45 (dd, J = 8.1, 6.7 Hz, 2H), 2.12 (d, J = 9.5 Hz, 1H), 1.83 (ddd, J = 
12.2, 9.1, 2.8 Hz, 1H), 0.98 - 0.93 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 156.1, 150.6, 142.7, 
140.9, 134.4, 130.2, 129.4, 129.2, 128.7, 126.3, 119.1, 113.0, 112.2, 102.8, 58.0, 57.1, 56.5, 54.7, 
42.4, 40.6, 31.9, 30.7, 23.3; LR-MS calcd. for C25H28NO2+ [M+H]+ 374.21, found 374.07. 
General Procedure for Preparation of Heteroarylazepines by Ni(0) C-H Insertion 
(29a-b). In a glovebox, a vial was charged with Ni(COD)2 (0.20 equivalents) and 1,3-bis(2,4,6-
trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene (IMes, 0.24 equivalents) followed by 
anhydrous heptane (0.100 M based on Ni((COD)2), and the resulting black solution was stirred at 
room temp. for 30 min. To this mixture was then added a solution of the N-
arylalkylisoquinuclidine substrate 28a-b (1 equivalent) in anhydrous heptane (0.333 M based on 
28), and the reaction vessel was sealed, removed from the glovebox, and heated at 130 °C for 3 h. 
After cooling to room temperature the reaction mixture was purified directly by a combination of 
column chromatography and/or preparative TLC as described below for each substrate. (*Note: 
For substrates that are insoluble in heptane, the catalyst solution is instead added into the 
heterogeneous mixture of the substrate and heptane.) 
Heteroarylazepine 29a. The crude reaction mixture was purified directly by column 
chromatography (20:1 hexanes:EtOAc + 2% Et3N) to yield the pure product 29a as a beige oil 
(27.1 mg, 55%). A few fractions contaminated with a co-eluting spot were further purified by 
preparative TLC using the same solvent system to yield additional product (9.3 mg, 19%). 1H 
NMR (400 MHz, CDCl3) δ 7.28 - 7.21 (m, 1H), 6.87 (d, J = 2.6 Hz, 1H), 6.81 (dd, J = 8.8, 2.6 
Hz, 1H), 3.85 (s, 3H), 3.57 (t, J = 8.9 Hz, 1H), 3.42 - 3.38 (m, 2H), 3.37 (s, 3H), 3.31 (dd, J = 
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9.0, 5.5 Hz, 1H), 3.24 - 3.14 (m, 3H), 3.00 (dt, J = 11.6, 1.9 Hz, 2H), 2.96 - 2.89 (m, 1H), 2.55 - 
2.44 (m, 1H), 2.13 - 1.96 (m, 2H), 1.88 (dq, J = 4.1, 2.0 Hz, 1H), 1.79 - 1.62 (m, 2H), 1.18 - 1.08 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 160.7, 155.7, 148.6, 131.4, 111.7, 111.4, 110.9, 101.8, 
75.2, 58.9, 56.1, 54.4, 52.9, 49.5, 40.5, 39.4, 33.2, 28.3, 26.1, 19.5; LR-MS calcd. for 
C20H26NO3+ [M+H]+ 328.19, found 327.79. 
Heteroarylazepine 29b. The crude reaction mixture was purified directly by column 
chromatography (30:1 hexanes:EtOAc + 1% Et3N) to yield the crude product as a yellow-orange 
oil. This material was further purified by preparative TLC (30:1 hexanes:EtOAc + 2% Et3N) to 
provide the pure product 29b as a nearly colorless glass (26.0 mg, 62%) as previously 
described.47 
General Procedure for Preparation of Hydroxyheteroarylazepines by 
Demethylation (30a-c). To a solution of the methoxyheteroarylazepine 29 (1 equivalent) in dry 
dichloromethane (0.125 M, based on 29) at 0 °C was added aluminum chloride (6 equivalents) 
followed by ethanethiol (18 equivalents), and the resulting mixture was allowed to warm to room 
temperature and stirred until TLC indicated the complete consumption of starting material 
(typically <1.5 h). The reaction was then quenched with saturated aqueous NaHCO3 (10 mL per 
mmol 29) and extracted with CH2Cl2 (4x-6x, until no further extraction by TLC). The combined 
organic layers were dried over Na2SO4 and concentrated to provide the crude product. This 
material was purified by column chromatography with an appropriate solvent mixture as 
described below for each substrate. 
Hydroxyheteroarylazepines 30a and 30b. The crude product was prepared according to 
the general procedure and purified by column chromatography (1:2 hexanes:EtOAc) to give both 
the ether (30a) and alcohol (30b) analogs. 
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30a. Ether 30a was prepared and separated as described above and obtained as a beige oil 
(10.3 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 2.5 Hz, 
1H), 6.71 (dd, J = 8.6, 2.6 Hz, 1H), 4.00 (br s, 1H), 3.61 (t, J = 9.2 Hz, 1H), 3.39 (s, 3H), 3.38 - 
3.28 (m, 2H), 3.16 - 3.07 (m, 2H), 3.04 (dd, J = 11.4, 2.8 Hz, 1H), 2.99 (t, J = 1.7 Hz, 1H), 2.92 
(d, J = 2.1 Hz, 2H), 2.43 - 2.35 (m, 1H), 2.03 - 1.96 (m, 2H), 1.85 (dp, J = 4.2, 2.2 Hz, 1H), 1.71 
(ddd, J = 14.1, 10.4, 4.1 Hz, 1H), 1.62 (dq, J = 10.2, 3.3 Hz, 1H), 1.15 - 1.07 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 160.4, 151.6, 148.5, 131.5, 111.8, 111.2, 110.9, 104.2, 75.0, 58.9, 54.4, 
53.0, 49.4, 40.1, 39.3, 32.9, 28.0, 25.9, 19.4; LR-MS calcd. for C19H24NO3+ [M+H]+ 314.18, 
found 314.47. 
30b. Alcohol 30b was prepared and separated as described above and obtained as a white 
solid (3.2 mg, 13%). 1H NMR (500 MHz, MeOD) δ 7.12 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 2.5 
Hz, 1H), 6.67 (dd, J = 8.7, 2.5 Hz, 1H), 3.69 (d, J = 5.4 Hz, 2H), 3.39 - 3.34 (m, 1H), 3.22 (d, J = 
3.5 Hz, 1H), 3.19 (s, 1H), 3.17 (d, J = 2.8 Hz, 1H), 3.13 (t, J = 1.9 Hz, 1H), 3.09 - 3.05 (m, 1H), 
2.95 (d, J = 9.4 Hz, 1H), 2.54 - 2.49 (m, 1H), 2.15 - 2.07 (m, 1H), 1.95 - 1.88 (m, 2H), 1.80 (ddd, 
J = 12.9, 4.1, 2.1 Hz, 1H), 1.69 - 1.62 (m, 1H), 1.41 (ddt, J = 12.9, 6.8, 2.4 Hz, 1H), 1.29 (s, 1H); 
13C NMR (126 MHz, MeOD) δ 161.2, 153.9, 149.5, 132.6, 112.8, 112.3, 111.4, 104.6, 66.3, 
57.2, 53.7, 50.2, 41.25, 41.22, 33.9, 28.4, 27.4, 19.9; LR-MS calcd. for C18H22NO3+ [M+H]+ 
300.16, found 300.44. 
Hydroxyheteroarylazepine 30c. The product 30c was prepared according to the general 
procedure and was purified by column chromatography (7:3 hexanes:EtOAc) and obtained as a 
white foamy solid (14.2 mg, 79%) as previously described.47 
Heteroarylazepine 31a. In a glovebox, a Schlenk flask was charged with 
Pd(CH3CN)4(BF4)2 (1.3 equivalents). It was then sealed and removed from the glovebox and 
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anhydrous CH3CN (0.093 M, based on Pd(CH3CN)4(BF4)2) was added to form a yellow solution. 
To this solution was added a solution of the substrate 28b (1 equivalent) in anhydrous CH3CN 
(0.028 M based on 28b) resulting in a color change (yellow to orange/orange-red). The reaction 
mixture was stirred for 2 h at room temperature and then warmed to 70 °C and stirred for a 
further 16 h. At this time, the reaction was cooled to 0 °C, and anhydrous MeOH (9 mL per 
mmol of 28b) was added followed by NaBH4 (3.2 equivalents), causing the immediate 
precipitation of palladium black. The resulting black mixture was stirred for 20 min. at 0 °C, then 
diluted with Et2O, filtered through celite, and the filter cake washed with additional Et2O (4x). 
The combined filtrate and washings were concentrated to afford the crude product. The product 
31c was purified by column chromatography (6:1 hexanes:EtOAc + 2% Et3N, 2 column volumes 
 4:1 hexanes:EtOAc + 2% Et3N, 2 column volumes  2:1 hexanes:EtOAc + 2% Et3N, 3 
column volumes) to provide a colorless oil (23.2 mg, 24%). 1H NMR (400 MHz, CDCl3) δ 7.28 
(s, 1H), 6.90 (d, J = 2.6 Hz, 1H), 6.84 (dd, J = 8.8, 2.6 Hz, 1H), 3.88 (s, 3H), 3.47 (dd, J = 5.2, 
2.4 Hz, 1H), 3.44 (dd, J = 5.2, 2.1 Hz, 1H), 3.39 (s, 3H), 3.35 (d, J = 2.0 Hz, 1H), 3.34 – 3.31 (m, 
1H), 3.29 – 3.27 (m, 1H), 3.26 – 3.23 (m, 1H), 3.13 (dt, J = 9.5, 2.9 Hz, 1H), 3.09 (m, 2H), 2.57 
– 2.48 (m, 2H), 2.02 (ddt, J = 22.6, 10.9, 2.8 Hz, 1H), 1.97 – 1.90 (m, 1H), 1.68 (dq, J = 13.4, 3.5 
Hz, 1H), 1.13 – 1.06 (m, 1H), 0.96 – 0.87 (m, 1H).; 13C NMR (101 MHz, CDCl3) δ 161.4, 
156.2, 148.7, 131.6, 112.6, 111.9, 111.3, 102.2, 76.0, 59.3, 56.5, 54.5, 53.6, 49.4, 39.8, 35.1, 
34.4, 28.1, 26.3, 19.4.; LR-MS calcd. for C20H26NO3+ [M+H]+ 328.19, found 328.19. 
Heteroarylazepine 31b. The product 31b was prepared according to the general 
procedure (see compound 31a above) was purified by column chromatography (10:1 
hexanes:EtOAc + 2% Et3N, 2 column volumes  6:1 hexanes:EtOAc + 2% Et3N, 2 column 
volumes  2:1 hexanes:EtOAc + 2% Et3N, 3 column volumes) followed by preparative TLC 
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(2:1 hexanes:EtOAc + 2% Et3N) and obtained as a yellow oil (20.5 mg, 20%). 1H NMR (400 
MHz, CDCl3) δ 7.32 – 7.24 (m, 5H), 7.23 – 7.18 (m, 1H), 6.89 (d, J = 2.5 Hz, 1H), 6.85 (ddd, J 
= 8.8, 2.6, 0.9 Hz, 1H), 3.88 (s, 3H), 3.52 – 3.47 (m, 1H), 3.43 – 3.37 (m, 1H), 3.27 – 3.19 (m, 
2H), 3.13 – 3.08 (m, 2H), 2.82 (dd, J = 3.3, 1.8 Hz, 1H), 2.76 – 2.72 (m, 2H), 2.54 (dtd, J = 10.6, 
5.9, 5.2, 3.1 Hz, 1H), 2.50 – 2.43 (m, 1H), 2.17 (ddt, J = 14.2, 11.9, 2.6 Hz, 1H), 2.03 – 1.94 (m, 
2H), 1.71 (dq, J = 13.3, 3.5 Hz, 1H), 0.95 – 0.87 (m, 1H).; 13C NMR (101 MHz, CDCl3) δ 
161.8, 156.2, 148.7, 145.4, 140.8, 131.6, 129.3, 128.9, 126.4, 112.7, 111.9, 111.5, 111.4, 102.1, 
56.5, 56.3, 53.8, 49.4, 41.8, 41.7, 34.9, 34.6, 31.8, 26.8, 19.3.; LR-MS calcd. for C25H28NO2+ 
[M+H]+ 374.21, found 374.31. 
Hydroxyheteroarylazepine 32a. The product 32a was prepared according to the general 
procedure (see compound 30 above) and purified by column chromatography (5% MeOH in 
CH2Cl2, 2 column volumes  10% MeOH in CH2Cl2, 2 column volumes  20% MeOH in 
CH2Cl2, 2 column volumes) to provide an off-white solid (5 mg, 28%). 1H NMR (500 MHz, 
MeOD) δ 7.13 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 6.67 (dd, J = 8.7, 2.5 Hz, 1H), 3.58 
(dd, J = 11.2, 6.4 Hz, 1H), 3.50 (dd, J = 11.2, 9.8 Hz, 1H), 3.41 – 3.35 (m, 2H), 3.17 – 3.11 (m, 
2H), 3.07 – 3.03 (m, 1H), 2.55 (dt, J = 16.8, 3.2 Hz, 1H), 2.38 (td, J = 9.0, 8.6, 4.1 Hz, 1H), 2.06 
(ddt, J = 14.3, 12.0, 2.7 Hz, 1H), 1.91 (h, J = 3.1 Hz, 1H), 1.89 – 1.84 (m, 1H), 1.63 (dq, J = 13.4, 
3.6 Hz, 1H), 1.11 (ddt, J = 13.0, 4.7, 2.5 Hz, 1H), 0.89 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
161.6, 154.0, 149.4, 132.3, 112.9, 111.5, 111.0, 104.5, 65.3, 55.3, 54.7, 49.9, 42.3, 34.7, 34.5, 
28.1, 26.9, 19.4; LR-MS calcd. for C18H22NO3+ [M+H]+ 300.16, found 300.27. 
Hydroxyheteroarylazepine 32b. The product 32b was prepared according to the general 
procedure (see compound 30 above) and purified by column chromatography (10:1 
hexanes:EtOAc, 2 column volumes   5:1 hexanes:EtOAc, 2 column volumes   2:1 
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hexanes:EtOAc, 2 column volumes) to provide an off-white solid (2 mg, 11%). 1H NMR (500 
MHz, CDCl3)  δ 7.22 (m, 5H), 7.20 (m, 1H), 6.82 – 6.78 (m, 1H), 6.72 – 6.68 (m, 1H), 3.87 – 
3.83 (m, 1H), 3.48 – 3.43 (m, 1H), 3.40 – 3.33 (m, 2H), 3.27 – 3.19 (m, 2H), 3.05 (s, 1H), 2.78 
(s, 1H), 2.72 – 2.67 (m, 2H), 2.50 (s, 1H), 2.41 – 2.36 (m, 1H), 2.17 – 2.11 (m, 1H), 2.05 – 1.99 
(m, 1H), 1.92 (s, 1H), 0.72 (t, J = 7.7 Hz, 2H); LR-MS calcd. for C24H26NO2+ [M+H]+ 360.20, 
found 360.38. 
Compounds 33-36. The synthesis of compounds 21-27 was carried out as previously 
reported in our group.47 
4-isopropyl-2,5,5-triphenyloxazolidine 2,2,2-trifluoroacetate (38). Oxazolidine 
catalyst 38 was prepared according to the procedures described previously47 and obtained as 
white solids.58 
N-(benzyloxycarbonyl)-1,2-dihydropyridine (39). Dihydropyridine 39 was prepared 
according to the procedures described and obtained as a pale yellow oil.99 
(1R)-exo-benzyl 7-(hydroxymethyl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate 
((1R)-17a) and (1R)-endo-benzyl 7-(hydroxymethyl)-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate ((1R)-17b). To a CH3CN (106 mL) solution of catalyst 38 (511 mg, 1.12 mmol), 
cold water (5.6 mL), trifluoroacetic acid (0.25 mL, 3.26 mmol), and freshly distilled acrolein 
(0.75 mL, 11.2 mmol) were added at 0 °C, and the solution was stirred. After 1 min., 39 (4.84 g, 
22.4 mmol, freshly purified) was added, and the solution was stirred at 0 °C for 24 h. The 
reaction was quenched with water (500 mL) and extracted with Et2O (3 x 200 mL). The 
combined organic extracts were washed with water and brine (100 mL), dried over Na2SO4, and 
concentrated under reduced pressure to give the crude endo-aldehyde (1R)-16 (5.7 g), which was 
used in the next reaction without further purification. 
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To a stirred solution of crude endo-aldehyde (1R)-16 (5.7 g) in anhydrous MeOH (30 
mL), NaOMe (3.0 g) was added, and the mixture was stirred at room temperature for 12 h. The 
reaction was quenched with water (500 mL), extracted with EtOAc (3 x 200 mL), dried over 
Na2SO4, and concentrated under reduced pressure to give the crude exo/endo mixture of 
aldehyde (4.5 g), which was used in the next reaction without further purification. 
To a stirred solution of the crude exo/endo-aldehyde (4.5 g) in ethanol (20 mL), NaBH4 
(488 mg, 12.9 mmol) was added, and the mixture was stirred at room temperature for 1 h. The 
solvent was evaporated under reduced pressure, and the residue was diluted with water (200 mL) 
and extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine 
(100 mL), dried over Na2SO4, and concentrated under reduced pressure. The epimers were 
separated by column chromatography (7:3 hexanes:EtOAc à 5:1 DCM:EtOAc) to give 18% 
(1R)-exo-alcohol (1R)-17a and 21% (1R)-endo-alcohol (1R)-17b over three steps. 
(1R)-17a. (1R)-exo-alcohol (1R)-17a was prepared and separated as described above and 
obtained as a colorless oil (560 mg, 18%). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 
6.52 – 6.38 (m, 2H), 5.27 – 5.04 (m, 3H), 4.81 (dt, J = 6.2, 1.7 Hz, 1H), 3.67 (dd, J = 11.7, 5.4 
Hz, 1H), 3.37 (d, J = 10.4 Hz, 1H), 3.28 – 3.17 (m, 2H), 3.03 (dt, J = 10.2, 2.5 Hz, 1H), 2.68 (tt, J 
= 3.7, 2.0 Hz, 1H), 1.97 – 1.78 (m, 1H), 1.62 – 1.49 (m, 1H), 0.85 (ddd, J = 12.9, 4.5, 2.2 Hz, 
1H), [OH not seen]. 13C NMR (101 MHz, CDCl3) (spectrum complicated by conformers) δ 
156.7, 155.5, 136.7, 134.6, 134.4, 132.5, 132.4, 128.5, 128.4, 128.4, 128.3, 127.9, 127.8, 127.6, 
127.6, 66.9, 66.8, 64.5, 53.5, 48.5, 48.3, 46.9, 46.3, 41.2, 41.1, 30.4, 30.2, 26.0, 25.7, 14.1. LR-
MS calcd. for C16H19NNaO3+ [M+Na]+  296.32, found 296.24. [α]23D = -52.1 (CHCl3). The 
enantiomeric excess was determined by chiral HPLC: tR = 20.3 min (Daicel Chiralcel OD 
column, Gradient 2% to 8% iPrOH in Hexanes, 0.3%/min, 1.2 mL/min), %ee = 85%. 
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(1R)-17b. (1R)-endo-alcohol (1R)-17b was prepared and separated as described above 
and obtained as a colorless oil (640 mg, 21%). 1H NMR (400 MHz, CDCl3) (spectrum 
complicated by conformers) δ 7.41 – 7.27 (m, 5H), 6.47 – 6.27 (m, 2H), 5.24 – 5.07 (m, 2H), 
4.95 – 4.81 (m, 1H), 3.33 – 3.23 (m, 2H), 3.17 (dd, J = 10.6, 8.9 Hz, 1H), 3.03 (m, 1H), 2.78 – 
2.68 (m, 1H), 2.37 (tt, J = 9.4, 5.2 Hz, 1H), 1.76 (ddd, J = 12.3, 7.9, 2.8 Hz, 1H), 0.87 – 0.79 (m, 
1H) [OH not seen]; 13C NMR (101 MHz, CDCl3) (spectrum complicated by conformers) δ 
155.1, 154.8, 136.6, 134.6, 134.4, 130.2, 129.9, 128.3, 128.3, 128.2, 127.7, 127.6, 127.4, 127.4, 
66.6, 66.5, 65.1, 64.9, 50.0, 47.2, 47.1, 46.8, 46.8, 41.3, 41.3, 30.6, 30.4, 25.9, 25.9. LR-MS 
calcd. for C16H19NNaO3+ [M+Na]+  296.32, found 296.31. [α]25D = -73.2 (CHCl3); The 
enantiomeric excess was determined by chiral HPLC: tR = 22.1 min (Daicel Chiralcel OD 
column, Gradient 2% to 8% iPrOH in Hexanes, 0.3%/min, 1.2 mL/min), %ee > 95%. 
Isoquinuclidine 40. To a solution of pyridine (0.12 mL, 1.48 mmol), (1R)-endo-alcohol 
(1R)-17b (180 mg, 0.66 mmol), 4-dimethylaminopyridine (DMAP, 4 mg, 0.03 mmol) in dry 
dichloromethane (5 mL) was added 2-iodobenzoylchloride (194.5 mg, 0.73 mmol) in 1 mL of 
dichloromethane. An additional 1 mL of dichloromethane was used to wash out the syringe. The 
reaction was stirred at room temperature for 45 h, after which time the reaction had gone to 
completion. The reaction was poured into 5% HCl (50 mL) and washed with additional 5% HCl 
(20 mL) and saturated NaHCO3 (20 mL). The organic layer was dried over MgSO4 and 
concentrated. The crude material was purified by column chromatography (1:9 MeOH:DCM) to 
give the product as a tan oil (210.5 mg, 65%). 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 8.0, 
3.0 Hz, 1H), 7.74 (dd, J = 7.8, 1.8 Hz, 1H), 7.63 (dd, J = 7.7, 1.8 Hz, 1H), 7.37 – 7.15 (m, 7H), 
7.07 (td, J = 7.7, 1.8 Hz, 1H), 6.47 – 6.25 (m, 2H), 5.06 (d, J = 12.0 Hz, 2H), 4.88 (ddd, J = 33.9, 
6.2, 2.8 Hz, 1H), 3.97 (dt, J = 10.7, 5.3 Hz, 1H), 3.77 (q, J = 11.0 Hz, 1H), 3.26 (dd, J = 10.3, 2.1 
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Hz, 1H), 2.97 (dq, J = 9.5, 3.0, 2.5 Hz, 1H), 2.79 – 2.67 (m, 1H), 2.66 – 2.53 (m, 1H), 1.81 (ddd, 
J = 12.2, 9.2, 2.8 Hz, 1H), 0.89 (ddd, J = 13.5, 6.8, 3.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
166.8, 155.6, 155.2, 141.7, 137.3, 135.8, 135.7, 135.3, 133.0, 131.5, 131.3, 130.9, 130.3, 128.9, 
128.4, 128.3, 128.2, 110.4, 94.5, 67.9, 67.8, 67.3, 67.2, 47.7, 47.6, 47.3, 38.6, 38.3, 31.2, 31.0, 
26.7, 26.6. LR-MS calcd. for C23H23INO4+ [M+H]+  504.34, found 504.23. 
Isoquinuclidine 41. Isoquinuclidine 40 was deprotected as described above (see 
compound 13). Briefly, isoquinuclidine 40 was dissolved in dichloromethane (3 mL) at 0 °C, and 
TMSI (0.24 mL, 1.62 mmol) was added. The reaction was stirred for 10 min. before warming to 
room temperature for 1 hr. The reaction was quenched with MeOH (3 mL) and concentrated to a 
crude brown oil that was washed with hexanes (5 X 1 mL). This crude oil was dried in vacuo 
before being dissolved in a minimal amount of MeOH and recrystallized overnight by vapor 
diffusion with diethyl ether. A first crop of 41 was isolated as a white solid (3.6 mg), and the 
mother liquors were concentrated and recrystallized in the same manner to yield a second crop 
(89 mg, 45% combined). 1H NMR (400 MHz, MeOD) δ 8.10 (dd, J = 8.0, 1.1 Hz, 1H), 7.85 (dd, 
J = 7.7, 1.7 Hz, 1H), 7.57 (td, J = 7.6, 1.2 Hz, 1H), 7.32 (td, J = 7.7, 1.7 Hz, 1H), 6.91 (ddd, J = 
8.3, 6.9, 1.5 Hz, 1H), 6.53 – 6.46 (m, 1H), 4.51 (ddd, J = 6.0, 2.6, 1.3 Hz, 1H), 4.22 (dd, J = 11.3, 
5.6 Hz, 1H), 4.00 (dd, J = 11.3, 9.6 Hz, 1H), 3.29 (dd, J = 11.4, 1.7 Hz, 1H), 3.12 (ddt, J = 5.8, 
2.9, 1.5 Hz, 1H), 2.86 (dt, J = 11.7, 3.0 Hz, 2H), 2.17 (ddd, J = 12.7, 9.3, 2.9 Hz, 1H), 1.20 – 
1.12 (m, 1H). 13C NMR (101 MHz, MeOD) δ 166.7, 140.8, 138.9, 135.8, 134.5, 132.54, 130.4, 
127.9, 125.9, 92.9, 66.1, 42.4, 33.6, 28.1, 24.9. LR-MS calcd. for C15H17INO2+ [M+H]+  370.21, 
found 370.14. 
Isoquinuclidine 42. Isoquinuclidine 41 (89 mg, 0.18 mmol) was dissolved in water (2.5 
mL), MeOH (2.5 mL), and saturated NH4PF6 (2.5 mL) and allowed to sit overnight at room 
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temperature. The product 42 was isolated as shiny beige crystals (66.9 mg, 73%). 1H NMR (400 
MHz, MeOD) δ 8.10 (d, J = 7.9 Hz, 1H), 7.86 (dd, J = 7.7, 1.7 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 
7.32 (td, J = 7.7, 1.7 Hz, 1H), 6.91 (t, J = 7.5 Hz, 1H), 6.53 – 6.41 (m, 1H), 4.53 – 4.45 (m, 1H), 
4.22 (dd, J = 11.3, 5.7 Hz, 1H), 4.00 (dd, J = 11.3, 9.5 Hz, 1H), 3.40 (p, J = 1.6 Hz, 1H), 3.27 (dd, 
J = 11.4, 1.8 Hz, 1H), 3.14 – 3.07 (m, 1H), 2.84 (ddt, J = 15.2, 9.0, 2.9 Hz, 2H), 2.16 (ddd, J = 
12.7, 9.3, 3.0 Hz, 1H), 1.16 (ddd, J = 10.3, 5.7, 2.8 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 
168.0, 142.7, 140.7, 137.5, 134.4, 132.2, 129.7, 127.6, 126.7, 94.4, 67.9, 44.2, 35.4, 29.8, 26.6. 
LR-MS calcd. for C15H17INO2+ [M+H]+  370.21, found 370.06. 
General Procedure for Preparation of Heteroarylazepines (1S)-exo-benzyl 7-ethyl-2-
azabicyclo[2.2.2]oct-5-ene-2-carboxylate (43a) and (1S)-endo-benzyl 7-butyl-2-
azabicyclo[2.2.2]oct-5-ene-2-carboxylate (43b) by Copper-Catalyzed Cross Coupling. A 
solution of trifluoromethanesulfonic anhydride (1.5 equivalents relative to alcohol (1R)-17) in 
anhydrous CH2Cl2 (to make 0.5 M solution) was added dropwise to a solution of alcohol (1R)-17 
(1 equivalent) and pyridine (11 equivalents) in anhydrous CH2Cl2 (0.18 M relative to (1R)-17) at 
0 °C over a period of 10 min.  The resulting mixture was stirred for 45 min. at 0 °C and then 
diluted with CH2Cl2 (10 mL per 0.2 mmol of (1R)-17), washed with 10% aqueous HCl (2X), 
water (1X) and 5% aqueous NaHCO3 (2X), and dried over Na2SO4. The solvent was removed 
under reduced pressure to afford essentially pure triflate product, which was used in the next step 
without further purification. 
Next, to a solution of freshly prepared crude triflate (1 equivalent) in anhydrous Et2O 
(0.18 M relative to (1R)-17) was added Li2CuCl4 (50 mol% from 0.1 M solution in THF) and 
then MeMgBr (3 equivalents, from 3.0 M solution in Et2O) slowly at -50 °C over 10 min, and the 
reaction mixture was stirred for 30 min at -50 °C. The reaction was quenched with saturated 
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NH4Cl (10 mL per 0.18 mmol of (1R)-17) and warmed to room temperature. The organic layer 
was separated, and the aqueous layer was extracted with diethyl ether (3 x 10 mL), dried over 
Na2SO4, and concentrated to afford the crude product. This material was purified by column 
chromatography (20:1 DCM:EtOAc) to provide pure isoquinuclidines.  
(1S)-exo-benzyl 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (43a). The 
compound was isolated according to the general procedure to give a pale yellow oil with minor 
impurities (0.91 g, 44%). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.27 (m, 5H), 6.53 – 6.21 (m, 
2H), 5.20 – 5.06 (m, 2H), 4.71 – 4.49 (m, 1H), 3.26 (m, 1H), 3.01 (m, 1H), 2.75 – 2.60 (m, 1H), 
2.00 (d, J = 7.3 Hz, 1H), 1.87 – 1.75 (m, 0.7H), 1.70 – 1.60 (m, 0.3H), 1.50 – 1.32 (m, 1H), 1.29 
– 1.12 (m, 1H), 1.05 – 0.92 (m, 2H), 0.86 (tt, J = 7.3, 5.0 Hz, 3H). 
(1S)-endo-benzyl 7-butyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (43b). The 
compound was isolated according to the general procedure to give a pale yellow oil (47.6 mg, 
96%). 1H NMR (500 MHz, CDCl3) (partial integrals due to conformers) δ 7.40 – 7.28 (m, 5H), 
6.43 – 6.29 (m, 1.6H), 6.25 (m, 0.4H), 5.19 – 5.09 (m, 2H), 4.69 (m, 0.6H), 4.58 (m, 0.4H), 3.25 
(m, 1H), 3.03 – 2.95 (m, 1H), 2.76 – 2.63 (m, 1H), 1.98 (m, 1H), 1.82 (m, 1H), 1.36 – 1.11 (m, 
2H), 1.04 – 0.94 (m, 1H), 0.87 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 155.6, 137.5, 135.1, 
134.6, 131.2, 130.5, 128.8, 128.8, 128.2, 128.1, 128.0, 67.0, 67.0, 50.0, 49.5, 47.6, 47.2, 41.4, 
41.1, 32.0, 31.6, 31.4, 30.6, 28.7, 28.8, 23.1, 14.5, 11.8, 11.8. LR-MS calcd. for C17H21NNaO2+  
[M+Na]+  294.35, found 294.29. [α]25D = -114.1 (CHCl3). 
(5S)-exo-7-Ethyl-2-(α-endo-1-(5-methoxybenzofuran-3-yl)propan-2-yl)-2-
azabicyclo[2.2.2]oct-5-ene and (5S)-exo-7-ethyl-2-(α-exo-1-(5-methoxybenzofuran-3-
yl)propan-2-yl)-2-azabicyclo[2.2.2]oct-5-ene (44). To a solution of isoquinuclidine 43a (744 
mg, 2.7 mmol) in anhydrous CH2Cl2 (20 mL) at 0 °C was added iodotrimethylsilane (1.6 mL, 
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11.2 mmol), and the orange solution was allowed to warm to room temperature and stirred for 1 
h. The reaction was then quenched with MeOH (20 mL) and concentrated to provide the 
isoquinuclidine HI salt as an orange-brown oil. This oil was washed with hexanes (5 X 5 mL) 
and then dried again in vacuo. This material was dissolved in anhydrous 1,2-dichloroethane (17 
mL), Et3N (772 µL, 5.5 mmol), ketone 33a (560 mg, 2.7 mmol), and NaBH(OAc)3 (1.2 mg, 5.7 
mmol) were added, and the pale-orange mixture was stirred at room temperature. After 26 h, an 
additional portion of NaBH(OAc)3 (1.2 mg, 5.7 mmol) was added. At 48 h, acetic acid (0.3 mL, 
5.4 mmol) was added. After 65 h, the reaction was diluted with water (100 mL), basified with 
concentrated aqueous NaOH, and extracted with CH2Cl2 (3 x 50 mL). The combined organics 
were washed with water (50 mL), dried over Na2SO4, and concentrated to provide a red-brown 
oil. This material was purified by repeated column chromatography (Column 1: 7:3 
hexanes:EtOAc à 7:3 hexanes:EtOAc + 2% Et3N; Column 2: 9:1 hexanes:EtOAc + 2% Et3N; 
Column 3: 30:1 hexanes:EtOAc + 2% Et3N) to provide a mixture of the two diastereomers 44 as 
a yellow-orange oil (254.3 mg, 29%, 68:32 α-endo:α-exo) with some minor impurities. 1H NMR 
(400 MHz, CDCl3) (Partial integrals due to 68:32 mixture of two diastereomers and some minor 
impurities) δ 7.55 – 7.53 (m, 0.5H), 7.47 (s, 0.2H), 7.46 – 7.44 (m, 1H), 7.38 (d, J = 2.7 Hz, 1H), 
7.35 (d, J = 8.9 Hz, 1H), 7.09 – 7.06 (m, 1H), 7.02 (dd, J = 8.9, 2.7 Hz, 1H), 6.98 (dd, J = 7.7, 2.6 
Hz, 1H), 6.89 (dd, J = 8.9, 2.6 Hz, 1H), 6.33 – 6.27 (m, 2H), 3.91 (s, 0.96H), 3.87 (d, J = 1.7 Hz, 
2.04H), 3.34 (dt, J = 5.6, 2.2 Hz, 1H), 3.10 (dd, J = 8.6, 2.6 Hz, 1H), 2.97 – 2.86 (m, 0.25H), 
2.81 – 2.75 (m, 0.75H), 2.76 – 2.68 (m, 1H), 2.55 (d, J = 6.0 Hz, 1H), 2.51 (dd, J = 6.1, 0.9 Hz, 
0.52H), 2.50 – 2.45 (m, 3H), 2.35 (m, 0.46H), 2.24 (dt, J = 8.5, 2.4 Hz, 1H), 1.64 – 1.42 (m, 2H), 
1.35 – 1.24 (m, 1H), 1.02 – 0.93 (m, 3H), 0.89 (t, J = 7.4 Hz, 2H), 0.83 (t, J = 7.4 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) (Additional peaks due to 68:32 mixture of two diastereomers and 
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some minor impurities) δ 156.1, 156.1, 150.6, 143.4, 133.9, 133.1, 132.5, 129.8, 129.1, 128.4, 
121.8, 119.0, 118.3, 115.2, 112.8, 112.7, 112.5, 112.1, 104.2, 103.2, 59.0, 56.7, 56.5, 55.3, 54.9, 
53.7, 51.7, 51.1, 43.0, 42.4, 41.8, 32.3, 32.2, 30.5, 30.4, 30.3, 29.9, 29.6, 27.4, 27.2, 18.4, 17.9, 
12.9, 12.8. LR-MS calcd. for C21H28NO2+ [M+H]+ 326.21, found 326.49. 
(5S)-12-Methoxy-7-α-endo-methyl-16-oxaibogamine (45). The product 45 was 
prepared according to the general procedure (see compound 14 above), starting from the mixed 
diastereomers 44, and obtained as a mixture with the α-exo-epimer. It was separated by repeated 
column chromatography (Column 1: 30:1 hexanes:EtOAc + 1% Et3N → 9:1 hexanes:EtOAc + 
2% Et3N→ 7:3 hexanes:EtOAc + 2% Et3N; Column 2: 40:1 hexanes:EtOAc + 1% Et3N → 20:1 
hexanes:EtOAc + 1% Et3N) to provide a very pale-brown oil (68.8 mg, 51%, 76% based on 
quantity of α-endo in starting material). 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.7 Hz, 1H), 
6.87 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.27 (m, 1H), 3.13 (dt, J = 
11.5, 2.7 Hz, 1H), 2.99 – 2.88 (m, 2H), 2.84 (dt, J = 8.7, 2.0 Hz, 1H), 2.78 (d, J = 2.3 Hz, 1H), 
2.54 (dd, J = 16.7, 4.1 Hz, 1H), 2.03 (m, 1H), 1.85 – 1.81 (m, 1H), 1.79 – 1.74 (m, 1H) (1.66 – 
1.59 (m, 1H), 1.52 (m, 3H), 1.24 (d, J = 6.7 Hz, 3H), 1.18 (m, 1H), 0.91 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 161.0, 155.8, 148.4, 131.5, 111.5, 110.9, 110.9, 101.8, 58.7, 58.3, 
56.1, 46.2, 41.4, 40.8, 33.8, 32.7, 27.5, 26.5, 26.4, 21.5, 11.9. LR-MS calcd. for C21H28NO2+ 
[M+H]+ 326.21, found 326.6. [α]20D = -26.9 (CHCl3). 
(5S)-12-Hydroxy-7-α-endo-methyl-16-oxaibogamine ((5S)-46). The product (5S)-46 
was prepared according to the general procedure (see compound 15 above) and purified by 
column chromatography (20:1 DCM:MeOH à 20:1 Acetone: MeOH) to provide a beige, foamy 
solid (24.7 mg, 57%). 1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 2.5 
Hz, 1H), 6.71 (dd, J = 8.6, 2.6 Hz, 1H), 5.13 (s, 1H), 3.23 (m, 1H), 3.10 (dt, J = 11.5, 2.7 Hz, 
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1H), 2.89 (td, J = 8.7, 4.5 Hz, 2H), 2.82 (dt, J = 8.8, 2.0 Hz, 1H), 2.77 – 2.72 (m, 1H), 2.47 (dd, J 
= 16.8, 4.1 Hz, 1H), 2.01 (m, 1H), 1.82 (m, 1H), 1.76 (m, 1H), 1.61 (m, 1H), 1.51-1.25 (m, 3H), 
1.21 (m, 3H), 1.14 (d, J = 6.9 Hz, 1H), 0.89 (t, J = 7.0 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 
161.2, 151.3, 148.5, 131.9, 111.5, 110.8, 110.7, 104.2, 58.7, 58.3, 46.2, 41.4, 40.8, 33.8, 32.7, 
27.5, 26.5, 26.3, 21.4, 11.9. LR-MS calcd. for C20H26NO2+ [M+H]+ 312.20, found 312.27. [α]19D 
= -13.8 (CHCl3). 
 
X-ray Structure Determinations 
X-ray diffraction data were collected on a Bruker Apex II diffractometer.  Crystal data, 
data collection and refinement parameters are summarized in Table 4.  The structures were 
solved using direct methods and standard difference map techniques, and were refined by full 
matrix least squares procedures on F2 with SHELXTL (Version 2014/7).100–102 
Property Isoquinuclidine 28 
lattice Monoclinic 
formula C30H34F12I2N2O4P2 
formula weight 1030.33 









temperature (K) 130(2) 
radiation (λ, Å) 0.71073 
r (calcd.) g cm-3 1.866 
µ (Mo Kα), mm-1 1.901 
θ max, deg. 30.751 
no. of data collected 13912 
no. of data 5600 
no. of parameters 238 
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R1 [I > 2s(I)] 0.0627 
wR2 [I > 2s(I)] 0.1492 
R1 [all data] 0.0904 




 Materials: BRET. HEK-293T cells were obtained from the American Type Culture 
Collection (Rockville, MD) and were cultured in a 5% CO2 atmosphere at 37 oC in Dulbecco’s 
Modified Eagle Medium (high glucose #11965; Life Technologies Corp.; Grand Island, NY) 
supplemented with 10% Fetal Bovine Serum (FBS, Premium Select, Atlanta Biologicals; Atlanta, 
GA) and 100 U/mL penicillin and 100 µg/mL streptomycin (#15140, Life Technologies). 
 DNA Constructs. The human MOR (hMOR), human DOR (hDOR), human KOR 
(hKOR), and GRK3 were obtained from the Missouri S&T Resource Center. The human G 
protein constructs used here have been previously described and were provided by C. Galés or 
were obtained from the Missouri S&T Resource Center unless otherwise noted.91,103 The G 
proteins used included untagged GαoB (GαoB); GαoB with Renilla luciferase 8 (RLuc8) inserted at 
position 91 (GαoB-RLuc8); Gβ1 (β1); untagged Gγ2 (γ2); Gγ2, which we fused to the full-length 
mVenus at its N-terminus via the amino acid linker GSAGT (mVenus-γ2). The plasmids 
employed in the arrestin recruitment assay, hKOR-RLuc8 and Arr3-mVenus, were synthesized 
in-house as previously described.91 All constructs were sequence-confirmed prior to use in 
experiments. 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
106 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg MOR/DOR/KOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; BRET recruitment: 0.2 µg hKOR-RLuc8, 15 µg Arr3-
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mVenus, 5 µg GRK3. Cells were maintained in the HEK-293T media described above. After 24 
hours the media was changed, and the experiment was performed 24 hours later (48 hours after 
transfection). 
 BRET. Transfected cells were dissociated and re-suspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were re-
suspended in PBS. For agonist experiments, after 5 minutes, 5 µM of the luciferase substrate 
coelenterazine H was added to each well. After 5 minutes, ligands were added and the BRET 
signal was measured 5 minutes later on a PHERAstar FS plate reader. For antagonist competition 
experiments, cells were pre-incubated with the antagonist at varying concentrations for 30 
minutes. Coelenterazine H (5 µM) was then added to each well for 5 minutes. Following 
coelenterazine H incubation, a fixed concentration of the reference agonist (5x EC50) was added, 
and the BRET signal was measured at 30 minutes on a PHERAstar FS plate reader. The BRET 
signal was quantified by calculating the ratio of the light emitted by the energy acceptor, mVenus 
(510-540 nm), over the light emitted by the energy donor, RLuc8 (485 nm). This drug-induced 
BRET signal was normalized using the Emax of [D-Ala2, N-Me-Phe4, Gly-ol5]-enkephalin 
(DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-50,488 as the maximal response at MOR, 
DOR, and KOR respectively. Dose response curves were fit using a three-parameter logistic 
equation in GraphPad Prism 6. 
 Inhibition of Monoamine Transporters. An EM4 cell line stably expressing hDAT 
(hDAT-EM4) was kindly provided by Drs. Jonathan Javitch and Mark Sonders of the 
Department of Psychiatry at Columbia University Medical Center. Cells were cultured in a 5% 
CO2 atmosphere at 37 oC in DMEM + GlutaMAX (Invitrogen #10569) supplemented with 10% 
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FBS (Atlanta Biologicals) and 100 U/mL penicillin and 100 µg/mL streptomycin. HEK-293 cell 
lines stably expressing hNET or hSERT were obtained from the laboratory of Professor Bryan 
Roth (University of North Carolina at Chapel Hill). hNET-HEK and hSERT-HEK cells were 
cultured as above with additional 500 µg/mL G418 (Calbiochem).  
 Cells were seeded at a density of 0.08-0.09 x 106 cells per well in black flat-bottom 96-
well plates and incubated in growth medium at 37 ºC for approximately 2 days to reach 
confluence. On the day of the experiment, the complete growth medium was aspirated, and wells 
were washed with 200 µL PBS and treated with 100 µL/well experimental medium (DMEM 
without phenol red containing 25 mM HEPES and 1% FBS) containing DMSO (vehicle), control 
inhibitor of varying concentrations (nomifensine for hDAT-EM4 and hNET-HEK cells, 
imipramine for hSERT-HEK cells) or experimental compound of varying concentrations. The 
cells were incubated for 60 min at 37 °C. Then 100 µL/well of NG54 (5 µM solution for hSERT-
HEK, 8.2 µM solution for hDAT-HEK, or 10.4 µM solution for hNET-HEK to keep the Cheng 
Prussoff equation consistent – i.e. 0.65Km) was added to each well in experimental medium and 
incubated for 30 min at 37 ºC. The experiment was terminated by one rapid PBS wash (200 
µL/well) followed by addition of fresh PBS buffer (120 µL/well). The fluorescence uptake in 
cells was immediately recorded using a BioTek H1MF plate reader (3x3 area scan, bottom read 
mode) with excitation and emission wavelengths set at 389 nm and 442 nm, respectively.  The 
extent of inhibition was determined as the difference between signal and basal measurements: 
mean fluorescence uptake of NG54 (with DMSO vehicle) minus that in the presence of the 
experimental compound. These values were normalized to the control inhibitor (100% inhibition) 
to yield a normalized fraction of inhibition. Dose response curves were fit using a three-
parameter logistic equation in GraphPad Prism 6. 
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Chapter 5 – A Tale of a Tail: Understanding the Tools Available to Measure 
Ligand Bias  
 
Introduction 
The PRESTO-TangoTM assay (Tango assay) is a useful tool developed by Bryan Roth 
and marketed by Invitrogen.1 In this reporter gene assay, the GPCR is C-terminally tagged with a 
portion of the vasopressin 2 receptor tail (V2 tail), followed by a TEV (tobacco etch virus) 
protease cleavage site and then a transcription 
factor, tTA (tetracycline controlled 
transcription activator). Also expressed in the 
cells is arrestin-3 tagged with the TEV 
protease. Upon receptor activation and arrestin 
recruitment, the protease is in close enough 
proximity to the protease cleavage site to 
release the transcription factor into the 
cytosol, which can then enter the nucleus and 
turn on reporter gene expression (Figure 1). 
While this assay is highly effective at 
measuring arrestin recruitment and many 
researchers have taken advantage of the technology (close to 150 citations to date), a closer look 
at the receptor construct leads to puzzlement. The V2 tail has been reported previously to 
enhance recruitment of arrestin to receptors, both in BRET-based contexts2 and others.3,4 There 
are independent reports that in the context of the Tango assay, the V2 tail had little effect on the 
signaling of certain receptors.5 However the authors who developed the Tango assays themselves 
find great variability among receptors in the presence or absence of the V2 tail: the LTBR4 
 
Figure 1. Mechanism of the Tango Assay. A TEV 
protease tagged-arrestin molecule cleaves and releases 
the tTA transcription factor upon recruitment to the 
receptor. The tTA then turns on expression of the 
luciferase reporter gene. 
 232 
leukotriene receptor showed no differences to removing the V2 tail, while the CMKLR1 
chemerin receptor had increased signal without the V2 tail and the FFAR2 free-fatty-acid 
receptor had decreased signal without the V2 tail.1 Such variability in the assay between different 
receptors, brings into question its validity as a mainstream platform for measuring arrestin 
recruitment, as it is difficult to know whether the V2 tail is an innocent bystander in the Tango 
assay, simply providing the necessary dynamic range to make the assay more robust, or whether 
instead the V2 tail is artificially affecting arrestin recruitment and thus making any bias 
calculations based this assay debatable. 
This chapter will explore the Tango assay and others in a systematic search to understand 
the best way to study and identify biased ligands in the context of opioid receptors, particularly 
the KOR. Through analysis and deconstruction of many assays, we ultimately verify the validity 
of many cell-based assays for arrestin recruitment and highlight the importance of choosing an 
appropriate assay for each particular drug in question. 
 
Results 
Uncovering the “Bias” of Endogenous KOR Agonist Dynorphin A 
Initial Findings in the Tango Assay. When first utilizing the Tango assay in experiments 
for measuring arrestin recruitment by the KOR, it was important to test various control ligands 
and compare those results to published potencies in the same cellular system and assay. For 
KOR, we initially chose to study dynorphin A (DYN)6,7, the endogenous neuropeptide for KOR, 
U-50,4888  (U-50), a synthetic compound widely used as a KOR agonist, salvinorin A9 (SALV), 
a naturally occurring terpenoid with potent KOR agonist activity, and 6’-guanidinonaltrindole 
(6’-GNTI), an example of a partial G protein biased agonist.10,11 When tested in the Tango assay 
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at KOR the compounds showed varying degrees 
of potency and efficacy for arrestin recruitment 
(Figure 2 and Table 1: EC50 DYN = 247 ± 192 nM, 
EMax = 100%; EC50 U-50 = 15 ± 12 nM, EMax = 
100%; EC50 SALV = 2.6 ± 1.3 nM, EMax = 100%; 
EC50 6’-GNTI = 0.3 ± 0.2 nM, EMax = 71%). 
Although our data compared nicely with those 
reported (Table 1), we were generally skeptical of 
the results with both dynorphin A and 6’-GNTI, 
first because endogenous agonists are usually balanced through G protein and arrestin pathways, 
and 6’-GNTI has previously been reported to have low arrestin signaling (see Introductory 
Chapter 1).  
Researching Dynorphin Results Further. Despite the initial surprise of the apparent weak 
potency for arrestin recruitment of 
dynorphin A (compared to the other KOR 
control ligands), there is precedent for 
dynorphins to show a G protein bias.12 In 
comparing the arrestin recruitment of 
dynorphin A we measured to those found 
by White and co-workers (published EC50 
= 268 nM, Table 1)12, the results are nearly identical – not surprising given that both measures 
were performed in the same cellular system (Tango Assay). Accordingly these results could 
indicate an example of “endogenous bias,” as suggested by White12, but overall it would 
Table 1. Summary of Experimental and Published 
Tango Assay Results. 




Dynorphin A 247 ± 192 nM (100%) 268 nM (74.8%) 
 (±)-U-50,488 15 ± 12 nM (100%) 0.822 nM (94.6%)§ 
Salvinorin A 2.6 ± 1.3 nM (100%) 5.6 nM (97.2%) 
6’-GNTI 0.3 ± 0.2 nM (63%) 7.38 nM (34.7%) 
§Reported with (-)-U-50,488 enantiomer.  (+)-U-50,488 is 
given an EC50 of 959 nM (92.3%). Data represent mean ± SEM 
of various independent trials.	
	
 
Figure 2. Arrestin-3 Recruitment as Measured in 
the Tango Assay. A Tango construct for hKOR 
was transfected into HTLA cells expressing a 
TEV-tagged arrestin-3. After overnight 
incubation with the drugs, the luciferase signal 
was measured through a luminescence readout. 
Data represent mean ± SEM of n ≥ 6. 
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represent a unique phenomena. Therefore, although our Tango arrestin results with dynorphin A 
were supported by an independent report that used the same assay format, we were skeptical 
about the prospect of dynorphin A, an endogenous KOR ligand, being G protein biased, 
especially when the experimental set-up for the Tango assay is taken into consideration (see 
below). 
Assessing the Stability of Dynorphin A in the Tango Assay Set-up. In order to perform the 
Tango assay, five days of experimental set-up is required. First the cells must be transfected with 
the fusion construct of the receptor of choice, and 24 hours later these cells are transferred to a 
96-well plate. Following an additional 24 hours, cells can be treated with drugs and allowed to 
incubate overnight at 37 °C. The long incubation step is critical to the success of the assay – 
based on a reporter gene mechanism, enough time must be allotted to not only activate the 
receptor but also to recruit arrestin and then turn on expression of the reporter gene (usually 
hours). With an extended incubation, there is ample time to allow for sufficient protein 
production from the reporter gene, luciferase in this case, such to provide a meaningful signal-to-
background ratio upon detection. For many small molecules, stability is not an issue, and an 
overnight incubation would not cause concern. There are several reports on the in vitro stability 
of dynorphins13,14, namely that several proteases can cleave the peptide bonds, making 
dynorphins especially susceptible to metabolism. Therefore as neuropeptides, they are likely 
unstable in an overnight incubation in cells, where various proteases and other factors are present 
that can cause peptide degradation. 
In order to assess the stability of dynorphin A in the Tango assay, an experiment was 
devised that would not only determine whether dynorphin A was present in cellular supernatant 
after overnight incubation with cells, but also whether this supernatant contained factors that 
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might degrade dynorphin in solution. The experiment set-up utilized our BRET assay for G 
protein activation as a method independent from the Tango assay to measure whether or not 
drugs were still viable after overnight treatment with the Tango cells. Experimental medium was 
changed to Hank’s Balanced Salt Solution (HBSS) since DMEM can contain luciferase 
inhibitors, such as phenol red and others, that might interfere with the BRET signal. 
The layout of these experiments is depicted in Figure 3. Three sets of drugs were tested 
in the G protein activation 
BRET assay: 1) drugs that were 
incubated overnight in HBSS 
in Tango cells; 2) drugs that 
were freshly prepared in HBSS 
that was incubated overnight in 
Tango cells; and 3) drugs that 
were freshly prepared in fresh 
HBSS (control). These three 
HBSS treatments were then added directly to cells transfected to measure G protein activation 
using BRET (Figure 3). By utilizing the three drug treatments, we could determine whether 
drugs degraded overnight in Tango cells or whether factors released into the media by cells 
overnight could degrade fresh stocks of drugs, all of which were compared to control treatments.  
As anticipated, when drugs incubated overnight on Tango cells were used in a separate 
BRET assay, all drugs activated the receptor normally except for dynorphin A (Figure 4). 
Dynorphin A under these conditions only showed one-point activity in the dose response curve 
with partial efficacy. Given this result, it is unlikely that an appreciable amount of dynorphin A 
 
Figure 3. Schematic Diagram of Experimental Set-up to Measure 
Dynorphin A’s Stability in Cells After Overnight Incubation. 
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exists in solution after overnight treatment. Interestingly, when new stock solutions were 
prepared with conditioned HBSS (i.e. HBSS that was incubated overnight with the Tango cells) 
 
Figure 4. Dynorphin A Stability After Overnight Incubation Differs from Other Drugs. hKOR was co-expressed 
with GαoB-RLuc8, β1, and mVenus-γ2 to assay G protein activation. Curves represent the average of n = 3, with 
error bars representing ± SEM. A. Control experiment showing functional activity of compounds using freshly 
prepared dose response curves in HBSS. B. When drugs are treated first overnight on Tango cells, most of the 
activity from dynorphin A is gone, suggesting it has degraded. The other drugs are stable after overnight treatment. 
C. When drugs are prepared fresh in HBSS that was incubated with Tango cells overnight, all functional responses 
are normal. 
 
for use in the BRET assay, dynorphin A showed potency and efficacy in the normal ranges for G 
protein activation, suggesting that factors released into the media by cells overnight either do not 
interfere with the functional activity of dynorphin A or require a longer incubation time for effect 
(Figure 4C).  
To explore the 
timing with which 
receptor activation is 
required to observe 
sufficient signal in the 
Tango assay, a pulse 
experiment was 
designed. The idea 
behind this experiment was to determine whether a short “pulse” of receptor activation from the 
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Figure 5. Pulse Experiment in the Tango Assay shows Arrestin Recruitment 
Can be Measured But With Much Weaker Potency. A Tango construct for 
hKOR was transfected into HTLA cells expressing a TEV-tagged arrestin-3. A. 
Pulse experiment with U-50,488 and Dynorphin A at two different pulse time 
points. B. Comparison to overnight treatment (reproduced from Figure 2). 
Data represent mean ± SEM of n = 4. 
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compound would be sufficient to start the reporter gene activation and subsequent protein 
production overnight, in the absence of drug, thus allowing use of dynorphin A in the Tango 
assay. When either dynorphin A or U-50,488 were added on the Tango cells for 10 minutes or 1 
hour prior to drug removal and overnight incubation in fresh media, some arrestin recruitment 
was observed (Figure 5). The 10-minute pulse with drugs was only enough time to see the early 
signs of arrestin recruitment, as the efficacy and potency for these treatments, while visible, was 
quite weak in comparison to overnight treatments (EC50 DYN ~ 402 ± 268 nM, EMax = 36%; EC50 
U-50 = 273 ± 95 nM, EMax = 73%). In contrast, the 60-minute pulse showed much more promise, 
activating the receptor recruitment mechanism with increased potency and efficacy when 
compared to the 10-minute pulsed treatment (EC50 DYN = 10 ± 8 nM, EMax = 50%; EC50 U-50 = 184 
± 75 nM, EMax = 100%). While dynorphin A led to arrestin recruitment in 60-minutes, the 
efficacy was much lower in comparison to that seen in overnight treatments while the potency 
was similar (more potent, in fact). The higher potency of 
dynorphin A in the 60-minute pulse indicates that the time 
domain of the receptor activation is very important as 
reported in this assay. At 60 minutes, U-50,488 was 
significantly less potent than the overnight incubation 
though with full efficacy, indicating that a longer pulse 
time may be necessary to illicit maximal potency for 
arrestin recruitment when compared to the usual overnight 
treatment (see Table 1 for comparison). Unfortunately, a 
longer pulse time still might not solve the issue of 
dynorphin A stability in the cells. In all likelihood, the longer dynorphin A is incubated in the 
 
Figure 6. Dynorphin A Recruits 
Arrestin in an Independent Assay for 
Arrestin Recruitment (BRET GAP43 
Translocation Assay). A Tango 
construct for hKOR was co-expressed 
with Rluc8-arrestin3-Sp1, mem-linker-
citrine-SH3, and GRK3. Dynorphin A 
showed an EC50 = 16 ± 5 nM (EMax = 
100%. Data represent mean ± SEM of 
n = 7. 
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cells, even without the need of overnight treatment times, the more chance of it degrading and 
thus clouding the true nature of the arrestin recruitment.  
Finally, to truly understand whether dynorphin A is capable of recruiting arrestin after 
receptor activation, dynorphin was tested in an alternate assay for arrestin recruitment, the BRET 
GAP43 translocation assay (see Introductory Chapter 1). The same DNA construct for KOR was 
used in this assay as in the Tango assay to account for any sequence variation. Interestingly, we 
found that dynorphin A was able to recruit arrestin with full efficacy (compared to both U-50 and 
salvinorin A, see Figure 10 below) in this independent assay, and highlights that perhaps 
dynorphin A is not G protein biased after all 
(Figure 6). More importantly, these results prove 
that since dynorphin A can recruit arrestin in a 
separate assay, the Tango assay should be 
revisited as a tool for measuring the functional 
activity of peptides and other sensitive 
compounds. 
Dissecting the Role of the V2 Tail in Arrestin 
Recruitment 
 Removing the V2 Tail From the Tango 
Construct. When analyzing the initial Tango 
results (see Figure 2), we were also concerned by 
the fact that 6’-GNTI was both potent and 
efficacious in arrestin recruitment – something that has not yet been observed in the context of 
this compound, a reported G protein biased ligand.10,11,15 We suspected that perhaps again the V2 
 
 
Figure 7. Schematic DNA Map Shows Easy 
Manipulation of Tango Construct. Digestion of 
(A) with AgeI restriction enzyme allows removal 
of the V2 Tail to get the construct shown in B. 
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tail was increasing sensitivity to arrestin recruitment measurements, which could make 6’-GNTI 
seem unbiased and simultaneously make dynorphin A seem more biased. While it is also 
possible that the unique in vitro results reported for 
6’-GNTI are an outcome of unidentified, independent 
signaling pathways and not from being G protein 
biased, we still wanted to understand better the role of 
the V2 tail in arrestin signaling. The cDNA construct 
for the receptors used in the Tango assay are cleverly 
constructed to allow easy manipulation of the 
individual components. As such, the V2 tail is flanked 
by AgeI restriction sites in the sequence, thus making its removal a straightforward experiment 
(Figure 7). When the modified receptor construct was used in the Tango assay, we found that no 
measureable signal could be detected, even when following identical experimental conditions 
(Figure 8). Given the known effects of the V2 tail on enhancing arrestin recruitment and signal-
to-background ratios (see Introduction), we were not surprised to find that the entire assay 
required this integral receptor modification. As the 
researchers who developed the Tango assay have 
acknowledged1, the V2 tail does not affect all receptors in 
the same way, so it is possible that the opioid receptors 
are more susceptible to the effects the V2 tail has on 
arrestin recruitment.  
 As a control, we tested this modified Tango 
construct for its ability to function in the G protein 
 
Figure 8. Removal of the V2 Tail from the 
hKOR Tango Construct Makes It Ineffective 
at Arrestin Recruitment. The modified Tango 
construct for hKOR was transfected into 
HTLA cells expressing a TEV-tagged 




Figure 9. Modified Tango Construct is a 
Functional Receptor. The modified 
Tango hKOR was co-expressed with 
GαoB-RLuc8, β1, and mVenus-γ2 to 
assay G protein activation. Curves 
represent the average of n = 2, with error 
bars representing ± SEM. 
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activation BRET assay. Although the sequence was confirmed, it was important to make sure 
that the receptor could still properly signal as that could be an alternative explanation for the 
construct’s inability to work in the Tango assay. Even without the V2 tail, the modified Tango 
construct was able to function normally in the G protein activation assay, verifying the influence 
of the V2 tail on the Tango assay (Figure 9). Given the dramatic changes observed in arrestin 
recruitment between the two constructs in the Tango assay, we were even more interested in 
understanding the role of the V2 tail in these assays and sought to explore it further in the context 
of other assays. 
 Utilizing the Tango Construct in Another Arrestin 
Assay. To further explore the role of the V2 tail in arrestin 
recruitment, the construct needed to be used in an alternate 
assay. In our BRET GAP43 translocation assay (see Figure 
18 in Chapter 1), the normal unmodified KOR construct is 
unable to show any appreciable amount of arrestin 
recruitment (Figure 10A). While various transfection and 
reaction conditions were attempted to make the assay work 
with the unmodified construct, ultimately the signals were 
too weak to be meaningful. In contrast, when the Tango 
construct (with V2 tail) was used in the same assay (as in 
Figure 6 above), an excellent dynamic and potency range 
was obtained for the drugs tested. These results again 
highlight the ability of the V2 tail to enhance arrestin 
recruitment, especially in an assay that did not work with a different construct of the same 
 
Figure 10. V2 Tail Enhances Dynamic 
Range of Independent BRET GAP43 
Translocation Assay for Arrestin 
Recruitment. Unmodified hKOR (A) 
or Tango construct for hKOR (B) were 
co-expressed with Rluc8-arrestin3-
Sp1, mem-linker-citrine-SH3, and 
GRK3. For the assay design, see 
Figure 18 in Chapter 1. Data represent 
mean ± SEM of n ≥ 4. 
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receptor. Interestingly, even in an alternate assay, the G protein biased agonist 6’-GNTI showed 
measurable recruitment of arrestin, indicating that either the V2 tail is artificially enhancing the 
arrestin recruitment (thus making a G protein biased ligand seem unbiased) or that 6’-GNTI has 
a lower degree of G protein bias than published previously. We also added an additional ligand, 
(-)-cyclazocine16, a partial agonist at KOR, as a control for efficacy effects on arrestin 
recruitment, and it also recruited arrestin similarly to 6’-GNTI. In order to further assess the role 
of the V2 tail in arrestin signaling, there was a need to expand these studies further into even 
more arrestin assays. 
 Bringing the V2 Tail into a Different KOR 
Construct. In addition to the BRET GAP43 
translocation assay, there is an additional BRET assay 
that uses a luciferase tagged receptor and mVenus 
tagged arrestin (BRET recruitment assay, see 
Introductory Chapter 1). We hypothesized that 
inserting the V2 tail between the receptor and RLuc8 
in the receptor construct for this assay might have 
similar effects on potency and efficacy as seen in the 
arrestin assays already explored (Tango and 
translocation assays specifically). In order to make 
this hypothetical construct, a molecular cloning strategy was designed and implemented (Figure 
11, also see more details in Experimental). In this strategy, primers were designed for separate 
PCR reactions with the KOR Tango construct and the KOR-RLuc8 construct. This reaction 
would yield two overlapping products, the first that contained the receptor and part of the V2 tail 
 
Figure 11. Molecular Biology Strategy for 
Synthesis of hKOR-V2 Tail-RLuc8 DNA 
Construct. An initial PCR reaction (A) 
provides two products that when run through 
a second PCR reaction (B) yield a single 
product that is digested and ligated (C) before 
transformation into E. coli (D). 
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and the second that contained the remainder of the V2 tail and RLuc8. A second PCR reaction 
allowed elongation from the overlapping base pairs, providing a single product that could be 
digested with appropriate restriction enzymes and ligated into a new vector for transformation. 
 With the new KOR-V2 Tail-RLuc8 construct synthesized, arrestin recruitment could be 
analyzed. In comparison to the parent KOR-RLuc8 construct (Table 2 and Figure 12A, EC50 DYN 
= 12.1 ± 8.2 nM, EMax = 100%; EC50 U-50 = 200 ± 78 nM, EMax = 100%; EC50 SALV = 55 ± 39 nM, 
EMax = 100%; EC50 6’-GNTI = 0.3 ± 0.1 nM, EMax = 37%; EC50 CYC = 2.7 ± 1.8 nM, EMax = 34%), 
the V2 tail enhanced the dynamic range of the assay (by about 3X), as well as the potency of all 
the compounds (Table 2 and Figure 12B, EC50 DYN = 4.1 ± 3.9 nM, EMax = 49%; EC50 U-50 = 17 ± 
5.6 nM, EMax = 100%; EC50 SALV = 7.3 ± 2.4 nM, EMax = 100%; EC50 6’-GNTI = 0.5 ± 0.4 nM, EMax 
= 36%; EC50 CYC = 1.7 ± 1.1 nM, EMax = 68%). While it is clear the unmodified KOR-RLuc8 
assay is less sensitive than 
any arrestin assay tested, 
some compounds are not 
greatly affected by the 
addition of the V2 tail. For 
instance, the partial agonists 
6’-GNTI and cyclazocine did 
not show significant changes 
in potency between the two constructs, although cyclazocine seemed much more efficacious in 
the presence of the V2 tail – not surprising given results in the Tango assay and the BRET 
GAP43 translocation assay. However all three of the full agonists showed significant increases in 
potency with the addition of the V2 tail. Interestingly, dynorphin A consistently showed partial 
 
Figure 12. Addition of the V2 Tail into an Independent Receptor Construct 
for Arrestin Recruitment Increases the Dynamic Range. hKOR-RLuc8 (A) 
or hKOR-V2 Tail-RLuc8 (B) were co-transfected with Arrestin3-mVenus 
and GRK3 in the BRET recruitment assay. Data represent mean ± SEM of 
n ≥ 4. 
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agonism in the presence of the V2 tail even though the potency increased somewhat. There is not 
yet any satisfying explanation for this observation. It is possible that dynorphin A does have 
special signaling properties in comparison to the other ligands tested. As such, perhaps the 
addition of the V2 tail changes the conformation of the receptor in a way that makes KOR more 
sensitive to dynorphin A, thus changing how much it activates arrestin recruitment. Another 
possibility is that dynorphin A really does have some bias for the G protein pathway, just not to 
the extent that was suggested by the Tango assay. The 
data is summarized in Table 2. 
Interpreting the Data in Terms of Bias Factors 
 G Protein Activation Data Provides Comparison 
for Bias Factor Calculations. As described in the 
Introductory Chapter 1, bias calculations cannot be made 
unless there are dose response curves for compounds 
along two or more different signaling pathways. By 
definition a compound can only be biased to one pathway 
over another – otherwise just observations about potency 
and efficacy can be made along a single signaling 
pathway. The control ligands were tested for their ability 
to activate KOR in the G protein Activation BRET assays 
in the presence (Tango construct) or absence (unmodified receptor) of the V2 tail (Figure 13). In 
general, all agonists seemed to be slightly more potent in the presence of the V2 tail for G protein 
activation. While the potencies of U-50,488 and salvinorin A show the greatest differences in 
potency between the two constructs, the differences were within an order of magnitude and can 
 
Figure 13. Unmodified and Tango 
hKOR Constructs Function Normally in 
G Protein Activation Signaling. hKOR 
(A) or Tango hKOR (B) were co-
expressed with GαoB-RLuc8, β1, and 
mVenus-γ2 to assay G protein activation. 
Data represent mean ± SEM of n ≥ 3.  
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thus be considered reasonable. There are also noticeable (though minor) differences in efficacy 
for 6’-GNTI and cyclazocine between the two constructs, indicating a potential role of the V2 tail 
enhancing the efficacy of partial agonists. These data are also provided in Table 2. 
 
 Calculating Ligand Bias From the Data. With a GraphPad Prism program developed by 
Professor J. Robert Lane (Pharmacy and Pharmaceutical Sciences, Monash University), the data 
could be fit using the operational model to provide estimates for log(τ/KA). Given the many ways 
in which ligand bias can be calculated, it seemed that utilizing the operational model as a way to 
estimate log(τ/KA) from actual data would be the most accurate way to represent bias factors 
between the two signaling pathways. In doing so, we would be able to compare bias factors 
between the different assays and interpret the effects of the V2 tail with confidence.  
Additionally, given the large fluctuation that was observed with U-50,488 across multiple 
arrestin assays, as well as literature precedent on what unbiased ligand to choose, we used 
salvinorin A as the reference unbiased ligand in all our bias calculations shown below.  
Table 2. Summary of Potencies and Efficacies of Drugs Measured. 















V2 Tail? - ✓ - ✓ ✓ 
Assay Activation Activation hKOR-Luc hKOR-Luc Translocation 
Dynorphin A 2.9 ± 0.5 nM 
(100%) 
1.4 ± 0.4 nM 
(100%) 
12 ± 8.2 nM 
(100%) 
4.1 ± 3.9 nM 
(49%) 
16 ± 5 nM 
(100%) 
 U-50,488 26 ± 6.0 nM 
(100%) 
6.3 ± 2.6 nM 
(100%) 
200 ± 78 nM 
(100 nM) 
17 ± 5.6 nM 
(100%) 
49 ± 15 nM 
(100%) 
Salvinorin A 16 ± 9.2 nM 
(100%) 
2.5 ± 1.5 nM 
(100%) 
55 ± 39 nM 
(100%) 
7.3 ± 2.4 nM 
(100%) 
21 ± 9 nM 
(100%) 
6’-GNTI 0.6 ± 0.05 nM 
(63%) 
0.4 ± 0.1 nM 
(78%) 
0.3 ± 0.1 nM 
(37%) 
0.5 ± 0.4 nM 
(36%) 
0.7 ± 0.3 nM 
(47%) 
(-)-Cyclazocine 1.2 ± 0.2 nM 
(63%) 
0.7 ± 0.1 nM 
(89%) 
2.7 ± 1.8 nM 
(65%) 
1.7 ± 1.1 nM 
(68%) 
1.2 ± 0.1 nM 
(63%) 
Data represent mean ± SEM of various independent trials.	 	 	 	
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Figure 14. ∆∆log(τ/KA) Values Calculated Using the Data in Table 2 for Each Individual Compound. 
Measurements without the V2 tail (red circle) and with the V2 tail (BRET GAP43 translocation assay shown with 
orange squares, BRET recruitment assay is shown with green triangles, and the Tango assay is shown with blue 
triangles) for dynorphin A (A), U-50,488 (B), 6’-GNTI (C), and (-)-cyclazocine (D) are shown. Data represent mean 
± SEM of n ≥ 4. Note: Salvinorin A was used as the unbiased agonist with ∆∆log(τ/KA) = 0 and is therefore not 
shown. 
 
Summary of Bias Factor Calculations. Table 3 summarizes the bias factors calculated 
from the G protein activation and arrestin data among all the different assays. Figure 14 shows a 
graphical representation of the log(bias factor) calculated for each compound in the different 
assays. Although there was much variation in potency between the different assays for U-50,488, 
the overall effect is that the calculated ∆∆log(τ/KA) (aka log(bias)) is relatively constant over all 
the different assays. Excluding the Tango results for dynorphin A, which are likely false given 
the low amounts of dynorphin A present in Tango cells after overnight incubation and the 
peculiar potency increase observed in the pulse experiment of the Tango assay (see Figure 4), 
dynorphin A also showed fairly consistent ∆∆log(τ/KA) over the different assays, even with the 
V2 tail. The only other exception, of course, is the interesting partial agonism in the KOR-Luc 
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is not significant. The partial agonists, on the other hand, were much more susceptible to 
variation between the assays, 
with some set-ups showing a 
G protein bias (positive 
∆∆log(τ/KA)) and others 
showing an arrestin bias 
(negative ∆∆log(τ/KA)). 
While there were no obvious 
patterns concerning the V2 tail in the calculated ∆∆log(τ/KA) for these partial agonists and the 
variation is not always dramatic, it does suggest that calculating and understanding ligand bias 
for a partial agonist might be more complicated than expected. Indeed it does seem that the V2 
tail may actually play little role in artificially enhancing arrestin signaling and just act to provide 
a better cellular read-out.   
 
Discussion 
 Interpreting the Variation of Arrestin Recruitment by Dynorphin Between Assays. While 
dynorphin A showed comparable arrestin recruitment to control ligands U-50,488 and salvinorin 
A in the BRET GAP43 translocation assay, two separate assays for arrestin recruitment showed 
distinct results. In the Tango assay, overnight incubation with dynorphin A (as described for the 
optimized assay protocol) resulted in low potency arrestin recruitment. These results would 
indicate a G protein bias for dynorphin A, as reported previously.12 Given our studies (see 
Figure 4 above), however, it is unlikely that dynorphin is stable overnight and therefore cannot 
accurately be defined as G protein biased, since this interpretation is based on the Tango assay 








V2 Tail? - ✓ ✓ ✓ 
Dynorphin A 0.7 1.42 7.31 221 
 U-50,488 1.65 1.04 1.54 3 
Salvinorin A 1 1 1 1 
6’-GNTI 0.93 0.47 5.79 0.75 
(-)-Cyclazocine 3.65 0.22 1.38 - 
Bias factors were calculated using the Black-Leff operational model and are 
in the direction of G protein (i.e. Arrestin Bias < 1 < G Protein Bias). A bias 
factor of 1 (Salvinorin A) indicates a balanced/unbiased ligand.	
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results that rely upon signaling from a metabolically unstable compound. In contrast, the 
increased potency from the 60-minute pulse with dynorphin A in the Tango assay indicates that 
two competing factors may be at play – both the instability of dynorphin A as well as potentially 
unique signaling observed in the presence of the V2 tail. These results are further supported by 
the BRET recruitment assay results, where the V2 tail consistently led to partial efficacy from 
dynorphin A. As indicated by the creators of the Tango assay (see Introduction), the V2 tail can 
either enhance or depress arrestin signaling depending on the receptor – though no clear trends 
have been identified. It therefore seems possible that the V2 reduces the arrestin recruitment of 
dynorphin A in certain assays. To be certain of the role of the V2 tail in dynorphin A’s arrestin 
recruitment, more assays should be studied. The phenomena does not seem universal over all 
assays (see BRET GAP43 translocation assay), and so certainly more data will be necessary to 
make firm conclusions. It therefore seems possible that under certain assay conditions with the 
V2 tail, dynorphin A might appear G protein biased.  
Uncovering True Examples of Biased Ligands. While the best way to determine ligand 
bias is still debatable, there continue to appear numerous examples of compounds in the 
literature with alleged bias for one signaling pathway over another. The more biased ligands that 
are uncovered, the better the understanding of what causes these phenomena at the receptor level. 
Interestingly there are numerous examples of supposedly biased ligands at KOR (see 
Introductory Chapter 1), which does bring into question whether some receptors are more 
capable of ligand bias over another. As more examples of potentially bias compounds are 
identified, especially specific to certain receptors, hopefully structural features of the receptor 
will allow ligand bias to be predicted or even designed into new molecules. 
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Applying Assay Principles to Specific Ligands. With so many assays available today for 
measuring signaling from receptor activation, it can be a daunting task to correctly identify what 
assay is the best for the ligand in question. Each assay has its own set of benefits and 
disadvantages, however ultimately a few key facts need to be decided upon. Will the ligand be 
stable under the prescribed assay conditions? As we found with dynorphin A in the Tango assay, 
overnight incubation of the peptide ligand with the cells greatly decreased its viability in the 
assay, which complicated the results and lead to interpretation difficulties. When utilized in 
several alternate assays for arrestin recruitment, we were able to show that dynorphin A is able to 
recruit arrestin without much issue, leading us to conclude that the ligand is probably not G 
protein biased after all. Another consideration to take into account is the cellular background of 
the assay. While overexpressed systems can be a helpful first pass at uncovering the signaling 
mechanisms of a ligand, utilizing endogenous systems and relevant cells may provide a better 
insight into how a novel ligand might behave in vivo. For example, morphine is unable to cause 
receptor internalization in overexpressed HEK cells, leading to the conclusion that morphine 
might be G protein biased. However morphine is able to induce receptor internalization in striatal 
neurons, indicating differential effects from two different cellular systems and opposite 
interpretations of arrestin signaling.17 As Terry Kenakin states in his textbook Principles of 
Pharmacology, it is always important to look ahead to the ultimate goal in understanding the 
pharmacology (Figure 15). If the end result is clinical work, then aim to utilize assays with 
human receptors before moving into endogenous systems. This concept applies well the example 
of 6’-GNTI, where testing in assays from multiple cellular backgrounds revealed a lack of 
activity in neurons, highlighting that overexpressed in vitro results may not translate well into 
natural systems.  
 249 
Correctly Interpreting Results for a 
Meaningful Bias Factor. Not only are 
there many assays to measure receptor 
signaling, but also there is an increasing 
number of ways in which bias factors can 
be calculated. In order to obtain the most 
accurate results, it is important to utilize 
the operational model, which takes into 
account both the efficacy, potency, and affinity of the ligand for the receptor, as used in the bias 
calculations shown in this chapter. Without the affinity, even calculated from a data set of 
concentration-response curves, an integral piece of information will be missing that affects 
understanding of the ligand bias. Methods that use only the potency and efficacy to calculate bias 
are fine for a cursory overview of the data but should be avoided in place of the more rigorous 
operational model. Additionally, data can be difficult to interpret for low efficacy compounds. 
All compounds analyzed in this chapter showed meaningful dose response curves that allowed 
use of standard operational model calculations. However ligand bias is near impossible to 
calculate if there is not a full curve of the ligand for each signaling pathway. Laura Bohn 
discusses this extensively in a recent study.18 Rather than fitting curves on data sets that show 
little to no efficacy, Bohn suggests instead to use a competitive method to obtain the data. In this 
way, low efficacy compounds might be able to instead show inhibition of a full agonist, thus 
providing a full curve that can be used in the operational model.18 A most important point is to 
view data with some level of skepticism and be convinced of results only after multiple assays 
and cellular systems have been used. Criticism of results we obtained in the Tango assay allowed 
 
Figure 15. Flow of the State of the Art of Pharmacology. 
Early studies often start in in vitro systems, but the 
ultimate goal should always be in mind towards in vivo 
and clinical studies if relevant. Adapted from A 
Pharmacology Primer (Figure 1.4, 3rd ed.).27 
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further study of the signaling of dynorphin A and led us to uncover an unexpected activity for 
recruiting arrestin of dynorphin A in an artificial, reconstructed system. Further study of 
dynorphin A’s signaling in endogenous systems or in vivo may provide more information about 
the true level of bias from this compound. 
Moving Assays Closer to In Vivo. One solution to the issue of highly modified, 
overexpressed cellular systems, like those studied in this chapter, is to bring some functional 
assays into an in vivo setting. While this is certainly an ambitious goal, some researchers are 
making attempts to start this process. In one example, researchers used fluorescein arsenical 
hairpin binder (FlAsH) technology in combination with fluorescence resonance energy transfer 
(FRET) to measure GPCR activation in live HeLa cells.19 Cyan fluorescence protein (CFP) and 
yellow fluorescent protein (YFP) were inserted into the human adenosine A2A receptor, which 
allowed FRET monitoring of receptor activation and kinetics. FlAsH technology has been 
utilized in vivo20, and thus if translated into the study of GPCRs there would be a method to 
image G protein activation signaling cascades live rather than just interpreting through plate 
reader-based assays currently utilized heavily. FlAsH technology is unfortunately another highly 
modified system and may not be able to measure bias of GPCRs. Another technology being 
utilized to measure GPCR activation in vivo is Designer Receptors Exclusively Activated by 
designer Drugs (DREADDs). Developed by Bryan Roth, this system utilized a specially 
engineered GPCR that is only activated by a synthetic ligand (usually clozapine N-oxide, CNO), 
not likely to hit any other receptors/targets.21 Once genetically encoded into animal models (mice 
mostly), receptors can be activated by addition of CNO. Updated versions of the technology 
utilizing channelrhodopsins allow receptors to be activated (and imaged) by certain wavelengths 
of light in the brain.22 Unfortunately, these methods require heavy genetic manipulation, and 
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while they can be performed in vivo, the results in some ways are no better than in vitro assays. 
Perhaps in the most relevant attempt, researchers have utilized positron emission tomography 
(PET) technology to measure the activation of MOR in the brain of subjects undergoing “social 
pain.”23 Using the MOR radioligand [11C]carfentanil, researchers showed that subjects with 
major depressive disorder (MDD) had reduced levels of endogenous opioid release in the brain 
in response to social rejection. Although this study could not show receptor activation on the 
cellular level, it does highlight the possibility to image opioid receptors in vivo (and in humans). 
In the advent of better technology for measuring G protein activation and arrestin recruitment, 
the results of ligands described in this chapter and others will be more reliable and hopefully 
translate well into more complex systems. 
It should be noted, however, that there are no methods for studying GPCR signaling or 
even bias directly in vivo. This lack of technology is seriously impeding further progress on 
understanding the implications of biased signaling on behavioral responses. Researchers are left 
trying to draw comparisons between in vitro signaling results and in vivo behavioral effects, 
which in all likelihood may not be comparable at all. While some assays can be applied to ex 
vivo analysis of excised tissue or dissociated cells (most commonly used are the [35S]GTPγS 
binding assay and western blotting, see Introductory Chapter 1 for more detail), they still cannot 
provide the complete picture of how biased signaling might affect the processes and function of 
living in vivo systems.  
Testing Ligands In Vivo. Laura Bohn accurately describes the predicament with biased 
ligands in a recent report.24 Although an increasing number of biased ligands are being 
discovered each year, the evidence of what it means to be biased in vivo is quite limited. Bohn 
notes that ideally biased calculations between two pathways should be performed using the same 
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cellular readout, thus eliminating any cellular discrepancies that may arise. Additionally, it is 
important to test lead compounds in an in vivo setting. Without analyzing the behavioral effects a 
biased ligand might have on an animal, then the whole concept of functional selectivity is limited 
to a cellular context only. There is also the added caveat that animal models for certain behaviors 
are not always a true depiction of how they will react in humans. However, hopefully in studying 
an increasing number of biased ligands both in vitro and in vivo, scientists will be better 
equipped to interpret results as those leads move into the clinic. There are still no true methods to 
study biased signaling in vivo, however (see above), so researchers must draw conclusions on 
functional selectivity with caution. 
 
Conclusions 
 We have shown, through a rigorous dissection and analysis of many assays for arrestin 
recruitment, that caution should be taken when choosing the appropriate assay for studying a 
particular ligand of GPCRs. After confirming dynorphin A bias in the Tango assay, we 
determined that conditions required for the Tango assay were not conducive to neuropeptides, 
leading to a potentially misleading conclusion of ligand bias. In studying the Tango assay 
further, we scrutinized the role of the V2 tail in the context of arrestin recruitment by both 
removing it from the Tango assay itself and applying it to other BRET-based arrestin assays. We 
found that while the V2 tail seems crucial for success of the Tango assay, its use in other arrestin 
assays did not alter bias calculations to a significant extent (although it did affect potency and 
efficacy parameters of some compounds). Therefore, although the V2 tail may enhance (or 
otherwise affect) recruitment of arrestin to GPCRs, it does not appear to artificially enhance 
arrestin levels to an extent that would significantly affect bias factor calculations. Through this 
 253 
exercise, we have come to appreciate the importance of testing novel ligands in multiple assays 
as a way to understand the complex molecular signaling with the utmost accuracy. 
 
Experimental 
Cell Culture. HEK-293T cells were obtained from the American Type Culture 
Collection (Rockville, MD) and were cultured in a 5% CO2 atmosphere at 37 oC in Dulbecco’s 
Modified Eagle Medium (high glucose #11965; Life Technologies Corp.; Grand Island, NY) 
supplemented with 10% FBS (Premium Select, Atlanta Biologicals; Atlanta, GA) and 100 U/mL 
penicillin and 100 µg/mL streptomycin (#15140, Life Technologies). HTLA cells (HEK293 cells 
stably transfected with tTA-dependent luciferase reporter and β-arrestin2-TEV fusion gene) were 
a gift from Bryan Roth and were culture in a 5% CO2 atmosphere at 37 oC in Dulbecco’s 
Modified Eagle Medium supplemented with 10% FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin, 100 µg/mL streptomycin, 2 µg/mL puromycin, and 100 µg/mL hygromycin B. 
 DNA Constructs. The human MOR (hMOR), human DOR (hDOR), human KOR 
(hKOR), and GRK3 were obtained from the Missouri S&T Resource Center. The human KOR 
Tango construct was generously provided by Bryan Roth. The human G protein constructs used 
here have been previously described and were provided by C. Galés or were obtained from the 
Missouri S&T Resource Center unless otherwise noted.10,25 The G proteins used included 
untagged GαoB (GαoB); GαoB with Renilla luciferase 8 (RLuc8) inserted at position 91 (GαoB-
RLuc8); Gβ1 (β1); untagged Gγ2 (γ2); Gγ2, which we fused to the full-length mVenus at its N-
terminus via the amino acid linker GSAGT (mVenus-γ2). The plasmids employed in the arrestin 
recruitment assay, hKOR-RLuc8 and Arr3-mVenus, were synthesized in-house as previously 
described.10 All constructs were sequence-confirmed prior to use in experiments. 
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Tango Assay. HTLA cells were added to a 10-cm plate at 5 x 106 cells/plate (day 1). On 
the next day (day 2), cells were transfected with 8 µg of receptor using the calcium phosphate 
method.26 After 24 hours (day 3), cells were transferred to a poly-D-lysine coated 96-well white, 
clear-bottomed plate at 40,000 cells/well. After another 24 hours (day 4), media was refreshed to 
100 µL/well, and ligands were added at 5X concentrated stocks in 25 µL of HBSS with 20 mM 
HEPES (assay buffer). Cells were incubated overnight at 37 oC. After 18-24 hours (day 5), cells 
were equilibrated to room temperature after which time the media was removed and replaced 
with 100 µL/well of Promega Bright-Glo (#E2610) solution (diluted 1:10 in assay buffer) in the 
absence of light. Luminescence was measured on a standard plate reader after 15 minutes.  
BRET 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
106 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg MOR/DOR/KOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; BRET GAP43 translocation: 2 µg hKOR, 0.25 µg 
Rluc8-arrestin3-Sp1, 5 µg mem-linker-citrine-SH3, 5 µg GRK3; BRET recruitment: 0.2 µg 
hKOR-RLuc8, 15 µg Arr3-mVenus, 5 µg GRK3. Cells were maintained in the HEK-293T media 
described above. After 24 hours the media was changed, and the experiment was performed 24 
hours later (48 hours after transfection). 
 BRET. Transfected cells were dissociated and re-suspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were re-
suspended in PBS. For agonist experiments, after 5 minutes, 5 µM of the luciferase substrate 
coelenterazine H was added to each well. After 5 minutes, ligands were added and the BRET 
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signal was measured 5 minutes later on a PHERAstar FS plate reader. For antagonist competition 
experiments, cells were pre-incubated with the antagonist at varying concentrations for 30 
minutes. Coelenterazine H (5 µM) was then added to each well for 5 minutes. Following 
coelenterazine H incubation, a fixed concentration of the reference agonist (5x EC50) was added, 
and the BRET signal was measured at 30 minutes on a PHERAstar FS plate reader. The BRET 
signal was quantified by calculating the ratio of the light emitted by the energy acceptor, mVenus 
(510-540 nm) or citrine (510-540 nm), over the light emitted by the energy donor, RLuc8 (485 
nm). This drug-induced BRET signal was normalized using the Emax of [D-Ala2, N-Me-Phe4, 
Gly-ol5]-enkephalin (DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-50,488 as the maximal 
response at MOR, DOR, and KOR respectively. Dose response curves were fit using a three-
parameter logistic equation in GraphPad Prism 6. 
Cloning 
 Synthesis of Tango hKOR without V2 Tail. The hKOR Tango construct was digested 
with AgeI-HF® (#R3552L; New England Biolabs, Ipswich, MA) according to the manufacturer’s 
protocol in CutSmart® Buffer (#B7204S; New England Biolabs) at 37 oC for 1.5 hours. A small 
portion of the reaction (10 µL) was loaded onto an agarose gel, and the correct band was cut out 
and purified using the QIAquick Gel Extraction kit (#28704; Qiagen Inc, Valencia, CA). Next, 
this cut vector (3 µL) was ligated according to the manufacturer’s protocol using T4 DNA ligase 
(#M0202, New England Biolabs) in T4 DNA ligase reaction buffer (#B0202S, New England 
Biolabs) overnight at 4 oC. The ligation reaction was transformed into E. coli and then amplified 
before using. 
 Synthesis of hKOR-V2 Tail-RLuc8. A PCR reaction was run with the hKOR Tango 
construct (Forward Primer = CTTGGTACCATGAAGACGAT; Reverse Primer = 
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GAAGCCATCCCCCCTCTTGACGATGAAGTGTCCTTGGC) and the hKOR-RLuc8 
construct (Forward Primer = GCCAAGGACACTTCATCGTCAAGAGGGGGGATGGCTTC; 
Reverse Primer = GCCCTCTAGATTACTGCTCGTTCTTCAGC) described previously.10 The 
PCR reactions were loaded onto an agarose gel, and the correct bands were cut out and purified 
using the QIAquick Gel Extraction Kit. These two PCR products were combined in a new PCR 
reaction (Forward Primer = CTTGGTACCATGAAGACGAT; Reverse Primer = 
GCCCTCTAGATTACTGCTCGTTCTTCAGC), which was then loaded onto an agarose gel and 
isolated again using the QIAquick Gel Extraction Kit. The second PCR product was digested 
with KpnI-HF® (#R3142, New England Biolabs) and XBaI (#R0145, New England Biolabs) for 
1 hour at 37 oC. The digestion was loaded onto an agarose gel and isolated again using the 
QIAquick Gel Extraction Kit. The purified cut PCR product was ligated with cut vector (digested 
in the presence of calf intestinal alkaline phosphatase, #M0290, New England Biolabs) (1 µg) 
with T4 DNA ligase (#M0202, New England Biolabs) in T4 DNA ligase reaction buffer 
(#B0202S, New England Biolabs) for 10 minutes at room temperature. This ligation product was 
immediately transformed into E. coli and then amplified before using. 
Calculations 
Operational Model Ligand Bias Calculations. Log(τ/KA) for individual data sets was 
estimated using a GraphPad Prism program developed by Professor L. Robert Lane (Monash 
University). For full agonists, the LogKA values were set to zero. EMax, n (Hill slope), and basal 
values were shared across all data sets. It was important to use the calculated LogKA (functional 
affinity) from the data sets, since experimental binding affinity may not account for multiple 
active receptor conformations. The calculated Log(τ/KA) were then converted into bias factors as 
shown in the Introductory Chapter 1 (Equations 2 and 3). 
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Chapter 6 – Potentiation of FGF2-Induced Glial Cell Line-Derived 
Neurotrophic Factor Release by a Novel Deconstructed Iboga Alkaloid Analog 
 
Introduction 
Glial cell line-derived neurotrophic factor (GDNF) is an important signaling protein in 
the central nervous system (CNS)1–5 that belongs to the GDNF-family of ligands (GFL), which 
together includes other members neurturin,6 persephin,7 and artemin.8 GDNF signals through the 
transmembrane receptor tyrosine kinase (RTK), which is known as rearranged during 
transfection receptor (Ret). Upon activation of Ret by GDNF, a tetrameric complex containing 
two molecules of Ret and two molecules of GDNF family receptor α (GFR1 in particular for 
GDNF) forms.9 This activated Ret/GFRα complex can then trigger intracellular signaling 
through the MEK, PI3K, and PLCγ pathways, which leads to a variety of cellular effects 
including modulation of differentiation, survival, proliferation, and plasticity of neurons.10  
GDNF and other neurotrophic factors such as brain-derived neurotrophic factor (BDNF), 
fibroblast growth factors (FGFs), and vascular endothelial growth factor (VEGF) are gaining 
popularity for their important role in mood disorders and addiction.11–14 Recent studies have 
found that there is cross-talk between different neurotrophins and growth factors. For instance, 
the fibroblast growth factor 2 (FGF2) induces GDNF release in both C6 glioma cells and in 
human neuroblastoma and glioblastoma cell lines through activation of the FGF receptor 1 
(FGFR1).15,16 The fibroblast growth factor system, currently comprised of 4 fibroblast growth 
factor receptors (FGFRs) and 18 fibroblast growth factors (FGFs), is a fundamental cellular 
system that plays critical roles in the development, maintenance, and regeneration of CNS 
tissues.11,17–19 Also, evidence suggests that the FGF system may play a direct role in 
neuropsychiatric disorders such as depression and anxiety (for further discussion on the FGF 
 261 
system, see Chapter 7). Proteins such as GDNF and FGF2 are not typically able to cross the 
blood-brain barrier, so small molecule modulators of neurotrophic factor signaling in situ 
represent a novel approach to treat complex neuropsychiatric diseases.20–25 
One such reported small molecule modulator of GDNF is the natural product ibogaine, 
from the Tabernanthe iboga plant. Among the many hypotheses on the mechanism of action of 
ibogaine (see Chapter 4), one intriguing suggestion that stands out links iboga alkaloids to the 
modulation of neurotrophic factor signaling systems. Namely, reports show that ibogaine can 
induce GDNF expression in the ventral tegmental area (VTA) of rats, suggesting that perhaps 
GDNF activates an autocrine loop, which in turn increases the long-term synthesis and release of 
GDNF (Figure 1A). These increased levels of GDNF could repair damage in the VTA-ventral 
striatum reward system and perhaps explain the long-lasting effects of ibogaine usage.26 
Additionally, GDNF infusion to the VTA also reduces self-administration of alcohol and cocaine 
in rats.26–29 It should be noted, however, that the role of GDNF in addiction may be more 
complex, as GDNF enhances the incubation of cocaine cravings during the first few weeks of 
withdrawal.27–29 Although this hypothesis does not provide a primary molecular target for the 
mechanism of ibogaine, it offers a larger physiological picture and a foundation for 
understanding the long-term effects of iboga alkaloids.  
Therefore, we chose to explore novel analogs of iboga alkaloids in order to discover 
superior releasers of GDNF that were also structurally distinct from ibogaine, which could 
provide a drug-like alternative to direct GDNF administration or viral gene delivery in the 
treatment of neuropsychiatric disorders. One can envision, therefore, that ibogaine analogs that 
more robustly increase GDNF production may in fact be superior therapeutics to ibogaine itself.  
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Figure 1. GDNF Release and Addiction. A. Glial-cell line derived neurotropic factor (GDNF) is a small protein that 
is synthesized and secreted in glial and neuronal cells. It has been shown to protect dopaminergic neurons in the 
brain and is linked to many brain disorders. Ibogaine, an alkaloid natural product isolated from Tabernanthe iboga 
has shown anti-addictive properties, possibly mediated through the induction of GDNF release in the reward circuits 
of the brain. It was suggested that the GDNF release repairs neuronal circuits altered by the development of the 
drug-dependent state (supported by reduction of alcohol consumption in rodents). B. Disconnection of the 
heteroarene and isoquinuclidine systems of the iboga skeleton reveals a novel class of iboga analogs. C. One such 
analog, XL-008, is a superior releaser of GDNF in comparison to the iboga alkaloid ibogamine, when tested at a 10 
µM concentration after 24 hours in C6 cells, an established secondary glial cell model. Data represent mean ± SD of 
biological replicates in one experiment from n = 4 independent experiments.  One-way ANOVA followed by 
Dunnett's Multiple Comparisons Test is shown (** p <0.01). 
 
In this chapter, the novel iboga analog XL-008 is described, including its synthesis and 
ability to induce GDNF release from C6 glioma cells. A full account of this work can be found in 
our published report.30 Not only does XL-008 induce GDNF release on its own, but it also 
greatly potentiates the GDNF release by FGF2. Additionally, the GDNF release by FGF2 and 
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XL-008 was found to depend on activation of the MEK and PI3K pathways of signal 
transduction but not the PLCγ pathway, which thus reveals a potentially interesting modulator of 
growth factors that could have therapeutic potential in treating neuropsychiatric disorders. 
 
Results 
Synthesis and Initial Biological Studies on Deconstructed Iboga Alkaloid Analogs 
Scheme 1. Synthesis of XL-008, Ibogamine, and CY-XL-008. 
 
Synthesis of XL-008 and Ibogamine. Compound XL-008 and ibogamine were prepared in 
racemic form according to a divergent Diels-Alder strategy as previously described (Scheme 1, 
chemistry optimized and completed by Andrew Kruegel).31 Briefly, the isoquinuclidine fragment 
was synthesized by a Diels-Alder reaction between a protected dihydropyridine and methyl vinyl 
ketone. The 7-acetyl group was then reduced via tosylhydrazone formation to provide both the 
endo- and exo-isoquinuclidine fragments. These were deprotected and alkylated with 
bromoethylindoles to provide N-heteroarylalkylisoquinuclidines, including XL-008. For 
ibogamine, the endo-isoquinuclidine was epimerized and reduced by a similar sequence. 
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afforded the selective bromination at the indole 2-position. 
This crude arylbromide intermediate was then cyclized 
under reductive Heck conditions to provide rac-ibogamine. 
XL-008 could further be cyclized utilizing an electrophilic 
palladation-type cyclization to provide cyclic XL-008 (CY-
XL-008). 
GDNF Release From C6 Glioma Cells. It is well-
recognized that GDNF release can be measured in the 
growth medium of conditioned C6 rat glioma cells using 
conventional ELISA with basal levels between 6 and 81 
pg/mL.32 C6 glioma cells are a model for astrocytes and are 
known to express the mRNA of GDNF, as well as that of Ret and GFRα1. Therefore, the cells 
can be utilized for measuring GDNF 
release induced by different 
compounds in vitro.33 In order to 
assay the GDNF release induced by 
novel compounds, C6 cells were 
incubated with test compounds for 
24–48 hours, and GDNF levels were 
then detected in the conditioned 
media with picogram sensitivity 
using a commercially available standard sandwich-style ELISA. The assay required extensive 
optimization of cell culture and release conditions, which allowed reproducible experiments to 
 
Figure 2. GDNF Release from XL-008 
and CY-XL-008 Derivatives. A. GDNF 
release from iboga alkaloid analog XL-
008 and cyclic derivative CY-XL-008 
after 48 hours. Error bars represent SD 
of biological replicates. Conditions 
were performed in duplicate and 
measured in triplicate. One-way 
ANOVA with Dunnett’s Multiple 
Comparisons Test are shown (* p < 
0.05, ** p < 0.01). Data obtained by 
Rich Karpowicz. 
A.     B. 
 
Figure 3. GDNF Release at 48 Hours is Cytotoxic. A. GDNF 
release from ibogamine and XL-008 at 48 hours. B. LDH release 
from C6 (P41) in 96-well plates after 48 hours. Conditions were 
performed in quadruplicate and measured in singlet. Error bars 
represent SD of a representative experiment of n = 3 independent 
experiments. One-way ANOVA with Dunnett’s Multiple 
Comparisons Test are shown (**** p < 0.0001). 
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be obtained (see Experimental below). In early experiments, XL-008 was identified as a 
superior releaser of GDNF in a screen of ibogamine analogs. In particular, its GDNF release was 
far greater than that of ibogamine (Figure 1C), which revealed the importance of the key 
disconnection in the iboga skeleton between the isoquinuclidine and indole 2-position to form 
"acyclic" analogs. This hypothesis was further supported when the GDNF release by CY-XL-
008 was measured, which showed a significant but lesser release than XL-008 when compared to 
DMSO (Figure 2). In the 48-hour experiments, substantial production of GDNF was noted 
(Figures 2 and 3A); however, it became clear that such release was stressful to the cells and 
resulted in marked cytotoxicity, as visualized by changes in cell morphology (Figures 3B and 4). 
Rather than showing a healthy, flat monolayer of cells (Figure 4A), the addition of XL-008 after 
 
Figure 4. Brightfield images (400X) of C6 morphology in response to 48-hour treatment with XL-008 at (A) 0.1% 
DMSO control, showing normal, flat, fibroblastic morphology, (B) 10 µM, and (C) 40 µM. An example process 
induced by XL-008 is indicated with an arrow. Data obtained by Rich Karpowicz. 
 
48 hours caused rounding of cells (Figure 4B) and the formation of processes (Figure 4C).34,35 
Therefore, all GDNF release experiments were conducted using a 24-hour treatment. Even 
though the GDNF release at 24 hours was not as robust in comparison to 48 hours, the measures 
were statistically significant while minimizing cytotoxic effects.  
XL-008 Potentiation of FGF2-Induced GDNF Release 
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dramatically evident at 40 µM (Figure 8C).   We reason that the mechanism of GDNF release 
may be intricately tied to the mechanism of this phenotypic change. 
 
A.            B.         C.  
 
Figure 8.  Brightfield images (400X) of C6 morphology in response to 48-hour treatment with 
XL-008 at (A) 0.1% DMSO control, showing normal, flat, fibroblastic morphology, (B) 10 µM, 
and (C) 40 µM.  An example process induced by XL-008 is indicated with an arrow.  Images 
courtesy of Rich Karpowicz.  
 
 Thus, we have characterized the time- and protein synthesis-dependent GDNF release 
induced by our compounds.  We know that more than 24 hours is required for GDNF synthesis 
and release to occur, but the signaling cascade is activated within a 24-hour period.  Treatment 
with the compounds induces dose-dependent GDNF release (Figure 5).  C6 cell morphology 
changes dose-dependently after 48-hour treatment with the compounds.  This information will 
aid us as we seek to elucidate the mechanism of action of these neurotrophin-releasing 
compounds.  
 
III. Hypotheses for the Mechanism of Action of Isoquinuclidines 
Preliminary results in the C6 cell release assay, combined with a thorough examination of 
the literature on receptor expression and GDNF production in these cells led us to utilize 
pharmacological tools for examining the signaling pathways involved in isoquinuclidine-induced 
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XL-008 Induces Potentiation of GDNF Release From FGF2. In addition to studying the 
effects of XL-008 on GDNF release from C6 cells, we were also interested in exploring whether 
there was any potential GDNF release caused by growth factors, FGF2 in particular (see 
Introduction for the rationale). Similar to previous reports, FGF2 afforded measurable GDNF 
release in our assays, and so we aimed to explore further the potential interactions of XL-008 and 
FGF2 on GDNF release.15,36 In a competition experiment where XL-008 and FGF2 were co-
incubated to determine if their GDNF releasing effects were additive, interesting results were 
obtained. The GDNF release induced by FGF2 (25 ng/mL) was greatly increased in the presence 
of 10 µM XL-008 (Figure 5A). In contrast, the effect of ibogamine on the GDNF release 
induced by FGF2 was only additive (Figure 5B). XL-008, therefore, not only induces release of 
GDNF independently but also potentiates the GDNF release by FGF2, another 
pharmacologically relevant target. In fact, the effects of FGF2 and XL-008 together on GDNF 
release are almost two-fold higher than the additive effects of their individual GDNF releases. 
Interested by the observed potentiation, it was necessary to study the effect of FGF2 (25 
ng/mL) on the GDNF release elicited by varying concentrations of XL-008. When the GDNF 
release was measured for FGF2 on a dose response curve of XL-008, we found that FGF2 both 
increases the efficacy of GDNF release by XL-008 in C6 glioma cells and potentiates the dose 
response curve, shifting the EC50 from more than 15 µM to 6.17 ± 2.40 µM, a greater than two- 
fold increase in potency (Figure 5C). Since higher concentrations of XL-008 caused cytotoxic 
effects in the C6 cells, a full dose response curve for XL-008 alone was not obtained. Typically, 
when concentrations greater than 30 µM were measured, they were found to be highly toxic even 
in the 24-hour treatment, as determined by visual observation, lactate dehydrogenase (LDH) 
assay, and water-soluble tetrazolium (WST-1) assay. Consequently, Figure 5C shows only an 
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Figure 5. FGF2-Induced GDNF Release in C6 Cells is Potentiated by Iboga Analog XL-008. A. Fibroblast growth factor 
2 (FGF2)-induced GDNF release is greatly enhanced by XL-008 in C6 cells after a 24-hour treatment time. B. Ibogamine 
gives much smaller induction effect in comparison to XL-008. C. FGF2 (25 ng/mL) potentiates the dose response of XL-
008 from an EC50 > 15 µM to 6.17 ± 2.40 µM (n=4). D. This effect is only additive on the dose response of ibogamine. E. 
The dose response curve of FGF2 is potentiated by XL-008 in a dose-dependent manner. F. The effect on FGF2 curve is 
less pronounced in the presence of ibogamine. Data represent mean ± SD of biological replicates in one experiment from n 
> 4 independent experiments. One-way ANOVA with Dunnett's Multiple Comparisons Test are shown (* p < 0.05, ** p < 
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approximate EC50 that has been used for comparative purposes. Interestingly, FGF2’s effects on 
the GDNF release from ibogamine were subtler. In contrast to XL-008, ibogamine trends 
towards GDNF release but does not reach statistical significance. However, in the presence of 
FGF2, the GDNF release from ibogamine did increase in a statistical manner, but these effects 
only added to the efficacy of this release rather than potentiating it, as in the case of XL-008 
(Figure 5D). 
To explore this potentiation 
further, the potency of FGF2-
induced GDNF release was then 
measured in the presence of a 
range of concentrations of both 
ibogamine and XL-008. The 
potency of FGF2-induced GDNF 
release increased by more than 2-
fold when co-incubated with XL-
008, from an EC50 of 7.85 ± 2.59 
ng/mL to 3.31 ± 0.98 ng/mL with 
10 µM XL-008 (Figure 5E). Statistical analysis with Tukey’s multiple comparisons test showed 
that this change in potency was statistically significant when compared to the EC50 of FGF2 
alone (Table 1, * p < 0.01). In the presence of lower concentrations of XL-008, the shift in the 
potency can still be seen; for instance, 5 µM XL-008 shifts the EC50 to 4.45 ± 2.68 ng/mL. 
Similar to the previous experiments, the effect is much lower with ibogamine. When lower 
concentrations of ibogamine are tested, such as 1 and 5 µM, there is little effect on the FGF2-
Table 1. Summary of GDNF Release Data 
Treatment EC50 
Ibogamine NS 
Ibogamine + FGF2 (25 ng/mL) >15 µM 
XL-008 >15 µM 
XL-008 + FGF2 (25 ng/mL) 6.17 ± 2.40 µM 
FGF2 7.85 ± 2.59 ng/mL 
(0.482 ± 0.159 nM) 
FGF2 + Ibogamine 1 µM 6.87 ± 2.08 ng/mL 
(0.422 ± 0.128 nM) 
FGF2 + Ibogamine 5 µM 6.24 ± 2.88 ng/mL 
(0.383 ± 0.177 nM) 
FGF2 + Ibogamine 10 µM 4.15 ± 2.22 ng/mL 
(0.255 ± 0.136 nM) 
FGF2 + XL-008 1 µM 6.87 ± 3.00 ng/mL 
(0.422 ± 0.184 nM) 
FGF2 + XL-008 5 µM 4.45 ± 2.68 ng/mL 
(0.273 ± 0.165 nM) 
FGF2 + XL-008 10 µM 3.31 ± 0.98 ng/mL* 
(0.203 ± 0.060 nM) 
*One-way ANOVA with Tukey’s Multiple Comparisons Test shows  
* p< 0.01 for FGF2 + XL-008 10 µM when compared to FGF2 alone.  
NS means “not significant.” GDNF, glial cell line-derived  
neurotrophic factor; FGF2, fibroblast growth factor 2. 
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induced GDNF release. Instead, there is a little increase in GDNF release by a 10 µM co-
treatment of ibogamine, which shifts the EC50 to 4.15 ± 2.22 ng/mL (Figure 5F). Unlike the 
potency shift with XL-008, this shift in potency is not statistically significant, which is an 
indication of the superiority of XL-008 as a potentiator of GDNF release by FGF2. The results of 
Figure 5 are summarized in Table 1. 
Understanding the Signaling Pathways Involved in FGF2-Induced GDNF Release. An 
important next step in studying this novel potentiation of FGF2-induced GDNF release from C6 
cells was to explore the mechanism of action. Initially, there was a serious push made to try and 
study the signal transduction pathways of GDNF release using conventional methods. To start, 
the ERK1/2 pathway and RET, the kinase involved in GFRα1 activation, were probed using 
traditional western blotting techniques. Unfortunately, because this glioma cell line is 
tumorogenic in nature, it is likely that many of the receptors are overexpressed, which leads to 
increased basal levels of ERK1/2. Therefore, using a western blot to quantify these critical 
signaling events remained challenging as the basal levels of ERK1/2 activation in western 
blotting were high. Furthermore, we observed that the ERK1/2 pathway was extremely sensitive 
to movement, temperature, and even the vehicle control DMSO, which only further obscured any 
ERK1/2 or RET activation that might have otherwise been observed using western blot.  Taken 
together, we decided to explore instead more sensitive techniques for measuring signaling 
pathway activation, including cell-based enzyme-linked immunosorbent assay (ELISA) for 
measuring both ERK1/2 and AKT phosphorylation. Again, the high levels of basal kinase 
activation were problematic to our studies, making it impossible to glean meaningful information 
about the signaling events. Instead the pathway for potentiation had to be studied through more 
indirect methods. 
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In an attempt to instead pharmacologically block the signaling pathways involved in the 
XL-008-induced GDNF release, small molecule inhibitors were utilized. The three major 
pathways of signal transduction, protein kinase B (PKB or Akt), mitogen-activated protein 
kinase (MAPK), and protein kinase C (PKC), each have well-studied inhibitors that can be used  
for blocking activation 
through these proteins.43 
In order to inhibit the 





LY294002 (20 µM),36,38 
the mitogen-activated 
protein kinase kinase 
(MEK1/2) inhibitor 
U0126 (10 µM),26,37 and 
the phospholipase C (PLC-γ) inhibitor U73122 (2 µM)21,37 were used. Additionally, given that 
the potentiation results require FGF2, it was important to study whether the whole FGF2 family 
was involved, using the FGFR inhibitor PD173074 (1 µM)39–41. Further, other growth factor-
activated RTKs could be involved in the potentiation effects and were therefore also probed. The 
inhibitor KRN633 (1 µM)37,42 targets both the platelet-derived growth factor receptor (PDGFR) 
and the vascular endothelial growth factor receptor (VEGFR) and was used in these experiments 
Table 2. Pharmacological Inhibitors of GDNF Release 


















































to study the involvement of transactivation in the GDNF signaling. The structures and targets of 
the inhibitors used are summarized in Table 2. 
 
 
Figure 6. Potentiation of FGF2-Induced GDNF Release by Iboga Analogs is Pathway Specific. A. The GDNF 
release by FGF2 in C6 glioma cells after 24 hours is mediated by the phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways. Pretreatment of cells with inhibitors for 1 hour (30 
minutes for U0126, as reported39) indicates involvement of PI3K (LY294002, 20 µM), MAPK (U0126, 10 µM), and 
fibroblast growth factor receptor (FGFR) (PD173074, 1 µM) pathways but not the phospholipase C (PLCγ) 
(U73122, 2 µM) and platelet-derived growth factor receptor/vascular endothelial growth factor receptor 
(PDGFR/VEGFR) (KRN633, 1 µM) pathways.  B. The GDNF release by XL-008 in C6 glioma cells after 24 hours 
shows similar pathway activation as that seen from FGF2 alone with the exception of some inhibition by 
PDGRF/VEGFR inhibitor KRN633. C. The GDNF release by XL-008/FGF2 in C6 glioma cells after 24 hours 
shows similar pathway activation to that seen from FGF2 alone. D. No GDNF release is observed in the presence of 
the inhibitors alone in C6 glioma cells after 24 hours. Data represent mean ± SD of biological replicates in one 
experiment from n = 9 independent experiments. One-way ANOVA followed by Dunnett's Multiple Comparisons Test 
is shown (** p < 0.01, *** p < 0.001, **** p < 0.0001). 
 
When these inhibitors were used in the GDNF release experiments, they helped to 




































+    +    +    +    +    +
-    +     -     -     -    -
-     -    +     -     -    -
-     -     -    +     -    -
-     -     -     -    +    -
-     -     -     -     -   +















































































+ FGF2 25 ng/mL




































+ XL-008 10 µM
** **** **** **** ****
C.
 272 
pathways but not the PKC pathway (Figure 6A). These results match with studies that were 
previously reported.22,36,37 In addition, this GDNF release depended upon FGFR but not PDGFR 
or VEGFR, which did confirm the selectivity of the inhibitors used. The GDNF release from XL-
008 alone shows similar trends in comparison to FGF2 with the interesting exception that the 
GDNF release from XL-008 does show some dependence on the PDGFR and VEGFR pathways 
(Figure 6B). These data do suggest that the mechanism of GDNF release from XL-008 may be 
unique when compared to that of FGF2. The potentiation of FGF2 by XL-008 was importantly 
noted to be dependent upon the same pathways as FGF2 alone (Figure 6C). Even though the 
exact target responsible for this XL-008-induced GDNF release is unclear, it is obvious that 
FGFR is involved in the potentiated GDNF release. To be sure that the inhibitors not were 
confounding the experiments in any way, the GDNF release induced by the inhibitors alone was 
measured. None of the inhibitors tested released any statistically significant amount of GDNF 
when compared to the DMSO vehicle control (Figure 6D).  
To explore the direct involvement of the 
FGFR system in this mechanism, the ability of XL-
008 to directly activate FGFR1 (fibroblast growth 
factor receptor 1) was measured. Using a sandwich-
style ELISA (see Chapter 7), XL-008 was unable to 
phosphorylate the FGFR1 (a measure of RTK 
activation) at any concentration up to 30 µM (Figure 
7). Additionally, as a reliable modulator of one 
growth factor system, is was imperative to determine 
whether XL-008 was able to cause release of FGF2 in 
 
Figure 7. XL-008 Does Not Activate FGFR1 in 
FGFR1-HEK Cells. FGFR1-HEK were treated 
with FGF2 or XL-008 for 1 hour. Cell lysate 
was analyzed using sandwich-style ELISA for 
detection of phosphorylated receptor. 
Treatments were normalized to total protein 
using the BCA assay. Data represent mean ± 
SD of biological replicates in one experiment 
from n = 3 independent experiments. 
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the same cellular system. Increased levels of FGF2 may be responsible for the potentiation 
observed as more FGF2 in the system could consequently lead to more GDNF release. XL-008 
was unable to cause any measurable release of FGF2 in C6 cells using an ELISA for detecting 
FGF2 levels (Figure 8), indicating that the direct molecular target of the XL-008-induced GDNF 
may not be FGFR1 itself. 
Cell Viability and Toxicity Effects From 
Treatment with XL-008 and FGF2. Given the 
known protective and proliferative effects for FGF2 
alone, there was motivation to confirm whether the 
potentiation of FGF2-induced GDNF release also 
retained some of these same cellular effects. 
Therefore we carefully analyzed any trends between 
GDNF release and cytotoxicity in the 24-hour 
release experiments. 
Two different measurements of cell viability were performed to provide a thorough 
understanding of any possible cytotoxic effects from drug treatments. LDH is an enzyme found 
in the cytosol of cells that is released upon their lysis, or bursting. Assays available today allow 
for the simple colorometric detection for measuring the amount of LDH present in conditioned 
media, which correlates well with cell membrane integrity and therefore with cell health.44 
Another assay for the measurement of cell viability is the WST-1 cell assay, which uses a 
formazan dye to colorometrically detect intact, metabolizing mitochondria, another indication of 
cell viability.42 Together, these assays were used to identify the cytotoxic effects, if any, 
occurring either independently or as a result of GDNF release. 
 
Figure 8. FGF2 Release from XL-008 in C6 
Cells. Iboga alkaloid analog XL-008 does not 
cause statistically significant release of FGF2 after 
24 hours as measured using an ELISA for FGF2 
detection. Data represent mean ± SD of 
biological replicates in one experiment from n 
= 3 independent experiments. 
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Figure 9. Cell Viability and Cytotoxicity Studies. Potentiation of FGF2-induced GDNF release by XL-008 also shows cell 
viability enhancing effects and little to no cytotoxicity as measured by lactate dehydrogenase (LDH) release and cell 
viability assays. A. LDH release after 24 hours of XL-008 in the presence of FGF2 (25 ng/mL) reveals no cytotoxic effects 
when compared to the DMSO vehicle control. B. LDH release in the presence of XL-008/FGF2 and the kinase inhibitors 
also indicates no cytotoxic effects, with the exception of a small LDH release in the presence of ERK inhibitor U0126 
alone. C. Cell viability measurement by tetrazolium (WST-1) assay shows minor cytotoxic effects in the presence of 
kinase inhibitors. D. LDH release of varying concentrations of FGF2 in the presence of XL-008 is increased only at higher 
concentrations of FGF2/XL-008 potentiation mixtures. E. Cell viability as measured by the WST-1 assay reveals no 
cytotoxic effects from the 24-hour treatment at increasing concentrations of FGF2/XL-008, where cell viability and 
metabolism is increased (nearly two-fold). Data represent mean ± SD of biological replicates in one experiment from n > 4 
independent experiments. One-way ANOVA followed by Dunnett's Multiple Comparisons Test is shown (* p < 0.05, ** p 
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After a 24-hour treatment in C6 cells, there were no obvious cytotoxic effects from 
increasing concentrations of XL-008 in the presence or absence of FGF2 (25 ng/mL) as 
measured by LDH release (Figure 9A). Based on these results, there does not appear to be any 
correlation between GDNF release and cytotoxicity using the 24-hour experimental conditions, 
in contrast to the 48-hour treatment (see Figure 3). Additionally, the use of the selected 
inhibitors with FGF2, XL-008, or FGF2/XL-008 resulted in no cytotoxicity as measured by LDH 
release (Figure 9B). The only 
treatment to sometimes cause 
statistically significant release of 
LDH when compared to DMSO 
was the addition of inhibitors 
alone, as seen for inhibitor 
U0126. This observation 
highlights the protective effects 
of FGF2/XL-008 as their 
addition to cytotoxic inhibitors 
resulted in reduced toxicity. 
Similar experiments were 
performed with the WST-1 
assay. The LDH results were 
supported in the WST-1 assay 
(Figure 9C), which show that, in 
general, treatments caused 
 
Figure 10. Cytotoxicity Effects From GDNF Release. GDNF release 
from FGF2 and ibogamine shows little to no effect on cytoxocity as 
measured by lactate dehydrogenase (LDH) release and cell viability 
assays. (A) LDH release after 24 hours of ibogamine in the presence of 
FGF2 (25 ng/mL) reveals few cytotoxic effects when compared to the 
DMSO vehicle control. (B) LDH release of varying concentrations of 
FGF2 in the presence of ibogamine demonstrates no toxicity. (C) Cell 
proliferation as measured by the WST assay reveals no cytotoxic effects 
from the 24-hour treatment at increasing concentrations of 
FGF2/ibogamine, where cell proliferation and metabolism is greatly 
increased. Data represent mean ± SD of biological replicates in one 
experiment from n = 4 independent experiments.  Results from One-
way ANOVA followed by Dunnett's Multiple Comparisons Test are 
shown (* p < 0.05, ** p < 0.01, **** p < 0.0001). 
 276 
increased metabolism, a measure of cell viability, which was statistically significant when 
compared to DMSO. This increased metabolism was consistent with increased production of 
GDNF. The only exception noted was with the PI3K/AKT inhibitor LY294002 pre-treatment, 
which consistently reduced cell viability. Since this pathway is well-known to mediate cell 
survival and proliferation,45,46 it was not surprising that the inhibitor LY294002 would cause 
reduced cell viability. Similar results were obtained in the treatments with ibogamine (Figure 
10). 
To explore the mechanism of increased cell viability further, the treatments were 
measured for their ability to cause cell proliferation using bromodeoxyuridine (BrdU) 
incorporation. The actual levels of proliferation in the cells for any treatment tested did not 
increase, which indicates that the increases in cell viability observed were independent of 
proliferation and likely occur via a metabolism-boosting effect (Figure 11). The LDH release 
and cell viability were additionally measured for the dose response of FGF2 in the absence or 
presence of increasing concentrations of XL-008. As predicted, the LDH release showed few 
cytotoxic effects under these treatment conditions (Figure 9D). The only exception was the 
highest concentrations of FGF2 in the presence of XL-008, which only occasionally resulted in 
elevated LDH levels in some experiments. In comparison to the 48-hour treatments, however, 
these “toxic” treatments showed a much lower LDH release (~12% LDH activity at 24 hours 
compared to >30% at 48 hours). The WST-1 assay additionally showed that cell viability was 
enhanced with increasing concentrations of both FGF2 and XL-008 (Figure 9E), suggesting that 
perhaps the combined treatment of FGF2 with XL-008, in fact, stimulates cell viability and 
metabolism at every concentration tested. These data indicate that these experimental conditions 
are likely protective to the cells. XL-008 also enhanced the viability effects of FGF2, even at 
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concentrations where FGF2 alone had no visible effect (sub-nanomolar concentrations, Figure 
9E), consistent with the potentiation of GDNF release. From this perspective, XL-008 
potentiates not only the release of FGF2-induced GDNF release but also the cell viability as a 
distinct cellular readout. The viability effects in this assay were dependent on the PI3K/AKT 
pathway (Figure 9C). However, in the 48-hour treatment experiments, the cytotoxic effects 
correlated closely with trends in GDNF release as measured by LDH release (Figure 3), which 
highlights the use of the 24-hour treatment time in these measurements. 
 
Figure 11. Bromodeoxyuridine (BrdU) Incorporation in C6 Cells. Cell proliferation was assessed by measuring 
BrdU incorporation in C6 cells after a 24-hour treatment with FGF2 and XL-008 using a commercially available 
ELISA for detection (Roche #11647229001). The co-treatment of XL-008 with increasing concentrations of FGF2 
does not cause increased proliferation during this treatment time. Data represent mean ± SD of biological replicates 
in one experiment from n = 3 independent experiments. Results from One-way ANOVA followed by Dunnett's 
Multiple Comparisons Test are shown (** p < 0.01, ** p < 0.001, **** p < 0.0001). 
 
Discussion 
Mechanism of Action. A proposed model for the mechanism of FGF2-induced GDNF 
release from C6 cells is depicted in Figure 12. Based on the data, XL-008 likely acts through 
some target that can either amplify the signaling events of FGF2 directly, which leads to 
increased GDNF production, or it transactivates FGFRs to increase the GDNF production 
through the pathways described. There are known examples of transactivation in the context of 
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induce GDNF mRNA expression in C6 cells, leading to higher levels of GDNF.37 Additional 
studies have connected a mu-opioid receptor-mediated transactivation of FGFRs in C6 cells, 
implicating many possibilities for this hypothesis.47 Transactivation of FGFRs is a plausible 
suggestion in understanding this mechanism, based on the evidence provided here. The FGFR 
 
 
Figure 12. Schematic representation of signaling pathways involved in potentiation of FGF2-induced GDNF release 
by XL-008. Pharmacological inhibition of XL-008/FGF2 reveals pathway specificity through MAPK and AKT. 
inhibitor PD173074 was able to fully block the GDNF release of XL-008 on its own (Figure 
6B), which ultimately makes transactivation of FGFRs by XL-008 a potential mechanism for the 
increased production of GDNF. It is also possibile that direct activation of FGFRs rather than 
transactivation leads to the observed changes in GDNF release. Again, the inhibition of XL-008 
by PD173074 would support this conclusion. However, as further indication of a direct 
involvement of FGFR activation, XL-008 was assessed for its ability to phosphorylate FGFR1 
FGF2
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(Figure 7). Since XL-008 was unable to phosphorylate the RTK at any concentration tested, it 
therefore is unlikely to be a small molecule agonist of the receptor. Furthermore, as XL-008 did 
not cause release of FGF2 itself (Figure 8), there is little indication that the FGF system plays a 
significant role in the mechanism of XL-008-induced potentiation of GDNF signaling. Although 
the direct target of XL-008 is still unclear, the data presented rule out direct action of the FGFRs, 
indicating that the direct molecular target is most likely downstream of FGFR1. 
 Difficulty in Working with C6 Cells. C6 glioma cells are a popular in vitro model of glial 
cells that have been used in thousands of publications. In the context of GDNF signaling, C6 
cells are often the gold standard for in vitro measurements, cited in dozens more studies alone. It 
was therefore an obvious choice for setting up GDNF detection experiments to evaluate our 
compounds. With careful experimental optimization, we were able to find reproducible results in 
the GDNF measurements (see Experimental). However, the difficulty encountered in obtaining 
meaningful signaling results in C6 cells certainly brings into question the use of these cells as a 
model system. For measuring acute signaling events, we found the C6 cells to be nearly 
impossible to use, consistently showing high basal levels of the protein targets that obscured 
important results. Replicating these studies in a better cellular system, such as primary neuronal 
culture or tissue, would provide more meaning to the results and confirm the findings in a 
broader context. Certainly measuring the potentiation effects would be fascinating to study in 
vivo and would highlight these targets further for therapeutic use. 
Use of Pharmacological Inhibitors. Although more direct signaling studies in the C6 
cells were preferable, the small molecule inhibitors used to probe the major signaling pathways 
of GDNF production provided the necessary insight to uncover a model for the mechanism of 
XL-008-induced potentiation of GDNF release. In order for these results to be meaningful, it was 
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necessary to strategically choose pharmacological inhibitors that were selective to each particular 
pathway at the concentrations employed. It is notoriously difficult to find inhibitors that are truly 
selective for one pathway/target over another. One recent publication thoroughly examined the 
selectivity of a large selection of protein kinase inhibitors, including those used in this study.43 
Researchers used a panel of 70-80 protein kinase targets to assess inhibitors for their selectivity. 
U0126, the inhibitor of the MAPK pathway, was confirmed as being selective. LY294002, on the 
other hand, did have some noticeable off-target activity at some proto-onocogene kinases, 
including PIM1 and PIM3. Despite this undesired activity, LY294002 still is assessed as the 
better Akt inhibitor over the widely used small molecule wortmannin, which is unsuitable for 
longer experiment durations such as those used here. Given the confirmed selectivity of these 
inhibitors, we are confident of the involvement of the MAPK and AKT pathways in the observed 
signaling in the GDNF release. 
 
Conclusions 
The modulation of growth factor synthesis and release (and/or potentiation of growth 
factor signaling) by a small molecule presents a novel approach for treating neurological, 
neurodegenerative and psychiatric disorders.24,25 Throughout this chapter, we have shown that 
the deconstructed iboga analog XL-008 is able to increase GDNF release on its own in the well-
established glial cell model, as well as potentiate the FGF2-induced GDNF release. In an 
independent cellular phenotype readout, the potentiation of the FGF2 signaling was also 
confirmed via increased cell viability. Although the exact molecular target for XL-008 remains 
unidentified, we were able to isolate the key kinase signaling pathways involved in the 
potentiation of GDNF release and cellular viability using pharmacological kinase inhibitors. XL-
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008 also does not activate FGFR1, as demonstrated through the use of ELISA for receptor 
phosphorylation and FGFR1 inhibitors, consistent with a mechanistic model where XL-008 acts 
downstream of FGFR1. The downstream effects of FGF2-induced signaling are well-known to 
be connected with many desirable physiological, cellular, and behavioral outcomes, including 
modulating neuronal spiking dynamics, inducing neurogenesis, and exerting antidepressant and 
anxiolytic effects.12,48 Therefore, the identification of a small molecule modulator that potentiates 
FGF2 signaling is relevant to the search for new therapeutic leads. As we move forward, a full 
examination will take place of this interesting new iboga analog and related compounds in brain 
tissue and in vivo.  
 
Experimental 
Chemical synthesis of XL-008, ibogamine, and CY-XL-008 was carried out as reported 
previously.31 
Reagents. Recombinant rat fibroblast growth factor basic (FGF2, 400-29) was purchased 
from Peprotech. Protease inhibitor cocktail (P8340) and phosphatase inhibitor cocktail 2 (P5726) 
were purchased from Sigma Aldrich. KRN633 was purchased from Selleck Chemicals, 
LY294002 was purchased from Cayman Chemical Company, PD173074 was purchased from 
Biotang, Inc, U0126 was purchased from Alfa Aesar, and U73122 was purchased from MP 
Biomedicals, LLC. 
Cell Culture. Rat C6 glioma cells were purchased from the American Type Culture 
Collection (CC-107) and maintained in Dulbecco’s Modified Eagle Medium (Life Technologies; 
10569) with 5% (v/v) fetal bovine serum (FBS, Atlanta Biologicals) and 100 U mL-1 of penicillin 
and streptomycin (Life Technologies). Cells were incubated at 37 °C with 5% CO2 humidified 
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atmosphere. The GDNF release in C6 cells is highly variable from one experiment to another and 
even from one passage to the next. Additionally, as a glioma cell line, C6 cells are highly 
susceptible to phenotypic drift, which can lead to varying expression levels of receptors and 
growth factors of interest. For the purposes of these experiments, it was found that if the C6 cells 
were maintained and used between a strict set of passages, experiments (though variable), 
provided reliable trends in GDNF release that were highly reproducible. Therefore, all data 
presented here show a single representative experiment of many independent replicate trials. C6 
glioma cells were used between passages 41–42. 
GDNF Release Experiments. Into a 96-well plate were added C6 cells at a density of 
25,300 cells/well in full growth medium (see above). Cells were allowed to adhere for 24 h at 37 
°C. Cells were then serum-starved with media containing 0.5% FBS (low serum) for an 
additional 24 h. Low serum media was refreshed prior to starting the experiment. Compounds 
were added in 50 µL of low serum media to obtain a final volume of 200 µL/well. All inhibitors 
were added for 1 hour in advance with the exception of U0126, which was pretreated for 30 
minutes, as reported.39 Treatments were performed in quadruplicate. Cells were incubated at 37 
°C for 24 hours. Experiments were terminated by removing the conditioned media from each 
well and storing at –80 °C until analyzed. GDNF was detected using a standard sandwich-style 
ELISA kit purchased from Promega Corporation following the manufacturer’s instructions. 
Briefly, monoclonal anti-GDNF antibodies were captured onto a 96-well Nunc Immulon 
Immunoassay plate at a dilution of 1:1000 in carbonate coating buffer (25 mM sodium 
bicarbonate, 25 mM sodium carbonate, pH 8.2) overnight at 4 °C. After removing the 
monoclonal antibody, wells were blocked with 1X Block and Sample Buffer for 1 hour at room 
temperature (200 µL/well). A GDNF standard curve was created by serially diluting the 
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recombinant human GDNF standard in 1X Block and Sample Buffer to a concentration range of 
0–1000 pg mL-1. To each sample well was added 100 µL of conditioned media from above and 
the standard curve (in duplicate), and plates were incubated for 6 hours with shaking at room 
temperature. After washing five times with TBST (150 mM sodium chloride, 10 mM Tris HCl, 
10 mM Tris base, 0.05% Tween 20, pH 7.6), wells were incubated with anti-human polyclonal 
GDNF antibodies (1:500) in 1X Block and Sample Buffer overnight at 4 °C. Following an 
additional five washes with TBST, wells were incubated with anti-chicken IgY-HRP conjugate 
antibody (1:250) for 2 hours with light shaking. After a final five washes, TMB One (100 
µL/well) was added to each well and allowed to develop in the absence of light until there were 
clear differences in color between the highest and lowest concentrations of the standard curve. 
Wells were then quenched with 1 M HCl (100 µL/well), and the plates were read at an 
absorbance wavelength of 450 nm using a BioTek Synergy H1 plate reader. 
LDH Cytotoxicity Assay. The lactate dehydrogenase cytotoxicity assay (Promega) was 
performed following the manufacturers instructions. Briefly, following compound treatment, 
conditioned media was removed, and untreated wells were washed twice with phosphate 
buffered saline. To untreated wells was added 40 µL of low serum media supplemented with 
lysis buffer provided in the kit (1:10), protease inhibitor cocktail (1:100), and phosphatase 
inhibitor cocktail 2 (1:100). Cells were lysed at 37 °C for 1 hour. Cell lysates were diluted with 
160 µL of conditioned media and used as 100% cytotoxicity in the LDH standard curve. Lysates 
were serially diluted down to 6.25% cytotoxicity with low serum media filling the last. The 
standard curve was added in duplicate to a 96-well plate followed by the conditioned media from 
each treated well at 50 µL/well. To each well was added 50 µL of the reconstituted Substrate 
Mix, and the plates were allowed to develop in the dark until differences were seen in the 
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standard curve. The wells were quenched with 50 µL of Stop Solution, and the plates were read 
at an absorbance wavelength of 490 nm. 
WST-1 Cell Viability Assay. After compound treatment, conditioned media was 
removed and replaced with 75 µL of warm low-serum media. To each well was added 5 µL of 
WST-1 Cell Proliferation Reagent (Roche Applied Science), and the cells were incubated at 37 
°C for no more than 1 hour. Plates were briefly shaken prior to reading the absorbance at 450 
nm. Treatments were compared to vehicle control. 
FGFR1 Phosphorylation ELISA. FGFR1-HEK were grown in DMEM supplemented 
with 10% FBS, 100 U mL-1 of penicillin and streptomycin, and 200 µg/mL G418. Cells were 
added to a collagen-coated 96-well plate at 40,000 cells/well and allowed to grow for 24 hours. 
The cells were then starved with low serum media (1% FBS supplement instead) for 5 hours 
before treatment with drugs for 1 hour. The experiment was stopped on ice by aspirating the 
cellular supernatant and adding 110 µL of lysis buffer (1% TritonX-100, 10% glycine, and 2 mM 
EDTA in TBS, pH 8.0 with 1:100 protease inhibitor cocktail and 1:100 phosphatase inhibitor 
cocktail 2) before storing at -80 °C. A separate 96-well plate (Nunc Immulon) was coated with 
primary FGFR1 antibody (Sigma Aldrich # WH0002260M3) at 1 µg/mL in PBS and stored 
overnight at 4 °C. The plate was then washed 5X with TBST and blocked (1% BSA in PBS) for 
1 hour at room temperature. The plate was washed again 5X with TBST, and 80 µL of the 
thawed cell lysate was transferred to the 96-well ELISA plate and stored overnight at 4 °C. The 
remaining 20 µL of cell lysate was used for protein quantification in the BCA assay. The plate 
was then washed again 5X with TBST and incubated with secondary anti-phospho tyrosine-HRP 
antibody (R&D Systems #HAM1676) at 1:2500 (in 0.05% Tween-20, 0.1% BSA in TBS, pH 
7.4). The plate was washed a final 5X with TBST and developed using TMBone (100 µL/well) 
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for 30 minutes in the absence of light. Wells were then quenched with 1 M HCl (100 µL/well), 
and the plates were read at an absorbance wavelength of 450 nm using a BioTek Synergy H1 
plate reader. Raw data were quantified as the phospho-FGFR1 signal divided by the total protein 
content for each well. 
FGF2 Release Experiments. Cells were treated according to the same procedure as for 
measuring GDNF release (see above). FGF2 release was measured using a commercially 
available ELISA according to the manufacturer’s protocol (R&D Systems #DY23305). Briefly, 
the human FGF2 capture antibody was diluted in PBS (2 µg/mL) and added to the 96-well plate 
provided with the kit at 100 µL/mL. The plate was sealed and stored overnight at 4 °C. The plate 
was then washed 3X with the wash buffer (0.05% Tween-20 in PBS, pH 7.2-7.4) and blocked at 
room temperature for 1 hour with 300 µL/well of reagent diluent (1% BSA in PBS, pH 7.2-7.4). 
The plate was washed again 3X. A standard curve was made with the human FGF2 standard 
provided in a concentration range of 15.6 – 1000 pg/mL, diluted in reagent diluent. The standard 
curve or experimental supernatant were added to the wells (100 µL) and incubated at room 
temperature for 2 hours. The wells were then aspirated and washed 3X as before. Next, the 
detection antibody was diluted in reagent diluent (0.25 µg/mL) and added to each well (100 
µL/well) for 2 hours at room temperature. The wells were then washed again. The streptavidin-
HRP antibody was diluted in reagent diluent (1:40 dilution) and added to each well (100 
µL/well) for 20 minutes at room temperature in the absence of light. The plate was then washed 
again. Substrate solution (1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(tetramethylbenzidine)) was added to each well (100 µL/well) for 20 minutes at room 
temperature in the absence of light. The reaction was quenched by adding Stop Solution (2 N 
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H2SO4) to each well (50 µL/well), and the plates were read at an absorbance wavelength of 450 
nm using a BioTek Synergy H1 plate reader. 
BrdU Incorporation Assay. Cells were treated according to the same procedure as for 
measuring GDNF release (see above). BrdU incorporation was measured using a commercially 
available kit according to the manufacturer’s protocol (Roche Life Sciences #11647229001). 
Briefly, after a 24-hour treatment with specified drugs, the BrdU labeling reagent was added to 
each well (20 µL/well, 10 µM final concentration) for 2 hours at 37 °C. The cell media was then 
aspirated, and the FixDenat provided was added to the wells (200 µL/well) and incubated at 
room temperature for 30 minutes. The FixDenat solution was aspirated thoroughly, and anti-
BrdU-POD (1:100 in antibody dilution solution provided) was added to the wells (100 µL/mL) 
for 90 minutes at room temperature. The plate was then thoroughly washed with PBS 3X. 
Substrate solution was then added to the wells (100 µL/mL) and incubated at room temperature 
for 5-30 min. The reaction was quenched with 1 N H2SO4 (25 µL/well), and the plates were read 
at an absorbance wavelength of 450 nm using a BioTek Synergy H1 plate reader. 
Statistical Analysis. Data analysis was performed using Graphpad Prism 6 Software 
(San Diego, CA). Conditions are expressed as mean ± SD and were subjected to ANOVA 
followed by either Dunnett’s or Tukey’s Multiple Comparisons Test with a significant level of p 
< 0.05. Dose response curves were fit using a four-parameter logistic equation. 
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Chapter 7 – Identifying Small Molecule Modulators of the Fibroblast 
Growth Factor Receptor 
 
Introduction 
The fibroblast growth factor family is currently made up of 18 protein ligands, called 
fibroblast growth factors (FGF1-18 with a few others still being characterized), and 4 fibroblast 
growth factor receptors (FGFR1-4) that play a critical role in the development, maintenance, and 
regeneration of numerous tissues throughout the central nervous system and body.1,2 FGF2 (also 
known as basic FGF, FGFb) is notably the most studied member of the FGF family of growth 
factors, especially in regard to function in the adult brain. FGF2 interacts with all four FGFRs 
but has the highest affinity for FGFR1, and therefore FGFR1 is often considered the main 
receptor target of this protein family.1 As a type of receptor tyrosine kinase (RTK), FGFRs are 
expressed on the surface of the cell (and along the intracellular protein expression pathways) and 
become activated by proteinaceous growth and trophic factors (i.e. FGFs).3 In particular, upon 
receptor dimerization and FGF2 binding, FGFR1 becomes activated, which ultimately leads to 
receptor autophosphorylation at the intracellular tyrosine kinase domain and subsequent 
recruitment of adaptor proteins and activation of the mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK), phosphatidylinositol-4,5-
bisphosphate 3-kinase/protein kinase B (PI3K/Akt), and protein kinase C/phospholipase C 
(PKC/PLCγ) signaling pathways.4 Further, FGFs are heparin-binding proteins, which means that 
heparan sulfate proteoglycans on the cell surface are essential for bringing FGFs into contact 
with their receptors (Figure 1).5–9 These three pathways are the main mediators of FGFR’s 
trophic activity, which includes neurogenesis, synaptogenesis, and synaptic plasticity (see 
below).  
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The FGF system is of particular interest in 
regard to depression and anxiety. When 
postmortem human brains were subjected to a 
genome-wide gene expression analysis, both 
FGF2 and FGFR1 were found to be 
downregulated in patients with major depressive 
disorder (MDD).10 In subsequent studies, these 
initial findings were confirmed by several 
independent groups and expanded to several 
specific brain areas.11,12 For instance, FGF2 
expression was found to be decreased in both the 
hippocampus and several other cortical regions in 
patients suffering from MDD. Additionally, some 
single nucleotide polymorphisms in the FGF2 
gene, specifically rs1449683 and rs308393, were indicated as strong predictors of antidepressant 
treatment efficacy and compliance (with selective serotonin reuptake inhibitors), while the 
rs1048201 SNP was associated with increased side effects and reduced response to 
antidepressants.13 In a rarity among target identification stories, the human data collected 
ultimately led to successive studies in animal models, where the focus was on the FGF system, 
most notably FGF2 and FGFR1. Rodents subjected to the social defeat paradigm, a verified 
model of depression and anxiety in vivo, leads to a decrease in the expression of FGF2 and 
FGFR1 in the hippocampus.14 When instead FGF2 is infused into the CNS directly, rapid 
	
Figure 1. Brief Overview of FGFR1 Signaling. 
FGFR1 exists in equilibrium between monomeric 
and dimeric receptor units. The dimeric form is 
stabilized by binding of two monomeric FGF 
units, which are brought to the receptor by 
extracellular heparan sulfate molecules. Receptor 
dimerization leads to autophosphorylation of the 
tyrosine kinase domain and subsequent activation 
of the downstream signaling pathways: Akt 
(protein kinase B), MAPK (mitogen-activated 
protein kinase), and PKC (protein kinase C). 
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antidepressant activity is noted for several rodent models, where the behavioral results were 
additionally linked to increased gliogenesis.15,16  
Connections between the FGF system and anxiety have only been made in animal 
models. For example, FGF2 was able to inhibit anxiety-related behavior in rats bred for 
increased anxiety and low novelty responsiveness, a measure of anxiety.17 Additionally the same 
study found that FGF2 expression in the hippocampus could be modified by environmental 
stimuli, such as stress, resulting in higher expression of FGF2 that correlates with a stress 
resistant phenotype. To further support this evidence, the neurogenic and gliogenic effects of 
FGF2 are most notable in the anxious phenotype and related to enhancing new cell survival. 
Given the growing evidence on this protein family (both clinical and preclinical), there is a high 
probability that FGF2 is not only an endogenous antidepressant and anxiolytic factor, but also a 
biomarker.11 FGF2 is known to exert wide-reaching effects that are acute (e.g., rapid 
antidepressant activity) and persistent (e.g., resilience to stress), and span the different systems of 
complexity from behavior (e.g. antidepressant activity) to cells (e.g. neurogenesis and 
gliogenesis). With an increasing number of patients suffering from MDD today and the lack of 
treatment options available that are effective for everyone (see Chapter 1)18, the FGF family 
represents an intriguing target to explore in the search for novel therapeutics.19 
The FGF2/FGFR1 system is further indicated in the potential treatment of 
neurodegenerative disorders and brain trauma. For example, in addition to providing 
antidepressant and anxiolytic effects (see above), infusion of FGF2 into the CNS provided both 
protective effects in acute stroke models and recovery-enhancing effects in the post-stroke 
period.20 In fact, in post-stroke recovery of sensory-motor function in adult animals, FGF2 
showed dramatic effects though new wiring, synapse formation, and neurogenesis.20 
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Furthermore, viral delivery and gene expression of FGF2 have shown beneficial effects in rodent 
models of traumatic brain injury, optic nerve injury, and Alzheimer’s disease, specifically 
through the restoration of special learning, hippocampal long-term potentiation (LTP), and 
neurogenesis.21  
In addition to the results implicating the FGF system in diseases, many studies have 
specifically focused on the FGF2 target, FGFR1.22 For example, FGFR1 is required for 
neurogenesis, or the birth of new neurons from neural stem or progenitor cells. In adult mice 
containing a conditional knockout of fgfr1, there were severe decreases in neurogenesis. 
Additionally, the LTP of synapses in the hippocampus was impaired, leading to deficits in 
memory consolidation.23 It is therefore highly likely that FGFR1 is necessary for neurogenesis, 
synaptic plasticity, and memory processes. This hypothesis is consistent with evidence showing 
that over-expression of FGF2 causes increased cell proliferation in the dentate gyrus (DG), while 
a decrease in the growth factor leads to permanent hippocampal atrophy in neural stem cells.24  
Given the vast body of work surrounding the FGF system, FGFR1, as the leading and the 
most studied member of FGFR family, represents an experimental target of high potential and 
significance in a number of CNS disorders. FGFR1 is a molecular target capable of not only 
modulating repair and remodeling of brain tissue on a cellular level via the processes of 
neurogenesis and synaptogenesis but also controlling acute molecular events necessary for 
synaptic and neuronal plasticity. In fact, recent evidence suggests that modest synaptic dystrophy 
may be a cellular biomarker for some neuropsychiatric disorders such as depression16 even 
though this pathology is traditionally associated with neurodegenerative disorders.25 Therefore, 
pharmacological stimulation of neurogenesis and synaptogenesis represents a new mechanistic 
approach for treating a range of CNS disorders. 
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Currently, there are no reliable small molecule, 
non-peptidic agonists of FGFR1. Sanofi has recently 
reported in a patent publication26 that compound 
SAR106881 is an FGFR agonist (Figure 2). 
Unfortunately, no data demonstrating activation of 
FGFR1 (or the other FGFRs) was provided, nor was any 
data shown for downstream signaling activation. There are, however, numerous reports of 
peptide agonists of FGFRs that are modeled after the neural cell adhesion molecule (NCAM) 
contacts made between FGF2 and FGFR1, as well as other extracellular domain contacts.27–35 All 
of these suffer in that their pharmacological characterization relies upon indirect methods, such 
as downstream signaling events measured through western blot and phenotypic readouts – none 
of which are shown to be truly receptor-dependent. Given the dearth of convincing examples of 
true small molecule agonists of FGFR1, we became interested in searching for novel scaffolds 
that might modulate the system. Small molecules have the advantage over proteins, in the case of 
direct FGF2 therapy, given their “tuneability” of blood brain barrier (BBB) penetration and other 
pharmacokinetic properties through synthesis.  
In this chapter, cellular assays were developed for the direct measurement of FGFR1 
activation and downstream signaling, as well as phenotypic readouts. Using these assays, and in 
collaboration with the National Center for Advancing Translational Sciences (NCATS), we 
employed a high-throughput screen (HTS) to find small molecule agonists and modulators of 




Figure 2. Structure of Reported FGFR 
Agonist SAR106881. 
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Developing Assays for the Measurement of FGFR1 Activation 
 Stably Expressing FGFR1 Cell Line. As a 
starting point for developing assays to measure 
functional activity of FGFR1, it was important to 
identify an appropriate cellular system in order to 
perform all the measurements. Although endogenous 
systems are preferable in order to understand receptor 
activation in a more natural context, these assays are 
often not sensitive enough to allow measurement of low 
efficacy/potency compounds. For this reason, we chose 
to create a cell line stably expressing FGFR1. In this overexpressed system, there would be 
sufficient receptor present to allow for a robust signal activation and signal-to-background ratio 
(S/B). A commercially available human FGFR1 construct (FGFR1IIIc variant) was chosen that 
contained the FLAG epitope C-terminally tagged to the receptor to allow for easy detection of 
the receptor in the cells, as well as a neomycin resistance gene to serve as a selectable marker 
following transfection. Human embryonic kidney (HEK) cells were transfected with the 
construct and grown in selective media to create the stably expressing hFGFR1-HEK cells. 
Western blotting confirmed expression of the receptor (Figure 3, see Experimental for more 
details). 
Detecting Receptor Phosphorylation. Based on the mechanism of receptor activation (see 
Introduction), it seemed that the best way to detect direct receptor activation would be to probe 
for autophosphorylation. As receptor phosphorylation is an early event in the receptor activation  
 
 
Figure 3. Western blotting enables 
confirmation of FLAG-tagged FGFR1 
expression in stably transfected HEK 
cells (FGFR1-HEK cells). Cell lysates 
were probed with the Flg antibody 
(FGFR1) and the FLAG antibody 
(DYKDDDDK epitope). Data represent 





Figure 4. Schematic Depiction of Sandwich-ELISA for FGFR1 Phosphorylation. 
cascade, this seemed like an appropriate target and the likely 
earliest point at which we could measure signaling. Inspired by 
the KIRA-ELISA (enzyme-linked immunosorbent assay)  
developed by Saddick36, we wanted to develop an antibody-
based assay that could be modified to work for multiple targets 
in various cellular systems. In the sandwich-style ELISA for 
RTK phosphorylation (Figure 4), a capture antibody specific 
to the receptor (FGFR1 in this case) is used to pull down 
receptor from cellular lysate. The samples are then probed with 
an antibody specific for phospho-tyrosine residues and will 
therefore specifically bind to the phosphorylated receptors that 
were immunoprecipitated in the first step. While the concept of 
this ELISA is simple, the task of finding appropriate antibodies 
suitable for this process is not trivial. In a small screen of four 
antibodies specific for either FGFR1 or phospho-FGFR1 (both 
monoclonal and polyclonal), two antibodies were found with a 
statistically significant increase in phosphorylation in 













Figure 5. Antibody Screening for 
Phospho-FGFR1 ELISA. 
Phosphorylation of FGFR1 was 
detected using either a Cell 
Signaling antibody (A; #3476) or 
a Sigma Aldrich antibody (B; 
#WH0002260M3). Data represent 
mean ± SD of biological 
replicates in one experiment from 
n = 3 independent experiments. 
Two-way ANOVA with Tukey’s 
multiple comparisons test shown 
in gray. Comparison to respective 
FGF2 treatment shown in black. 
*p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001. 
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HEK cells (Figure 5). The Cell Signaling antibody detects phospho-FGFR (tyrosines 653 and 
654) while the Sigma Aldrich antibody detects total FGFR1. The antibody from Sigma Aldrich 
was chosen as the lead for future assays for its increased 
S/B in comparison to the Cell Signaling antibody and for its 
ability to measure statistically significant differences in 
phosphorylation at different treatment times of control. 
Unfortunately, no antibody was found suitable for the 
detection of total FGFR1 in the cells, so instead cell signal 
was normalized to total protein content. 
In initial experiments, the ELISA was able to 
measure phosphorylation of FGFR1 in the presence of 
increasing concentrations of FGF2 (Figure 6A). This 
receptor activation could be blocked by FGFR inhibitor 
PD173074 (PD17). These experiments show that the assay 
can detect acute phosphorylation events that are dependent 
upon FGFR1. As an additional control, phosphorylation 
from growth factor FGF1 (or FGFa) could also be detected 
(Figure 6B). A dose response curve was also measured for 
inhibitor PD17 in the presence of FGF2 (Figure 6C). 
Overall, the assay was able to robustly measure FGFR1 
phosphorylation with a typical S/B between 2 and 5 and 
could be blocked by the presence of inhibitor. Although the 
assay was not ideal for use in HTS, it would be an 
	
Figure 6. Sandwich-style ELISA 
Quantitatively Measures the 
Activation of FGFR1 in FGFR1-HEK 
Cells. FGF2 (A) or FGF1 (B) activates 
FGFR1 in a dose-dependent manner 
with an EC50 of 2.9 ± 1.9 nM and S/B 
of 4.9 or EC50 of 1.8 ± 0.9 nM and S/B 
of 3.5, respectively. FGFR1 activation 
is blocked by FGFR inhibitor 
PD173074. C. FGFR inhibitor 
PD173074 dose-dependently inhibits 
the signal from FGF2 (5.8 nM, EC90) 
with an IC50 of 8.9 ± 4.7 nM. Data 
represent mean ± SD of biological 
replicates in one experiment from n > 
3 independent experiments 
(normalized to DMSO vehicle 
control).	
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important secondary assay used to rule out initial hits. Table 1 summarizes the potencies of 
FGF1 and FGF2 in FGFR1 phosphorylation. 
 A serious attempt was made at 
translating the assay to endogenous systems, 
including primary neuronal culture (both rat 
cortical and rat hippocampal)37 and PC12 
cells, a rat pheochromocytoma cell line that 
expresses FGFR1 endogenously.38 
Unfortunately, finding a usable antibody for 
the assay proved challenging, as the 
antibody discussed above was specific to the human isoform of the receptor and was unable to 
show much signal from the activation of these rat receptors. Given the robustness of the assay 
already working, we decided to instead focus on developing independent assays that would 
complement the ELISA already in use. 
 
Figure 7. Schematic Depiction of enzyme-linked fixed-cell immunoassay (ELFI) for ERK, Akt, and PLCγ 
Detection. 
 
 Detecting Downstream Signaling Events. Following receptor dimerization and 
phosphorylation, the downstream MAPK, Akt, and PLCγ signaling pathways become activated. 
As an indirect measure of receptor activation, we also developed an assay to measure the 









Table 1. Summary of FGFR1 Data  
Treatment EC50 ([IC50]) Assay 
FGF1 1.8 ± 0.9 (3.5) Phospho-FGFR1 
FGF2 2.9 ± 1.9 (4.9) Phospho-FGFR1 
PD173074 [8.9 ± 4.7] Phospho-FGFR1 
FGF2 0.3 ± 0.1 (20) pERK 
FGF2 0.68 ± 0.03 (4.2) pAkt 
FGF1 0.1 ± 0.01 (3.5) pPLCγ 
PD173074 [24.1 ± 6] pERK 
FGF2 0.06 ± 0.003 (5.5) pERK (PC12) 
PD173074 [2.0 ± 0.01] pERK (PC12) 
FGF2 0.59 ± 0.23 (3.5) PathHunter® 
Naloxonazine 3300 ± 568 Phospho-FGFR1 
PD173074 
w/ Naloxonazine 
[8.4 ± 3.5] Phospho-FGFR1 
Data represent mean ± SD of various replicates (nM). S/B 
is shown in parentheses.   
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Figure 8. ELFI Enables Measuring of FGFR1’s Downstream Signaling Targets. The degree of activation is 
expressed as the ratio of phosphorylated to total kinase protein (after 5-minute activation pulse). A. FGF2 activates 
ERK1/2 in FGFR1-HEK cells in a dose-dependent manner with an EC50 of 0.3 ± 0.1 nM and S/B of 20. B. FGF2 
activates Akt in FGFR1-HEK cells in a dose-dependent manner with an EC50 of 0.68 ± 0.03 nM and S/B of 4.2. C. 
FGF1 activates phospho-PLCγ in FGFR1-HEK cells in a dose-dependent manner with an EC50 of 0.1 ± 0.01 nM and 
S/B of 3.5. No suitable antibody for PLCγ was found, so data are not normalized to total PLCγ levels. Data represent 
mean ± SD of biological replicates in one experiment from n > 3 independent experiments (normalized to DMSO 
vehicle control). 
 
enzyme-linked fixed-cell immunoassay (ELFI) that mimics the technique of 
immunofluorescence. In this assay, cells are fixed immediately following treatment with FGF or 
test compounds and then probed directly with antibodies for each of the downstream signaling 
pathways (Figure 7). Much like western blotting, plates can 
be stripped and reprobed with new antibodies, allowing one 
experiment to provide measurements on multiple 
downstream signaling pathways.  
 
FGF2 (and FGF1) was able to induce robust 
phosphorylation of the ERK, Akt, and PLCγ pathways in the 
hFGFR1-HEK cell line (Figure 8). A relatively high 
concentration of PD17 was used to inhibit the activation by 
FGF2 (1 µM, data not shown), so it was important to confirm 
that the inhibitor was specific to the FGFR pathway at that 
concentration. A dose response curve was collected for PD17 
in the presence of either FGF2 or PMA, an FGFR-independent stimulator of the MAPK 
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Figure 9. Selectivity of FGFR 
Inhibitor PD173074 on ERK 
Activation. FGFR inhibitor 
PD173074 did not inhibit ERK 
phosphorylation triggered by an 
independent pathway (by phorbol-
12-myristate-13-acetate, PMA, a 
PKC activator), while it inhibited 
ERK phosphorylation induced by 
FGF2 (2.9 nM) with an IC50 of 24.1 
± 6 nM. Data represent mean ± SD 
of biological replicates in one 




pathway39 (and PKC). By comparing the dose response curves, we hoped to identify the 
concentration window in which PD17 would be selective for the FGFR pathway and not the 
MAPK pathway. Interestingly, PD17 had little effect on the signal from PMA, indicating that 
even at higher concentrations, PD17 is selective to FGFR signaling (Figure 9). We also noted 
some time and potency differences in the downstream signaling assays in comparison to the 
receptor phosphorylation assay. For instance, while the receptor phosphorylation was typically 
measured at 60 minutes, a time point where the signal was both maximal and stable, the 
downstream signaling was 
measured at 5-10 minutes. Since 
complete RTK phosphorylation 
is likely slower than the 
downstream signaling triggered 
by rapid partial receptor 
activation40,41, it is not surprising 
that there a difference in peak 
activities. RTK phosphorylation might also be sustained in comparison to downstream signaling 
due to slow dephosphorylation rates. Additionally, the potencies for downstream signaling are 
markedly greater than those for receptor activation, in line with the idea of downstream signal 
amplification by which one molecule upstream can trigger the activity of multiple molecules of 
downstream effectors resulting in an amplified (more potent) signal. 
As before, we attempted to utilize this new assay in other cell lines that express FGFR1 
endogenously. We were unable to measure a meaningful signal in either primary neuronal 
cultures tested, which could indicate a lack of FGFR1 in these preparations. However, in PC12 
	
Figure 10. Measuring ERK Activation in PC12 Cells that 
Endogenously Express FGFR1. A. FGF2 activates ERK1/2 in PC12 
cells with an EC50 of 55.1 ± 3.3 pM and S/B of 5.5, which can be 
blocked by FGFR inhibitor PD173074. B. FGFR inhibitor PD173074 
dose-dependently inhibits the signal from FGF2 (5.8 nM, EC90) with 
an IC50 of 2.0 ± 0.01 nM. Data represent mean ± SD of biological 
replicates in one experiment from n > 3 independent experiments. 
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cells, FGF1 and FGF2 robustly activates the ERK signaling pathway and can be blocked by 
PD17 (FGF2 shown in Figure 10A), consistent with previously reported FGFR expression in 
these cells (also confirmed in this study, see Figure 11). No signal was detected for either the 
Akt or PLCγ pathways. Although we could not measure activation of an endogenously expressed 
receptor, the ERK assay in PC12 cells at least provided some insight into FGFR1’s downstream 
signaling. The results of the downstream signaling assays are reported in Table 1. 
Phenotypic Screen for Receptor Activation. As a complement to the ELISAs developed, a 
phenotypic screen was developed as an 
alternate measure of FGFR1 activation. It 
is well known that PC12 cells are able to 
undergo differentiation in the form of 
neurite outgrowth, either in response to 
nerve growth factor (NGF), acting upon 
the TrkA receptor42, or in response to 
FGF1 or FGF2, acting upon FGFR1.38,43,44 
Utilizing native PC12 cells, we were able 
to detect neurite outgrowth in response to 
either FGF1 or FGF2 (FGF2 shown in 
Figure 11). Thus the consequences of 
receptor signaling can also be assessed via 
a phenotypic assay.  
Reported Small Molecule Agonists 
are Inactive in Assays. In a first test, the assays were utilized to measure the response from 
 
Figure 11. Phenotypic Assay Dependent on Activation of 
FGFR1. PC12 cells are used to measure neurite outgrowth in 
response to FGFR1 activation. A,B. FGF2 (6 nM, 100 
ng/mL) induces neurite outgrowth in native PC12 cells after 
24 hours. Sanofi agonist SAR106881 does not cause neurite 
outgrowth. C. The length of neurite outgrowth in PC12 cells 
increased over time when treated with FGF2. D. 
Immunofluorescence images show expression of FGFR1 in 
PC12 cells. E. Western blotting of PC12 cells shows 
expression of FGFR1 (Flg antibody used). Data represent 
mean ± SD of biological replicates in one experiment from n 
> 3 independent experiments. 
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reported small molecule agonist SAR106881 (see Introduction, Figure 2). Based on the 
structure of a supposed FGFR antagonist reported in the patent, SAR106881 is dimeric in 
structure and is supposed to function by favoring the dimeric form of FGFR1, leading to  
 
Figure 12. Reported Sanofi FGFR Agonist SAR106881 Does Not Activate FGFR1. A. SAR106881 does not 
activate FGFR1 in the FGFR1 phosphorylation ELISA. B. SAR106881 does not activate ERK in the ERK ELISA in 
FGFR1-HEK cells. C. SAR106881 does not activate ERK in the ERK ELISA in PC12 cells. See Figure 11A for 
neurite outgrowth. Data represent mean ± SD of biological replicates in one experiment from n = 3 independent 
experiments. 
 
activation. SAR106881 was unable to activate FGFR1 in any assay utilized, including receptor 
phosphorylation, downstream signaling, or neurite 
outgrowth (Figure 11). However the control endogenous 
protein agonists worked well in all assays. In the original 
patent, no direct evidence was provided on the activity of 
SAR106881 at FGFRs and presumes the pharmacology 
based on angiogenesis activity.26 We also tested the 
activity of a reported small peptide agonist, FGL 
monomer (mapped from the FG loop, FGL; sequence: 
EVYVVAENQQGKSKA)34,35, for its ability to activate 
FGFR1. Similarly to SAR106881, FGL was unable to activate FGFR1 in any assay tested 
(phospho-FGFR1 assay shown, Figure 13). Given the inability of two different reported agonists 
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Figure 13. FGL Peptide Monomer is 
Inactive in Phospho-FGFR1 ELISA in 
FGFR1-HEK. Data represent mean ± SD 
of biological replicates in one 




to activate FGFR1, there was even greater necessity of accomplishing a HTS to find true small 
molecule agonists of this receptor.  
Putting Assays in Place for HTS 
 The Primary Assay for FGFR1 Activation. While the assays developed above were 
appropriate for validating hits from the HTS (as well as evaluation of reported compounds), they 
do not offer sufficient throughput for the primary screening assay. For this purpose, a U2OS cell 
line stably transfected with human FGFR1 
receptor (hFGFR1-U2OS PathHunter® cells, 
developed by DiscoverX) were used. Similar to 
the PathHunter® assay used to measure arrestin 
recruitment discussed in Chapter 1, the output 
signal is generated through the reconstitution of β-
galactosidase (β-gal) (Figure 14). A small 
complementary fragment of β-gal is fused to the 
FGFR1 C-terminus, while the rest of the enzyme is fused to the SH2 domain of an 
adaptor/partner protein (DiscoverX proprietary fusion protein). Activation of FGFR1 through 
autophosphorylation leads to recruitment of the adaptor/partner protein, complementation of the 
two fragments, and reconstitution of a functional enzyme. Activity of the enzyme is recorded 
through chemiluminescence. 
Adaptation of the Primary Assay to HTS Format. The PathHunter® assay with hFGFR1-
U2OS cells was adapted to 1536-well format at NCATS with our collaborator Dr. Marc Ferrer. 
The cells were incubated with varying concentrations of FGF2 and the PathHunter® 
luminescence detection reagent. The luminescence intensity of the assay plates was quantified 
	
Figure 14. Schematic Depiction of the DiscoverX 
PathHunter® Primary Assay Used for HTS. 
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using a ViewLux CCD-based plate reader after a one-hour incubation at room temperature.  The 
dose-response curve was obtained for FGF2, and the derived EC50 value, a measure of potency, 
(0.59 ± 0.23 nM, Figure 15A) was similar to those reported in the literature (~0.5 nM)45 and to 
those obtained in the ELISA developed for hit validation (see above). The Z'-factor, a statistical 
measure of the quality of a high-throughput assay at a single concentration,46,47 was 0.65 ± 0.09, 
and the other experimental parameters, namely the S/B (between 3-4) and coefficient of variation 
(CV<8%), indicated that the assay was suitable for 1536-well format HTS.47 
Using the Library of Pharmacologically Active Compounds (LOPAC) for an Initial 
Screen. As an initial 
measure of the suitability 
of the hFGFR1-U2OS 
PathHunter® assay for 
quantitative HTS (qHTS), 
the LOPAC library of 
1280 bioactive small 
molecules was screened 
at 4 different 
concentrations and 
normalized to FGF2 as 
100% efficacy. The data 
was then corrected by 
applying a pattern correction algorithm using compound-free control plates (DMSO plates).48 
The scatter plots of the assay plate with DMSO (Figure 15B), and the assay plate with 
 
Figure 15.  PathHunter® Assay Adaptation for HTS of FGFR1 Activation. A. 
Dose-response curve for FGF2 (EC50 of 0.59 ± 0.23 nM). B. This assay was 
adapted to 1536-well HTS format and afforded adequate statistical parameters. 
The scatter plot of a plate with DMSO is provided. The y-axis shows 
luminescence (arbitrary units); the x-axis shows columns on the plate. Columns 
1 and 2, DMSO controls (0% control); column 3, a control column with an 
FGF2 dose response; and column 4, an EC100 FGF2 (100% control). C. The 
1536-well HTS platform was used to screen a library of 1280 bioactive 
compounds, shown as a scatter plot with compounds at 46 uM. D. Five hits 
were identified. Representative hit compound 15587 is shown alongside 
SAR106881. Data represent mean ± SEM of one representative experiment of 
n = 3 independent experiments. Data obtained by Dr. Jennifer Fox (NCATS). 
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compounds at 46 uM (Figure 15C) are shown. To rule out any nonselective hits, the LOPAC 
library was also counter-screened in U2OS cells expressing other receptor targets (GPR40, 
GPR120, and TSHR-beta-arrestin – data not shown). In this way, any compounds that were 
active at more than one target could be dismissed from further validation and analysis. 
Determining Hit Selection From Screening Results. To gain a handle on the 
reproducibility of the results, two independent screens of the LOPAC library were performed. 
These two screens were then compared to the results from three other targets – free fatty acid 
receptor 1 (GPR40), free fatty acid receptor 4 (GPR120), and thyroid stimulating hormone 
receptor (TSHR) β-Arrestin (three counter-screens total). From the LOPAC screen, five 
compounds were selected as active in the primary screen (and inactive in the counter-screens). 
Activity of representative compound 15587 is shown in Figure 15D, alongside the Sanofi 
compound SAR106881, which was also found to be inactive in this independent assay. The hits 
were selected using the curve response classification (CRC) algorithms developed at NCATS for 
hit selection from dose response qHTS.48,49 In this method, the data is used to fit dose-response 
curves, according to a published algorithm50 and provide CRC values for each compound. The 
curves are then classified according to the quality of data (level of curve fitting to the observed 
data), well-defined upper and lower asymptotes, and efficacy. Curves were categorized as 
follows: complete response (curve class 1), CRC 1.1, has two well-defined asymptotes, high 
efficacy (>80%), and good fit (r2>=0.9); partial response, CRC 1.2, is as 1.1 but with efficacy 
<80%; incomplete curve (curve class 2), CRC 2.1, has one asymptote, high efficacy (>80%), and 
good fit (r2>=0.9); incomplete partial response, CRC 2.2, has one asymptote and low efficacy 
(<80%); inconclusive response (curve class 3), CRC 3, shows poor fit and single point activity; 
and inactive (curve class 4), CRC 4, shows no dose response. All five hits found from the initial 
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LOPAC screen were categorized as either curve class 1 (1.1 and 1.2) or 2 (2.1 and 2.2) in both 
trials of the screen. This initial screen highlights the ability of our assay and counter screens to 
properly identify compounds not in a single concentration format but in a format that instantly 
provides some information about potency and efficacy in a practice that is not fully utilized in 
the HTS community.  
Validating the Agonist Activity of LOPAC Hit 
 Small Molecule Hit From LOPAC Screen. The five hits found in the LOPAC screening 
(Figure 16A) were tested in our secondary assays to validate their activity. Interestingly, only 
one compound, NCATS-2 was 
found to be active in the ELISA 
for FGFR1 phosphorylation 
(Figure 16A) while the other 
four showed no agonist activity 
in concentrations up to 30 µM. 
The identity of NCATS-2 is the 
small molecule naloxonazine 
(Figure 16B). Naloxonazine is a potent antagonist of the mu-opioid receptor (MOR) that 
allegedly binds irreversibly to its target.51–53 Naloxonazine is dimeric in structure, forming in 
acidic solutions of the antagonist monomer unit naloxazone. Given the dimeric structure of 
naloxonazine, it is possible that this small molecule fulfills the criteria of bringing together two 
receptor units for activation. As the other four compounds were unable to cause receptor 
phosphorylation as measured in the ELISA, they were not pursued further and categorized as 
false positives. We confirmed the activity of NCATS-2 with a commercially available stock of 
	
Figure 16. Five Hits from LOPAC Screen Were Measured in FGFR1 
Phosphorylation ELISA. A. Five hits from LOPAC screen in 
PathHunter® assay are tested for their ability to phosphorylate 
FGFR1. B. Naloxonazine (formerly NCATS-2) was found to activate 
FGFR1. Data represent mean ± SD of biological replicates in one 
experiment from n = 3 independent experiments. 
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naloxonazine in a time course next to FGF2, and a noticeably different activation profile was 
observed (Figure 17A). While FGF2’s signal increased and plateaued rather quickly (< 20 min), 
naloxonazine showed more of a linear activation profile and higher level of receptor 
phosphorylation. Since the two molecules differ in the kinetics of their receptor phosphorylation, 
it seemed possible that activation (if confirmed in additional assays) was occurring through 
  
Figure 17. Profile of Naloxonazine in Phospho-FGFR1 ELISA. A time course (A), dose response curve (B), and 
inhibition curve with PD17 (C) were taken for naloxonazine in the ELISA for measuring phosphorylation of 
FGFR1. Naloxonazine showed an EC50 of 3.3 ± 0.7 µM for FGFR1 phosphorylation. Data represent mean ± SD of 
biological replicates in one experiment from n > 3 independent experiments. 
 
distinct mechanisms. A full dose response curve for FGFR1 phosphorylation revealed an EC50 = 
3.3 ± 0.6 µM that could be blocked by FGFR inhibitor PD17 (Figure 17B). Further, PD17 dose 
dependently inhibits the naloxonazine-induced phosphorylation of FGFR1 (Figure 17C), 
indicating that the phosphorylation detected seems to be 
receptor specific.  
 As a measure of selectivity, naloxonazine was 
tested in a closely related ELISA for TrkB 
phosphorylation. TrkB is another RTK that together with 
its growth factor agonist, brain-derived neurotrophic 
factor (BDNF), is believed to be connected to depression, 
as well.54–56 In contrast to FGFR1 phosphorylation, 
naloxonazine was only able to phosphorylate TrkB at the highest concentration tested (30 µM) 
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Figure 18. Naloxonazine is Not a TrkB 
Agonist. TrkB phosphorylation was 
measured in hTrkB-HEK cells with two 
stocks of naloxonazine (shown in black 
and gray) using an analogous ELISA to 
FGFR1 phosphorylation. Data represent 
mean ± SD of biological replicates in 




and only partially at approximately 30% of the maximal BDNF signal (Figure 18). These results, 
in combination with the inhibition data, indicate that there appears to be some measure of 
selectivity in the actions of naloxonazine on FGFR1 and that likely naloxonazine does not act as 
a general phosphatase inhibitor. 
 
Figure 19. Naloxonazine Does Not Activate Downstream Signaling Cascades. There was minimal activation by 
naloxonazine at any time tested in the ERK (A), Akt (B), and PLCγ (C) pathways in FGFR1-HEK cells. 
Naloxonazine also did not activate/inhibit ERK (D) or Akt (E) at any concentration tested either in the presence of 
absence of FGF1. F. PD17 was able to inhibit the ERK signal from naloxonazine at 90 min, however the S/B is low. 
G. Naloxonazine could not activate the ERK pathway in PC12 cells. Data represent mean ± SD of biological 
replicates in one experiment from n = 3 independent experiments. 
 
 Measuring Downstream Signaling From Naloxonazine. Next, naloxonazine was 
measured for its ability to activate the downstream signaling pathways ERK, Akt, and PLCγ. In a 
time course, naloxonazine was unable to activate any of the downstream signaling pathways 
(Figure 19A-C). Upon closer inspection, there is a slight increase in the signal at the 90-minute 
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time point in the ERK, Akt, and PLCγ signals, however when a dose response curve of 
naloxonazine is measured at 90 minutes, rather than the usual 10 minutes, there is still no dose-
dependent response to the drug (Figure 19D-E). Interestingly, PD17 was able to block the 
minimal ERK activation of naloxonazine dose-dependently (Figure 19F), which does suggest 
some involvement in signaling, though very minor. Additionally, naloxonazine did not activate 
the ERK signaling pathway in PC12 cells that natively express FGFR1 (Figure 19G). To 
determine whether naloxonazine acts as an allosteric modulator (i.e. a ligand that acts upon a 
receptor site distinct from the endogenous ligand) for downstream signaling at FGFR1, the dose 
response curve of naloxonazine was measured in the presence of a low concentration of FGF1. 
Even in this setup, no dose response curve was measured from naloxonazine (Figure 19D-E), 
which further indicates that it either indirectly acts upon FGFR1 or has a unique mechanism of 
action, one that disfavors the activation of downstream signaling cascades.  
 Neurite Outgrowth From Naloxonazine. To further study the actions of this interesting 
compound, naloxonazine was assessed in the neurite outgrowth assay. After 4 days, 
naloxonazine was unable to cause neurite outgrowth in PC12 cells in comparison to FGF2 
(Figure 20). This result was not surprising when considering the lack of signaling activation 
found in these cells. 
 
 
Figure 20. Naloxonazine Does Not Cause Neurite Outgrowth in PC12 Cells. Data represent one representative 





 Exploring the Mechanism of Action of Naloxonazine. As naloxonazine exhibits an 
unusual pharmacological profile, we 
were interested in understanding its 
mechanism of action further. 
Naloxonazine induces dose-
dependently phosphorylation of 
FGFR1 (as indicated by the ELISAs) 
but did not induce downstream 
signaling or neurite outgrowth. Based 
on these observations, it seemed 
possible that naloxonazine perhaps 
was not acting through an orthosteric 
mechanism but perhaps an allosteric 
one. Orthosteric agonists bind to the 
same receptor site as the endogenous 
ligands, while allosteric bind to and 
modulate receptors through a separate 
site. In order to distinguish between 
these mechanisms in the ELISA, a dose response curve of FGF2 can be measured in the presence 
of increasing concentrations of naloxonazine. If naloxonazine is an orthosteric agonist, there 
should be a right shift of the dose response curve of FGF2 (i.e., a shift of EC50 to higher 
concentrations).57,58 If naloxonazine instead is an allosteric agonist, the effects can be more 
complex, the most common effect being a leftward shift in potency and an increase in efficacy. 
	
Figure 21. Probing the Mechanism of Naloxonazine Activity at 
FGFR1. A dose response curve for FGF1 or FGF2 was 
measured in the presence of increasing concentrations of 
naloxonazine and measured for FGFR1 phosphorylation at 60 
minutes (A), ERK activation (B), or Akt activation (C) at 10 
minutes. FGF1 (D) or naloxonazine (E) dose response curves 
were measured in the presence of naloxone. Data represent 
mean ± SD of biological replicates in one experiment from n = 
3 independent experiments. 
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However, the effects are not limited to this scenario. For instance, if the system already reaches a 
maximal response from FGF2 alone, then an increase in efficacy by co-treatment with an 
allosteric agonist may not be observed. In fact, co-treatment with the allosteric agonist may 
decrease the efficacy of the native ligand. In general, however, because the allosteric agonist 
activates the receptor on its own, there should be an increase in the basal level of receptor 
activation as a result of this co-treatment.57,58 When naloxonazine was co-incubated with a dose 
response curve of FGF2, there was no dramatic right shift of the curves, indicating that 
naloxonazine is likely not an orthosteric ligand – as predicted (Figure 21A). In fact, the addition 
of naloxonazine just seems to increase the basal signal of the curve, ultimately leading to a flat 
curve as the response from the system is maximal and indicating a likely allosteric mechanism if 
naloxonazine is an agonist of FGFR1 at all. 
To further explore this hypothesis, the same experiment was performed in the ERK and 
Akt assays. Ideally, the effect of downstream amplification would take part in this experiment to 
show how naloxonazine might modulate the signaling of FGF even though it had no effect on its 
own. Interestingly, in the presence of increasing concentrations of naloxonazine, there was no 
change in the dose response curve from FGF1 at either ERK or Akt (Figure 21B-C). This result 
is not surprising in the context of other experiments, as naloxonazine had little effect on 
downstream signaling itself. Although naloxonazine may have some allosteric effects on receptor 
phosphorylation, those effects do not appear to translate into the downstream signaling cascades. 
Without receptor phosphorylation that leads to a fully functional receptor, the probability of 
naloxonazine being a true FGFR1 agonist is low. 
As an additional measure, a dose response curve of either FGF1 or naloxonazine were 
measured in the presence of naloxone, a modified monomer unit of naloxonazine. If 
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naloxonazine is making a physical interaction with FGFR1, leading to receptor phosphorylation, 
then in all likelihood, a monomer of naloxonazine should act as an inhibitor of this process, 
much like the rationale behind the design of Sanofi agonist SAR106881. In these experiments, 
naloxone had some effect on the phosphorylation of FGFR1 induced by FGF1 and did seem to 
inhibit the dose response curve of naloxonazine (Figure 21D-E), indicating that perhaps FGFs 
and naloxonazine are interacting at the same sites on the FGFR1. Together with the results from 
Figure 21A-C, there still remains some uncertainty about the mechanism of action of 
naloxonazine in these assays. 
Visualizing Receptor Phosphorylation Through Western Blot. Although the ELISA 
developed is able to detect phosphorylation of the receptor, an independent control is required to 
confirm that the chosen 
antibodies pull down the 
receptor of interest and that 
the receptor is 
phosphorylated. Further, it is 
conceivable that the anti-
FGFR1 capturing antibody is 
not as specific as advertised, 
in which case the ELISA may 
be detecting phosphorylation 
of other proteins (induced by 
naloxonazine), leading to a 
false positive signal. The best 
	
Figure 22. Western Blot of FGFR1 and P-FGFR1 and Controls in FGFR1-
HEK Cells Treated with Naloxonazine. The gel was probed for phospho-
FGFR1, total FGFR1, the FLAG epitope, and “housekeeping” protein 
actin. Quantification of the blot reveals increased phosphorylation of 
FGFR1 by FGF1 and naloxonazine. Data represent one representative 
experiment of n = 3 independent experiments. 
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way then to visualize the receptor phosphorylation directly is to use western blotting techniques. 
In this case, even if the receptor is in some complex at the time of the experiment, the denaturing 
conditions of the electrophoresis will separate the proteins and allow visualization of individual 
targets.  
When receptor phosphorylation was measured in the hFGFR1-HEK cell line as detected 
with western blot, both FGF1 and naloxonazine were able to phosphorylate the receptor using a 
phospho-FGFR1 antibody specific to tyrosine residues 653 and 654 (Figure 22). These tyrosines 
are essential for activation of FGFR1’s tyrosine kinase domain, as well as downstream ERK and 
Akt signaling. In contrast, phosphorylation of tyrosine 766 leads to PLCγ signaling.59 We were 
concerned, however, by the relatively low signal visible from the phospho-FGFR1 blot; the 
bands were visible in both FGF1 (or FGF2 – data not shown) and naloxonazine, but the high 
background ultimately provided a low quality blot. It seems that perhaps this antibody is not 
specific enough, leading 
to a noisy signal that is 
difficult to quantify. 
In a separate blot, 
our collaborators at Yale 
University, who have 
access to more specific 
FGFR1 antibodies (rat 
species), tested 
naloxonazine alongside 
FGF1 in a time course in 
	
Figure 23. Western Blot of Naloxonazine and Controls in FGFR1-L6 Cells. A. 
Immunoprecipitation (IP) using two different phospho-antibodies shows no 
phosphorylation induced by naloxonazine. B. Direct probing of total cell 
lysates (TCL) at either FGFR1 or ERK shows no activity from naloxonazine. 
Data represent mean ± SEM of one representative experiment of n = 2 
independent experiments. Data obtained by Dr. Leiliane Sousa (Schlessinger 
Lab, Yale University). 
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FGFR1-L6 cells, a rat muscle cell line. In these experiments, naloxonazine was unable to 
phosphorylate the receptor using two different antibodies and was not able to phosphorylate 
ERK, in-line with the ELISA results (Figure 23). In contrast, the FGF1 control worked very 
well, highlighting the specificity of these in-house antibodies. As western blot analysis with 
trustworthy antibodies shows no phosphorylation of FGFR1 by naloxonazine, we are confident 
that this compound is indeed a false positive picked up by the LOPAC screening. This process, 
while able to correctly identify a false positive, does show the importance of using multiple 
assays for hit validation. The ELISAs developed for drug pharmacology are an important first 
step, but given the results with naloxonazine there are some limitations to the assay, and looking 
at the proteins directly in western blot is an important counter-assay to confirm results.  
Continuing Forward with HTS. Currently, a library of 45,000 compounds has been 
screened for agonism at FGFR1 using the PathHunter® assay utilized for the LOPAC screen. 
Compounds were tested at four different concentrations for agonism and counter screened as 
described above. After eliminating non-selective hits, 72 hit have been identified that require 
further testing. These compounds are being retested by our collaborators with fresh powder 
stocks of each prior to being validated by secondary assays in our laboratory.  
Moving forward, we are hopeful that within these 72 hits there will be a true small 
molecule agonist at FGFR1. However, to prepare for a larger campaign, a larger library of 
70,000 is currently being designed for testing in our primary assay. The new library will likely be 
screened in the presence and absence of a small concentration of FGF2 to test for positive 
allosteric modulators, or compounds that enhance the signaling of receptor agonist already 
present. By redoubling our efforts and increasing the scope of our screen, we increase the 
probability of successfully finding small molecules that will be effective at modulating FGFR1. 
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Discussion 
Mechanism of Action of Naloxonazine. In our pilot screen utilizing the primary 
PathHunter® assay from DiscoverX, naloxonazine was found as a hit among 1280 compounds 
tested. When naloxonazine was measured in the direct ELISA for FGFR1 phosphorylation, a 
robust signal was detected that was even more efficacious than the FGF2 control. In early 
experiments, it was clear that naloxonazine did not activate the receptor in the same way as the 
native growth factor. For instance, the time profile for activation was strikingly different between 
FGF2 and naloxonazine. Suspiciously, however, naloxonazine was ineffective at signaling 
through downstream pathways or at causing neurite outgrowth in PC12 cells. For these reasons, 
we began to question whether naloxonazine was a true agonist of FGFR1 or just had unique 
modulatory properties at the receptor. There are known examples of RTK modulation and 
regulation by tyrosine kinase phosphatases. For example, at the epidermal growth factor receptor 
(EGFR), inhibition of protein tyrosine phosphatase activity by reactive oxygen species led to 
increased phosphorylation of the receptor.60 In a second study, inhibition of protein tyrosine 
phosphatase-1B also led to increased phosphorylation of both EGFR and platelet-derived growth 
factor receptor (PDGFR), however downstream signaling from either ERK or Akt was 
minimal.61 Given the similarities between the activities of these phosphatase inhibitors and 
naloxonazine, it seems plausible that in fact naloxonazine acts as a phosphatase inhibitor. This 
hypothesis does seem less likely, however, by the observation that naloxonazine was unable to 
phosphorylate a separate RTK, TrkB, beyond one point activity. As a general phosphatase 
inhibitor, naloxonazine would in theory be non-selective in its receptor phosphorylation and 
therefore react similarly with TrkB. It is still possible that naloxonazine is an inhibitor of a more 
specific phosphatase inhibitor that only acts upon the kinase domain of FGFR1, but such a target 
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has yet to be identified. Another possibility is that the antibody pair for the phospho-FGFR1 
ELISA is not as specific as expected. Although the assay works well with controls, the 
antibodies being used to capture the receptor could be pulling down proteins other than just 
FGFR1, as well as bringing FGFR1 complexed with other proteins. The result of such a scenario 
is that naloxonazine may appear to phosphorylate the receptor when in fact it is acting upon 
some other target. Testing naloxonazine with much more specific antibodies in a western blot 
showed no receptor phosphorylation, indicating that either the compound is not a true agonist of 
the receptor or the phosphorylation detected in our FGFR1-HEK cell line is not robust enough to 
work in other cells lines or to cause measurable downstream signaling. Working with 
naloxonazine proved to be an important exercise in understanding the secondary assays. First, 
the cascade of assays was able to successfully eliminate the compound as a true agonist of the 
receptor. Second, the use of western blotting was key to the discovery of naloxonazine as a false 
positive; this fact is important because although western blotting is inferior to ELISA when it 
comes to measuring quantifiable signaling events, it still plays a complementary role and 
provides necessary information missing from the ELISA. Finally, the false activity of 
naloxonazine in the phospho-FGFR1 ELISA suggests that perhaps more specific antibodies 
should be utilized in this assay. In doing so, we may be able to eliminate false positives earlier in 
the series of secondary assays or have more sensitive antibodies that can be used in other cellular 
systems.  
Advantages of Using a Small Molecule Modulator. In our search to find true agonists of 
FGFR1, there are various reasons for pursuing the development of small molecule modulators 
the receptor (and RTKs in general) rather than endogenous protein agonists. First, as proteins, 
native growth factors and neurotrophins face many challenges as therapeutics, including limited 
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ability to cross BBB, short half-life in the bloodstream, and poor oral bioavailability. This 
concern is supported by the many failed clinical trials performed with growth factors, including 
BDNF, glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor 
(CNTF), where even with direct infusion the growth factors often suffer from poor 
penetration.62–65 Second, the pharmacological and pharmacokinetic properties of small molecules 
can be readily optimized via the iterative process of medicinal chemistry. Ideally, once a lead 
compound is identified from HTS, a full SAR exploration will commence to determine important 
areas of the scaffold for functional activity, as well as the tuning of pharmacokinetic properties. 
Third, the degree to which an RTK is activated can be achieved by small molecule control of 
different activation mechanisms. For example, small molecules can act as partial agonists at the 
RTK, wherein they only achieve partial receptor activation in comparison to the maximal 
response elicited by native neurotrophins. In particular, partial agonism may be one way to avoid 
the negative side effects of longer-term FGFR1 activation (see below).11 Finally, a small 
molecule agonist may be able to bias the signaling to specific pathways in comparison to the 
native neurotrophins. While there are many studies documenting biased agonism in the context 
of G-protein coupled receptors (GPCRs),66 a few reports also suggest a possibility of biasing 
RTK-induced signaling with small molecule agonists.67,68 A small molecule would allow the 
fine-tuning of RTK signaling, which would ultimately provide tools to better understand the 
roles of these receptors in neurogenesis, synaptogenesis, and related processes and ultimately 
may provide varied therapeutic options in the clinic.  
The Difficulty and Likelihood of Developing Small Molecule Agonists for RTKs. Given 
the high therapeutic value that RTK signaling represents, it is no wonder that the development of 
RTK small molecule agonists is an active area of research.69 Unlike for GPCRs, where small 
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molecule agonists are plentiful and well studied, there is still limited precedent for the activation 
of RTKs by small molecules. Additionally, there is increased skepticism in general about the true 
selectivity of many small molecule probes that perhaps were inadequately characterized at the 
time of discovery.70 RTKs are diverse and activated by many unique protein agonists; some 
RTKs are activated by receptor dimerization induced by a dimeric protein ligand (e.g., TrkA 
receptor activation by nerve growth factor), however others are activated by monomeric protein 
ligands, as shown by FGF2 and FGFR1. There are hypotheses that FGFR1, in fact, exists in a 
dynamic equilibrium between the monomeric receptor and the dimeric receptor complex, the 
latter of which is stabilized by two monomeric molecules of FGF2.3 When additional FGF2 
binds to the receptor, the receptor is activated (likely due to conformational change of the 
receptor complex), which then begins the cascade of mutual receptor phosphorylation via the 
intracellular kinase domains and downstream signaling. Given this rationale, it is not 
unreasonable to suggest that a small, drug-like molecule could bind to the receptor and favor its 
dimerization and activation, either as an orthosteric or allosteric agonist. For example, there are 
reports of small molecule agonists for both the insulin receptor and nerve growth factor receptor 
(TrkA)71,72, which highlight the feasibility of this approach and the possibility for success in the 
context of FGFR1. 
FGFR1 Activation and Cancer. While the idea of increasing FGFR1/FGF2 signaling 
makes sense in the context of neuropsychiatric disorders, it is important to consider that FGFR 
inhibition also has its benefits. Currently, increased expression of FGFR1 alone has been linked 
to different types of cancer, including breast73, ovarian74, bladder75, lung76, and 
rhabdomyosarcoma.77,78 Consequently, there are many small molecule inhibitors currently in 
various stages of the clinical trial process that target various FGFR-related tumors.77,79 All of 
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these compounds, however, target multiple RTKs at once as it is notoriously difficult to design a 
selective RTK inhibitor, suggesting that cancer risk is not necessarily an FGFR specific problem 
but globally related to RTKs. In any case, this connection to cancer should be taken into account 
when considering modulating the FGFR system. Presumably patients that require therapeutic 
FGFR1 intervention will suffer from a deficit in receptor activity, which initially caused the 
neuropsychiatric disorder. In this sense, the small molecule agonist of FGFR1 would simply be 
acting to bring FGFR1 signaling up to a higher basal level, repairing any damage caused by the 
depressed signaling and treating the effects of the mood disorder. A therapeutic dose of agonist, 
therefore, would likely pose a limited threat of causing cancer.  
 
Conclusions 
The recent human and animal data reveal FGFR1 as an important molecular target that 
modulates neurogenesis, synaptogenesis, and neuronal wiring repair. The application of this 
receptor to a broad range of CNS disorders, including neurological, neurodegenerative, and 
psychiatric disorders, is obvious and makes FGFR1 a highly attractive experimental target. 
Given the lack of true small molecule agonists available today for FGFR1, there is a need to 
develop novel pharmacological tools and potentially novel therapeutic leads through HTS. Many 
assays were developed to measure not only receptor activation and downstream signaling but 
also phenotypic attributes of the cells. Through this battery of secondary assays, a small 
molecule hit from an initial pilot screen in the primary assay was identified as a false positive, 
even though two assays found it to be active. A full HTS is now complete, and 72 hits have been 
identified for validation. The success of correctly eliminating naloxonazine as an FGFR1 agonist 
proves that lead compounds will be found if they exist. These probes, once identified, will not 
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only highlight the feasibility of generating small molecule agonists of FGFR1 but will also 
represent pharmacological validation of FGFR1 as a therapeutic target.  
 
Experimental 
Reagents. Recombinant rat or human fibroblast growth factor basic or acidic were 
purchased from Peprotech. Protease inhibitor cocktail (P8340), phosphatase inhibitor cocktail 2 
(P5726), rat tail collagen, poly-D-lysine hydrobromide (30-70 kDa), and PMA were purchased 
from Sigma Aldrich. PD173074 was purchased from Biotang, Inc. FGL peptide was purchased 
from Phoenix Pharmaceuticals (#073-36). Naloxonazine hydrochloride was purchased from 
Tocris. 
Cell Culture. hFGFR1-HEK were generated in-house and maintained in Dulbecco’s 
Modified Eagle Medium (Life Technologies; 10569) with 10% (v/v) fetal bovine serum (FBS, 
Atlanta Biologicals), 100 U mL-1 of penicillin and streptomycin (Life Technologies), and 200 
µg/mL G418 (Life Technologies). For stable transfection, HEK-293 were seeded in a 10-cm 
plate with 1.8 million cells and allowed to grow overnight in media without G418. Then 10 µg of 
the FGFR1IIIC cDNA (Origene #RC202080) was transfected using turbofectin (3:1 ratio to 
cDNA in OptiMEM media, 1 mL). After 24 hours, cells were subcultured into media contained 
G418 (400 µg/mL). By the second subculture, all cells in a mock transfection plate were dead. 
Newly transfected cells were then permanently maintained in G418 at a concentration of 200 
µg/mL. The transfection was confirmed via western blot. PC12 cells were maintained in RPMI 
1640 medium (Life Technologies; 11875085) with 10% horse serum (heat inactivated), 5% FBS, 
and 100 U mL-1 of penicillin and streptomycin. Cells were incubated at 37 °C with 5% CO2 
humidified atmosphere. 
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DiscoverX PathHunter® assay. PathHunter® U2OS FGFR1 cells were detached by 
detachment reagent (DiscoverX) and resuspended in plating 16 reagent (DiscoverX). Cells (2500 
cells/well) were plated into 1536-well plate using a BioRAPTR FRD Microfluidic Workstation. 
Plates were incubated at 37 °C in 5% CO2 overnight. Compounds or FGF2 were pin-transferred 
to the cells. Cells were incubated with compounds for 3 hours at 37 °C. The luminescent 
detection reagent (DiscoverX) was added for 1 hour at room temperature in the dark. The 
luminescence was quantified using a ViewLux CCD-based plate reader (PerkinElmer). 
FGFR1 Phosphorylation ELISA. FGFR1-HEK were grown in DMEM supplemented 
with 10% FBS, 100 U mL-1 of penicillin and streptomycin, and 200 µg/mL G418. Cells were 
added to a collagen-coated 96-well plate at 40,000 cells/well and allowed to grow for 24 hours. 
The cells were then starved with low serum media (1% FBS supplement instead) for 5 hours 
before treatment with drugs for 1 hour. The experiment was stopped on ice by aspirating the 
cellular supernatant and adding 110 µL of lysis buffer (1% TritonX-100, 10% glycine, and 2 mM 
EDTA in TBS, pH 8.0 with 1:100 protease inhibitor cocktail and 1:100 phosphatase inhibitor 
cocktail 2) before storing at -80 °C. A separate 96-well plate (Nunc Immulon) was coated with 
primary FGFR1 antibody (Sigma Aldrich # WH0002260M3) at 1 µg/mL in PBS and stored 
overnight at 4 °C. The plate was then washed 5X with TBST and blocked (1% BSA in PBS) for 
1 hour at room temperature. The plate was washed again 5X with TBST, and 80 µL of the 
thawed cell lysate was transferred to the 96-well ELISA plate and stored overnight at 4 °C. The 
remaining 20 µL of cell lysate was used for protein quantification in the BCA assay. The plate 
was then washed again 5X with TBST and incubated with secondary anti-phospho tyrosine-HRP 
antibody (R&D Systems #HAM1676) at 1:2500 (in 0.05% Tween-20, 0.1% BSA in TBS, pH 
7.4). The plate was washed a final 5X with TBST and developed using TMBone (100 µL/well) 
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for 30 minutes in the absence of light. Wells were then quenched with 1 M HCl (100 µL/well), 
and the plates were read at an absorbance wavelength of 450 nm using a BioTek Synergy H1 
plate reader. Raw data were quantified as the phospho-FGFR1 signal divided by the total protein 
content for each well. 
ELFI. Phosphorylation levels of downstream signaling proteins were quantified using 
enzyme-linked fixed-cell immunoassay (ELFI). Cells were treated similarly as in the phospho-
FGFR1 ELISA with a few noted exceptions. FGFR1-HEK cells were seeded at 20,000 cells/well 
and allowed to grow for 48 hours. Then cells were starved with serum-free media for 30 minutes 
prior to drug addition. For PC12, cells were seeded at 25,000 cells/well and allowed to grow for 
48 hours. The cells were then starved for 48 hours in low serum RPMI (RPMI supplemented 
with 0.25% horse serum (heat inactivated) and 0.25% fbs) prior to drug addition. Experiments 
were stopped by fixing the cells in 4% formaldehyde (Sigma, #F8775) for 15 min. Cells were 
then permeabilized with TBST, blocked in TBST containing 10% BSA, and incubated with 
detecting antibody for protein of interest for 2 hours at RT or overnight at 4 °C. An appropriate 
HRP-linked secondary antibody was applied, and luminescence (SuperSignal® ELISA Pico 
Chemiluminescent Substrate, ThermoScientific #37070) was detected on the plate reader. To 
quantify different proteins in the same plate, antibodies were stripped using stripping buffer (6M 
GuanidineHCl, 0.2% Triton X-100, 20 mM TrisHCl, pH 7.5)80 for 5 min, washed, blocked, 
and treated with another antibody. Stripping and reprobing cycles were done up to 6 times.  
Neurite Outgrowth. PC12 cells were added to a PDL-coated 12-well plate at 50,000 
cells/well. After 24 hours, drugs were added to the wells (Day 0). On Day 2, media was aspirated 
and refreshed with new drug solutions. The experiment was stopped on Day 4. Neurite 
outgrowth from PC12 cells was measured by light microscopy using a Leica DMI4000B 
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microscope. Analysis of number and lengths of the neurite outgrowth was quantified using 
NeuronJ software, where cells having neurites longer than two cell-body lengths were considered 
differentiated.38,81 
Western Blot (FGFR1-HEK). Cells were added to a PDL-coated 12-well plated at 
300,000 cell/well. After the experiment, cells were lysed with 100 µL of lysis buffer (4% SDS, 
0.125 M TrisHCl, 20% glycerol, pH 6.8 with 1:100 protease inhibitor cocktail, phosphatase 
inhibitor 2 cocktails, and 0.5 M EDTA) and incubated over ice for 15 minutes to an hour, after 
which cells were scraped and the lysates transferred into microcentrifigue tubes. The tubes were 
sonicated for 30 s and then centrifuged at 14,500 rpm for 10 minutes. The supernatant was 
transferred to fresh tubes, and the protein content was measured using the Pierce BCA assay. The 
lysates were diluted bromophenol for color and β-mercaptoethanol (10% final concentration), 
and any necessary amount of water. Equal quantities of protein (typically 15-30 µg/lane) were 
added to each well of a 10% bis-tris acrylamide gel and were blotted onto Immobilon P PVDF 
transfer membranes. Blots were blocked in 3% BSA in TBS for at least 1 hour, followed by 
incubation with the primary antibody overnight (manufacturer recommended dilution and 
buffer). The blots were washed 3 x 5 minutes with TBST (0.05% Tween20), incubated for 1 hour 
with secondary antibody (typically 1:1000) in the buffer indicated on the antibody’s 
corresponding data sheet, then washed again for 3 x 5 minutes prior to development with the 
ECL kit. Chemiluminescence and light absorbance (for protein ladder) was visualized with a 
Kodak Image Station 440CF imager. Membranes were stripped and reprobed with the stripping 
buffer used in the ELFI followed by the same detection procedure for the next target protein. 
Data were routinely quantified using densitometry by the gel analysis tools in ImageJ (NIH, 
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Bethesda, MD) following instructions at 
http://137.122.232.177/Protocols/ImageJ(ACM%20revisedv5).pdf.  
Western Blot (FGFR1-L6). After serum starvation, L6 cells stably expressing FGFR1 
were stimulated with 100 ng/mL of FGF1 (positive control) or 10 µM Naloxonazine 
dihydrochoride (NXZ) at 37 °C for the indicated time points and collected in lysis buffer (50mM 
HEPES, 150mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol, 1% Triton X-100, 25mM NaF, 
10 M ZnCl2, 1mM NaVO4, and complete protein inhibitor cocktail, Roche). The same amount of 
total cell lysates (TCL) or lysates subjected to FGFR1 inmunoprecipitation (IP) were 
inmunoblotting by standard methods using the following antibodies: ERK and pERK (Santa 
Cruz); FGFR1, pSer777-FGFR1 and 4G10 anti-phosphotyrosine (Schlessinger’s lab). Primary 
antibodies were detected by anti-mouse HRP and Protein A-HRP (Santa Cruz) and visualized by 
chemiluminescence kit (Denville, Scientific Inc.) Equal amounts of proteins submitted to WB or 
IP analysis were also guaranteed by re-probing stripped membranes (0.2 M NaOH, 5 min).  
Immunofluorescence. PC12 cells were then fixed with 4% formaldehyde in PBS, 
washed with PBS, permeabilized (0.25% Triton X-100 in PBS), washed, blocked (2% glycine, 
2% bovine serum albumin in 50 mM NH4Cl) for 30 min at 37 oC and incubated overnight with 
anti-FGFR1 antibodies (1:200 in blocking solution; #WH0002260M3, Sigma Aldrich) at 4 oC. 
Cells were then washed 5X with PBS, blocked again for 30 min at 37 oC, and incubated with a 
mixture of anti-mouse Alexa Fluor® 594 secondary antibody (1:1000 in blocking solution; Cell 
Signaling #8890) and Hoechst 33258 stain (1:10,000). The cells were then washed 5X in PBS 
and imaged on a Leica DMI4000B microscope. 
Statistical Analysis. Data analysis was performed using Graphpad Prism 6 Software 
(San Diego, CA). Conditions are expressed as mean ± SD and were subjected to ANOVA 
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followed by either Dunnett’s or Tukey’s Multiple Comparisons Test with a significant level of p 
< 0.05. Dose–response curves were fit using a four-parameter logistic equation. 
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